pyrazinamide has been researched along with Koch's Disease in 851 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Increased dosing of rifampicin and pyrazinamide seems a viable strategy to shorten treatment and prevent relapse of drug-susceptible tuberculosis (TB), but safety and efficacy remains to be confirmed." | 9.51 | Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP). ( Alffenaar, JC; Augustinsson, D; Bornefall, A; Carlsson, B; Ekqvist, D; Fredrikson, M; Niward, K; Nordvall, MJ; Paues, J; Sandstedt, M; Simonsson, USH; Sönnerbrandt, M, 2022) |
| "Pyrazinamide is a potent sterilising agent that shortens the treatment duration needed to cure tuberculosis." | 9.41 | Optimising pyrazinamide for the treatment of tuberculosis. ( Aarnoutse, R; Bliven-Sizemore, E; Boeree, MJ; Dooley, KE; Heinrich, N; Hoelscher, M; Mac Kenzie, W; Morlock, G; Peloquin, CA; Phillips, PPJ; Posey, J; Savic, RM; Stout, JE; Weiner, M; Whitworth, W; Zhang, N, 2021) |
| "Clinical studies suggest that isoniazid contributes rapid bacterial killing during the initial two days of tuberculosis treatment but that isoniazid's activity declines significantly after day three." | 9.34 | Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial. ( Bishai, W; Dawson, R; De Jager, V; Diacon, A; Donahue, K; Fletcher, CV; Hafner, R; Hogg, E; Miyahara, S; Sun, X; Swindells, S; Urbanowski, M, 2020) |
| "Pyrazinamide (PZA) has remained a keystone of tuberculosis (TB) therapy, and it possesses high imperative sterilizing action that can facilitate reduction in the present chemotherapy regimen." | 9.22 | Mutations Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis: A Review and Update. ( Palaniyandi, K; Rajendran, A, 2022) |
| "We developed a Markov model of anti-tuberculosis treatment to compare two regimens for treating TB: a 6-month standard (rifampin-based) treatment and a 4-month regimen using high-dose RPT." | 9.22 | Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis. ( Hamilton, CD; Holland, DP; Stout, JE, 2016) |
| "To evaluate the efficacy and safety of a 6-month intermittent regimen of rifampin (RMP), pyrazinamide (PZA) and ethambutol (EMB) in human immunodeficiency virus (HIV) negative patients with culture-confirmed pulmonary or extra-pulmonary tuberculosis and either isoniazid (INH) resistance or INH intolerance." | 9.19 | Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. ( Bock, N; Bozeman, L; Goldberg, SV; Hamilton, CD; Heilig, CM; Hershfield, E; Kyle, RP; Narita, M; Reves, R; Tapy, JM; Wing, D, 2014) |
| "To evaluate the blood levels, pharma-cokinetics and pharmacodynamic indices of pyrazinamide (PZA) in children suffering from tuberculosis, at doses administered under the weight band system of Revised National Tuberculosis Control Program of India (RNTCP) of India." | 9.16 | Blood levels of pyrazinamide in children at doses administered under the Revised National Tuberculosis Control Program. ( Gupta, P; Khanna, A; Roy, V; Sahni, P; Sethi, GR, 2012) |
| " The aim of the study was to document the pharmacokinetics of the first-line anti-TB agents in children <2 years of age comparing previous and revised WHO dosages of isoniazid (INH; 5 versus 10 mg/kg/day), rifampin (RMP; 10 versus 15 mg/kg/day), and pyrazinamide (PZA; 25 versus 35 mg/kg/day) and to investigate the effects of clinical covariates, including HIV coinfection, nutritional status, age, gender, and type of tuberculosis (TB), and the effect of NAT2 acetylator status." | 9.15 | Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ( Donald, PR; Hesseling, AC; Magdorf, K; Roll, S; Rosenkranz, B; Schaaf, HS; Seddon, JA; Seifart, HI; Thee, S; Werely, CJ, 2011) |
| "To evaluate the pharmacokinetics and pharmacodynamic indices of pyrazinamide at doses of 15 and 25 mg kg(-1) in children suffering from tuberculosis." | 9.13 | Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses. ( Gupta, P; Mishra, TK; Roy, V; Sethi, GR, 2008) |
| "Pyrazinamide (PZA) is an important component of a standard combination therapy against tuberculosis." | 9.12 | Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug. ( Hussain, Z; Ma, X; Zhu, J, 2021) |
| "Two months of treatment with rifampin-pyrazinamide (RZ) and 9 months of treatment with isoniazid are both recommended for treatment of latent tuberculosis infection in adults without human immunodeficiency virus infection, but the relative cost-effectiveness of these 2 treatments is unknown." | 9.11 | Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial. ( Bernardo, J; Daley, CL; Hopewell, PC; Jasmer, RM; Kawamura, LM; King, MD; Saukkonen, JJ; Snyder, DC, 2004) |
| "We evaluated the effects of human immunodeficiency virus (HIV) disease on pharmacokinetics of antituberculosis medications by measuring concentrations of isoniazid and rifampin in blood and of pyrazinamide and ethambutol in urine." | 9.11 | Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. ( Bhagavathy, S; Gurumurthy, P; Hemanth Kumar, AK; Mahilmaran, A; Padmapriyadarsini, C; Paramesh, P; Rajasekaran, S; Ramachandran, G; Ravichandran, N; Sekar, L; Swaminathan, S; Venkatesan, P, 2004) |
| "To determine the rates of hepatotoxicity and treatment completion associated with intermittent rifampin and pyrazinamide (RZ) therapy for latent tuberculosis infection, we evaluated a cohort of patients from a targeted tuberculin testing site in Tennessee." | 9.11 | Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program. ( Haley, CA; Hoy, DP; Priest, DH; Sherfy, EA; Vossel, LF, 2004) |
| "A higher incidence of hepatotoxicity was associated with rifampin plus pyrazinamide than isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong." | 9.10 | Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. ( Chan, CK; Chang, KC; Law, WS; Leung, CC; Tam, CM; Wong, MY; Yew, WW, 2003) |
| "To determine population pharmacokinetic parameters of pyrazinamide after multiple oral doses given to children and adults with tuberculosis." | 9.10 | Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. ( Ashkin, D; Berning, SE; Bulpitt, AE; Burman, WJ; Peloquin, CA; Stambaugh, JJ; Starke, JR; Steiner, P; Zhu, M, 2002) |
| "To compare a 2-month regimen of daily rifampin and pyrazinamide with a 12-month regimen of daily isoniazid in preventing tuberculosis in persons with human immunodeficiency virus (HIV) infection." | 9.09 | Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O ( Barry, MA; Chaisson, RE; Coberly, J; de Lourdes Garcia, M; Gordin, F; Hafner, R; Klukowicz, AJ; Matts, JP; Miller, C; O'Brien, RJ; Schechter, M; Valdespino, JL, 2000) |
| "To characterize the susceptibility to levofloxacin of clinical isolates of Mycobacterium tuberculosis (MTB) obtained from patients with HIV-related tuberculosis and to characterize the molecular genetics of levofloxacin resistance." | 9.08 | Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinica ( Chirgwin, K; El Sadr, WM; Hafner, R; Heifets, LB; Klein, O; Kreiswirth, BN; Matts, JP; Musser, JM; Nelson, ET; Perlman, DC; Salomon, N; Telzak, EE, 1997) |
| "Short-course chemotherapy of six-month duration with an initial combination of three drugs (isoniazid [H], rifampin [R] and pyrazinamide [Z]) is recommended as the treatment of choice in tuberculosis today." | 9.07 | [Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide]. ( Brändli, O; Dreher, D; Morger, D, 1993) |
| "To compare the incidence of severe hepatitis in HIV-infected patients receiving rifampicin plus pyrazinamide (RZ) for antituberculosis prophylaxis with that of patients receiving a conventional isoniazid-based regime for 6 to 12 months (6-12H)." | 8.86 | [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials]. ( Camacho, A; Castón, JJ; Gallo, M; García-Lázaro, M; Kindelán, JM; Natera, C; Pérez-Camacho, I; Rivero, A; Torre-Cisneros, J, 2010) |
| " isoniazid (INH) for the prevention of tuberculosis (TB) among persons with or without human immunodeficiency virus (HIV) infection." | 8.83 | Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. ( Gao, XF; Li, YP; Liu, GJ; Sun, X; Wang, L; Wen, J; Xie, Y, 2006) |
| "Site-of-action concentrations for bedaquiline and pretomanid from tuberculosis patients are unavailable." | 8.31 | Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic Modeling. ( Guo, T; Mehta, K; van der Graaf, PH; van Hasselt, JGC, 2023) |
| " Here, two murine models of tuberculosis were used to test whether novel regimens replacing rifapentine and isoniazid with bedaquiline and another drug would maintain or increase the sterilizing activity of the regimen." | 8.12 | Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. ( Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD, 2022) |
| "The chemotherapeutic regimens of patients with drug-susceptible (DS)- tuberculosis (TB) comprise four primary anti-TB drugs: rifampicin (RMP), isoniazid (INH), ethambutol (EMB) and pyrazinamide (PZA), administered for six-to-nine months." | 8.12 | Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro. ( Anderson, R; Cholo, MC; Mashele, SA; Matjokotja, MT; Rasehlo, SSM; Steel, HC, 2022) |
| "Pyrazinamide (PZA) is one of the first-line anti-tuberculous drugs used in the treatment of tuberculosis (TB)." | 8.12 | [Investigation of pncA, rpsA and panD Gene Mutations Associated with Resistance in Pyrazinamide-Resistant Mycobacterium tuberculosis Isolates and Spoligotyping]. ( Aslan, G; Aslantürk, A; Biçmen, C; Kayar, MB; Özgür, D; Tezcan Ülger, S; Ülger, M, 2022) |
| "Pyrazinamide is one of the first-line antituberculosis drugs." | 8.12 | Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis. ( Abolhassani-Chimeh, R; Akkerman, OW; Alffenaar, JC; Bolhuis, MS; Kosterink, JGW; Punt, NC; Saktiawati, AMI; Sturkenboom, MGG; Subronto, YW; van der Werf, TS, 2022) |
| "TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China." | 8.12 | Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. ( Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H, 2022) |
| " The anti-tuberculosis (anti-TB) drug pyrazinamide (PZA) was successfully intercalated into interlayer galleries of MgLH, resulting in the formation of the nanocomposite, PZA-MgLH, having an average size of about 107 ± 24 nm with a uniform circular shape." | 8.12 | Development of a novel anti-tuberculosis nanodelivery formulation using magnesium layered hydroxide as the nanocarrier and pyrazinamide as a model drug. ( Arulselvan, P; Bullo, N; El Zowalaty, ME; Fakurazi, S; Hussein, MZ; Saifullah, B; Webster, TJ, 2022) |
| "Pyrazinamide (PZA) plays a crucial role in first-line tuberculosis drug therapy." | 8.02 | Pyrazinamide Susceptibility Is Driven by Activation of the SigE-Dependent Cell Envelope Stress Response in Mycobacterium tuberculosis. ( Aflakpui, R; Baughn, AD; Dillon, NA; Hoffner, SE; Howe, MD; Minato, Y; Modlin, SJ; Thiede, JM; Valafar, F, 2021) |
| "We compared the efficacy of an all oral DR tuberculosis drug regimen consisting of bedaquiline (25 mg/kg), delamanid (2." | 8.02 | Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model. ( Bax, HI; de Steenwinkel, JEM; Keutzer, L; Pieterman, ED; Simonsson, USH; van den Berg, S; van der Meijden, A; Wang, H; Zimmerman, MD, 2021) |
| "Pyrazinamide has been a mainstay in the multidrug regimens used to treat tuberculosis." | 7.96 | The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD. ( Li, X; Perez, LM; Sacchettini, JC; Shi, W; Sun, Q; Zhang, Y, 2020) |
| "Calcitriol alone had little effect on tuberculosis infection, whereas PZA, compared with saline control treatment, decreased the bacterial burden (spleens: PZA vs." | 7.91 | Calcitriol enhances pyrazinamide treatment of murine tuberculosis. ( Bao, R; Dai, M; Guo, M; Huang, ZX; Rao, Y; Wang, X; Yu, Q; Zhang, J, 2019) |
| "Pyrazinamide (PZA) is a key component of current and future regimens for tuberculosis (TB)." | 7.91 | The impact of inclusion, dose and duration of pyrazinamide (PZA) on efficacy and safety outcomes in tuberculosis: systematic review and meta-analysis protocol. ( Bonnett, LJ; Davies, GR; Mackay, EA; Millard, JD, 2019) |
| "Pyrazinamide (PZA) is an important component of first-line drugs because of its distinctive capability to kill subpopulations of persistent Mycobacterium tuberculosis (MTB)." | 7.91 | Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan. ( Afzal, MT; Ali, S; Khan, AS; Khan, MT; Malik, SI; Masood, N; Nadeem, T, 2019) |
| "The classic fixed-dose combination (FDC) of 4 tuberculosis drugs, namely rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA), and ethambutol dihydrochloride (EDH) has the twin issues of physical stability and RIF cross-reaction in the 4-FDC." | 7.88 | Improved Stability of Tuberculosis Drug Fixed-Dose Combination Using Isoniazid-Caffeic Acid and Vanillic Acid Cocrystal. ( Battini, S; Mannava, MKC; Nangia, A, 2018) |
| "We mimicked the concentration-time profiles achieved by human equivalent doses of moxifloxacin 800 mg/day, rifampin 1800 mg/day, and pyrazinamide 4000 mg/day (high-dose regimen) vs isoniazid 300 mg/day, rifampin 600 mg/day, and pyrazinamide 2000 mg/day (standard therapy) in bactericidal and sterilizing effect studies in the hollow fiber system model of tuberculosis (HFS-TB)." | 7.88 | Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet! ( Deshpande, D; Gumbo, T; Magombedze, G; Srivastava, S, 2018) |
| "Despite the importance of pyrazinamide (PZA) in tuberculosis treatment, PZA susceptibility testing is not routinely performed because of its acid pH requirement." | 7.85 | Detection of pyrazinamide resistance of Mycobacterium tuberculosis using nicotinamide as a surrogate. ( Fu, Y; Hu, Y; Huang, H; Li, Y; Liang, Q; Luo, J; Ma, Y; Shang, Y; Wu, X; Zhao, L, 2017) |
| "Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 7.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
| "Pyrazinamide (PZA) plays a unique role in the treatment for multidrug-resistant tuberculosis (MDR-TB) in both first- and second-line regimens." | 7.85 | Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. ( Hu, Y; Liu, J; Pang, Y; Shen, J; Zhao, Y; Zheng, H; Zhu, D, 2017) |
| "Through mutant selection on agar containing pyrazinoic acid (POA), the bioactive form of the prodrug pyrazinamide (PZA), we recently showed that missense mutations in the aspartate decarboxylase PanD and the unfoldase ClpC1, and loss-of-function mutation of polyketide synthases Mas and PpsA-E involved in phthiocerol dimycocerosate synthesis, cause resistance to POA and PZA in Mycobacterium tuberculosis." | 7.85 | In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1. ( Dartois, V; Dick, T; Gopal, P; Lanoix, JP; Li, L; Nuermberger, E; Rasic, G; Sarathy, J; Tasneen, R; Yee, M, 2017) |
| "To compare the pharmacokinetics of rifampicin (RMP), isoniazid (INH) and pyrazinamide (PZA) between HIV-infected and HIV-uninfected children with tuberculosis (TB) and correlate it with TB treatment outcome." | 7.83 | Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status. ( Agarwal, D; Banurekha, VV; Bhavani, PK; Gangadevi, NP; Kalpana, S; Kannan, T; Kumar, AK; Kumar, SR; Mathevan, G; Ramachandran, G; Ravichandran, N; Sanjeeva, GN; Sudha, V; Swaminathan, S; Venkatesh, S, 2016) |
| "Experimental and clinical studies have indicated that the antileprosy drug clofazimine may contribute treatment-shortening activity when included in tuberculosis treatment regimens." | 7.83 | Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy. ( Adamson, J; Almeida, DV; Ammerman, NC; Bester, LA; Dorasamy, A; Grosset, JH; Mgaga, Z; Moodley, C; Moodley, S; Ngcobo, B; Singh, SD; Swanson, RV, 2016) |
| "To investigate the clinical characteristics, adverse drug reactions, and outcomes of the oldest old patients (aged ≥80 years) with tuberculosis (TB) treated with rifampicin, isoniazid, and pyrazinamide (RIP)-containing regimens." | 7.83 | The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide. ( Chang, PJ; Cheng, CW; Chou, YL; Lin, HS; Lin, JC; Lin, MS; Ye, JJ, 2016) |
| "For the past decades, an acidic pH has been used to render Mycobacterium tuberculosis susceptible to pyrazinamide for in vitro testing." | 7.83 | Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature. ( Anthony, RM; den Hertog, AL; Menting, S; Pfeltz, R; Siddiqi, SH; Warns, M, 2016) |
| "To study the pharmacokinetics of rifampicin (RMP), isoniazid (INH) and pyrazinamide (PZA) in adult tuberculosis (TB) patients and examine factors that influence drug pharmacokinetics." | 7.83 | Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India. ( Chandrasekaran, V; Hemanth Kumar, AK; Kannan, T; Lavanya, J; Ramachandran, G; Ramesh, K; Sudha, V; Swaminathan, S; Vijayakumar, A, 2016) |
| "Pyrazinamide (PZA) is one the first line anti-tuberculosis drugs that require activation by the pyrazinamidase (PZase)." | 7.81 | Biochemical Characterization and Computational Identification of Mycobacterium tuberculosis Pyrazinamidase in Some Pyrazinamide-Resistant Isolates of Iran. ( Chaparzadeh, N; Doustdar, F; Falahati, H; Mehrnejad, F; Mir-Derikvand, M; Pazhang, M; Rabiei, D; Safarzadeh, M, 2015) |
| "We used previously published data for 76 South African children with tuberculosis to describe the population pharmacokinetics of rifampicin, pyrazinamide and isoniazid." | 7.80 | Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. ( Denti, P; Donald, PR; McIlleron, HM; Schaaf, HS; Seddon, JA; Seifart, HI; Simonsson, US; Smith, PJ; Thee, S; Zvada, SP, 2014) |
| "Pyrazinamide (PZA) is a first line agent for the treatment of active tuberculosis." | 7.80 | Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California. ( Budzik, JM; Grinsdale, J; Higashi, J; Hopewell, PC; Jarlsberg, LG; Kato-Maeda, M; Nahid, P, 2014) |
| "Monoresistance to pyrazinamide (PZA) has infrequently been associated with Mycobacterium tuberculosis." | 7.80 | Outbreak of pyrazinamide-monoresistant tuberculosis identified using genotype cluster and social media analysis. ( Heysell, SK; Houpt, ER; Keller, SJ; Moore, JL; Thomas, TA, 2014) |
| "To investigate the effect of natural pyrazinamidase (PncA) mutations on protein function, we analyzed expression and PncA activity of eight pncA point mutants identified in nineteen pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates." | 7.80 | Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Korea and analysis of the correlation between the mutations and pyrazinamidase activity. ( Kim, KJ; Nam, JS; Ro, YT; Yoon, JH, 2014) |
| " in a recent issue of this Journal address one of the current debates regarding the potential role of thioridazine in the treatment of tuberculosis." | 7.80 | Thioridazine for treatment of tuberculosis: promises and pitfalls. ( Dutta, NK; Karakousis, PC, 2014) |
| "Pyrazinamide (PZA) is a prodrug that is converted to pyrazinoic acid by the enzyme pyrazinamidase, encoded by the pncA gene in Mycobacterium tuberculosis." | 7.80 | Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. ( Ambrosi, A; Augustynowicz-Kopeć, E; Bakonyte, D; Cabibbe, AM; Casali, N; Cirillo, DM; Degano, M; Drobniewski, F; Feuerriegel, S; Hoffner, S; Mansjö, M; Miotto, P; Niemann, S; Pimkina, E; Rodionova, Y; Rüsch-Gerdes, S; Stakenas, P; Werngren, J, 2014) |
| "Assessment of the activity of thioridazine towards Mycobacterium tuberculosis (Mtb), in vitro and in vivo as a single drug and in combination with tuberculosis (TB) drugs." | 7.80 | Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. ( Aarnoutse, R; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; ten Kate, MT; van Soolingen, D, 2014) |
| "It has been widely accepted, that pyrazinamide (PZA) resistance in Mycobacterium tuberculosis is correlated with mutations in the pncA gene." | 7.79 | Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene. ( Bhuju, S; de Oliveira Vieira, GB; Fonseca, Lde S; Marsico, AG; Saad, MH; Singh, M; Sobral, LF; Stehr, M, 2013) |
| "Pyrazinamide is one of the first line four drugs for treatment of tuberculosis." | 7.79 | Study of pyrazinamidase structural changes in pyrazinamide resistant and susceptible isolates of Mycobacterium tuberculosis. ( Ahmady, A; Arjomandzadegan, M; Kahbazi, M; Poolad, T; Rafee, P; Tousheh, M, 2013) |
| "Pyrazinamide (PZA) is a key drug in the treatment of tuberculosis (TB), including multidrug-resistant TB." | 7.79 | Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience. ( Angeby, K; Hoffner, S; Johansson, A; Jönsson, B; Sellin, M; Sturegård, E; Werngren, J, 2013) |
| "Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6) polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in HIV/tuberculosis-coinfected (HIV/TB) patients is unavailable." | 7.79 | Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. ( Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S, 2013) |
| "Pyrazinamide is important in the treatment of tuberculosis." | 7.78 | Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. ( Boeree, MJ; Dekhuijzen, PN; Mulder, A; Simons, SO; van der Laan, T; van Ingen, J; van Soolingen, D, 2012) |
| "2% of all tuberculosis (TB) isolates from Canadian-born patients are resistant to pyrazinamide (PZA) alone." | 7.78 | Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec. ( Brassard, P; Menzies, D; Yee, DP, 2012) |
| "The optimal management strategy for patients with isoniazid (INH) monoresistant forms of tuberculosis (TB) has been widely debated." | 7.78 | Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. ( Cohen, T; Furin, J; Gegia, M; Kalandadze, I; Vashakidze, L, 2012) |
| "Pyrazinamide (PZA) is an important component of first-line therapy for the treatment of tuberculosis." | 7.78 | Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA. ( Alexander, DC; Blair, J; Chedore, P; Guthrie, JL; Jamieson, FB; Ma, JH, 2012) |
| "Standard tuberculosis (TB) treatment includes an initial regimen containing drugs that are both rapidly bactericidal (isoniazid) and sterilizing (rifampin and pyrazinamide), and ethambutol to help prevent the emergence of drug resistance." | 7.78 | Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. ( Almeida, D; Ammerman, NC; Bishai, WR; Converse, PJ; Grosset, J; Hafner, R; Lalloo, U; Li, SY; Pym, AS; Swindells, S; Tyagi, S; Wallengren, K, 2012) |
| "Pyrazinamide is an essential component of first line anti-tuberculosis regimen as well as most of the second line regimens." | 7.78 | Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis. ( Ahmad, Z; Almeida, D; Baughn, AS; Grosset, JH; Jacobs, WR; Minkowsk, A; Nuermberger, EL; Peck, KM; Tyagi, S; Welch, JT, 2012) |
| "All tested methods in this preliminary study showed excellent sensitivity and specificity for the determination of pyrazinamide susceptibility of M." | 7.77 | Rapid detection of resistance to pyrazinamide in Mycobacterium tuberculosis using the resazurin microtitre assay. ( Campanerut, PA; Cardoso, RF; Ghiraldi, LD; Hirata, MH; Hirata, RD; Leite, CQ; Sato, DN; Spositto, FL, 2011) |
| "The microscopic observation drug susceptibility assay (MODS) was evaluated to determine susceptibility to pyrazinamide in Mycobacterium tuberculosis, and compared with the broth microdilution method (BMM), absolute concentration method (ACM), and pyrazinamidase (PZase) determination." | 7.77 | Evaluation of the microscopic observation drug susceptibility assay for detection of Mycobacterium tuberculosis resistance to pyrazinamide. ( Campanerut, PA; Cardoso, RF; Ghiraldi, LD; Hirata, M; Hirata, RD; Leite, CQ; Sato, DN; Spositto, FL, 2011) |
| "Pyrazinamide (PZA) is an important first-line anti-tuberculosis drug." | 7.77 | Rapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method. ( Chen, J; Deng, J; Geng, X; Wang, D; Wang, W; Wang, X; Wei, H; Zhang, XE; Zhang, Z; Zhou, M, 2011) |
| "Resistance to pyrazinamide in Mycobacterium tuberculosis is usually associated with a reduction of pyrazinamidase activity caused by mutations in pncA, the pyrazinamidase coding gene." | 7.76 | Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance. ( Gilman, RH; Gutierrez, A; Quiliano, M; Sheen, P; Zimic, M, 2010) |
| "Pyrazinamide is an important front line antimycobacterial drug, which is also being used in the treatment of multi drug resistant tuberculosis along with second line drugs in DOTS plus programme." | 7.76 | Comparison of MGIT 960 & pyrazinamidase activity assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. ( Malhotra, B; Pal, N; Rishi, S; Sharma, B; Vyas, L, 2010) |
| "Pyrazinamide (PZA) has been in use for almost 50 years as a first-line drug for short-course chemotherapy against Mycobacterium tuberculosis." | 7.76 | Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of mycobacterium tuberculosis from South India. ( Ayalusamy, N; Jagadeesan, S; Muthaiah, M; Muthuraj, U; Prabhu, SS; Senthilkumar, K; Sreenivasan, M; Veerappan, S, 2010) |
| "Susceptibility testing of pyrazinamide (PZA) against Mycobacterium tuberculosis is difficult to perform because the acidity of culture medium that is required for drug activity also inhibits the growth of bacteria." | 7.76 | Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. ( Chaiprasert, A; Jonmalung, J; Leechawengwongs, M; Prammananan, T, 2010) |
| "Risk factors and treatment outcomes under program conditions for isoniazid (INH)-monoresistant tuberculosis have not been well described." | 7.75 | Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. ( Cattamanchi, A; Dantes, RB; Grinsdale, J; Hopewell, PC; Jarlsberg, LG; Kawamura, LM; Metcalfe, JZ; Nahid, P; Osmond, D, 2009) |
| "Ethambutol and pyrazinamide are two first-line anti-tuberculosis drugs." | 7.75 | A rapid and robust liquid chromatography/tandem mass spectrometry method for simultaneous analysis of anti-tuberculosis drugs--ethambutol and pyrazinamide in human plasma. ( Basir, Y; Chu, D; Gong, Z; McCort-Tipton, M, 2009) |
| "Pyrazinamide is a first-line drug for treating tuberculosis, but pyrazinamide resistance testing is usually too slow to guide initial therapy, so some patients receive inappropriate therapy." | 7.75 | Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients. ( Caviedes, L; Evans, CA; Gilman, RH; Méndez, M; Moore, DA; Peña, L; Sheen, P; Zhang, Y; Zimic, MJ, 2009) |
| "These results suggest that regimens consisting of isoniazid or moxifloxacin plus rifapentine and pyrazinamide may dramatically shorten the duration of treatment needed to cure human tuberculosis." | 7.74 | Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? ( Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M, 2008) |
| "Aspirin (acetylsalicylic acid) or ibuprofen [2-(4-isobutyl-phenyl)-propionic acid] was administered to mice undergoing treatment of tuberculosis infection with pyrazinamide to determine if these non-steroidal anti-inflammatory drugs (NSAIDs) enhance pyrazinamide activity in vivo." | 7.74 | Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. ( Byrne, ST; Denkin, SM; Zhang, Y, 2007) |
| "Resistance of Mycobacterium tuberculosis to pyrazinamide (PZA) derives mainly from mutations in the pncA gene." | 7.74 | Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains. ( Augustynowicz-Kopec, E; Kato, S; Kirikae, F; Kirikae, T; Kobayashi, I; Miyoshi-Akiyama, T; Mori, T; Morita, K; Nakamura, T; Sekiguchi, J; Suetake, T; Yoshida, H; Zwolska, Z, 2007) |
| "To compare the performance of the BacT/ALERT PZA kit (BioMerieux, Marcy l'Etoile, France) with the radiometric BACTEC 460TB PZA test (Becton-Dickinson method) for testing Mycobacterium tuberculosis susceptibility to pyrazinamide." | 7.74 | Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide. ( Aragón, LM; Coll, P; Español, M; Garrigó, M; Moreno, C, 2007) |
| "A simple fibroblast-based assay (SFA) was found to be efficient in evaluating the susceptibilities of clinical isolates of Mycobacterium tuberculosis to pyrazinamide (PZA)." | 7.73 | Simple fibroblast-based assay to test the pyrazinamide susceptibility of Mycobacterium tuberculosis. ( Abe, C; Hamasaki, S; Hirano, K; Onozaki, K; Takii, T, 2005) |
| "The case of a 30-y-old male with latent tuberculosis who developed chemical hepatitis requiring hospitalization after 50 d of treatment with rifampin and pyrazinamide is reported." | 7.73 | Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis. ( Mantadakis, E; Potolidis, E; Samonis, G; Zeniodi, MH, 2005) |
| "Cases of severe and fatal liver injury were reported after a 2-month course of rifampin-pyrazinamide therapy was recommended in 2000 as an alternative to isoniazid for treatment of latent tuberculosis infection." | 7.73 | National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. ( Castro, KG; Iademarco, MF; Ijaz, K; Jereb, JA; Lambert, LA; McElroy, PD; Navin, TR, 2005) |
| "Severe liver injuries were attributed to the rifampin and pyrazinamide (RZ) regimen after it was recommended for treating latent tuberculosis infection." | 7.73 | Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. ( Bower, WA; Castro, KG; Iademarco, MF; Ijaz, K; Jereb, JA; Lambert, LA; McElroy, PD; Navin, TR; Spradling, PR, 2006) |
| "This study was designed to characterize the population pharmacokinetics of pyrazinamide in South African pulmonary tuberculosis patients, with special reference to interindividual and interoccasional variability (IIV and IOV, respectively)." | 7.73 | Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. ( Langdon, G; McIlleron, H; Pillai, GC; Simonsson, US; Smith, PJ; Wilkins, JJ, 2006) |
| "To investigate the presence of mutations in the pncA gene in 31 pyrazinamide-resistant Mycobacterium tuberculosis and 5 susceptible strains." | 7.73 | pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. ( Barco, P; Campanerut, PA; Cardoso, RF; de Melo, FF; Hirata, MH; Hirata, RD; Leite, CQ; Mamizuka, EM; Pandolfi, JR; Sato, DN; Shikama, ML, 2006) |
| "An alternative regimen for the treatment of latent tuberculosis infection is 2 months of rifampin and pyrazinamide, but some patients have died of hepatitis associated with this therapy." | 7.72 | Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. ( Cheng, AC; Engemann, JJ; Fortenberry, ER; Hamilton, CD; Stout, JE, 2003) |
| "CDC has reported previously surveillance data of severe liver injury in patients treated for latent tuberculosis infection (LTBI) with a daily and twice-weekly 2-month regimen of rifampin with pyrazinamide (RZ)." | 7.72 | Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. ( , 2003) |
| "A total of 76 clinical Mycobacterium tuberculosis isolates from Taiwan were tested for pyrazinamidase activity, pyrazinamide susceptibility, and pncA mutations." | 7.72 | Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. ( Chen, YS; Huang, CK; Huang, TS; Huang, WK; Lee, SS; Lin, HH; Liu, YC; Tu, HZ; Wann, SR, 2003) |
| "The pharmacokinetics of pyrazinamide (PZA) in patients with human immunodeficiency virus (HIV)-related tuberculosis are incompletely characterized." | 7.72 | The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis. ( Chirgwin, K; Hafner, R; Peloquin, CA; Perlman, DC; Rainey, PM; Remmel, RP; Rosenkranz, S; Salomon, N; Segal, Y, 2004) |
| "The pncA gene mutations associated with pyrazinamide (PZA) resistance in Mycobacterium tuberculosis complex were determined in 26 PZA-resistant isolates in Japan." | 7.72 | Genetic and phenotypic characterization of pyrazinamide-resistant mycobacterium tuberculosis complex isolates in Japan. ( Ano, H; Miyagi, C; Takashima, T; Yamane, N; Yogesh, B, 2004) |
| "To characterize the treatment of latent tuberculosis infection and the impact on treatment completion of the 2-month rifampin and pyrazinamide regimen as compared to the traditional 6- to 12-month isoniazid regimen among persons incarcerated at a county correctional facility." | 7.72 | Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin/pyrazinamide with isoniazid regimens. ( Brannan, GL; Clancey, T; Conklin, TJ; Lincoln, T; Lynch, V; Rose, DN; Tuthill, RJ, 2004) |
| "The nucleotide sequences of the pncA genes within 55 multidrug-resistant pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates were determined." | 7.72 | pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal. ( Barreiro, L; Brum, L; Moniz-Pereira, J; Portugal, I, 2004) |
| "Severe liver injury has been attributed to preventive treatment of latent tuberculosis infection with a 2-month course of rifampin-pyrazinamide." | 7.72 | Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. ( Baars, H; Borgdorff, M; Cobelens, F; Kalisvaart, N; Keizer, S; Kik, S; Mensen, M; Trompenaars, MC; van Gerven, P; van Hest, R, 2004) |
| "In 2000, results of a multinational trial demonstrated that a 2-month course of rifampin and pyrazinamide (RZ) was as effective as isoniazid (INH) in reducing tuberculosis in human immunodeficiency virus (HIV)-infected individuals with latent tuberculosis infection (LTBI)." | 7.72 | Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? ( Chaisson, RE; Cohn, DL; Gordin, FM; Matts, JP; O'Brien, RJ, 2004) |
| "Reports of fatal and severe liver injury associated with treatment of latent tuberculosis infection (LTBI) with the drug combination rifampin and pyrazinamide (RZ) prompted CDC to issue revised guidelines for the use of this regimen on August 31, 2001." | 7.71 | Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. ( , 2002) |
| "The fully automated BACTEC MGIT 960 PZA medium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA) was evaluated using 101 Mycobacterium tuberculosis clinical isolates." | 7.71 | Evaluation of BACTEC MGIT 960 PZA medium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA): compared with the results of pyrazinamidase assay and Kyokuto PZA test. ( Abe, C; Aono, A; Hamasaki, S; Hirano, K, 2002) |
| "Mycobacterium bovis is naturally resistant to the antituberculosis drug pyrazinamide (PZA)." | 7.71 | Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States. ( Crawford, JT; Desmond, EP; Hannan, MM; Mazurek, GH; Morlock, GP, 2001) |
| "To determine whether short-course treatment of latent tuberculosis infection (LTBI) with 2 months of rifampin and pyrazinamide (2RZ) is well tolerated and leads to increased treatment completion among jail inmates, a group who may benefit from targeted testing and treatment for LTBI but for whom completion of > or = 6 months of isoniazid treatment is difficult because of the short duration of incarceration." | 7.71 | Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. ( Bock, NN; DeVoe, B; Geiter, LJ; Herron, GD; Rogers, T; Tapia, JR, 2001) |
| "One of the recommended treatments for latent tuberculosis infection (LTBI) is a 9-month regimen of isoniazid (INH); a 2-month regimen of rifampin (RIF) and pyrazinamide (PZA) is an alternative in some instances." | 7.71 | Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000. ( , 2001) |
| "The chemotherapeutic agent pyrazinamide was used as a marker for the occurrence of tuberculosis." | 7.71 | Pyrazinamide use as a method of estimating under-reporting of tuberculosis. ( Hekster, YA; Kalisvaart, NA; Leufkens, HG; van Loenhout-Rooyackers, JH, 2001) |
| "During February 12-August 24, 2001, a total of 21 cases of liver injury associated with a 2-month rifampin-pyrazinamide (RIF-PZA) regimen for the treatment of latent tuberculosis infection (LTBI) was reported to CDC." | 7.71 | Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001. ( , 2001) |
| "Pyrazinamide (PZA) is an important front-line anti-tuberculosis drug that is active only at acid pH." | 7.71 | Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. ( Permar, S; Sun, Z; Zhang, Y, 2002) |
| "To determine the long-term tolerability of prophylactic administration of pyrazinamide and levofloxacin in patients possibly exposed to multidrug-resistant tuberculosis (MDRTB) after undergoing solid organ transplantation." | 7.71 | Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. ( Lou, HX; McKaveney, TP; Shullo, MA, 2002) |
| "Pyrazinamide (PZA) is recommended as the third drug in the 6-month regimens for tuberculosis." | 7.70 | Is pyrazinamide really the third drug of choice in the treatment of tuberculosis? ( Constantopoulos, SH; Demou, GS; Koumbaniou, C; Manda-Stachouli, C; Nicopoulos, C; Sakellariou, K; Vassiliou, M, 1998) |
| "To establish the chemotherapeutic value of a depot drug preparation of isoniazid and pyrazinamide against experimental tuberculosis." | 7.70 | Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide. ( Gangadharam, PR; Geeta, N; Hsu, YY; Wise, DL, 1999) |
| " In this study, we evaluated the ability of rifapentine (RFP), in monotherapy and combination therapy, to completely eradicate a Mycobacterium tuberculosis infection and to prevent relapse posttreatment in a Swiss mouse model." | 7.70 | Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. ( Chase, SE; Chmielewski, AJ; Cynamon, MH; Lenaerts, AM, 1999) |
| "Pyrazinamide (PZA) is an important first-line tuberculosis drug that is part of the currently used short-course tuberculosis chemotherapy." | 7.70 | pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. ( Cheng, SJ; Heifets, L; Sanchez, T; Thibert, L; Zhang, Y, 2000) |
| "A new agar medium to perform pyrazinamide (PZA) susceptibility testing with Mycobacterium tuberculosis has been developed." | 7.70 | New agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. ( Heifets, L; Sanchez, T, 2000) |
| "The effectiveness of various once-weekly 10 mg/kg rifapentine (P)- containing regimens for treatment of tuberculosis was assessed in mice infected intravenously with 4." | 7.70 | Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens. ( Daniel, N; Geiter, LJ; Grosset, J; Hejblum, G; Ji, B; Lounis, N; O'Brien, RJ; Szpytma, M; Truffot-Pernot, C; Vernon, A, 2000) |
| "We report three patients who experienced hepatotoxic reactions in association with acetaminophen ingestion while undergoing treatment for active tuberculosis with isoniazid, rifampin, and other agents." | 7.69 | Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. ( Nelson, SD; Nolan, CM; Sandblom, RE; Slattery, JT; Thummel, KE, 1994) |
| "The effectiveness of intermittent administration of rifapentine (RPT), with or without isoniazid (INH), for preventive therapy of tuberculosis was evaluated in immunocompetent (normal) and nude mice." | 7.69 | Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. ( Chapuis, L; Grosset, JH; Ji, B; O'Brien, RJ; Raviglione, MC; Truffot-Pernot, C, 1994) |
| "The activity of pyrazinamide (PZA) against eight isolates of Mycobacterium tuberculosis in a murine infection model was evaluated." | 7.69 | Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility. ( Cynamon, MH; Klemens, SP; Sharpe, CA, 1996) |
| "The efficacies of rifampin-containing preventive regimens were measured in Cornell model mice in which an initially severe infection with Mycobacterium tuberculosis H37Rv was first treated for 7 weeks with 25 mg of isoniazid and 1,000 mg of pyrazinamide per kg of body weight in the diet and then with one of four test regimens given by daily oral gavage for 6 weeks." | 7.69 | Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. ( Dhillon, J; Dickinson, JM; Mitchison, DA; Sole, K, 1996) |
| "The combination of clarithromycin and pyrazinamide was found to be synergistic against Mycobacterium tuberculosis in human macrophages." | 7.69 | Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. ( Esfandiari, A; Mor, N, 1997) |
| "20 Patients of tuberculous pleural effusion were administered a combination of pyrazinamide (30 mg/kg) + isoniazid (300 mg) orally for 7 consecutive days and pyrazinamide was estimated by spectrophotometric method in serum and pleural fluid." | 7.68 | Alteration in the levels of pyrazinamide in pleural fluid following simultaneous administration of prednisoline in patients of tubercular pleural effusion. ( Bhargava, R; Singhal, KC; Wagay, AR, 1990) |
| "In a first experiment, the efficacy of a 6-month course of isoniazid (INH) alone in comparison with 2-month courses of rifampin (RMP) alone, RMP + pyrazinamide (PZA), or RMP + PZA + INH as preventive therapy of tuberculosis was evaluated in the mouse." | 7.67 | Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. ( Grosset, JH; Lecoeur, HF; Truffot-Pernot, C, 1989) |
| "The bioavailability of isoniazid, rifampin, and pyrazinamide in 2 combined formulations of the 3 drugs (Rifater) for use primarily in the short-course chemotherapy of tuberculosis has been studied in Chinese patients in Singapore and Hong Kong." | 7.67 | The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis. ( Allen, BW; Chan, SL; Ellard, DR; Ellard, GA; Girling, DJ; Ng, HK; Nunn, AJ; Tan, TH; Teo, SK, 1986) |
| "Results are presented of the incidence of hepatitis, nearly always with jaundice, among 1686 patients in clinical trials of the treatment of spinal tuberculosis, of tuberculosis meningitis and of pulmonary tuberculosis with short-course regimens containing rifampicin, isoniazid, streptomycin and pyrazinamide." | 7.67 | Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. ( Janardhanam, B; Parthasarathy, R; Ramachandran, P; Santha, T; Sarma, GR; Sivasubramanian, S; Somasundaram, PR; Tripathy, SP, 1986) |
| "Pyrazinamide (PZA) is an indispensable first-line drug used for the treatment of TB." | 6.53 | Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update. ( Guo, J; Mugweru, J; Njire, M; Tan, S; Tan, Y; Wang, C; Yew, W; Zhang, T, 2016) |
| "To re-evaluate pyrazinamide (PZA) which has been a key drug for short course anti-tuberculosis chemotherapy in the world, we started a clinical trial of short course chemotherapy containing PZA (2S (E) HRZ/EHR), and obtained information about the estimation of PZA in the tuberculosis specialists in Japan through a questionnaire." | 6.17 | [Re-evaluation of pyrazinamide]. ( Kajiki, A, 1994) |
| "Children with drug-susceptible tuberculosis in Malawi and South Africa underwent pharmacokinetic sampling while receiving first-line tuberculosis drugs as single formulations according the 2010 WHO recommended doses." | 5.72 | Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study. ( Bekker, A; Davies, G; Denti, P; Gonzalez-Martinez, C; Hesseling, AC; McIlleron, HM; Rabie, H; Svensson, EM; van der Laan, LE; van Rie, A; Wasmann, RE; Wiesner, L; Winckler, J; Zar, HJ, 2022) |
| "Pyrazinamide resistance was found in 6/80 (7." | 5.72 | Pyrazinamide resistance in rifampicin discordant tuberculosis. ( Mlisana, KP; Mvelase, NR; Singh, R; Swe Swe-Han, K, 2022) |
| "tuberculosis) is usually treated by oral antimycobacterial agents, including rifampicin, ethambutol, and pyrazinamide, but the treatment regimen with intravenous and/or intramuscular antimycobacterial agents for patients who cannot take medications orally remains unclear." | 5.72 | A Mycobacterium tuberculosis-Infected Patient Who Could Not Tolerate Oral Intake Successfully Treated Using an Intravenous Tedizolid-Containing Regimen. ( Kamoshita, F; Karaushi, H; Mitsutake, K; Miyawaki, Y; Seki, M; Watanabe, N, 2022) |
| "Pyrazinamide (PZA) has a controversial safety profile in older patients." | 5.62 | Safety of Pyrazinamide for the Treatment of Tuberculosis in Older Patients Over 75 Years of Age: A Retrospective Monocentric Cohort Study. ( Delobel, P; Derumeaux, H; Gandia, P; Guet-Revillet, H; Lafaurie, M; Le Grusse, J; Martin-Blondel, G; Nourhashemi, F; Protin, C; Rousset, S; Sailler, L; Sommet, A, 2021) |
| "Pyrazinamide (PZA) is an important component for short-course treatment regimens and first- and second-line treatment regimens." | 5.62 | An explainable machine learning platform for pyrazinamide resistance prediction and genetic feature identification of Mycobacterium tuberculosis. ( Alterovitz, G; Teng, L; Zhang, A, 2021) |
| "Isoniazid was later substituted with rifabutin in 2 patients with isoniazid-resistant tuberculosis." | 5.62 | Successful Use of Rifamycin-Sparing Regimens for the Treatment of Active Tuberculosis in Lung Transplant Recipients. ( Alameer, R; Almaghrabi, RS; Almohaizeie, A; Alrajhi, AA; Alshehri, N; Nizami, I; Omrani, AS, 2021) |
| "Pyrazinamide (PZA) is a common drug that causes serious adverse events (SAEs)." | 5.56 | The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis. ( Cho, YJ; Kim, Y; Kwon, BS; Lee, CT; Lee, JH; Lee, SH; Lee, YJ; Lim, SY; Park, JS; Yoon, HI, 2020) |
| "Increased dosing of rifampicin and pyrazinamide seems a viable strategy to shorten treatment and prevent relapse of drug-susceptible tuberculosis (TB), but safety and efficacy remains to be confirmed." | 5.51 | Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP). ( Alffenaar, JC; Augustinsson, D; Bornefall, A; Carlsson, B; Ekqvist, D; Fredrikson, M; Niward, K; Nordvall, MJ; Paues, J; Sandstedt, M; Simonsson, USH; Sönnerbrandt, M, 2022) |
| "Metformin (MET) is a potential combination drug to elevate anti-TB efficacy." | 5.51 | Metformin induced autophagy in diabetes mellitus - Tuberculosis co-infection patients: A case study. ( Ali, M; Mertaniasih, NM; Novita, BD; Pranoto, A; Soediono, EI, 2019) |
| "Pyrazinamide (PZA) is a key drug for current and future TB treatment regimens; however, it was reported that predictive power for PZA resistance by the available tools is low." | 5.51 | Overcoming the pitfalls of automatic interpretation of whole genome sequencing data by online tools for the prediction of pyrazinamide resistance in Mycobacterium tuberculosis. ( Aono, A; Arikawa, K; Iwamoto, T; Kato, K; Kato, S; Kuroda, M; Mitarai, S; Murase, Y; Sekizuka, T; Takii, T; Yamashita, A; Yoshida, S, 2019) |
| "Pyrazinamide clearance was higher in men than women." | 5.46 | Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation. ( Bisson, GP; Gumbo, T; Modongo, C; Pasipanodya, J; Ravimohan, S; Srivastava, S; Tamuhla, N; Vinnard, C; Weissman, D; Zetola, NM, 2017) |
| "Pyrazinamide (PZA) is a prodrug requiring conversion to pyrazinoic acid (POA) by an amidase encoded by pncA for in vitro activity." | 5.43 | High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis. ( Alland, D; Dartois, V; Lanoix, JP; Nuermberger, E; O'Brien, P; Pinn, M; Safi, H; Sarathy, J; Tasneen, R, 2016) |
| "46 μm, as measured by inertial impaction, for POA-leu and POA-NH4, respectively) and with properties (stoichiometric 1:1 ratio of salt to drug, melting points at ∼180 °C, with water content of <1%) that would support further development as an inhaled dosage form." | 5.42 | Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy. [Corrected]. ( Dhillon, J; Durham, PG; Fourie, PB; German, N; Hickey, AJ; Mitchison, DA; Mortensen, N; Zhang, Y, 2015) |
| "Hyperuricemia is frequently reported in adults, but there are few data for the pediatric population." | 5.42 | Is Hyperuricemia Overlooked when Treating Pediatric Tuberculosis Patients with Pyrazinamide? ( Aslan, AT; Budakoğlu, I; Şişmanlar, T, 2015) |
| " We included studies in children aged <18 years being treated for drug-susceptible tuberculosis with rifampicin (RIF), pyrazinamide, isoniazid, and ethambutol." | 5.41 | Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis. ( Béranger, A; Gegia, M; Linh, NN; Mirzayev, F; Mohamed, A; Nahid, P; Radtke, K; Savic, RM; Schumacher, SG; Solans, BP, 2023) |
| "Pyrazinamide (PZA) is an essential first-line tuberculosis drug for its unique mechanism of action active against multidrug-resistant-TB (MDR-TB)." | 5.41 | Global status of phenotypic pyrazinamide resistance in ( Ghanavati, R; Heidari, H; Kazemian, H; Koohsar, F; Kouhsari, E; Molaeipour, L; Tang, Z; Wang, Z, 2023) |
| "Pyrazinamide is a potent sterilising agent that shortens the treatment duration needed to cure tuberculosis." | 5.41 | Optimising pyrazinamide for the treatment of tuberculosis. ( Aarnoutse, R; Bliven-Sizemore, E; Boeree, MJ; Dooley, KE; Heinrich, N; Hoelscher, M; Mac Kenzie, W; Morlock, G; Peloquin, CA; Phillips, PPJ; Posey, J; Savic, RM; Stout, JE; Weiner, M; Whitworth, W; Zhang, N, 2021) |
| " However, further studies to identify the optimal statin and dosing are required." | 5.40 | Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. ( Bruiners, N; Gennaro, ML; Karakousis, PC; Pine, R; Pinn, ML; Skerry, C, 2014) |
| " Daily dosing of rifapentine (P), a potent rifamycin with high intracellular accumulation, in place of rifampin (R) in the standard antitubercular regimen significantly shortens the duration of treatment needed to prevent relapse in a murine model of active TB." | 5.38 | Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. ( Dutta, NK; Grosset, JH; Illei, PB; Karakousis, PC; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Pinn, ML, 2012) |
| "Clinical studies suggest that isoniazid contributes rapid bacterial killing during the initial two days of tuberculosis treatment but that isoniazid's activity declines significantly after day three." | 5.34 | Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial. ( Bishai, W; Dawson, R; De Jager, V; Diacon, A; Donahue, K; Fletcher, CV; Hafner, R; Hogg, E; Miyahara, S; Sun, X; Swindells, S; Urbanowski, M, 2020) |
| "Pyrazinamide liposomes were prepared employing the phospholipid molar ratios; dipalmitoyl phosphatidyl choline (7):cholesterol (2) neutral and dipalmitoyl phosphatidyl choline (7):cholesterol (2):dicetyl phosphate (1) negatively charged." | 5.34 | Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis. ( Abd El-Alim, S; El-Ridy, MS; Mostafa, DM; Nasr, EA; Shehab, A, 2007) |
| "Moxifloxacin is an 8-methoxyfluoroquinolone currently used in second-line regimens." | 5.34 | Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. ( Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, KN; Zhang, M, 2007) |
| "Evaluation of sources of pharmacokinetic variation can facilitate optimization of tuberculosis treatment regimens by identification of avoidable sources of variation and of risk factors for low or high drug concentrations in patients." | 5.33 | Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. ( Burger, A; Folb, PI; McIlleron, H; Norman, J; Smith, P; Wash, P, 2006) |
| "tuberculosis has transcriptional activity." | 5.31 | Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. ( Butcher, PD; Coates, AR; Dhillon, J; Hu, Y; Mangan, JA; Mitchison, DA; Sole, KM, 2000) |
| "The aim of the study was to compare plasma concentrations of rifampicin (RMP), isoniazid (INH) and pyrazinamide (PZA) between tuberculosis (TB) patients with and without diabetes mellitus (DM)." | 5.24 | Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus. ( Chandrasekaran, V; Kannan, T; Kumar, AK; Lavanya, J; Murali, AL; Ramachandran, G; Sudha, V; Swaminathan, S, 2017) |
| "Pyrazinamide (PZA) has remained a keystone of tuberculosis (TB) therapy, and it possesses high imperative sterilizing action that can facilitate reduction in the present chemotherapy regimen." | 5.22 | Mutations Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis: A Review and Update. ( Palaniyandi, K; Rajendran, A, 2022) |
| "We developed a Markov model of anti-tuberculosis treatment to compare two regimens for treating TB: a 6-month standard (rifampin-based) treatment and a 4-month regimen using high-dose RPT." | 5.22 | Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis. ( Hamilton, CD; Holland, DP; Stout, JE, 2016) |
| "The objective of this report was to study the pharmacokinetics of rifampin (RMP), isoniazid (INH), and pyrazinamide (PZA) in HIV-infected children with tuberculosis (TB) treated with a thrice-weekly anti-TB regimen in the government program in India." | 5.20 | Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. ( Banurekha, VV; Bhavani, PK; Dayal, R; Gangadevi, NP; Kannan, T; Kumar, AK; Kumar, SR; Mathevan, G; Ramachandran, G; Ravichandran, N; Sanjeeva, GN; Sekar, L; Swaminathan, S, 2015) |
| "To evaluate the efficacy and safety of a 6-month intermittent regimen of rifampin (RMP), pyrazinamide (PZA) and ethambutol (EMB) in human immunodeficiency virus (HIV) negative patients with culture-confirmed pulmonary or extra-pulmonary tuberculosis and either isoniazid (INH) resistance or INH intolerance." | 5.19 | Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. ( Bock, N; Bozeman, L; Goldberg, SV; Hamilton, CD; Heilig, CM; Hershfield, E; Kyle, RP; Narita, M; Reves, R; Tapy, JM; Wing, D, 2014) |
| "To evaluate the blood levels, pharma-cokinetics and pharmacodynamic indices of pyrazinamide (PZA) in children suffering from tuberculosis, at doses administered under the weight band system of Revised National Tuberculosis Control Program of India (RNTCP) of India." | 5.16 | Blood levels of pyrazinamide in children at doses administered under the Revised National Tuberculosis Control Program. ( Gupta, P; Khanna, A; Roy, V; Sahni, P; Sethi, GR, 2012) |
| " The aim of the study was to document the pharmacokinetics of the first-line anti-TB agents in children <2 years of age comparing previous and revised WHO dosages of isoniazid (INH; 5 versus 10 mg/kg/day), rifampin (RMP; 10 versus 15 mg/kg/day), and pyrazinamide (PZA; 25 versus 35 mg/kg/day) and to investigate the effects of clinical covariates, including HIV coinfection, nutritional status, age, gender, and type of tuberculosis (TB), and the effect of NAT2 acetylator status." | 5.15 | Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ( Donald, PR; Hesseling, AC; Magdorf, K; Roll, S; Rosenkranz, B; Schaaf, HS; Seddon, JA; Seifart, HI; Thee, S; Werely, CJ, 2011) |
| "To compare the efficacy of an intermittent 6-month regimen (Reg6M: 2EHRZ(3)/4HR(3) [ethambutol, 1,200 mg; isoniazid, 600 mg; rifampicin, 450 or 600 mg depending on body weight <60 or > or =60 kg; and pyrazinamide, 1,500 mg for 2 mo; followed by 4 mo of isoniazid and rifampicin at the same doses]) versus a 9-month regimen (Reg9M: 2EHRZ(3)/7HR(3)) in HIV/tuberculosis (TB)." | 5.14 | Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. ( Chinnaiyan, P; Iliayas, S; Menon, PA; Narayanan, PR; Narendran, G; Padmapriyadarsini, C; Ramachandran, R; Sakthivel, R; Santhanakrishnan, R; Suhadev, M; Swaminathan, S; Venkatesan, P, 2010) |
| " According to the findings of the present study, all 3 of the potentially hepatotoxic drugs (isoniazid, rifampicin, and pyrazinamide) can be reintroduced simultaneously at full dosage safely from day 1, especially for patients with bilateral extensive pulmonary tuberculosis, to halt disease transmission or to treat patients with life-threatening tuberculosis." | 5.14 | Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. ( Jayaswal, A; Makharia, G; Mohan, A; Sarda, P; Sharma, SK; Singh, S; Singla, R; Sreenivas, V, 2010) |
| "To evaluate the pharmacokinetics and pharmacodynamic indices of pyrazinamide at doses of 15 and 25 mg kg(-1) in children suffering from tuberculosis." | 5.13 | Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses. ( Gupta, P; Mishra, TK; Roy, V; Sethi, GR, 2008) |
| "Pyrazinamide (PZA) is an important component of a standard combination therapy against tuberculosis." | 5.12 | Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug. ( Hussain, Z; Ma, X; Zhu, J, 2021) |
| "Two months of treatment with rifampin-pyrazinamide (RZ) and 9 months of treatment with isoniazid are both recommended for treatment of latent tuberculosis infection in adults without human immunodeficiency virus infection, but the relative cost-effectiveness of these 2 treatments is unknown." | 5.11 | Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial. ( Bernardo, J; Daley, CL; Hopewell, PC; Jasmer, RM; Kawamura, LM; King, MD; Saukkonen, JJ; Snyder, DC, 2004) |
| "We evaluated the effects of human immunodeficiency virus (HIV) disease on pharmacokinetics of antituberculosis medications by measuring concentrations of isoniazid and rifampin in blood and of pyrazinamide and ethambutol in urine." | 5.11 | Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. ( Bhagavathy, S; Gurumurthy, P; Hemanth Kumar, AK; Mahilmaran, A; Padmapriyadarsini, C; Paramesh, P; Rajasekaran, S; Ramachandran, G; Ravichandran, N; Sekar, L; Swaminathan, S; Venkatesan, P, 2004) |
| "To determine the rates of hepatotoxicity and treatment completion associated with intermittent rifampin and pyrazinamide (RZ) therapy for latent tuberculosis infection, we evaluated a cohort of patients from a targeted tuberculin testing site in Tennessee." | 5.11 | Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program. ( Haley, CA; Hoy, DP; Priest, DH; Sherfy, EA; Vossel, LF, 2004) |
| "A higher incidence of hepatotoxicity was associated with rifampin plus pyrazinamide than isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong." | 5.10 | Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. ( Chan, CK; Chang, KC; Law, WS; Leung, CC; Tam, CM; Wong, MY; Yew, WW, 2003) |
| "To determine population pharmacokinetic parameters of pyrazinamide after multiple oral doses given to children and adults with tuberculosis." | 5.10 | Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. ( Ashkin, D; Berning, SE; Bulpitt, AE; Burman, WJ; Peloquin, CA; Stambaugh, JJ; Starke, JR; Steiner, P; Zhu, M, 2002) |
| "To compare a 2-month regimen of daily rifampin and pyrazinamide with a 12-month regimen of daily isoniazid in preventing tuberculosis in persons with human immunodeficiency virus (HIV) infection." | 5.09 | Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O ( Barry, MA; Chaisson, RE; Coberly, J; de Lourdes Garcia, M; Gordin, F; Hafner, R; Klukowicz, AJ; Matts, JP; Miller, C; O'Brien, RJ; Schechter, M; Valdespino, JL, 2000) |
| "To test the hypothesis that antituberculous drug disposition is altered in patients with AIDS, we studied the steady-state pharmacokinetics of isoniazid (300 mg/d), rifampin (600 mg/d), and pyrazinamide (1,500 mg/d) in 29 adults (14 patients infected with human immunodeficiency virus [HIV] and 15 non-HIV-infected patients) with tuberculosis in Nairobi, Kenya." | 5.08 | Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. ( Aoki, FY; Choudhri, SH; Gathua, S; Hawken, M; Long, R; Minyiri, GO; Sahai, J; Sitar, DS; Watkins, W, 1997) |
| "To characterize the susceptibility to levofloxacin of clinical isolates of Mycobacterium tuberculosis (MTB) obtained from patients with HIV-related tuberculosis and to characterize the molecular genetics of levofloxacin resistance." | 5.08 | Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinica ( Chirgwin, K; El Sadr, WM; Hafner, R; Heifets, LB; Klein, O; Kreiswirth, BN; Matts, JP; Musser, JM; Nelson, ET; Perlman, DC; Salomon, N; Telzak, EE, 1997) |
| " Adults in the Cape Town municipal area with a first episode of pulmonary tuberculosis were treated either with Rifater or a regimen consisting of isoniazid, rifampicin, pyrazinamide and ethambutol." | 5.07 | Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town. ( Bohmer, PD; Macnab, MF; Seager, JR, 1994) |
| "Short-course chemotherapy of six-month duration with an initial combination of three drugs (isoniazid [H], rifampin [R] and pyrazinamide [Z]) is recommended as the treatment of choice in tuberculosis today." | 5.07 | [Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide]. ( Brändli, O; Dreher, D; Morger, D, 1993) |
| "In a study in Singapore, patients of Chinese, Malay, or Indian ethnic origin with sputum-smear-positive pulmonary tuberculosis received 2 months of daily treatment with streptomycin, isoniazid, rifampin, and pyrazinamide followed by daily isoniazid and rifampin, either with or without pyrazinamide, allocated at random." | 5.06 | Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. ( , 1986) |
| " Recently, we discovered that an antibacterial drug, the anti-tuberculosis antibiotic pyrazinamide, functions as a promotor of degradation of its bacterial target." | 5.05 | Targeted protein degradation in antibacterial drug discovery? ( Dick, T; Gopal, P, 2020) |
| "Inclusion of pyrazinamide (PZA) in the tuberculosis (TB) drug regimen during the 1970s enabled a reduction in treatment duration from 12 to 6 months." | 5.01 | Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide. ( Dartois, V; Dick, T; Gopal, P; Grüber, G, 2019) |
| "To compare the incidence of severe hepatitis in HIV-infected patients receiving rifampicin plus pyrazinamide (RZ) for antituberculosis prophylaxis with that of patients receiving a conventional isoniazid-based regime for 6 to 12 months (6-12H)." | 4.86 | [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials]. ( Camacho, A; Castón, JJ; Gallo, M; García-Lázaro, M; Kindelán, JM; Natera, C; Pérez-Camacho, I; Rivero, A; Torre-Cisneros, J, 2010) |
| "The cornerstone of tuberculosis management is a 6-month course of isoniazid, rifampicin, pyrazinamide and ethambutol." | 4.84 | Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. ( Aarnoutse, RE; Boeree, MJ; de Lange, WC; Dekhuijzen, R; Tostmann, A; van der Ven, AJ, 2008) |
| " isoniazid (INH) for the prevention of tuberculosis (TB) among persons with or without human immunodeficiency virus (HIV) infection." | 4.83 | Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. ( Gao, XF; Li, YP; Liu, GJ; Sun, X; Wang, L; Wen, J; Xie, Y, 2006) |
| "Isoniazid, pyrazinamide and rifampicin have hepatotoxic potential, and can lead to such reactions during antituberculosis chemotherapy." | 4.83 | Antituberculosis drugs and hepatotoxicity. ( Leung, CC; Yew, WW, 2006) |
| "Pyrazinamide (PZA) is an important front line anti-tuberculosis drug because of its sterilizing activity against semi-dormant tubercle bacilli." | 4.83 | The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria. ( Chauhan, DS; Katoch, VM; Malonia, SK; Mishra, AK; Sharma, VD; Singh, P; Venkatesan, K, 2006) |
| "Site-of-action concentrations for bedaquiline and pretomanid from tuberculosis patients are unavailable." | 4.31 | Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic Modeling. ( Guo, T; Mehta, K; van der Graaf, PH; van Hasselt, JGC, 2023) |
| "Data on protein binding are incomplete for first-line antituberculosis drugs, and lacking for second-line antituberculosis drugs that are used extensively for multi-drug-resistant tuberculosis (levofloxacin, linezolid and moxifloxacin)." | 4.31 | Protein binding investigation of first-line and second-line antituberculosis drugs. ( Aalhoul, F; Cotton, F; Fage, D, 2023) |
| "We used nonlinear mixed-effects modeling to characterize the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide, and investigated the association of human immunodeficiency virus (HIV), antiretroviral therapy (ART), drug formulation, age, and body size with their pharmacokinetics." | 4.31 | Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis. ( Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H, 2023) |
| " Here, two murine models of tuberculosis were used to test whether novel regimens replacing rifapentine and isoniazid with bedaquiline and another drug would maintain or increase the sterilizing activity of the regimen." | 4.12 | Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. ( Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD, 2022) |
| "The chemotherapeutic regimens of patients with drug-susceptible (DS)- tuberculosis (TB) comprise four primary anti-TB drugs: rifampicin (RMP), isoniazid (INH), ethambutol (EMB) and pyrazinamide (PZA), administered for six-to-nine months." | 4.12 | Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro. ( Anderson, R; Cholo, MC; Mashele, SA; Matjokotja, MT; Rasehlo, SSM; Steel, HC, 2022) |
| "Pyrazinamide (PZA) is one of the first-line anti-tuberculous drugs used in the treatment of tuberculosis (TB)." | 4.12 | [Investigation of pncA, rpsA and panD Gene Mutations Associated with Resistance in Pyrazinamide-Resistant Mycobacterium tuberculosis Isolates and Spoligotyping]. ( Aslan, G; Aslantürk, A; Biçmen, C; Kayar, MB; Özgür, D; Tezcan Ülger, S; Ülger, M, 2022) |
| "Pyrazinamide is one of the first-line antituberculosis drugs." | 4.12 | Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis. ( Abolhassani-Chimeh, R; Akkerman, OW; Alffenaar, JC; Bolhuis, MS; Kosterink, JGW; Punt, NC; Saktiawati, AMI; Sturkenboom, MGG; Subronto, YW; van der Werf, TS, 2022) |
| "TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China." | 4.12 | Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. ( Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H, 2022) |
| " The anti-tuberculosis (anti-TB) drug pyrazinamide (PZA) was successfully intercalated into interlayer galleries of MgLH, resulting in the formation of the nanocomposite, PZA-MgLH, having an average size of about 107 ± 24 nm with a uniform circular shape." | 4.12 | Development of a novel anti-tuberculosis nanodelivery formulation using magnesium layered hydroxide as the nanocarrier and pyrazinamide as a model drug. ( Arulselvan, P; Bullo, N; El Zowalaty, ME; Fakurazi, S; Hussein, MZ; Saifullah, B; Webster, TJ, 2022) |
| "Mycobacterium tuberculosis-infected mice were treated for up to 13 weeks with bedaquiline and pretomanid combined with moxifloxacin and pyrazinamide (BPaMZ) or linezolid (BPaL)." | 4.12 | Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data. ( Ayoun Alsoud, R; Bax, HI; de Steenwinkel, JEM; Lotlikar, MU; Mudde, SE; Simonsson, USH; Upton, AM; van der Meijden, A, 2022) |
| " Therefore, to satisfy the need for comprehensive monitoring of anti-tuberculosis drugs in human plasma, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for simultaneous quantification of first-line anti-tuberculosis drugs (ethambutol, isoniazid, pyrazinamide, and rifampicin) along with their six primary metabolites." | 4.02 | LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: Implications for therapeutic drug monitoring. ( Bandere, D; Cirule, A; Grinberga, S; Igumnova, V; Kivrane, A; Krams, A; Pole, I; Pugovics, O; Ranka, R; Sevostjanovs, E; Viksna, A, 2021) |
| "Pyrazinamide (PZA) plays a crucial role in first-line tuberculosis drug therapy." | 4.02 | Pyrazinamide Susceptibility Is Driven by Activation of the SigE-Dependent Cell Envelope Stress Response in Mycobacterium tuberculosis. ( Aflakpui, R; Baughn, AD; Dillon, NA; Hoffner, SE; Howe, MD; Minato, Y; Modlin, SJ; Thiede, JM; Valafar, F, 2021) |
| "We compared the efficacy of an all oral DR tuberculosis drug regimen consisting of bedaquiline (25 mg/kg), delamanid (2." | 4.02 | Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model. ( Bax, HI; de Steenwinkel, JEM; Keutzer, L; Pieterman, ED; Simonsson, USH; van den Berg, S; van der Meijden, A; Wang, H; Zimmerman, MD, 2021) |
| "Pyrazinamide is a first-line drug used in the treatment of tuberculosis." | 4.02 | Factors Affecting the Pharmacokinetics of Pyrazinamide and Its Metabolites in Patients Coinfected with HIV and Implications for Individualized Dosing. ( Äbelö, A; Ashton, M; Bienvenu, E; Hoffmann, KJ; Sundell, J; Wijk, M, 2021) |
| "Pyrazinamide has been a mainstay in the multidrug regimens used to treat tuberculosis." | 3.96 | The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD. ( Li, X; Perez, LM; Sacchettini, JC; Shi, W; Sun, Q; Zhang, Y, 2020) |
| "Pyrazinamide plays an important role in tuberculosis treatment; however, its use is complicated by side-effects and challenges with reliable drug susceptibility testing." | 3.96 | Structure guided prediction of Pyrazinamide resistance mutations in pncA. ( Ascher, DB; Denholm, JT; Horan, K; Karmakar, M; Rodrigues, CHM, 2020) |
| "Pyrazinamide is a sterilizing first-line tuberculosis drug." | 3.96 | Pyrazinamide triggers degradation of its target aspartate decarboxylase. ( Akopian, T; Bhushan, S; Dick, T; Gengenbacher, M; Gopal, P; Grüber, G; Kandror, O; Lim, TK; Lin, Q; Ragunathan, P; Rubin, EJ; Sarathy, JP; Shin, J; Yee, M; Zhu, J, 2020) |
| "In order to determine the characteristics of drug-induced liver injury (DILI), adult patients diagnosed with tuberculosis and with an anti-tuberculosis treatment scheme including pyrazinamide were studied." | 3.96 | Clinical characteristics of pyrazinamide-associated hepatotoxicity in patients at a hospital in Lima, Peru. ( Amado, J; Moscol, S; Oscanoa, T, 2020) |
| "Calcitriol alone had little effect on tuberculosis infection, whereas PZA, compared with saline control treatment, decreased the bacterial burden (spleens: PZA vs." | 3.91 | Calcitriol enhances pyrazinamide treatment of murine tuberculosis. ( Bao, R; Dai, M; Guo, M; Huang, ZX; Rao, Y; Wang, X; Yu, Q; Zhang, J, 2019) |
| "Regimens that could treat both rifampin-resistant (RR) and rifampin-susceptible tuberculosis (TB) while shortening the treatment duration have reached late-stage clinical trials." | 3.91 | Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations. ( Cook-Scalise, S; Denkinger, CM; Dowdy, DW; Kendall, EA; Malhotra, S, 2019) |
| "Pyrazinamide (PZA) is a key component of current and future regimens for tuberculosis (TB)." | 3.91 | The impact of inclusion, dose and duration of pyrazinamide (PZA) on efficacy and safety outcomes in tuberculosis: systematic review and meta-analysis protocol. ( Bonnett, LJ; Davies, GR; Mackay, EA; Millard, JD, 2019) |
| " Subjects who experienced hypersensitivity reactions, including maculopapular exanthema (MPE) and drug reaction with eosinophilia and systemic symptoms (DRESS), to first-line anti-tuberculosis medications (isoniazid [INH], ethambutol [EMB], rifampin [RFP], and pyrazinamide [PZA]) were enrolled." | 3.91 | Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications. ( Ban, GY; Jeong, YJ; Kim, SH; Lee, SH; Park, HS; Shin, SS; Shin, YS; Ye, YM, 2019) |
| "Pyrazinamide (PZA) is an important component of first-line drugs because of its distinctive capability to kill subpopulations of persistent Mycobacterium tuberculosis (MTB)." | 3.91 | Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan. ( Afzal, MT; Ali, S; Khan, AS; Khan, MT; Malik, SI; Masood, N; Nadeem, T, 2019) |
| " We estimated tuberculosis treatment outcomes in children younger than 5 years following WHO guidelines (children are dosed by weight bands corresponding to the number of fixed-dose combination tablets [75 mg rifampicin, 50 mg isoniazid, 150 mg pyrazinamide]) and two alternative dosing strategies: one based on a proposed algorithm that uses age, weight, and available formulations, in which underweight children would receive the same drug doses as would normal weight children of the same age; and another based on an individualised algorithm without dose limitations, in which derived doses results in target exposure attainment for the typical child." | 3.91 | Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study. ( Dodd, PJ; Dooley, KE; Garcia-Prats, AJ; Hesseling, AC; McKenna, L; Radtke, KK; Savic, RM, 2019) |
| "We aim to optimize the paediatric dosing regimen of isoniazid, rifampicin and pyrazinamide for the first-line treatment of tuberculosis, based on a fixed dose combination (FDC) mini-tablet using simulations." | 3.91 | Optimization of a paediatric fixed dose combination mini-tablet and dosing regimen for the first line treatment of tuberculosis. ( Dokoumetzidis, A; Nalda-Molina, R; Sfouni, M; Tsiligiannis, A, 2019) |
| "The classic fixed-dose combination (FDC) of 4 tuberculosis drugs, namely rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA), and ethambutol dihydrochloride (EDH) has the twin issues of physical stability and RIF cross-reaction in the 4-FDC." | 3.88 | Improved Stability of Tuberculosis Drug Fixed-Dose Combination Using Isoniazid-Caffeic Acid and Vanillic Acid Cocrystal. ( Battini, S; Mannava, MKC; Nangia, A, 2018) |
| "The 4-drug regimen of rifampin, isoniazid, pyrazinamide, and ethambutol is an inexpensive, reliable option for treating patients with drug-susceptible tuberculosis (TB)." | 3.88 | Protein Binding of First-Line Antituberculosis Drugs. ( Al-Shaer, MH; Alghamdi, WA; Peloquin, CA, 2018) |
| "In the 1970s, inclusion of pyrazinamide (PZA) in the drug regimen of tuberculosis (TB) patients for the first 2 mo achieved a drastic reduction of therapy duration." | 3.88 | Impact of immunopathology on the antituberculous activity of pyrazinamide. ( Alvarez Cabrera, N; Blanc, L; Dartois, V; Dias-Freedman, I; Dick, T; Gengenbacher, M; Ioerger, T; Mina, M; O'Brien, P; Podell, BK; Prideaux, B; Sacchettini, J; Sarathy, JP; Savic, RM, 2018) |
| "We obtained whole-genome sequences and associated phenotypes of resistance or susceptibility to the first-line antituberculosis drugs isoniazid, rifampin, ethambutol, and pyrazinamide for isolates from 16 countries across six continents." | 3.88 | Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. ( Allix-Béguec, C; Arandjelovic, I; Beckert, P; Bi, L; Bonnet, M; Bradley, P; Cabibbe, AM; Cancino-Muñoz, I; Caulfield, MJ; Chaiprasert, A; Cirillo, DM; Clifton, DA; Comas, I; Crook, DW; De Filippo, MR; de Neeling, H; Diel, R; Drobniewski, FA; Faksri, K; Farhat, MR; Fleming, J; Fowler, P; Fowler, TA; Gao, Q; Gardy, J; Gascoyne-Binzi, D; Gibertoni-Cruz, AL; Gil-Brusola, A; Golubchik, T; Gonzalo, X; Grandjean, L; Guthrie, JL; He, G; Hoosdally, S; Hunt, M; Iqbal, Z; Ismail, N; Johnston, J; Khanzada, FM; Khor, CC; Kohl, TA; Kong, C; Lipworth, S; Liu, Q; Maphalala, G; Martinez, E; Mathys, V; Merker, M; Miotto, P; Mistry, N; Moore, DAJ; Murray, M; Niemann, S; Omar, SV; Ong, RT; Peto, TEA; Posey, JE; Prammananan, T; Pym, A; Rodrigues, C; Rodrigues, M; Rodwell, T; Rossolini, GM; Sánchez Padilla, E; Schito, M; Shen, X; Shendure, J; Sintchenko, V; Sloutsky, A; Smith, EG; Snyder, M; Soetaert, K; Starks, AM; Supply, P; Suriyapol, P; Tahseen, S; Tang, P; Teo, YY; Thuong, TNT; Thwaites, G; Tortoli, E; van Soolingen, D; Walker, AS; Walker, TM; Wilcox, M; Wilson, DJ; Wyllie, D; Yang, Y; Zhang, H; Zhao, Y; Zhu, B, 2018) |
| "We mimicked the concentration-time profiles achieved by human equivalent doses of moxifloxacin 800 mg/day, rifampin 1800 mg/day, and pyrazinamide 4000 mg/day (high-dose regimen) vs isoniazid 300 mg/day, rifampin 600 mg/day, and pyrazinamide 2000 mg/day (standard therapy) in bactericidal and sterilizing effect studies in the hollow fiber system model of tuberculosis (HFS-TB)." | 3.88 | Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet! ( Deshpande, D; Gumbo, T; Magombedze, G; Srivastava, S, 2018) |
| "Despite the importance of pyrazinamide (PZA) in tuberculosis treatment, PZA susceptibility testing is not routinely performed because of its acid pH requirement." | 3.85 | Detection of pyrazinamide resistance of Mycobacterium tuberculosis using nicotinamide as a surrogate. ( Fu, Y; Hu, Y; Huang, H; Li, Y; Liang, Q; Luo, J; Ma, Y; Shang, Y; Wu, X; Zhao, L, 2017) |
| "Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 3.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
| "Pyrazinamide (PZA) plays a unique role in the treatment for multidrug-resistant tuberculosis (MDR-TB) in both first- and second-line regimens." | 3.85 | Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. ( Hu, Y; Liu, J; Pang, Y; Shen, J; Zhao, Y; Zheng, H; Zhu, D, 2017) |
| "Through mutant selection on agar containing pyrazinoic acid (POA), the bioactive form of the prodrug pyrazinamide (PZA), we recently showed that missense mutations in the aspartate decarboxylase PanD and the unfoldase ClpC1, and loss-of-function mutation of polyketide synthases Mas and PpsA-E involved in phthiocerol dimycocerosate synthesis, cause resistance to POA and PZA in Mycobacterium tuberculosis." | 3.85 | In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1. ( Dartois, V; Dick, T; Gopal, P; Lanoix, JP; Li, L; Nuermberger, E; Rasic, G; Sarathy, J; Tasneen, R; Yee, M, 2017) |
| "To compare the pharmacokinetics of rifampicin (RMP), isoniazid (INH) and pyrazinamide (PZA) between HIV-infected and HIV-uninfected children with tuberculosis (TB) and correlate it with TB treatment outcome." | 3.83 | Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status. ( Agarwal, D; Banurekha, VV; Bhavani, PK; Gangadevi, NP; Kalpana, S; Kannan, T; Kumar, AK; Kumar, SR; Mathevan, G; Ramachandran, G; Ravichandran, N; Sanjeeva, GN; Sudha, V; Swaminathan, S; Venkatesh, S, 2016) |
| "Experimental and clinical studies have indicated that the antileprosy drug clofazimine may contribute treatment-shortening activity when included in tuberculosis treatment regimens." | 3.83 | Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy. ( Adamson, J; Almeida, DV; Ammerman, NC; Bester, LA; Dorasamy, A; Grosset, JH; Mgaga, Z; Moodley, C; Moodley, S; Ngcobo, B; Singh, SD; Swanson, RV, 2016) |
| "To investigate the clinical characteristics, adverse drug reactions, and outcomes of the oldest old patients (aged ≥80 years) with tuberculosis (TB) treated with rifampicin, isoniazid, and pyrazinamide (RIP)-containing regimens." | 3.83 | The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide. ( Chang, PJ; Cheng, CW; Chou, YL; Lin, HS; Lin, JC; Lin, MS; Ye, JJ, 2016) |
| "For the past decades, an acidic pH has been used to render Mycobacterium tuberculosis susceptible to pyrazinamide for in vitro testing." | 3.83 | Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature. ( Anthony, RM; den Hertog, AL; Menting, S; Pfeltz, R; Siddiqi, SH; Warns, M, 2016) |
| "To study the pharmacokinetics of rifampicin (RMP), isoniazid (INH) and pyrazinamide (PZA) in adult tuberculosis (TB) patients and examine factors that influence drug pharmacokinetics." | 3.83 | Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India. ( Chandrasekaran, V; Hemanth Kumar, AK; Kannan, T; Lavanya, J; Ramachandran, G; Ramesh, K; Sudha, V; Swaminathan, S; Vijayakumar, A, 2016) |
| "Pyrazinamide (PZA) is a critical component of first- and second-line treatments of tuberculosis (TB), yet its mechanism of action largely remains an enigma." | 3.83 | Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis. ( Dartois, V; Dick, T; Gengenbacher, M; Gopal, P; Kaya, F; Low, JL; Sarathy, J; Sarathy, JP; Yee, M, 2016) |
| "We prospectively examined the incidence of drug-induced hepatitis in 2070 patients treated for TB with the standard regimen based on 6 months of rifampicin (R, RMP) and isoniazid (H, INH), with 2 months of initial pyrazinamide (Z, PZA) and ethambutol (E, EMB), over a 30-year period from 1981 to 2010, in Blackburn, UK." | 3.83 | Drug-related hepatitis in patients treated with standard anti-tuberculosis chemotherapy over a 30-year period. ( Bright-Thomas, RJ; Gondker, AR; Morris, J; Ormerod, LP, 2016) |
| "Pyrazinamide (PZA), an important first-line drug for anti-tuberculosis treatment, demonstrates potent activity against semi-dormant bacilli in acidic environments." | 3.81 | Mutations in the pncA and rpsA genes among 77 Mycobacterium tuberculosis isolates in Kazakhstan. ( Abildaev, T; Akhmetova, A; Bismilda, V; Chingissova, L; Dymova, M; Filipenko, M; Kozhamkulov, U; Ramanculov, E, 2015) |
| "The World Health Organization recommends for tuberculosis retreatment a regimen of isoniazid (H), rifampicin (R), ethambutol (E), pyrazinamide (Z), and streptomycin (S) for 2 months, followed by H, R, E, and Z for 1 month and H, R, and E for 5 months." | 3.81 | High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study. ( Acuña-Villaorduña, C; Ayakaka, I; Dryden-Peterson, S; Fennelly, KP; Hosford, J; Jones-López, EC; Nakubulwa, S; Okwera, A; Reilly, N; Worodria, W, 2015) |
| "Pyrazinamide (PZA) is one the first line anti-tuberculosis drugs that require activation by the pyrazinamidase (PZase)." | 3.81 | Biochemical Characterization and Computational Identification of Mycobacterium tuberculosis Pyrazinamidase in Some Pyrazinamide-Resistant Isolates of Iran. ( Chaparzadeh, N; Doustdar, F; Falahati, H; Mehrnejad, F; Mir-Derikvand, M; Pazhang, M; Rabiei, D; Safarzadeh, M, 2015) |
| " The major revision was to increase isoniazid, rifampicin and pyrazinamide dosages according to body weight in children." | 3.81 | The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children. ( Gie, RP; Graham, SM; Grzemska, M, 2015) |
| "To compare the free and total plasma drug concentrations of rifampicin (RMP), isoniazid and pyrazinamide in subjects with or without anti-tuberculosis drug-induced hepatotoxicity (DIH)." | 3.80 | Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. ( Biswas, A; Makharia, GK; Satyaraddi, A; Sharma, A; Sharma, SK; Singh, S; Sinha, S; Sirohiwal, A; Velpandian, T; Vishnubhatla, S, 2014) |
| "We used previously published data for 76 South African children with tuberculosis to describe the population pharmacokinetics of rifampicin, pyrazinamide and isoniazid." | 3.80 | Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. ( Denti, P; Donald, PR; McIlleron, HM; Schaaf, HS; Seddon, JA; Seifart, HI; Simonsson, US; Smith, PJ; Thee, S; Zvada, SP, 2014) |
| "Pyrazinamide (PZA) is a first line agent for the treatment of active tuberculosis." | 3.80 | Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California. ( Budzik, JM; Grinsdale, J; Higashi, J; Hopewell, PC; Jarlsberg, LG; Kato-Maeda, M; Nahid, P, 2014) |
| "Monoresistance to pyrazinamide (PZA) has infrequently been associated with Mycobacterium tuberculosis." | 3.80 | Outbreak of pyrazinamide-monoresistant tuberculosis identified using genotype cluster and social media analysis. ( Heysell, SK; Houpt, ER; Keller, SJ; Moore, JL; Thomas, TA, 2014) |
| "To investigate the effect of natural pyrazinamidase (PncA) mutations on protein function, we analyzed expression and PncA activity of eight pncA point mutants identified in nineteen pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates." | 3.80 | Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Korea and analysis of the correlation between the mutations and pyrazinamidase activity. ( Kim, KJ; Nam, JS; Ro, YT; Yoon, JH, 2014) |
| " in a recent issue of this Journal address one of the current debates regarding the potential role of thioridazine in the treatment of tuberculosis." | 3.80 | Thioridazine for treatment of tuberculosis: promises and pitfalls. ( Dutta, NK; Karakousis, PC, 2014) |
| "Pyrazinamide (PZA) is a prodrug that is converted to pyrazinoic acid by the enzyme pyrazinamidase, encoded by the pncA gene in Mycobacterium tuberculosis." | 3.80 | Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. ( Ambrosi, A; Augustynowicz-Kopeć, E; Bakonyte, D; Cabibbe, AM; Casali, N; Cirillo, DM; Degano, M; Drobniewski, F; Feuerriegel, S; Hoffner, S; Mansjö, M; Miotto, P; Niemann, S; Pimkina, E; Rodionova, Y; Rüsch-Gerdes, S; Stakenas, P; Werngren, J, 2014) |
| "Assessment of the activity of thioridazine towards Mycobacterium tuberculosis (Mtb), in vitro and in vivo as a single drug and in combination with tuberculosis (TB) drugs." | 3.80 | Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. ( Aarnoutse, R; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; ten Kate, MT; van Soolingen, D, 2014) |
| "It has been widely accepted, that pyrazinamide (PZA) resistance in Mycobacterium tuberculosis is correlated with mutations in the pncA gene." | 3.79 | Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene. ( Bhuju, S; de Oliveira Vieira, GB; Fonseca, Lde S; Marsico, AG; Saad, MH; Singh, M; Sobral, LF; Stehr, M, 2013) |
| "Pyrazinamide is one of the first line four drugs for treatment of tuberculosis." | 3.79 | Study of pyrazinamidase structural changes in pyrazinamide resistant and susceptible isolates of Mycobacterium tuberculosis. ( Ahmady, A; Arjomandzadegan, M; Kahbazi, M; Poolad, T; Rafee, P; Tousheh, M, 2013) |
| "Pyrazinamide (PZA) is a key drug in the treatment of tuberculosis (TB), including multidrug-resistant TB." | 3.79 | Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience. ( Angeby, K; Hoffner, S; Johansson, A; Jönsson, B; Sellin, M; Sturegård, E; Werngren, J, 2013) |
| "Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6) polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in HIV/tuberculosis-coinfected (HIV/TB) patients is unavailable." | 3.79 | Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. ( Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S, 2013) |
| "Pyrazinamide is important in the treatment of tuberculosis." | 3.78 | Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. ( Boeree, MJ; Dekhuijzen, PN; Mulder, A; Simons, SO; van der Laan, T; van Ingen, J; van Soolingen, D, 2012) |
| "2% of all tuberculosis (TB) isolates from Canadian-born patients are resistant to pyrazinamide (PZA) alone." | 3.78 | Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec. ( Brassard, P; Menzies, D; Yee, DP, 2012) |
| "The optimal management strategy for patients with isoniazid (INH) monoresistant forms of tuberculosis (TB) has been widely debated." | 3.78 | Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. ( Cohen, T; Furin, J; Gegia, M; Kalandadze, I; Vashakidze, L, 2012) |
| "Pyrazinamide (PZA) is an important component of first-line therapy for the treatment of tuberculosis." | 3.78 | Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA. ( Alexander, DC; Blair, J; Chedore, P; Guthrie, JL; Jamieson, FB; Ma, JH, 2012) |
| "Standard tuberculosis (TB) treatment includes an initial regimen containing drugs that are both rapidly bactericidal (isoniazid) and sterilizing (rifampin and pyrazinamide), and ethambutol to help prevent the emergence of drug resistance." | 3.78 | Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. ( Almeida, D; Ammerman, NC; Bishai, WR; Converse, PJ; Grosset, J; Hafner, R; Lalloo, U; Li, SY; Pym, AS; Swindells, S; Tyagi, S; Wallengren, K, 2012) |
| "To study the efficacy and safety of Category III DOTS treatment (intermittent thrice-weekly rifampicin [RMP], isoniazid [INH] and pyrazinamide for 2 months, followed by RMP and INH for 4 months) under India's Revised National Tuberculosis Control Programme in patients with uncomplicated small unilateral pleural effusion (<1500 ml)." | 3.78 | Outcomes of Category III DOTS treatment in immunocompetent patients with tuberculosis pleural effusion. ( Chauhan, LS; Jain, NK; Mohan, A; Sharma, SK; Solanki, R, 2012) |
| "Pyrazinamide is an essential component of first line anti-tuberculosis regimen as well as most of the second line regimens." | 3.78 | Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis. ( Ahmad, Z; Almeida, D; Baughn, AS; Grosset, JH; Jacobs, WR; Minkowsk, A; Nuermberger, EL; Peck, KM; Tyagi, S; Welch, JT, 2012) |
| "All tested methods in this preliminary study showed excellent sensitivity and specificity for the determination of pyrazinamide susceptibility of M." | 3.77 | Rapid detection of resistance to pyrazinamide in Mycobacterium tuberculosis using the resazurin microtitre assay. ( Campanerut, PA; Cardoso, RF; Ghiraldi, LD; Hirata, MH; Hirata, RD; Leite, CQ; Sato, DN; Spositto, FL, 2011) |
| " Between day 52 and 5 mo after infection, 10 of the 170 mice infected according to this protocol developed torticollis, including mice in treatment groups that received combination antibiotic therapy of rifampin-pyrazinamide or moxifloxacin-rifampin-pyrazinamide." | 3.77 | Torticollis in mice intravenously infected with Mycobacterium tuberculosis. ( DeGroote, MA; Gilliland, JC; Kendall, LV; Lenaerts, AJ; Magden, ER; Weiner, CM, 2011) |
| "The microscopic observation drug susceptibility assay (MODS) was evaluated to determine susceptibility to pyrazinamide in Mycobacterium tuberculosis, and compared with the broth microdilution method (BMM), absolute concentration method (ACM), and pyrazinamidase (PZase) determination." | 3.77 | Evaluation of the microscopic observation drug susceptibility assay for detection of Mycobacterium tuberculosis resistance to pyrazinamide. ( Campanerut, PA; Cardoso, RF; Ghiraldi, LD; Hirata, M; Hirata, RD; Leite, CQ; Sato, DN; Spositto, FL, 2011) |
| "Pyrazinamide (PZA) is an important first-line anti-tuberculosis drug." | 3.77 | Rapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method. ( Chen, J; Deng, J; Geng, X; Wang, D; Wang, W; Wang, X; Wei, H; Zhang, XE; Zhang, Z; Zhou, M, 2011) |
| "A case-control study including Caucasian patients with tuberculosis (TB) treated with isoniazid, rifampicin and pyrazinamide." | 3.77 | N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. ( Agúndez, JA; Botana-Rial, M; Constenla, L; Fernández-Villar, A; Leiro-Fernandez, V; Valverde, D; Vázquez-Gallardo, R, 2011) |
| "Resistance to pyrazinamide in Mycobacterium tuberculosis is usually associated with a reduction of pyrazinamidase activity caused by mutations in pncA, the pyrazinamidase coding gene." | 3.76 | Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance. ( Gilman, RH; Gutierrez, A; Quiliano, M; Sheen, P; Zimic, M, 2010) |
| "Pyrazinamide is an important front line antimycobacterial drug, which is also being used in the treatment of multi drug resistant tuberculosis along with second line drugs in DOTS plus programme." | 3.76 | Comparison of MGIT 960 & pyrazinamidase activity assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. ( Malhotra, B; Pal, N; Rishi, S; Sharma, B; Vyas, L, 2010) |
| "TMC207, rifapentine, and moxifloxacin are in clinical testing for the treatment of tuberculosis." | 3.76 | Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. ( Andries, K; Gevers, T; Lounis, N, 2010) |
| "Pyrazinamide (PZA) has been in use for almost 50 years as a first-line drug for short-course chemotherapy against Mycobacterium tuberculosis." | 3.76 | Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of mycobacterium tuberculosis from South India. ( Ayalusamy, N; Jagadeesan, S; Muthaiah, M; Muthuraj, U; Prabhu, SS; Senthilkumar, K; Sreenivasan, M; Veerappan, S, 2010) |
| "Susceptibility testing of pyrazinamide (PZA) against Mycobacterium tuberculosis is difficult to perform because the acidity of culture medium that is required for drug activity also inhibits the growth of bacteria." | 3.76 | Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. ( Chaiprasert, A; Jonmalung, J; Leechawengwongs, M; Prammananan, T, 2010) |
| "Risk factors and treatment outcomes under program conditions for isoniazid (INH)-monoresistant tuberculosis have not been well described." | 3.75 | Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. ( Cattamanchi, A; Dantes, RB; Grinsdale, J; Hopewell, PC; Jarlsberg, LG; Kawamura, LM; Metcalfe, JZ; Nahid, P; Osmond, D, 2009) |
| "Ethambutol and pyrazinamide are two first-line anti-tuberculosis drugs." | 3.75 | A rapid and robust liquid chromatography/tandem mass spectrometry method for simultaneous analysis of anti-tuberculosis drugs--ethambutol and pyrazinamide in human plasma. ( Basir, Y; Chu, D; Gong, Z; McCort-Tipton, M, 2009) |
| "Pyrazinamide is a first-line drug for treating tuberculosis, but pyrazinamide resistance testing is usually too slow to guide initial therapy, so some patients receive inappropriate therapy." | 3.75 | Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients. ( Caviedes, L; Evans, CA; Gilman, RH; Méndez, M; Moore, DA; Peña, L; Sheen, P; Zhang, Y; Zimic, MJ, 2009) |
| "To describe the molecular basis of pyrazinamide (PZA) resistance among Mycobacterium tuberculosis in New Zealand, and to compare the pncA gene sequence among isolates with phenotypic (Bactec 960 and Wayne's assay) evidence of PZA resistance." | 3.75 | Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand. ( Drinković, D; Newton, S; Pandey, S; Roberts, S; Upton, A, 2009) |
| "The activity of different analogs of pyrazinamide on Mycobacterium tuberculosis fatty acid synthase type I (FASI) in replicating bacilli was studied." | 3.74 | Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli. ( Arai, M; Jacobs, WR; Vilchèze, C; Welch, JT; Zimhony, O, 2007) |
| "These results suggest that regimens consisting of isoniazid or moxifloxacin plus rifapentine and pyrazinamide may dramatically shorten the duration of treatment needed to cure human tuberculosis." | 3.74 | Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? ( Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M, 2008) |
| "Aspirin (acetylsalicylic acid) or ibuprofen [2-(4-isobutyl-phenyl)-propionic acid] was administered to mice undergoing treatment of tuberculosis infection with pyrazinamide to determine if these non-steroidal anti-inflammatory drugs (NSAIDs) enhance pyrazinamide activity in vivo." | 3.74 | Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. ( Byrne, ST; Denkin, SM; Zhang, Y, 2007) |
| "Resistance of Mycobacterium tuberculosis to pyrazinamide (PZA) derives mainly from mutations in the pncA gene." | 3.74 | Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains. ( Augustynowicz-Kopec, E; Kato, S; Kirikae, F; Kirikae, T; Kobayashi, I; Miyoshi-Akiyama, T; Mori, T; Morita, K; Nakamura, T; Sekiguchi, J; Suetake, T; Yoshida, H; Zwolska, Z, 2007) |
| "To compare the performance of the BacT/ALERT PZA kit (BioMerieux, Marcy l'Etoile, France) with the radiometric BACTEC 460TB PZA test (Becton-Dickinson method) for testing Mycobacterium tuberculosis susceptibility to pyrazinamide." | 3.74 | Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide. ( Aragón, LM; Coll, P; Español, M; Garrigó, M; Moreno, C, 2007) |
| "Standard treatment of active tuberculosis (TB) consists of isoniazid (INH), rifampin (RMP), pyrazinamide (PZA) and ethambutol (EMB)." | 3.74 | Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. ( Bruchet, N; Elwood, RK; Fitzgerald, JM; Marra, CA; Marra, F; Moadebi, S; Richardson, K, 2007) |
| "For a strain of Mycobacterium tuberculosis mono-resistant to pyrazinamide (PZA), we report the geographic distribution within Quebec of the 77 cases diagnosed during 1990-2000." | 3.74 | Geography and genealogy of the human host harbouring a distinctive drug-resistant strain of tuberculosis. ( Brassard, P; Henry, KA; Jomphe, M; Olson, SH; Schwartzman, K, 2008) |
| "A simple fibroblast-based assay (SFA) was found to be efficient in evaluating the susceptibilities of clinical isolates of Mycobacterium tuberculosis to pyrazinamide (PZA)." | 3.73 | Simple fibroblast-based assay to test the pyrazinamide susceptibility of Mycobacterium tuberculosis. ( Abe, C; Hamasaki, S; Hirano, K; Onozaki, K; Takii, T, 2005) |
| "The case of a 30-y-old male with latent tuberculosis who developed chemical hepatitis requiring hospitalization after 50 d of treatment with rifampin and pyrazinamide is reported." | 3.73 | Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis. ( Mantadakis, E; Potolidis, E; Samonis, G; Zeniodi, MH, 2005) |
| "The present study was planned to evaluate the chemotherapeutic potential of nebulized solid lipid particles (SLPs) incorporating rifampicin, isoniazid and pyrazinamide against experimental tuberculosis." | 3.73 | Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. ( Khuller, GK; Pandey, R, 2005) |
| "Mycobacterium bovis is best identified by screening those isolates of the Mycobacterium tuberculosis complex that have any pyrazinamide (PZA) resistance, using a confirmatory test such as spoligotyping, biochemical testing, or genomic deletion analysis." | 3.73 | Does resistance to pyrazinamide accurately indicate the presence of Mycobacterium bovis? ( Aga, RS; de Jong, BC; DeRiemer, K; Gagneux, S; Onipede, A; Pym, AS; Small, PM, 2005) |
| "Cases of severe and fatal liver injury were reported after a 2-month course of rifampin-pyrazinamide therapy was recommended in 2000 as an alternative to isoniazid for treatment of latent tuberculosis infection." | 3.73 | National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. ( Castro, KG; Iademarco, MF; Ijaz, K; Jereb, JA; Lambert, LA; McElroy, PD; Navin, TR, 2005) |
| "Severe liver injuries were attributed to the rifampin and pyrazinamide (RZ) regimen after it was recommended for treating latent tuberculosis infection." | 3.73 | Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. ( Bower, WA; Castro, KG; Iademarco, MF; Ijaz, K; Jereb, JA; Lambert, LA; McElroy, PD; Navin, TR; Spradling, PR, 2006) |
| "This study was designed to characterize the population pharmacokinetics of pyrazinamide in South African pulmonary tuberculosis patients, with special reference to interindividual and interoccasional variability (IIV and IOV, respectively)." | 3.73 | Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. ( Langdon, G; McIlleron, H; Pillai, GC; Simonsson, US; Smith, PJ; Wilkins, JJ, 2006) |
| " Although the overall risk of hepatotoxicity in patients receiving pyrazinamide and rifampin daily for the treatment of latent tuberculosis infection was higher, liver functions returned to normal after the medications were discontinued." | 3.73 | Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection. ( Cook, PP; Holbert, D; Maldonado, RA; Yarnell, CT, 2006) |
| "The objective of the present study was to identify the optimal R207910-containing regimen to administer to patients who cannot receive rifampin (RIF) and isoniazid (INH) because of multidrug-resistant tuberculosis (MDR-TB), concomitant use of antiretroviral drugs, or toxicity." | 3.73 | Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. ( Andries, K; Chauffour, A; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N, 2006) |
| "To investigate the presence of mutations in the pncA gene in 31 pyrazinamide-resistant Mycobacterium tuberculosis and 5 susceptible strains." | 3.73 | pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. ( Barco, P; Campanerut, PA; Cardoso, RF; de Melo, FF; Hirata, MH; Hirata, RD; Leite, CQ; Mamizuka, EM; Pandolfi, JR; Sato, DN; Shikama, ML, 2006) |
| "An alternative regimen for the treatment of latent tuberculosis infection is 2 months of rifampin and pyrazinamide, but some patients have died of hepatitis associated with this therapy." | 3.72 | Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. ( Cheng, AC; Engemann, JJ; Fortenberry, ER; Hamilton, CD; Stout, JE, 2003) |
| "To optimise an anti-tuberculosis extemporaneous powder formulation for suspension in order to develop a fixed combination of rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride as a powder to be reconstituted with water by the patient prior to administration." | 3.72 | Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination. ( Danckwerts, MP; Ebrahim, S; Pillay, V, 2003) |
| "CDC has reported previously surveillance data of severe liver injury in patients treated for latent tuberculosis infection (LTBI) with a daily and twice-weekly 2-month regimen of rifampin with pyrazinamide (RZ)." | 3.72 | Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. ( , 2003) |
| "A total of 76 clinical Mycobacterium tuberculosis isolates from Taiwan were tested for pyrazinamidase activity, pyrazinamide susceptibility, and pncA mutations." | 3.72 | Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. ( Chen, YS; Huang, CK; Huang, TS; Huang, WK; Lee, SS; Lin, HH; Liu, YC; Tu, HZ; Wann, SR, 2003) |
| "Two months of rifampin and pyrazinamide (RIF/PZA) for tuberculosis prevention has been advocated as a way to improve adherence in mobile populations, such as recent immigrants." | 3.72 | Tuberculosis prevention in Mexican immigrants: limitations of short-course therapy. ( Carroll, MR; Dworkin, MS; Kandula, NR; Lauderdale, DS, 2004) |
| "The pharmacokinetics of pyrazinamide (PZA) in patients with human immunodeficiency virus (HIV)-related tuberculosis are incompletely characterized." | 3.72 | The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis. ( Chirgwin, K; Hafner, R; Peloquin, CA; Perlman, DC; Rainey, PM; Remmel, RP; Rosenkranz, S; Salomon, N; Segal, Y, 2004) |
| "The pncA gene mutations associated with pyrazinamide (PZA) resistance in Mycobacterium tuberculosis complex were determined in 26 PZA-resistant isolates in Japan." | 3.72 | Genetic and phenotypic characterization of pyrazinamide-resistant mycobacterium tuberculosis complex isolates in Japan. ( Ano, H; Miyagi, C; Takashima, T; Yamane, N; Yogesh, B, 2004) |
| "To characterize the treatment of latent tuberculosis infection and the impact on treatment completion of the 2-month rifampin and pyrazinamide regimen as compared to the traditional 6- to 12-month isoniazid regimen among persons incarcerated at a county correctional facility." | 3.72 | Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin/pyrazinamide with isoniazid regimens. ( Brannan, GL; Clancey, T; Conklin, TJ; Lincoln, T; Lynch, V; Rose, DN; Tuthill, RJ, 2004) |
| "National mycobacteriology reference laboratory in Peru conducting routine testing of susceptibility to isoniazid, rifampin, ethambutol, pyrazinamide, and streptomycin, in Mycobacterium tuberculosis isolates from previously treated patients." | 3.72 | Drug resistance trends among previously treated tuberculosis patients in a national registry in Peru, 1994-2001. ( Asencios-Solis, L; Bayona, J; Becerra, MC; Leo-Hurtado, E; Quispe-Torres, N; Salazar-Lindo, E; Vásquez-Campos, L, 2004) |
| "The nucleotide sequences of the pncA genes within 55 multidrug-resistant pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates were determined." | 3.72 | pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal. ( Barreiro, L; Brum, L; Moniz-Pereira, J; Portugal, I, 2004) |
| "Severe liver injury has been attributed to preventive treatment of latent tuberculosis infection with a 2-month course of rifampin-pyrazinamide." | 3.72 | Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. ( Baars, H; Borgdorff, M; Cobelens, F; Kalisvaart, N; Keizer, S; Kik, S; Mensen, M; Trompenaars, MC; van Gerven, P; van Hest, R, 2004) |
| "In 2000, results of a multinational trial demonstrated that a 2-month course of rifampin and pyrazinamide (RZ) was as effective as isoniazid (INH) in reducing tuberculosis in human immunodeficiency virus (HIV)-infected individuals with latent tuberculosis infection (LTBI)." | 3.72 | Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? ( Chaisson, RE; Cohn, DL; Gordin, FM; Matts, JP; O'Brien, RJ, 2004) |
| "Reports of fatal and severe liver injury associated with treatment of latent tuberculosis infection (LTBI) with the drug combination rifampin and pyrazinamide (RZ) prompted CDC to issue revised guidelines for the use of this regimen on August 31, 2001." | 3.71 | Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. ( , 2002) |
| "After clinical illness, treatment, and death of a captive male bongo antelope (Tragelaphus eurycerus isaaci) caused by tuberculosis involving Mycobacterium bovis, four tuberculin test reactive captive bongos were treated for 6 mo with isoniazid (INH) and rifampin (RIF) and intermittent single doses of other medications before being euthanized." | 3.71 | Population pharmacokinetics of antituberculous drugs and treatment of Mycobacterium bovis infection in bongo antelope (Tragelaphus eurycerus isaaci). ( Aguilar, R; Auclair, B; Maslow, JN; Mikota, SK; Peloquin, CA, 2002) |
| "The fully automated BACTEC MGIT 960 PZA medium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA) was evaluated using 101 Mycobacterium tuberculosis clinical isolates." | 3.71 | Evaluation of BACTEC MGIT 960 PZA medium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA): compared with the results of pyrazinamidase assay and Kyokuto PZA test. ( Abe, C; Aono, A; Hamasaki, S; Hirano, K, 2002) |
| "Mycobacterium bovis is naturally resistant to the antituberculosis drug pyrazinamide (PZA)." | 3.71 | Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States. ( Crawford, JT; Desmond, EP; Hannan, MM; Mazurek, GH; Morlock, GP, 2001) |
| "To determine whether short-course treatment of latent tuberculosis infection (LTBI) with 2 months of rifampin and pyrazinamide (2RZ) is well tolerated and leads to increased treatment completion among jail inmates, a group who may benefit from targeted testing and treatment for LTBI but for whom completion of > or = 6 months of isoniazid treatment is difficult because of the short duration of incarceration." | 3.71 | Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. ( Bock, NN; DeVoe, B; Geiter, LJ; Herron, GD; Rogers, T; Tapia, JR, 2001) |
| "One of the recommended treatments for latent tuberculosis infection (LTBI) is a 9-month regimen of isoniazid (INH); a 2-month regimen of rifampin (RIF) and pyrazinamide (PZA) is an alternative in some instances." | 3.71 | Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000. ( , 2001) |
| "The chemotherapeutic agent pyrazinamide was used as a marker for the occurrence of tuberculosis." | 3.71 | Pyrazinamide use as a method of estimating under-reporting of tuberculosis. ( Hekster, YA; Kalisvaart, NA; Leufkens, HG; van Loenhout-Rooyackers, JH, 2001) |
| "During February 12-August 24, 2001, a total of 21 cases of liver injury associated with a 2-month rifampin-pyrazinamide (RIF-PZA) regimen for the treatment of latent tuberculosis infection (LTBI) was reported to CDC." | 3.71 | Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001. ( , 2001) |
| "Pyrazinamide (PZA) is an important front-line anti-tuberculosis drug that is active only at acid pH." | 3.71 | Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. ( Permar, S; Sun, Z; Zhang, Y, 2002) |
| "To determine the long-term tolerability of prophylactic administration of pyrazinamide and levofloxacin in patients possibly exposed to multidrug-resistant tuberculosis (MDRTB) after undergoing solid organ transplantation." | 3.71 | Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. ( Lou, HX; McKaveney, TP; Shullo, MA, 2002) |
| "Pyrazinamide (PZA) is recommended as the third drug in the 6-month regimens for tuberculosis." | 3.70 | Is pyrazinamide really the third drug of choice in the treatment of tuberculosis? ( Constantopoulos, SH; Demou, GS; Koumbaniou, C; Manda-Stachouli, C; Nicopoulos, C; Sakellariou, K; Vassiliou, M, 1998) |
| "Isoniazid prophylaxis for 12 months effectively prevents tuberculosis in HIV-infected persons and may decrease the incidence of other HIV-related disease and mortality." | 3.70 | Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis. ( Rose, DN, 1998) |
| "To establish the chemotherapeutic value of a depot drug preparation of isoniazid and pyrazinamide against experimental tuberculosis." | 3.70 | Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide. ( Gangadharam, PR; Geeta, N; Hsu, YY; Wise, DL, 1999) |
| " In this study, we evaluated the ability of rifapentine (RFP), in monotherapy and combination therapy, to completely eradicate a Mycobacterium tuberculosis infection and to prevent relapse posttreatment in a Swiss mouse model." | 3.70 | Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. ( Chase, SE; Chmielewski, AJ; Cynamon, MH; Lenaerts, AM, 1999) |
| "Pyrazinamide (PZA) is an important first-line tuberculosis drug that is part of the currently used short-course tuberculosis chemotherapy." | 3.70 | pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. ( Cheng, SJ; Heifets, L; Sanchez, T; Thibert, L; Zhang, Y, 2000) |
| "A new agar medium to perform pyrazinamide (PZA) susceptibility testing with Mycobacterium tuberculosis has been developed." | 3.70 | New agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. ( Heifets, L; Sanchez, T, 2000) |
| "The effectiveness of various once-weekly 10 mg/kg rifapentine (P)- containing regimens for treatment of tuberculosis was assessed in mice infected intravenously with 4." | 3.70 | Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens. ( Daniel, N; Geiter, LJ; Grosset, J; Hejblum, G; Ji, B; Lounis, N; O'Brien, RJ; Szpytma, M; Truffot-Pernot, C; Vernon, A, 2000) |
| "A sample of 35 pyrazinamide (PZA)-resistant and 30 PZA-susceptible clinical isolates recovered from Beijing and Taiyuan City, China were characterized by SSCP and sequence analysis for mutations in the pncA gene that encodes the Mycobacterium tuberculosis PZase." | 3.70 | Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China. ( Hou, L; Kano, K; Osei-Hyiaman, D; Wang, B; Yang, A; Zhang, Z, 2000) |
| "(1) The recommended treatment protocol for the vast majority of cases of tuberculosis is a 6-month course of isoniazid and rifampicin, plus pyrazinamide and ethambutol for the first two months." | 3.70 | Treatment of tuberculosis: a well-standardised protocol. ( , 2000) |
| "Study results presented at the 5th Conference on Retroviruses and Opportunistic Infections showed that a two-month regimen of rifampin with pyrazinamide proved to be as effective as a twelve-month regimen of isoniazid in the prevention of tuberculosis (TB) in HIV-positive individuals." | 3.70 | A short two-drug regimen prevents active TB. ( Torres, G, 1998) |
| "We report three patients who experienced hepatotoxic reactions in association with acetaminophen ingestion while undergoing treatment for active tuberculosis with isoniazid, rifampin, and other agents." | 3.69 | Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. ( Nelson, SD; Nolan, CM; Sandblom, RE; Slattery, JT; Thummel, KE, 1994) |
| "The effectiveness of intermittent administration of rifapentine (RPT), with or without isoniazid (INH), for preventive therapy of tuberculosis was evaluated in immunocompetent (normal) and nude mice." | 3.69 | Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. ( Chapuis, L; Grosset, JH; Ji, B; O'Brien, RJ; Raviglione, MC; Truffot-Pernot, C, 1994) |
| "Substituted pyrazinoic acid esters have previously been reported to have in vitro activity against Mycobacterium avium and Mycobacterium kansasii as well as Mycobacterium tuberculosis." | 3.69 | Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters. ( Bergmann, KE; Cynamon, MH; Welch, JT, 1996) |
| "The activity of pyrazinamide (PZA) against eight isolates of Mycobacterium tuberculosis in a murine infection model was evaluated." | 3.69 | Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility. ( Cynamon, MH; Klemens, SP; Sharpe, CA, 1996) |
| "The efficacies of rifampin-containing preventive regimens were measured in Cornell model mice in which an initially severe infection with Mycobacterium tuberculosis H37Rv was first treated for 7 weeks with 25 mg of isoniazid and 1,000 mg of pyrazinamide per kg of body weight in the diet and then with one of four test regimens given by daily oral gavage for 6 weeks." | 3.69 | Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. ( Dhillon, J; Dickinson, JM; Mitchison, DA; Sole, K, 1996) |
| "The combination of clarithromycin and pyrazinamide was found to be synergistic against Mycobacterium tuberculosis in human macrophages." | 3.69 | Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. ( Esfandiari, A; Mor, N, 1997) |
| "2 weeks after infection with Mycobacterium tuberculosis H37Rv, groups of mice were treated with rifampicin (R) 15 mg/kg, isoniazid (H) 25 mg/kg, pyrazinamide (Z) 300 mg/kg, ethambutol (E) 100 mg/kg three times weekly (RHZE3); RH/ZE, an alternating regimen of RH on days 1, 3 and 5 of the week and ZE on days 2, 4 and 6, RZ/HE or RE/HZ." | 3.68 | Turning intermittent regimens into daily regimens using blister-packs. An exploration in murine tuberculosis. ( Dickinson, JM; Guy, A; Mitchison, DA, 1993) |
| "20 Patients of tuberculous pleural effusion were administered a combination of pyrazinamide (30 mg/kg) + isoniazid (300 mg) orally for 7 consecutive days and pyrazinamide was estimated by spectrophotometric method in serum and pleural fluid." | 3.68 | Alteration in the levels of pyrazinamide in pleural fluid following simultaneous administration of prednisoline in patients of tubercular pleural effusion. ( Bhargava, R; Singhal, KC; Wagay, AR, 1990) |
| "Treatment of tuberculosis in a hemodialysis patient with isoniazid, rifampin, and pyrazinamide resulted in the development of acute cerebellar dysfunction." | 3.68 | Cerebellar syndrome caused by isoniazid. ( Blumberg, EA; Gil, RA, 1990) |
| "In a first experiment, the efficacy of a 6-month course of isoniazid (INH) alone in comparison with 2-month courses of rifampin (RMP) alone, RMP + pyrazinamide (PZA), or RMP + PZA + INH as preventive therapy of tuberculosis was evaluated in the mouse." | 3.67 | Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. ( Grosset, JH; Lecoeur, HF; Truffot-Pernot, C, 1989) |
| "Over a 2-year period, all patients with incipient tuberculosis seen in a hospital unit were given a 6-month treatment consisting of rifampicine, isoniazide, pyrazinamide and ethambutol." | 3.67 | [Routine use of 6-month antitubercular treatment in 300 patients]. ( Aeberhardt, G; Bernheim, J; Dautzenberg, B; Gallinari, C; Grosset, J; Lévy, A; Sors, C, 1986) |
| "Treatment of tuberculosis: A 6-month regimen consisting of isoniazid, rifampin, and pyrazinamide given for 2 months followed by isoniazid and rifampin for 4 months is effective treatment in patients with fully susceptible organisms who comply with the treatment regimen." | 3.67 | American Thoracic Society. Medical Section of the American Lung Association: Treatment of tuberculosis and tuberculosis infection in adults and children. ( , 1986) |
| "The bioavailability of isoniazid, rifampin, and pyrazinamide in 2 combined formulations of the 3 drugs (Rifater) for use primarily in the short-course chemotherapy of tuberculosis has been studied in Chinese patients in Singapore and Hong Kong." | 3.67 | The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis. ( Allen, BW; Chan, SL; Ellard, DR; Ellard, GA; Girling, DJ; Ng, HK; Nunn, AJ; Tan, TH; Teo, SK, 1986) |
| "Results are presented of the incidence of hepatitis, nearly always with jaundice, among 1686 patients in clinical trials of the treatment of spinal tuberculosis, of tuberculosis meningitis and of pulmonary tuberculosis with short-course regimens containing rifampicin, isoniazid, streptomycin and pyrazinamide." | 3.67 | Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. ( Janardhanam, B; Parthasarathy, R; Ramachandran, P; Santha, T; Sarma, GR; Sivasubramanian, S; Somasundaram, PR; Tripathy, SP, 1986) |
| "Short-course chemotherapy with isoniazid and rifampin is well established for pulmonary tuberculosis but not yet for extrapulmonary disease." | 3.67 | Short-course chemotherapy for extrapulmonary tuberculosis. Nine years' experience. ( Dutt, AK; Moers, D; Stead, WW, 1986) |
| "In a first experiment mice infected intravenously with 10(6) Mycobacterium tuberculosis were randomly treated either with isoniazid (INH) + rifampicin (RMP) 25 mg/kg or with INH + RMP + pyrazinamide (PZA) or with INH + RMP + PZA + streptomycin (SM)." | 3.66 | [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)]. ( Fermanian, J; Grosset, J; Lecoeur, H; Truffot, C, 1982) |
| "The incidence of tuberculosis in Romania has decreased considerably over the past years, particularly since 1972 when the combined rifampicin-ethambutol-pyrazinamide therapy was introduced." | 3.66 | [Tuberculosis in Romania (author's transl)]. ( Anastasatu, C; Plopeanu, D, 1979) |
| "Pyrazinamide is a first-line tuberculosis therapy that shortens prophylactic duration from twelve to six months." | 3.01 | Anti-Tubercular Activity of Pyrazinamide Conjugates: Synthesis and Structure-Activity Relationship Studies. ( Chawla, PA; Sharma, S; Wahan, SK, 2023) |
| "The duration of the standard treatment for tuberculosis can be shortened to four months but this treatment regimen is also based on rifapentine, in addition to isoniazid, pyrazinamide, and moxifloxacin." | 3.01 | [Treatment of tuberculosis: what is new?] ( Brehm, TT; Friesen, I; Heyckendorf, J; Kalsdorf, B; Kandulla, J; Köhler, N; Kuhns, M; Lange, C; Martensen, J; Schmiedel, S; Terhalle, E, 2023) |
| "Outcomes of treatment of tuberculosis patients with regimens including pretomanid have not yet been systematically reviewed." | 2.82 | Pretomanid for tuberculosis: a systematic review. ( de Jong, BC; Decroo, T; Gils, T; Lynen, L; Van Deun, A, 2022) |
| " The pharmacokinetic parameters of rifampin, isoniazid, ethambutol, and pyrazinamide were determined for each patient." | 2.80 | Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. ( Chigutsa, E; Gumbo, T; McIlleron, H; Pasipanodya, JG; Sirgel, FA; Smith, PJ; van Helden, PD; Visser, ME, 2015) |
| " All doses were safe and well tolerated." | 2.76 | Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. ( Bedarida, G; Campbell, S; Jakubiec, W; Kumar, V; Ladutko, L; Miller, PF; Mitton-Fry, M; Paige, D; Silvia, A; Wallis, RS; Zhu, T, 2011) |
| " The purpose of this study was to demonstrate utility of a physiologically-based pharmacokinetic modeling approach to predict plasma and lung concentrations of 11 compounds used or under development as TB therapies (bedaquiline [and N-desmethyl bedaquiline], clofazimine, cycloserine, ethambutol, ethionamide, isoniazid, kanamycin, linezolid, pyrazinamide, rifampicin, and rifapentine)." | 2.72 | Development of physiologically-based pharmacokinetic models for standard of care and newer tuberculosis drugs. ( Almond, L; Berg, A; Gardner, I; Hatley, O; Humphries, H; Jamei, M; Pan, X; Romero, K; Small, B; Zhang, M, 2021) |
| " In this study, the relative bioavailability of rifampicin, isoniazid and pyrazinamide was assessed in a group of 14 healthy male subjects using the FDC tablet containing 4 drugs versus separate formulations at the same dose levels." | 2.70 | Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations. ( Agrawal, S; Bhade, SR; Kaul, CL; Kaur, KJ; Panchagnula, R; Singh, I, 2002) |
| "Tuberculosis was associated with an increased mortality (adjusted rate ratio 1." | 2.70 | Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. ( Fuchs, D; Godfrey-Faussett, P; Hosp, M; Lisse, I; Mwinga, A; Quigley, MA, 2001) |
| "The perceived need for simple, non-invasive methods of assessing the relative bioavailability of rifampicin in fixed-dose combination (FDC) anti-tuberculosis formulations." | 2.70 | The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations. ( Ellard, GA; Fourie, PB; Pillai, G; Smith, PJ, 2001) |
| " New data on optimal drug selection and dosing are emerging with the inclusion of children in clinical trials and ongoing research on age-related pharmacokinetics and pharmacodynamics." | 2.66 | Tuberculosis treatment in children: The changing landscape. ( Huynh, J; Marais, BJ; Schaaf, HS; Thwaites, G, 2020) |
| " Inter-individual pharmacokinetic variability and the effect of age, nutritional status, Human immunodeficiency virus (HIV) infection, acetylator genotype may need to be accounted for in striving for the dosages best suited for an individual." | 2.61 | Pharmacokinetics of First-Line Anti-Tubercular Drugs. ( Kabra, SK; Lodha, R; Mukherjee, A, 2019) |
| "GB tuberculosis is a difficult diagnosis preoperatively." | 2.58 | A comprehensive review on Primary gallbladder tuberculosis. ( Agrawal, S; Anjum, R; Gupta, A; Mallik, D, 2018) |
| "Tuberculous liver abscess is a rare disease entity even in endemic areas of Mycobacterium tuberculosis." | 2.53 | Isolated tuberculous liver abscess in an immunocompetent adult patient: A case report and literature review. ( Chen, TC; Chou, LT; Huang, CC; Lai, AB; Wang, JH, 2016) |
| "Pyrazinamide (PZA) is an indispensable first-line drug used for the treatment of TB." | 2.53 | Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update. ( Guo, J; Mugweru, J; Njire, M; Tan, S; Tan, Y; Wang, C; Yew, W; Zhang, T, 2016) |
| " We pooled data by study quality, design, region, dosing modality and patient characteristics." | 2.53 | Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis. ( Al-Efraij, K; Campbell, JR; Cook, VJ; Johnston, J; Marra, F; Mota, L, 2016) |
| "This review will introduce pharmacokinetic parameters for key anti-TB drugs, as well as the indications and limitations of measuring these parameters in clinical practice." | 2.50 | Understanding pharmacokinetics to improve tuberculosis treatment outcome. ( Heysell, SK; Reynolds, J, 2014) |
| "Tuberculosis is a bacterial disease that predominantly affects the lungs and results in extensive tissue pathology." | 2.49 | A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. ( Barry, CE; Dartois, V, 2013) |
| "Intracranial tubercular subdural empyema in the pediatric age group is an extremely rare but curable entity." | 2.46 | Pediatric intracranial subdural empyema caused by Mycobacterium tuberculosis--a case report and review of literature. ( Ambekar, S; Banerjee, AD; Chandramouli, BA; Pandey, P, 2010) |
| "Treatment of tuberculosis has three major goals: healing the patient, preventing selection of resistant strains and control transmission of tuberculosis." | 2.40 | [Antitubercular chemotherapy]. ( Dautzenberg, B; Jouveshomme, S, 1997) |
| "Pharyngeal tuberculosis is an uncommon condition." | 2.40 | [Pharyngeal tuberculosis: an analytical study and report of 10 cases]. ( Kharoubi, S, 1998) |
| "Optimum treatment of tuberculosis in persons with human immunodeficiency virus (HIV) infection is still being defined." | 2.38 | Failure of therapy for tuberculosis in human immunodeficiency virus infection. ( Nolan, CM, 1992) |
| "Pyrazinamide, an antituberculous drug discovered in 1952, was first considered as a toxic drug." | 2.36 | [Toxicity of pyrazinamide in antituberculous treatments (author's transl)]. ( Perdrizet, S; Pretet, S, 1980) |
| " When recommended dosage regiments are followed, the incidence of adverse reactions is low with short-course therapy, and in only 5% or less of patients is it necessary to withdraw one or more drugs." | 2.36 | Short-course therapy for tuberculosis. ( Aquinas, M, 1982) |
| " To address this issue, we utilized a murine model of antibiotic-induced dysbiosis to assay the bioavailability of rifampicin, moxifloxacin, pyrazinamide, and isoniazid in mouse plasma over a period of 12 h following individual oral administration." | 1.91 | The Dysbiosis Triggered by First-Line Tuberculosis Antibiotics Fails to Reduce Their Bioavailability. ( Dartois, V; Mittereder, LR; Namasivayam, S; Oland, S; Sher, A; Wang, H; Zimmerman, M, 2023) |
| "Tuberculosis is a serious contagious disease mainly affecting the lungs and is common in the developing countries." | 1.91 | Anti-tubercular therapy (ATT) induced exfoliative dermatitis-A case series. ( Balijepalli, MK; Butti, L; Kandra, N; Masapogu, S; Somarouthu, VS; Uppala, PK; Uttaravalli, U; Vangoori, Y; Varghese, AM, 2023) |
| " To address this gap, we formulate a whole-body physiologically-based pharmacokinetic (PBPK) model for EPTB that for the first time includes the ability to simulate drug concentrations in the pleura and lymph node, the most commonly affected sites of EPTB." | 1.91 | A physiologically-based pharmacokinetic model for tuberculosis drug disposition at extrapulmonary sites. ( Gadgil, CJ; Ramachandran, A, 2023) |
| "Children with drug-susceptible tuberculosis in Malawi and South Africa underwent pharmacokinetic sampling while receiving first-line tuberculosis drugs as single formulations according the 2010 WHO recommended doses." | 1.72 | Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study. ( Bekker, A; Davies, G; Denti, P; Gonzalez-Martinez, C; Hesseling, AC; McIlleron, HM; Rabie, H; Svensson, EM; van der Laan, LE; van Rie, A; Wasmann, RE; Wiesner, L; Winckler, J; Zar, HJ, 2022) |
| " Often antitubercular human dose selection is derived from pharmacokinetic data in plasma." | 1.72 | Prediction of lung exposure to anti-tubercular drugs using plasma pharmacokinetic data: Implications for dose selection. ( Della Pasqua, O; Ferrer, S; Muliaditan, M; Ortega-Muro, F; Teutonico, D, 2022) |
| "Primary psoas tuberculosis is the presence of "Koch's bacillus'' within the iliopsoas muscle caused by hematogenous or lymphatic seeding from a distant site." | 1.72 | Primary psoas tuberculosis abscess with an iliac bone lytic lesion: a case report. ( Abouhareb, R; Alasadi, L; Alrstom, A; Alsuliman, T; Daher, N; Karam, B; Mohandes, AF; Rajab Bek, MW, 2022) |
| "58 children were assessed for eligibilty and enrolled between June 25, 2016, and Feb 6, 2018; 44 had complete stool testing and serum pharmacokinetic data, and they were included in the analyses." | 1.72 | Enteropathogen spectrum and effect on antimycobacterial pharmacokinetics among children with tuberculosis in rural Tanzania: a prospective cohort study. ( Alshaer, MH; Gratz, J; Heysell, SK; Houpt, ER; Justine, M; Kosek, M; Liu, J; Maro, A; Mduma, E; Mpagama, SG; Mujaga, B; Peloquin, CA; Rogawski McQuade, ET; Thomas, TA; Van Aartsen, D, 2022) |
| "Pyrazinamide resistance was found in 6/80 (7." | 1.72 | Pyrazinamide resistance in rifampicin discordant tuberculosis. ( Mlisana, KP; Mvelase, NR; Singh, R; Swe Swe-Han, K, 2022) |
| "tuberculosis) is usually treated by oral antimycobacterial agents, including rifampicin, ethambutol, and pyrazinamide, but the treatment regimen with intravenous and/or intramuscular antimycobacterial agents for patients who cannot take medications orally remains unclear." | 1.72 | A Mycobacterium tuberculosis-Infected Patient Who Could Not Tolerate Oral Intake Successfully Treated Using an Intravenous Tedizolid-Containing Regimen. ( Kamoshita, F; Karaushi, H; Mitsutake, K; Miyawaki, Y; Seki, M; Watanabe, N, 2022) |
| "Pyrazinamide (PZA) is a critical component of the first-line TB treatment regimen because of its sterilizing activity against non-replicating Mycobacterium tuberculosis (Mtb), but its mechanism of action has remained enigmatic." | 1.72 | Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents. ( Aldrich, CC; Aragaw, WW; Cole, MS; Dick, T; Grüber, G; Harikishore, A; Hegde, PV; Jachak, G; Ragunathan, P; Sharma, S, 2022) |
| "Drug products used for treating tuberculosis are one of the most widely reported medicines to be classified as falsified or substandard in low- and middle-income countries, representing a major hazard to health." | 1.72 | Development and Optimization of a New UPLC-UV/MS Method through DoE and MLR for Detecting Substandard Drug Products to Treat Tuberculosis. ( Cáceres-Pérez, AR; Fariña, JB; Oliva, A; Santoveña-Estévez, A; Suárez-González, J, 2022) |
| "Pyrazinamide exposures were similar to those in adults." | 1.72 | Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations. ( Aarnoutse, R; Chabala, C; Chirehwa, M; Choo, L; Gibb, D; Hesseling, AC; Hissar, S; Kapasa, M; Kinikar, A; LeBeau, K; Mave, V; McIlleron, H; Mulenga, V; Palmer, M; Turkova, A; van der Zalm, M; Wiesner, L; Wobudeya, E; Zimba, KM, 2022) |
| " Population pharmacokinetic modeling generated estimates of drug exposure (Cmax and AUC) from individual-level post hoc Bayesian estimates of plasma and intrapulmonary pharmacokinetics." | 1.62 | Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis. ( Chasweka, M; Chirambo, AP; Chitani, A; Davies, GR; Dilly-Penchala, S; Else, LJ; Gordon, SB; Khoo, SH; Malamba, RD; McCallum, AD; Meghji, JZ; Mwandumba, HC; Pertinez, HE; Sheha, I; Sloan, DJ, 2021) |
| "Pyrazinoic acid (1: ) was esterified first (2: ) followed by amination to produce hydrazide (3: ) which was refluxed with POCl3 to obtain 2-chloromethyl-5pyrazino-1, 3, 4-oxadiazole (4: )." | 1.62 | Evaluation and Docking Study of Pyrazine Containing 1, 3, 4-Oxadiazoles Clubbed with Substituted Azetidin-2-one: A New Class of Potential Antimicrobial and Antitubercular. ( Das, R; Mehta, DK, 2021) |
| " The effect of CART-derived thresholds for individualized dosing on treatment outcome should be studied in a randomized controlled trial." | 1.62 | Drug Exposure and Minimum Inhibitory Concentration Predict Pulmonary Tuberculosis Treatment Response. ( Alffenaar, JW; Bao, Z; Bruchfeld, J; Forsman, LD; Gao, Y; Hoffner, S; Hu, Y; Li, X; Ren, W; Zheng, X, 2021) |
| "Pyrazinamide (PZA) has a controversial safety profile in older patients." | 1.62 | Safety of Pyrazinamide for the Treatment of Tuberculosis in Older Patients Over 75 Years of Age: A Retrospective Monocentric Cohort Study. ( Delobel, P; Derumeaux, H; Gandia, P; Guet-Revillet, H; Lafaurie, M; Le Grusse, J; Martin-Blondel, G; Nourhashemi, F; Protin, C; Rousset, S; Sailler, L; Sommet, A, 2021) |
| "Pyrazinamide (PZA) is an important component for short-course treatment regimens and first- and second-line treatment regimens." | 1.62 | An explainable machine learning platform for pyrazinamide resistance prediction and genetic feature identification of Mycobacterium tuberculosis. ( Alterovitz, G; Teng, L; Zhang, A, 2021) |
| "Isoniazid was later substituted with rifabutin in 2 patients with isoniazid-resistant tuberculosis." | 1.62 | Successful Use of Rifamycin-Sparing Regimens for the Treatment of Active Tuberculosis in Lung Transplant Recipients. ( Alameer, R; Almaghrabi, RS; Almohaizeie, A; Alrajhi, AA; Alshehri, N; Nizami, I; Omrani, AS, 2021) |
| "Ethambutol was stopped in all these 8 patients." | 1.56 | Ocular adverse events in drug sensitive TB patients on daily fixed dose combination anti-TB drugs: A record review study from Kerala, India. ( Balakrishnan, S; Das, M; Manu, MS; Mehta, K; Neena, PS; Rakesh, PS; Satyanarayana, S; Sindhu, MP; Sunil Kumar, M; Valamparampil, MJ, 2020) |
| "Pyrazinamide (PZA) is a common drug that causes serious adverse events (SAEs)." | 1.56 | The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis. ( Cho, YJ; Kim, Y; Kwon, BS; Lee, CT; Lee, JH; Lee, SH; Lee, YJ; Lim, SY; Park, JS; Yoon, HI, 2020) |
| "Tuberculosis-related hemophagocytic syndrome (HPS) is reported, but not HPS caused by Mycobacterium bovis in children." | 1.56 | Hemophagocytic syndrome associated with Mycobacterium bovis in a patient with X-SCID: a case report. ( Chen, M; Cheng, Y; Huang, C; Huang, T; Li, Y; Qin, C; Shi, B; Tang, W; Xia, Z; Xiao, S; Xu, H, 2020) |
| "Dosing recommendations for treating childhood tuberculosis (TB) were revised by the World Health Organization, yet so far, pharmacokinetic studies that have evaluated these changes are relatively limited." | 1.56 | Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania. ( Augustino, D; Gratz, J; Heysell, SK; Houpt, ER; Justine, M; Kibiki, GS; Kivuyo, S; Mduma, E; Mfinanga, S; Mmbaga, B; Nicodemu, I; Peloquin, CA; Thomas, TA; Yeconia, A; Zagurski, T, 2020) |
| " Higher or more frequent dosing is needed to improve TB treatment outcomes in India." | 1.56 | Subtherapeutic Rifampicin Concentration Is Associated With Unfavorable Tuberculosis Treatment Outcomes. ( Agibothu Kupparam, HK; Balasubramanian, U; Chandrasekaran, P; Dhanasekaran, K; Dooley, KE; Gaikwad, S; Golub, J; Gupta, A; Gupte, A; Gupte, N; Hanna, LE; Kadam, D; Kagal, A; Kulkarni, V; Mave, V; Murali, L; Paradkar, M; Pradhan, N; Ramachandran, G; Shivakumar, SVBY; Sivaramakrishnan, GN; Swaminathan, S; Thiruvengadam, K; Thomas, B, 2020) |
| "Ethambutol concentration was associated with creatinine clearance (Ccr, P = ." | 1.51 | Determinants of serum concentration of first-line anti-tuberculosis drugs from China. ( Dang, L; Lei, Q; Lv, X; Wang, H; Zhao, Y; Zhou, J; Zhu, C, 2019) |
| "Tuberculosis is a bacterial infectious disease that is usually transmitted by inhalation of droplets containing the bacteria." | 1.51 | [Tuberculosis]. ( Heyckendorf, J; Kalsdorf, B; Lange, C; Maurer, FP, 2019) |
| "Metformin (MET) is a potential combination drug to elevate anti-TB efficacy." | 1.51 | Metformin induced autophagy in diabetes mellitus - Tuberculosis co-infection patients: A case study. ( Ali, M; Mertaniasih, NM; Novita, BD; Pranoto, A; Soediono, EI, 2019) |
| "Pyrazinamide (PZA) is a key drug for current and future TB treatment regimens; however, it was reported that predictive power for PZA resistance by the available tools is low." | 1.51 | Overcoming the pitfalls of automatic interpretation of whole genome sequencing data by online tools for the prediction of pyrazinamide resistance in Mycobacterium tuberculosis. ( Aono, A; Arikawa, K; Iwamoto, T; Kato, K; Kato, S; Kuroda, M; Mitarai, S; Murase, Y; Sekizuka, T; Takii, T; Yamashita, A; Yoshida, S, 2019) |
| "In the treatment of murine tuberculosis, a rifampicin dose of 30 mg/kg was sufficient to eradicate persistent M." | 1.48 | Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. ( Alameda-Martin, L; Coates, A; Davies, G; Harrison, T; Hu, Y; Liu, Y; Ortega-Muro, F; Pertinez, H, 2018) |
| " Isoniazid, rifampin, and pyrazinamide concentration-time profiles and treatment outcome were obtained from 161 Indian children with drug-sensitive tuberculosis undergoing thrice-weekly dosing as per previous Indian pediatric guidelines." | 1.48 | Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications. ( Bhavani, PK; Dooley, KE; Gangadevi, NP; Guiastrennec, B; Gupta, A; Karlsson, MO; Kumar, AKH; Ramachandran, G; Savic, RM; Swaminathan, S, 2018) |
| "Dried blood spot (DBS) sampling for pharmacokinetic (PK) studies and therapeutic drug monitoring have unique advantages over venous sampling." | 1.48 | Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children. ( Aarnoutse, RE; Aguirre, S; Alffenaar, JW; Chaparro, G; Coronel, R; Gomez, R; Gonzalez, F; Huisman, J; Jongedijk, E; Kerkhoff, J; Magis-Escurra, C; Martial, LC; Martinez, N; Molinas, G; Pérez, D; Rodríguez, M; Roman, M; Touw, DJ, 2018) |
| "As current treatment of tuberculosis is burdensomely long, provoking non-adherence and drug resistance, effective short-course treatments are needed." | 1.48 | Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility. ( Clemens, DL; Dillon, BJ; Ho, CM; Horwitz, MA; Lee, BY; Masleša-Galić, S; Nava, S; Silva, A, 2018) |
| " There is a need for more research on optimization of dosing to maximize efficacy and safety of currently used drugs." | 1.46 | Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs. ( Chandrasekaran, V; Kawaskar, M; Kumar, AK; Kumar, AKH; Lavanya, J; Ramachandran, G; Swaminathan, S, 2017) |
| "Pyrazinamide clearance was higher in men than women." | 1.46 | Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation. ( Bisson, GP; Gumbo, T; Modongo, C; Pasipanodya, J; Ravimohan, S; Srivastava, S; Tamuhla, N; Vinnard, C; Weissman, D; Zetola, NM, 2017) |
| "Pyrazinamide (PZA) is a prodrug requiring conversion to pyrazinoic acid (POA) by an amidase encoded by pncA for in vitro activity." | 1.43 | High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis. ( Alland, D; Dartois, V; Lanoix, JP; Nuermberger, E; O'Brien, P; Pinn, M; Safi, H; Sarathy, J; Tasneen, R, 2016) |
| " Due to hepatotoxicity worries, there are no dose-response studies in children." | 1.43 | A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies. ( Cirrincione, KN; Crosswell, HE; Deshpande, D; Gumbo, T; Pasipanodya, JG; Ramachandran, G; Sherman, CM; Shuford, S; Srivastava, S; Swaminathan, S, 2016) |
| "46 μm, as measured by inertial impaction, for POA-leu and POA-NH4, respectively) and with properties (stoichiometric 1:1 ratio of salt to drug, melting points at ∼180 °C, with water content of <1%) that would support further development as an inhaled dosage form." | 1.42 | Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy. [Corrected]. ( Dhillon, J; Durham, PG; Fourie, PB; German, N; Hickey, AJ; Mitchison, DA; Mortensen, N; Zhang, Y, 2015) |
| "Hyperuricemia is frequently reported in adults, but there are few data for the pediatric population." | 1.42 | Is Hyperuricemia Overlooked when Treating Pediatric Tuberculosis Patients with Pyrazinamide? ( Aslan, AT; Budakoğlu, I; Şişmanlar, T, 2015) |
| " However, further studies to identify the optimal statin and dosing are required." | 1.40 | Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. ( Bruiners, N; Gennaro, ML; Karakousis, PC; Pine, R; Pinn, ML; Skerry, C, 2014) |
| "Pyrazinamide (PZA) is an important first-line drug in multidrug-resistant tuberculosis treatment." | 1.40 | Drug resistance mechanism of PncA in Mycobacterium tuberculosis. ( Rajendran, V; Sethumadhavan, R, 2014) |
| "The currently recommended dosages of rifampicin (RMP), isoniazid (INH), pyrazinamide (PZA) and ethambutol in children are extrapolated from adult pharmacokinetic studies, and have not been adequately evaluated in children." | 1.39 | Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children. ( Banu Rekha, VV; Bhavani, PK; Hemanth Kumar, AK; Mathevan, G; Poorana Gangadevi, N; Ramachandran, G; Ramesh Kumar, S; Ravichandran, N; Sekar, L; Swaminathan, S; Vijayasekaran, D, 2013) |
| "Antituberculosis therapy-associated cutaneous leukocytoclastic vasculitis (CLV) has been rarely reported." | 1.39 | Antituberculosis therapy-associated cutaneous leukocytoclastic vasculitis. ( Bhatia, V; Rajgarhia, S; Sibal, A, 2013) |
| " Rifampicin concentrations during the dosing interval were determined by HPLC at three different timepoints: (i) after 2 weeks of TB therapy and before starting HIV therapy (T0); (ii) after 4 weeks of combined therapy (T1); and (iii) after 10 weeks of combined therapy (T2)." | 1.38 | Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. ( Bonkoungou, V; Carvalho, AC; Comelli, M; Cusato, M; Dembélé, SM; Kouanda, S; Matteelli, A; Nacanabo, R; Regazzi, M; Saleri, N; Villani, P, 2012) |
| " In this article, a case series is presented to illustrate the value of individualized TB drug dosing in four patients with low TB drug concentrations." | 1.38 | Therapeutic drug monitoring in the treatment of tuberculosis patients. ( Aarnoutse, R; Boeree, M; Ijdema, D; Magis-Escurra, C; van den Boogaard, J, 2012) |
| " Drug therapy either alone or in combination with BCG, was more effective at lessening clinical disease and lesion severity compared to control animals or those receiving BCG alone." | 1.38 | Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with Mycobacterium tuberculosis. ( Ackart, D; Basaraba, RJ; Caraway, ML; Hascall-Dove, L; Henao-Tamayo, M; Ordway, DJ; Orme, EA; Orme, IM; Shang, S; Shanley, CA, 2012) |
| " Daily dosing of rifapentine (P), a potent rifamycin with high intracellular accumulation, in place of rifampin (R) in the standard antitubercular regimen significantly shortens the duration of treatment needed to prevent relapse in a murine model of active TB." | 1.38 | Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. ( Dutta, NK; Grosset, JH; Illei, PB; Karakousis, PC; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Pinn, ML, 2012) |
| "5% of tuberculosis (TB) cases reported in 2003 in Taipei City had no recorded pre-treatment body weight and that among those who had, inconsistent dosing of anti-TB drugs was frequent." | 1.38 | Improved consistency in dosing anti-tuberculosis drugs in Taipei, Taiwan. ( Bai, KJ; Chiang, CY; Hsu, YL; Lin, TP; Shih, HC; Yang, SL; Yen, MY; Yu, MC, 2012) |
| " No pharmacokinetic data are available from South American children." | 1.38 | Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations. ( Aarnoutse, RE; de Groot, R; de Waard, JH; García, JF; Hermans, PW; López, D; Verhagen, LM; Warris, A, 2012) |
| "Incomplete transverse myelitis (ITM) of unknown origin is associated with high rates of morbidity and mortality." | 1.37 | Mycobacteria infection in incomplete transverse myelitis is refractory to steroids: a pilot study. ( Chen, X; Feng, Y; Guo, N; Huang, F; Lai, R; Liu, J; Sun, Q, 2011) |
| "Pyrazinamide (PZA) plays a unique role in shortening therapy because it kills a population of semilatent tubercle bacilli residing in an acidic environment." | 1.37 | Niosomal encapsulation of the antitubercular drug, pyrazinamide. ( Abd El-Alim, SH; Abdelbary, A; El-Batal, AI; El-Ridy, MS; Khalil, RM; Mostafa, DM; Nasr, EA, 2011) |
| " Population pharmacokinetic parameters and their variability encountered in tuberculosis patients were utilized in Monte Carlo simulations to determine the probability that particular daily doses of the drugs would achieve or exceed the EC(90) in the epithelial lining fluid of 10,000 tuberculosis patients." | 1.36 | New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ( Gumbo, T, 2010) |
| " For the first 2 weeks of therapy, the dosing frequency was 5 days/week, and for the remaining period, twice weekly." | 1.36 | Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. ( Ahmad, Z; Grosset, JH; Karakousis, PC; Nuermberger, EL; Peloquin, CA; Pinn, ML; Tasneen, R; Williams, KN, 2010) |
| "Isoniazid resistance has been described before in those who are immunocompromised." | 1.36 | Human bovine tuberculosis - remains in the differential. ( Bilal, S; Iqbal, M; Murphy, P; Power, J, 2010) |
| "When active tuberculosis is identified, combination therapy with isoniazid, rifampin, pyrazinamide, and ethambutol should be promptly initiated for a two-month "intensive phase," and in most cases, followed by isoniazid and a rifamycin product for a four- to seven-month "continuation phase." | 1.35 | Update on the treatment of tuberculosis. ( Inge, LD; Wilson, JW, 2008) |
| "Mycobacterium tuberculosis infection has been shown to result in increased HIV replication and disease progression in HIV-infected individuals through increased immune activation." | 1.35 | Incomplete immunological recovery following anti-tuberculosis treatment in HIV-infected individuals with active tuberculosis. ( Hanna, LE; Narayanan, PR; Nayak, K; Subramanyam, S; Swaminathan, S; Venkatesan, P, 2009) |
| "Pyrazinamide was the most common causative agent, followed by rifampicin." | 1.35 | Serious adverse reactions in a tuberculosis programme setting in Kyrgyzstan. ( Enarson, DA; Hinderaker, SG; Veen, J; Ysykeeva, J, 2009) |
| "Pyrazinamide liposomes were prepared employing the phospholipid molar ratios; dipalmitoyl phosphatidyl choline (7):cholesterol (2) neutral and dipalmitoyl phosphatidyl choline (7):cholesterol (2):dicetyl phosphate (1) negatively charged." | 1.34 | Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis. ( Abd El-Alim, S; El-Ridy, MS; Mostafa, DM; Nasr, EA; Shehab, A, 2007) |
| "tuberculosis have striking similarities, such as necrosis, mineralization, and hypoxia, to natural infections in humans." | 1.34 | Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. ( Aly, S; Andries, K; Basaraba, RJ; Cantarero, L; Ehlers, S; Hoff, D; Lenaerts, AJ; Orme, IM, 2007) |
| "Moxifloxacin is an 8-methoxyfluoroquinolone currently used in second-line regimens." | 1.34 | Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. ( Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, KN; Zhang, M, 2007) |
| "Evaluation of sources of pharmacokinetic variation can facilitate optimization of tuberculosis treatment regimens by identification of avoidable sources of variation and of risk factors for low or high drug concentrations in patients." | 1.33 | Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. ( Burger, A; Folb, PI; McIlleron, H; Norman, J; Smith, P; Wash, P, 2006) |
| "To improve the bioavailability of antitubercular drugs (ATDs) as well as to assess the feasibility of administering ATDs via the respiratory route, this study reports the formulation of three frontline ATDs, i." | 1.32 | Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. ( Khuller, GK; Pandey, R; Prasad, B; Sharma, A; Sharma, S; Zahoor, A, 2003) |
| "Patient non-compliance is the major drawback associated with the long-duration chemotherapy of tuberculosis (TB); hence, reduction in dosing frequency forms an important therapeutic strategy." | 1.32 | Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. ( Khuller, GK; Pandey, R; Sharma, S; Zahoor, A, 2003) |
| " The mean residence time and absolute bioavailability were increased several-fold as compared with unencapsulated drugs." | 1.32 | Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. ( Khuller, GK; Pandey, R, 2004) |
| "tuberculosis has transcriptional activity." | 1.31 | Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. ( Butcher, PD; Coates, AR; Dhillon, J; Hu, Y; Mangan, JA; Mitchison, DA; Sole, KM, 2000) |
| "To test whether the bioavailability of antituberculosis drugs is altered in HIV-infected patients with tuberculosis." | 1.30 | Does AIDS impair the absorption of antituberculosis agents? ( Smith, PJ; Taylor, B, 1998) |
| "tuberculosis are treated with antibiotics (isoniazid and pyrazinamide), resulting in no detectable bacilli by organ culture." | 1.30 | Reactivation of latent tuberculosis: variations on the Cornell murine model. ( Chan, J; Flynn, JL; Joseph, H; Mohan, VP; Scanga, CA; Yu, K, 1999) |
| " Results show that RIF/PZA, dosed either daily or twice weekly, is as effective in preventing tuberculosis in dually-infected adults, as INH/pyridoxine given for 6-12 months." | 1.30 | Short course preventive therapy for tuberculosis is successful in HIV-infected patients. ( Chaisson, RE, 1998) |
| "Acute dacryocystitis is uncommon later and tuberculosis is exceptionally responsible for it." | 1.29 | [Tuberculous dacryocystitis]. ( Bureau, E; Chetail, N; Cotton, JB; Durra, A; Grenier, JL; Ligeon-Ligeonnet, P; Sartre, J, 1995) |
| "Treatment with isoniazid and rifampicin for 9 months is adequate for patients with localized pleuropulmonary disease." | 1.29 | The high incidence of tuberculosis among renal transplant recipients in India. ( Chugh, KS; Jha, V; Joshi, K; Sakhuja, V; Varma, PP, 1996) |
| "Forty-one of our patients had pulmonary tuberculosis, 38 had extra pulmonary and in 61 it was disseminated." | 1.28 | AIDS and tuberculosis in Spain. A report of 140 cases. ( Adrados, M; Díaz, F; García Aguado, C; González Lahoz, JM; Laguna, F; Martínez, R; Puente, S, 1991) |
| "Seven patients received no treatment because tuberculosis was first diagnosed after death." | 1.28 | Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. ( Chaisson, RE; Goodman, PC; Hopewell, PC; Sande, MA; Schecter, GF; Small, PM, 1991) |
| "A case of tuberculous brain abscess occurred in spite of 4 months' treatment of pulmonary tuberculosis with a triple drug anti-tuberculous regimen." | 1.27 | Successful treatment of tuberculous brain abscess. ( Berfelo, WF; Greve, LH; Hupperts, RM; Janevski, B; Vreeling, FW; Willebrand, D; Wouters, EF, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 280 (32.90) | 18.7374 |
| 1990's | 97 (11.40) | 18.2507 |
| 2000's | 158 (18.57) | 29.6817 |
| 2010's | 209 (24.56) | 24.3611 |
| 2020's | 107 (12.57) | 2.80 |
| Authors | Studies |
|---|---|
| Zimhony, O | 2 |
| Vilchèze, C | 1 |
| Arai, M | 1 |
| Welch, JT | 5 |
| Jacobs, WR | 3 |
| Matsumoto, M | 1 |
| Hashizume, H | 1 |
| Tomishige, T | 1 |
| Kawasaki, M | 1 |
| Tsubouchi, H | 1 |
| Sasaki, H | 1 |
| Shimokawa, Y | 1 |
| Komatsu, M | 1 |
| Ranjith Kumar, R | 1 |
| Perumal, S | 1 |
| Senthilkumar, P | 1 |
| Yogeeswari, P | 3 |
| Sriram, D | 4 |
| García, A | 2 |
| Bocanegra-García, V | 1 |
| Palma-Nicolás, JP | 1 |
| Rivera, G | 1 |
| Dartois, V | 9 |
| Barry, CE | 4 |
| Avupati, VR | 1 |
| Yejella, RP | 1 |
| Parala, VR | 1 |
| Killari, KN | 1 |
| Papasani, VM | 1 |
| Cheepurupalli, P | 1 |
| Gavalapu, VR | 1 |
| Boddeda, B | 1 |
| Zitko, J | 3 |
| Servusová, B | 1 |
| Janoutová, A | 1 |
| Paterová, P | 3 |
| Mandíková, J | 1 |
| Garaj, V | 1 |
| Vejsová, M | 1 |
| Marek, J | 1 |
| Doležal, M | 3 |
| Ramprasad, J | 1 |
| Nayak, N | 1 |
| Dalimba, U | 1 |
| Peethambar, SK | 1 |
| Achur, R | 1 |
| Kumar, HS | 1 |
| Tanwar, B | 1 |
| Kumar, A | 1 |
| Chakraborti, AK | 1 |
| Salve, PS | 1 |
| Alegaon, SG | 1 |
| Hu, YQ | 2 |
| Zhang, S | 4 |
| Zhao, F | 1 |
| Gao, C | 3 |
| Feng, LS | 5 |
| Lv, ZS | 4 |
| Xu, Z | 5 |
| Wu, X | 4 |
| Ding, JW | 1 |
| Ren, QC | 2 |
| Chang, L | 1 |
| Song, XF | 1 |
| Fan, YL | 1 |
| Jin, XH | 1 |
| Huang, ZP | 1 |
| Yu, HF | 1 |
| Zeng, ZG | 1 |
| Gao, T | 1 |
| Bhosle, GS | 1 |
| Nawale, L | 1 |
| Yeware, AM | 1 |
| Sarkar, D | 1 |
| Fernandes, M | 1 |
| Verma, SK | 1 |
| Verma, R | 1 |
| Verma, S | 1 |
| Vaishnav, Y | 1 |
| Tiwari, SP | 1 |
| Rakesh, KP | 1 |
| Cordeiro, R | 1 |
| Kachroo, M | 1 |
| Girase, PS | 1 |
| Dhawan, S | 1 |
| Kumar, V | 2 |
| Shinde, SR | 1 |
| Palkar, MB | 1 |
| Karpoormath, R | 1 |
| Sharma, A | 3 |
| Agrahari, AK | 1 |
| Rajkhowa, S | 2 |
| Tiwari, VK | 1 |
| Liu, D | 1 |
| Huang, F | 2 |
| Zhang, G | 1 |
| He, W | 1 |
| Ou, X | 1 |
| He, P | 1 |
| Zhao, B | 1 |
| Zhu, B | 4 |
| Liu, F | 1 |
| Li, Z | 1 |
| Liu, C | 1 |
| Xia, H | 1 |
| Wang, S | 2 |
| Zhou, Y | 1 |
| Walker, TM | 2 |
| Liu, L | 2 |
| Crook, DW | 2 |
| Zhao, Y | 4 |
| Lee, CS | 1 |
| Shu, CC | 1 |
| Chen, YC | 1 |
| Liao, KM | 1 |
| Ho, CH | 1 |
| Humphries, H | 1 |
| Almond, L | 1 |
| Berg, A | 2 |
| Gardner, I | 1 |
| Hatley, O | 1 |
| Pan, X | 1 |
| Small, B | 1 |
| Zhang, M | 3 |
| Jamei, M | 1 |
| Romero, K | 2 |
| Denti, P | 5 |
| Wasmann, RE | 2 |
| van Rie, A | 2 |
| Winckler, J | 1 |
| Bekker, A | 1 |
| Rabie, H | 2 |
| Hesseling, AC | 5 |
| van der Laan, LE | 1 |
| Gonzalez-Martinez, C | 1 |
| Zar, HJ | 1 |
| Davies, G | 2 |
| Wiesner, L | 3 |
| Svensson, EM | 1 |
| McIlleron, HM | 2 |
| Nardotto, GHB | 1 |
| Bollela, VR | 1 |
| Rocha, A | 1 |
| Della Pasqua, O | 2 |
| Lanchote, VL | 1 |
| Kivrane, A | 1 |
| Grinberga, S | 1 |
| Sevostjanovs, E | 1 |
| Igumnova, V | 1 |
| Pole, I | 1 |
| Viksna, A | 1 |
| Bandere, D | 1 |
| Krams, A | 1 |
| Cirule, A | 1 |
| Pugovics, O | 1 |
| Ranka, R | 1 |
| Barros, ILE | 1 |
| Meneguello, JE | 1 |
| Ghiraldi-Lopes, LD | 1 |
| Arita, GS | 1 |
| de Oliveira Silva, JV | 1 |
| Ferracioli, KRC | 1 |
| de Lima Scodro, RB | 1 |
| Siqueira, VLD | 1 |
| Pilau, EJ | 1 |
| Campanerut-Sá, PAZ | 1 |
| Cardoso, RF | 4 |
| Lien, KA | 1 |
| Dinshaw, K | 1 |
| Nichols, RJ | 1 |
| Cassidy-Amstutz, C | 1 |
| Knight, M | 1 |
| Singh, R | 2 |
| Eltis, LD | 1 |
| Savage, DF | 1 |
| Stanley, SA | 1 |
| Thiede, JM | 2 |
| Dillon, NA | 1 |
| Howe, MD | 2 |
| Aflakpui, R | 1 |
| Modlin, SJ | 1 |
| Hoffner, SE | 1 |
| Valafar, F | 1 |
| Minato, Y | 2 |
| Baughn, AD | 2 |
| Muliaditan, M | 1 |
| Teutonico, D | 1 |
| Ortega-Muro, F | 2 |
| Ferrer, S | 1 |
| Turkova, A | 3 |
| Wills, GH | 1 |
| Wobudeya, E | 2 |
| Chabala, C | 3 |
| Palmer, M | 2 |
| Kinikar, A | 2 |
| Hissar, S | 2 |
| Choo, L | 2 |
| Musoke, P | 1 |
| Mulenga, V | 2 |
| Mave, V | 3 |
| Joseph, B | 1 |
| LeBeau, K | 2 |
| Thomason, MJ | 1 |
| Mboizi, RB | 1 |
| Kapasa, M | 2 |
| van der Zalm, MM | 1 |
| Raichur, P | 1 |
| Bhavani, PK | 5 |
| McIlleron, H | 8 |
| Demers, AM | 1 |
| Aarnoutse, R | 6 |
| Love-Koh, J | 1 |
| Seddon, JA | 3 |
| Welch, SB | 1 |
| Graham, SM | 3 |
| Gibb, DM | 1 |
| Crook, AM | 1 |
| Ekqvist, D | 1 |
| Bornefall, A | 1 |
| Augustinsson, D | 1 |
| Sönnerbrandt, M | 1 |
| Nordvall, MJ | 1 |
| Fredrikson, M | 1 |
| Carlsson, B | 1 |
| Sandstedt, M | 1 |
| Simonsson, USH | 4 |
| Alffenaar, JC | 4 |
| Paues, J | 1 |
| Niward, K | 1 |
| Tasneen, R | 6 |
| Converse, PJ | 2 |
| Zimmerman, MD | 3 |
| Kurbatova, E | 1 |
| Vernon, AA | 2 |
| Carr, W | 1 |
| Stout, JE | 4 |
| Dooley, KE | 6 |
| Nuermberger, EL | 12 |
| Santucci, P | 1 |
| Aylan, B | 1 |
| Botella, L | 1 |
| Bernard, EM | 1 |
| Bussi, C | 1 |
| Pellegrino, E | 1 |
| Athanasiadi, N | 1 |
| Gutierrez, MG | 1 |
| Mashele, SA | 1 |
| Steel, HC | 1 |
| Matjokotja, MT | 1 |
| Rasehlo, SSM | 1 |
| Anderson, R | 1 |
| Cholo, MC | 1 |
| Özgür, D | 1 |
| Tezcan Ülger, S | 1 |
| Kayar, MB | 1 |
| Biçmen, C | 1 |
| Aslantürk, A | 1 |
| Ülger, M | 1 |
| Aslan, G | 1 |
| Jiang, H | 1 |
| Li, X | 4 |
| Xing, Z | 1 |
| Niu, Q | 1 |
| Xu, J | 1 |
| Mohandes, AF | 1 |
| Karam, B | 1 |
| Alrstom, A | 1 |
| Alasadi, L | 1 |
| Rajab Bek, MW | 1 |
| Daher, N | 1 |
| Alsuliman, T | 1 |
| Abouhareb, R | 1 |
| Anderson, G | 1 |
| Vinnard, C | 2 |
| Van Aartsen, D | 1 |
| Justine, M | 2 |
| Mduma, E | 2 |
| Mpagama, SG | 3 |
| Alshaer, MH | 2 |
| Peloquin, CA | 14 |
| Mujaga, B | 1 |
| Maro, A | 2 |
| Gratz, J | 3 |
| Kosek, M | 1 |
| Liu, J | 5 |
| Rogawski McQuade, ET | 1 |
| Houpt, ER | 4 |
| Thomas, TA | 3 |
| Heysell, SK | 6 |
| Niu, H | 2 |
| Bai, C | 1 |
| Li, F | 1 |
| Ma, L | 1 |
| He, J | 1 |
| Shi, X | 1 |
| Han, X | 1 |
| Zhang, Y | 12 |
| Cole, MS | 2 |
| Buonomo, JA | 1 |
| Sharma, S | 7 |
| Lamont, EA | 1 |
| Brody, SI | 1 |
| Mishra, NK | 1 |
| Aldrich, CC | 3 |
| Abolhassani-Chimeh, R | 1 |
| Akkerman, OW | 3 |
| Saktiawati, AMI | 1 |
| Punt, NC | 1 |
| Bolhuis, MS | 1 |
| Subronto, YW | 1 |
| van der Werf, TS | 1 |
| Kosterink, JGW | 1 |
| Sturkenboom, MGG | 1 |
| Perumal, R | 2 |
| Arodola-Oladoyinbo, O | 1 |
| Naidoo, A | 2 |
| Kawuma, AN | 1 |
| Naidoo, K | 2 |
| Gengiah, TN | 1 |
| Chirehwa, M | 3 |
| Padayatchi, N | 2 |
| Ding, Y | 1 |
| Zhu, H | 1 |
| Fu, L | 1 |
| Zhang, W | 5 |
| Wang, B | 2 |
| Guo, S | 1 |
| Chen, X | 4 |
| Wang, N | 1 |
| Liu, H | 2 |
| Lu, Y | 1 |
| Saifullah, B | 1 |
| Arulselvan, P | 1 |
| Fakurazi, S | 1 |
| Webster, TJ | 1 |
| Bullo, N | 1 |
| Hussein, MZ | 1 |
| El Zowalaty, ME | 1 |
| Wahan, SK | 1 |
| Chawla, PA | 1 |
| Hartman-Adams, H | 1 |
| Gerbo, RM | 1 |
| George, S | 1 |
| Mvelase, NR | 1 |
| Swe Swe-Han, K | 1 |
| Mlisana, KP | 1 |
| Rajendran, A | 1 |
| Palaniyandi, K | 1 |
| Karaushi, H | 1 |
| Seki, M | 1 |
| Miyawaki, Y | 1 |
| Watanabe, N | 1 |
| Kamoshita, F | 1 |
| Mitsutake, K | 1 |
| Hegde, PV | 1 |
| Aragaw, WW | 1 |
| Jachak, G | 1 |
| Ragunathan, P | 2 |
| Harikishore, A | 1 |
| Grüber, G | 3 |
| Dick, T | 8 |
| Suárez-González, J | 1 |
| Cáceres-Pérez, AR | 1 |
| Oliva, A | 1 |
| Santoveña-Estévez, A | 1 |
| Fariña, JB | 1 |
| Pršo, K | 1 |
| Žideková, N | 1 |
| Porvazník, I | 1 |
| Solovič, I | 1 |
| Mokrý, J | 1 |
| Kertys, M | 1 |
| Lyons, MA | 1 |
| Bouz, G | 1 |
| Šlechta, P | 1 |
| Jand'ourek, O | 1 |
| Konečná, K | 2 |
| Bárta, P | 2 |
| Novák, M | 2 |
| Kučera, R | 2 |
| Dal, NK | 1 |
| Fenaroli, F | 1 |
| Zemanová, J | 1 |
| Forbak, M | 1 |
| Korduláková, J | 1 |
| Pavliš, O | 1 |
| Kubíčková, P | 1 |
| Solans, BP | 1 |
| Béranger, A | 1 |
| Radtke, K | 1 |
| Mohamed, A | 1 |
| Mirzayev, F | 1 |
| Gegia, M | 2 |
| Linh, NN | 1 |
| Schumacher, SG | 1 |
| Nahid, P | 4 |
| Savic, RM | 5 |
| Alshabrmi, FM | 1 |
| Alatawi, EA | 1 |
| Mary Rebecca, Y | 1 |
| Sudha, V | 4 |
| Bharathiraja, T | 1 |
| Kannan, T | 6 |
| Lavanya, J | 5 |
| Hemanth Kumar, AK | 5 |
| Mehta, K | 2 |
| Guo, T | 1 |
| van der Graaf, PH | 1 |
| van Hasselt, JGC | 1 |
| Zheng, X | 2 |
| Gui, X | 1 |
| Yao, L | 1 |
| Ma, J | 1 |
| He, Y | 1 |
| Lou, H | 1 |
| Gu, J | 1 |
| Ying, R | 1 |
| Chen, L | 1 |
| Sun, Q | 3 |
| Liu, Y | 3 |
| Ho, CM | 2 |
| Lee, BY | 2 |
| Clemens, DL | 2 |
| Horwitz, MA | 2 |
| Ding, X | 1 |
| Hao, X | 1 |
| Yang, H | 2 |
| Sha, W | 1 |
| Namasivayam, S | 1 |
| Zimmerman, M | 1 |
| Oland, S | 1 |
| Wang, H | 4 |
| Mittereder, LR | 1 |
| Sher, A | 1 |
| Lopez, JM | 1 |
| Zimic, M | 2 |
| Vallejos, K | 1 |
| Sevilla, D | 1 |
| Quispe-Carbajal, M | 1 |
| Roncal, E | 1 |
| Rodríguez, J | 2 |
| Antiparra, R | 1 |
| Arteaga, H | 1 |
| Gilman, RH | 3 |
| Maruenda, H | 1 |
| Sheen, P | 3 |
| Zhu, J | 3 |
| Bao, Z | 2 |
| Cao, H | 1 |
| Ning, Z | 1 |
| Hoffner, S | 4 |
| Hu, Y | 7 |
| Davies Forsman, L | 2 |
| Varghese, AM | 1 |
| Kandra, N | 1 |
| Uppala, PK | 1 |
| Vangoori, Y | 1 |
| Butti, L | 1 |
| Masapogu, S | 1 |
| Uttaravalli, U | 1 |
| Somarouthu, VS | 1 |
| Balijepalli, MK | 1 |
| Feng, Z | 2 |
| Miao, Y | 1 |
| Peng, Y | 1 |
| Sun, F | 2 |
| Li, R | 2 |
| Ge, S | 2 |
| Song, L | 1 |
| Li, Y | 4 |
| Wang, X | 3 |
| Jia, L | 1 |
| Yu, H | 1 |
| Huang, Y | 1 |
| Wu, Q | 2 |
| Xiao, M | 1 |
| Li, Q | 2 |
| Xu, Y | 1 |
| Shi, W | 4 |
| Wang, Z | 2 |
| Tang, Z | 1 |
| Heidari, H | 1 |
| Molaeipour, L | 1 |
| Ghanavati, R | 1 |
| Kazemian, H | 1 |
| Koohsar, F | 1 |
| Kouhsari, E | 1 |
| Bakshi, S | 1 |
| Kaur, M | 1 |
| Verma, A | 1 |
| Dwivedi, V | 1 |
| Gautam, S | 1 |
| Beamer, G | 1 |
| Stromberg, PC | 1 |
| Headley, CA | 1 |
| Turner, J | 1 |
| Brehm, TT | 1 |
| Köhler, N | 1 |
| Schmiedel, S | 1 |
| Terhalle, E | 1 |
| Martensen, J | 1 |
| Kalsdorf, B | 2 |
| Kandulla, J | 1 |
| Heyckendorf, J | 2 |
| Kuhns, M | 1 |
| Friesen, I | 1 |
| Lange, C | 2 |
| Chen, RH | 1 |
| Michael, T | 1 |
| Kuhlin, J | 1 |
| Schön, T | 1 |
| Stocker, S | 1 |
| Ramachandran, A | 1 |
| Gadgil, CJ | 1 |
| Fage, D | 1 |
| Aalhoul, F | 1 |
| Cotton, F | 1 |
| Galileya, LT | 1 |
| Lee, J | 1 |
| Njahira Mukui, I | 1 |
| Hesseling, A | 1 |
| Zar, H | 1 |
| Gibb, D | 2 |
| Cotton, MF | 2 |
| Antwi, S | 1 |
| Maranchick, N | 1 |
| Dompreh, A | 1 |
| Amissah, AK | 1 |
| Sly-Moore, E | 1 |
| Martyn-Dickens, C | 1 |
| Opoku, T | 1 |
| Enimil, A | 1 |
| Bosomtwe, D | 1 |
| Ojewale, O | 1 |
| Sarfo, AD | 1 |
| Appiah, AF | 1 |
| Kusi-Amponsah, I | 1 |
| Dong, SK | 1 |
| Osei Kuffour, B | 1 |
| Morgan, R | 1 |
| Kwara, A | 1 |
| Zhang, J | 1 |
| Guo, M | 1 |
| Huang, ZX | 1 |
| Bao, R | 1 |
| Yu, Q | 1 |
| Dai, M | 1 |
| Rao, Y | 1 |
| Kendall, EA | 1 |
| Malhotra, S | 1 |
| Cook-Scalise, S | 1 |
| Denkinger, CM | 1 |
| Dowdy, DW | 1 |
| Romain, AS | 1 |
| Mornand, P | 1 |
| Chaput, U | 1 |
| Guedj, R | 1 |
| Grimprel, E | 1 |
| Lei, Q | 1 |
| Dang, L | 1 |
| Zhu, C | 1 |
| Lv, X | 1 |
| Zhou, J | 1 |
| Maurer, FP | 1 |
| Bai, H | 1 |
| Wu, T | 1 |
| Jiao, L | 1 |
| Zhao, Z | 1 |
| Song, J | 2 |
| Liu, T | 1 |
| Lv, Y | 1 |
| Lu, X | 1 |
| Ying, B | 1 |
| Gopal, P | 6 |
| Srivastava, S | 5 |
| Deshpande, D | 3 |
| Magombedze, G | 2 |
| van Zyl, J | 1 |
| Cirrincione, K | 1 |
| Martin, K | 1 |
| Bendet, P | 1 |
| Hanna, D | 1 |
| Hermann, D | 1 |
| Gumbo, T | 7 |
| McKenna, L | 2 |
| Furin, J | 2 |
| Millard, JD | 1 |
| Mackay, EA | 1 |
| Bonnett, LJ | 1 |
| Davies, GR | 3 |
| Wu, L | 1 |
| Ye, Z | 2 |
| Guo, H | 1 |
| Lin, J | 1 |
| Zheng, L | 1 |
| Chu, N | 1 |
| Liu, X | 1 |
| Schutz, C | 1 |
| Barr, D | 1 |
| Ward, A | 1 |
| Janssen, S | 1 |
| Burton, R | 1 |
| Wilkinson, RJ | 2 |
| Shey, M | 1 |
| Maartens, G | 1 |
| Meintjes, G | 1 |
| Perez, LM | 1 |
| Sacchettini, JC | 1 |
| Ramachandran, G | 13 |
| Requena-Mendez, A | 1 |
| Sekaggya-Wiltshire, C | 1 |
| Matteelli, A | 2 |
| Fehr, J | 2 |
| Karmakar, M | 1 |
| Rodrigues, CHM | 1 |
| Horan, K | 1 |
| Denholm, JT | 1 |
| Ascher, DB | 1 |
| Decroo, T | 3 |
| de Jong, BC | 4 |
| Piubello, A | 2 |
| Lynen, L | 3 |
| Van Deun, A | 3 |
| Souleymane, MB | 1 |
| Miyahara, S | 2 |
| von Groote-Bidlingmaier, F | 2 |
| Sun, X | 3 |
| Hafner, R | 6 |
| Rosenkranz, SL | 1 |
| Ignatius, EH | 1 |
| Moran, L | 1 |
| Donahue, K | 2 |
| Swindells, S | 3 |
| Vanker, N | 1 |
| Diacon, AH | 2 |
| Zhao, H | 1 |
| Wang, Y | 1 |
| Zhang, T | 2 |
| Wang, Q | 1 |
| Xie, W | 1 |
| Juhás, M | 1 |
| Kučerová, L | 1 |
| Horáček, O | 1 |
| Janďourek, O | 1 |
| Kubíček, V | 1 |
| Janoušek, J | 1 |
| Kuneš, J | 1 |
| Huynh, J | 1 |
| Thwaites, G | 2 |
| Marais, BJ | 1 |
| Schaaf, HS | 5 |
| Sarathy, JP | 4 |
| Yee, M | 3 |
| Shin, J | 1 |
| Bhushan, S | 1 |
| Akopian, T | 1 |
| Kandror, O | 1 |
| Lim, TK | 1 |
| Gengenbacher, M | 3 |
| Lin, Q | 1 |
| Rubin, EJ | 1 |
| Kort, F | 1 |
| Fournier Le Ray, L | 1 |
| Chauffour, A | 3 |
| Jarlier, V | 4 |
| Lounis, N | 5 |
| Andries, K | 7 |
| Aubry, A | 2 |
| Guglielmetti, L | 1 |
| Veziris, N | 5 |
| Reisinger, AC | 1 |
| Hermann, J | 1 |
| Vagena, FR | 1 |
| Hackl, G | 1 |
| Eller, P | 1 |
| Manu, MS | 1 |
| Das, M | 1 |
| Balakrishnan, S | 1 |
| Sunil Kumar, M | 1 |
| Rakesh, PS | 1 |
| Sindhu, MP | 1 |
| Valamparampil, MJ | 1 |
| Neena, PS | 1 |
| Satyanarayana, S | 1 |
| Desai, U | 1 |
| Doshi, K | 1 |
| Joshi, JM | 1 |
| Kwon, BS | 1 |
| Kim, Y | 2 |
| Lee, SH | 2 |
| Lim, SY | 1 |
| Lee, YJ | 1 |
| Park, JS | 1 |
| Cho, YJ | 1 |
| Yoon, HI | 2 |
| Lee, CT | 2 |
| Lee, JH | 2 |
| Xiao, K | 1 |
| Zhong, L | 4 |
| McCallum, AD | 1 |
| Pertinez, HE | 1 |
| Else, LJ | 1 |
| Dilly-Penchala, S | 1 |
| Chirambo, AP | 1 |
| Sheha, I | 1 |
| Chasweka, M | 1 |
| Chitani, A | 1 |
| Malamba, RD | 1 |
| Meghji, JZ | 1 |
| Gordon, SB | 1 |
| Khoo, SH | 1 |
| Sloan, DJ | 1 |
| Mwandumba, HC | 1 |
| Hernandez, J | 1 |
| Ashley, D | 1 |
| Cao, R | 2 |
| Abrahem, R | 2 |
| Nguyen, T | 1 |
| To, K | 1 |
| Yegiazaryan, A | 1 |
| Akinwale David, A | 1 |
| Kumar Tiwari, R | 1 |
| Venketaraman, V | 2 |
| Shi, B | 1 |
| Chen, M | 1 |
| Xia, Z | 1 |
| Xiao, S | 1 |
| Tang, W | 1 |
| Qin, C | 1 |
| Cheng, Y | 1 |
| Huang, T | 1 |
| Huang, C | 2 |
| Xu, H | 1 |
| Das, R | 1 |
| Mehta, DK | 1 |
| Domaszewska, T | 1 |
| Karo, B | 1 |
| Preuss, U | 1 |
| Kollan, C | 1 |
| Reuss, A | 1 |
| Blank, HP | 1 |
| Brodhun, B | 1 |
| Hauer, B | 1 |
| Altmann, D | 1 |
| Fiebig, L | 1 |
| Haas, W | 1 |
| Perumal, N | 1 |
| Forsman, LD | 1 |
| Ren, W | 1 |
| Gao, Y | 1 |
| Bruchfeld, J | 2 |
| Alffenaar, JW | 3 |
| Rousset, S | 1 |
| Lafaurie, M | 1 |
| Guet-Revillet, H | 1 |
| Protin, C | 1 |
| Le Grusse, J | 1 |
| Derumeaux, H | 1 |
| Gandia, P | 1 |
| Nourhashemi, F | 1 |
| Sailler, L | 1 |
| Sommet, A | 1 |
| Delobel, P | 1 |
| Martin-Blondel, G | 1 |
| Anton, C | 1 |
| Lemos, CX | 1 |
| Machado, FD | 1 |
| Bernardi, RM | 1 |
| Freitas, AA | 1 |
| Silva, DR | 1 |
| Hernández-González, O | 1 |
| Zarazúa, S | 1 |
| Veytia-Bucheli, JI | 1 |
| González-Chávez, MM | 1 |
| Rodríguez-Pinal, CJ | 1 |
| Medellín-Garibay, SE | 1 |
| Uresti-Rivera, EE | 1 |
| Pérez-Vázquez, FJ | 1 |
| Portales-Pérez, DP | 1 |
| Romano-Moreno, S | 1 |
| Milán-Segovia, RDC | 1 |
| Zhang, A | 1 |
| Teng, L | 1 |
| Alterovitz, G | 1 |
| Einbeck, CO | 1 |
| Hunter, CJ | 1 |
| Yasukawa, K | 1 |
| Oscanoa, T | 1 |
| Moscol, S | 1 |
| Amado, J | 1 |
| Pieterman, ED | 1 |
| Keutzer, L | 1 |
| van der Meijden, A | 2 |
| van den Berg, S | 1 |
| Bax, HI | 3 |
| de Steenwinkel, JEM | 3 |
| Almaghrabi, RS | 1 |
| Nizami, I | 1 |
| Alameer, R | 1 |
| Alshehri, N | 1 |
| Almohaizeie, A | 1 |
| Alrajhi, AA | 1 |
| Omrani, AS | 1 |
| Zhang, N | 1 |
| Boeree, MJ | 4 |
| Weiner, M | 1 |
| Heinrich, N | 1 |
| Bliven-Sizemore, E | 1 |
| Phillips, PPJ | 1 |
| Hoelscher, M | 1 |
| Whitworth, W | 1 |
| Morlock, G | 1 |
| Posey, J | 1 |
| Mac Kenzie, W | 1 |
| Mudde, SE | 1 |
| Ayoun Alsoud, R | 1 |
| Upton, AM | 2 |
| Lotlikar, MU | 1 |
| Diacon, A | 1 |
| Dawson, R | 2 |
| Hogg, E | 1 |
| Urbanowski, M | 1 |
| De Jager, V | 1 |
| Fletcher, CV | 1 |
| Bishai, W | 1 |
| Sundell, J | 1 |
| Wijk, M | 1 |
| Bienvenu, E | 1 |
| Äbelö, A | 1 |
| Hoffmann, KJ | 1 |
| Ashton, M | 1 |
| Hussain, Z | 1 |
| Ma, X | 1 |
| Hase, I | 1 |
| Toren, KG | 1 |
| Hirano, H | 1 |
| Sakurai, K | 1 |
| Horne, DJ | 2 |
| Saito, T | 1 |
| Narita, M | 3 |
| Gils, T | 1 |
| Zimba, KM | 1 |
| van der Zalm, M | 1 |
| Luo, J | 1 |
| Fu, Y | 1 |
| Zhao, L | 1 |
| Ma, Y | 1 |
| Liang, Q | 1 |
| Shang, Y | 1 |
| Huang, H | 1 |
| Ma, C | 1 |
| Cui, P | 1 |
| Feng, J | 1 |
| Sullivan, D | 1 |
| Larson, A | 1 |
| Gleeson, F | 1 |
| Rajan, E | 1 |
| Pasipanodya, JG | 3 |
| Kumar, AKH | 3 |
| Chandrasekaran, V | 5 |
| Kumar, AK | 4 |
| Kawaskar, M | 1 |
| Swaminathan, S | 14 |
| Mustazzolu, A | 2 |
| Iacobino, A | 2 |
| Giannoni, F | 3 |
| Piersimoni, C | 2 |
| Fattorini, L | 3 |
| Park, S | 1 |
| Jo, KW | 1 |
| Lee, SD | 1 |
| Kim, WS | 1 |
| Shim, TS | 2 |
| Ravimohan, S | 1 |
| Tamuhla, N | 1 |
| Pasipanodya, J | 1 |
| Modongo, C | 1 |
| Zetola, NM | 1 |
| Weissman, D | 1 |
| Bisson, GP | 2 |
| Pang, Y | 1 |
| Zhu, D | 1 |
| Zheng, H | 1 |
| Shen, J | 1 |
| Sellami, M | 1 |
| Mnejja, M | 1 |
| Charfi, S | 1 |
| Ghorbel, A | 1 |
| Via, LE | 2 |
| Weiner, D | 1 |
| Blanc, L | 2 |
| Boshoff, H | 1 |
| Eugenin, EA | 1 |
| Dartois, VA | 1 |
| Pertinez, H | 1 |
| Alameda-Martin, L | 1 |
| Harrison, T | 1 |
| Coates, A | 1 |
| Guiastrennec, B | 1 |
| Karlsson, MO | 1 |
| Gangadevi, NP | 3 |
| Gupta, A | 4 |
| Cao, J | 1 |
| Mi, Y | 1 |
| Shi, C | 2 |
| Bian, Y | 1 |
| Miao, L | 1 |
| Battini, S | 1 |
| Mannava, MKC | 1 |
| Nangia, A | 1 |
| Adane, K | 1 |
| Spigt, M | 1 |
| Dinant, GJ | 1 |
| Alvarez-Uria, G | 1 |
| Midde, M | 1 |
| Gao, S | 1 |
| Xie, X | 1 |
| You, C | 1 |
| Yang, Y | 2 |
| Xi, Y | 1 |
| Chen, W | 2 |
| Mourik, BC | 1 |
| Svensson, RJ | 1 |
| de Knegt, GJ | 2 |
| Verbon, A | 1 |
| Alghamdi, WA | 1 |
| Al-Shaer, MH | 1 |
| Martial, LC | 1 |
| Kerkhoff, J | 1 |
| Martinez, N | 1 |
| Rodríguez, M | 1 |
| Coronel, R | 1 |
| Molinas, G | 1 |
| Roman, M | 1 |
| Gomez, R | 1 |
| Aguirre, S | 1 |
| Jongedijk, E | 1 |
| Huisman, J | 1 |
| Touw, DJ | 2 |
| Pérez, D | 1 |
| Chaparro, G | 1 |
| Gonzalez, F | 1 |
| Aarnoutse, RE | 4 |
| Magis-Escurra, C | 2 |
| Jagadeb, M | 1 |
| Rath, SN | 1 |
| Sonawane, A | 1 |
| Das, A | 2 |
| Das, SK | 2 |
| Anjum, R | 1 |
| Agrawal, S | 2 |
| Mallik, D | 1 |
| Bouzouita, I | 1 |
| Cabibbe, AM | 3 |
| Trovato, A | 1 |
| Draoui, H | 1 |
| Ghariani, A | 1 |
| Midouni, B | 1 |
| Essalah, L | 1 |
| Mehiri, E | 1 |
| Cirillo, DM | 3 |
| Slim-Saidi, L | 1 |
| Alvarez Cabrera, N | 1 |
| O'Brien, P | 3 |
| Dias-Freedman, I | 1 |
| Mina, M | 1 |
| Sacchettini, J | 1 |
| Podell, BK | 1 |
| Prideaux, B | 2 |
| Ioerger, T | 1 |
| Teskey, G | 1 |
| Islamoglu, H | 1 |
| Munjal, S | 1 |
| Gyurjian, K | 1 |
| Allix-Béguec, C | 1 |
| Arandjelovic, I | 1 |
| Bi, L | 1 |
| Beckert, P | 1 |
| Bonnet, M | 1 |
| Bradley, P | 1 |
| Cancino-Muñoz, I | 1 |
| Caulfield, MJ | 1 |
| Chaiprasert, A | 2 |
| Clifton, DA | 1 |
| Comas, I | 1 |
| De Filippo, MR | 1 |
| de Neeling, H | 1 |
| Diel, R | 1 |
| Drobniewski, FA | 2 |
| Faksri, K | 1 |
| Farhat, MR | 1 |
| Fleming, J | 1 |
| Fowler, P | 1 |
| Fowler, TA | 1 |
| Gao, Q | 1 |
| Gardy, J | 1 |
| Gascoyne-Binzi, D | 1 |
| Gibertoni-Cruz, AL | 1 |
| Gil-Brusola, A | 1 |
| Golubchik, T | 1 |
| Gonzalo, X | 1 |
| Grandjean, L | 1 |
| He, G | 1 |
| Guthrie, JL | 2 |
| Hoosdally, S | 1 |
| Hunt, M | 1 |
| Iqbal, Z | 1 |
| Ismail, N | 1 |
| Johnston, J | 2 |
| Khanzada, FM | 1 |
| Khor, CC | 1 |
| Kohl, TA | 1 |
| Kong, C | 1 |
| Lipworth, S | 1 |
| Liu, Q | 1 |
| Maphalala, G | 1 |
| Martinez, E | 1 |
| Mathys, V | 1 |
| Merker, M | 1 |
| Miotto, P | 2 |
| Mistry, N | 1 |
| Moore, DAJ | 1 |
| Murray, M | 1 |
| Niemann, S | 2 |
| Omar, SV | 1 |
| Ong, RT | 1 |
| Peto, TEA | 1 |
| Posey, JE | 1 |
| Prammananan, T | 2 |
| Pym, A | 1 |
| Rodrigues, C | 2 |
| Rodrigues, M | 1 |
| Rodwell, T | 1 |
| Rossolini, GM | 1 |
| Sánchez Padilla, E | 1 |
| Schito, M | 1 |
| Shen, X | 1 |
| Shendure, J | 1 |
| Sintchenko, V | 1 |
| Sloutsky, A | 1 |
| Smith, EG | 1 |
| Snyder, M | 1 |
| Soetaert, K | 1 |
| Starks, AM | 1 |
| Supply, P | 1 |
| Suriyapol, P | 1 |
| Tahseen, S | 1 |
| Tang, P | 1 |
| Teo, YY | 1 |
| Thuong, TNT | 1 |
| Tortoli, E | 1 |
| van Soolingen, D | 3 |
| Walker, AS | 1 |
| Wilcox, M | 1 |
| Wilson, DJ | 1 |
| Wyllie, D | 1 |
| Zhang, H | 1 |
| Yeconia, A | 1 |
| Nicodemu, I | 1 |
| Augustino, D | 1 |
| Kivuyo, S | 1 |
| Mfinanga, S | 1 |
| Zagurski, T | 1 |
| Kibiki, GS | 2 |
| Mmbaga, B | 1 |
| Silva, A | 1 |
| Dillon, BJ | 1 |
| Masleša-Galić, S | 1 |
| Nava, S | 1 |
| Dekkers, BGJ | 1 |
| Alffenaar, JWC | 1 |
| Ban, GY | 1 |
| Jeong, YJ | 1 |
| Shin, SS | 1 |
| Shin, YS | 1 |
| Park, HS | 1 |
| Kim, SH | 1 |
| Ye, YM | 1 |
| Khan, MT | 1 |
| Malik, SI | 1 |
| Ali, S | 1 |
| Masood, N | 1 |
| Nadeem, T | 1 |
| Khan, AS | 1 |
| Afzal, MT | 1 |
| Juma, SP | 1 |
| Pholwat, S | 1 |
| Liyoyo, A | 1 |
| Mmbaga, BT | 1 |
| Novita, BD | 1 |
| Ali, M | 1 |
| Pranoto, A | 1 |
| Soediono, EI | 1 |
| Mertaniasih, NM | 1 |
| Iwamoto, T | 1 |
| Murase, Y | 1 |
| Yoshida, S | 1 |
| Aono, A | 2 |
| Kuroda, M | 1 |
| Sekizuka, T | 1 |
| Yamashita, A | 1 |
| Kato, K | 1 |
| Takii, T | 2 |
| Arikawa, K | 1 |
| Kato, S | 2 |
| Mitarai, S | 1 |
| Churchyard, GJ | 1 |
| Mukherjee, A | 3 |
| Lodha, R | 3 |
| Kabra, SK | 3 |
| Gardner Toren, K | 1 |
| Spitters, C | 1 |
| Pecha, M | 1 |
| Bhattarai, S | 1 |
| Pardini, M | 1 |
| Piccaro, G | 1 |
| Chandrasekaran, P | 1 |
| Gaikwad, S | 1 |
| Agibothu Kupparam, HK | 1 |
| Thiruvengadam, K | 1 |
| Gupte, N | 1 |
| Paradkar, M | 1 |
| Dhanasekaran, K | 1 |
| Sivaramakrishnan, GN | 1 |
| Kagal, A | 1 |
| Thomas, B | 1 |
| Pradhan, N | 1 |
| Kadam, D | 1 |
| Hanna, LE | 2 |
| Balasubramanian, U | 1 |
| Kulkarni, V | 1 |
| Murali, L | 1 |
| Golub, J | 2 |
| Gupte, A | 1 |
| Shivakumar, SVBY | 1 |
| Radtke, KK | 1 |
| Dodd, PJ | 1 |
| Garcia-Prats, AJ | 1 |
| Tsiligiannis, A | 1 |
| Sfouni, M | 1 |
| Nalda-Molina, R | 1 |
| Dokoumetzidis, A | 1 |
| Saikia, N | 1 |
| Deka, RC | 1 |
| Bouchentouf, R | 2 |
| Bouaity, B | 2 |
| Touati, M | 2 |
| Benjelloun, A | 1 |
| Ali Aitbenasser, M | 1 |
| Aljalil, A | 1 |
| Chihani, M | 1 |
| Ammar, H | 1 |
| Braga, JU | 1 |
| da Conceição, DA | 1 |
| Trajman, A | 1 |
| Ahmad, Z | 5 |
| Tyagi, S | 4 |
| Minkowski, A | 3 |
| Grosset, JH | 10 |
| Poorana Gangadevi, N | 1 |
| Sekar, L | 3 |
| Vijayasekaran, D | 1 |
| Banu Rekha, VV | 1 |
| Ramesh Kumar, S | 1 |
| Ravichandran, N | 4 |
| Mathevan, G | 3 |
| Zhou, Z | 1 |
| Wei, Q | 1 |
| Liu, P | 1 |
| Ma, A | 1 |
| Zou, F | 1 |
| Bhuju, S | 1 |
| Fonseca, Lde S | 1 |
| Marsico, AG | 1 |
| de Oliveira Vieira, GB | 1 |
| Sobral, LF | 1 |
| Stehr, M | 1 |
| Singh, M | 1 |
| Saad, MH | 1 |
| Bhatia, V | 1 |
| Sibal, A | 1 |
| Rajgarhia, S | 1 |
| Chang, KC | 4 |
| Dheda, K | 1 |
| Ahmady, A | 1 |
| Poolad, T | 1 |
| Rafee, P | 1 |
| Tousheh, M | 1 |
| Kahbazi, M | 1 |
| Arjomandzadegan, M | 1 |
| Dewan, P | 1 |
| Thomas, A | 1 |
| Wang, P | 1 |
| Wang, L | 2 |
| Bai, Y | 1 |
| Kang, J | 1 |
| Hao, Y | 1 |
| Luo, T | 1 |
| Angeby, K | 1 |
| Sturegård, E | 1 |
| Jönsson, B | 1 |
| Johansson, A | 1 |
| Sellin, M | 1 |
| Werngren, J | 2 |
| Chen, TC | 1 |
| Chou, LT | 1 |
| Huang, CC | 1 |
| Lai, AB | 1 |
| Wang, JH | 1 |
| Satyaraddi, A | 1 |
| Velpandian, T | 2 |
| Sharma, SK | 4 |
| Vishnubhatla, S | 1 |
| Sirohiwal, A | 1 |
| Makharia, GK | 1 |
| Sinha, S | 1 |
| Biswas, A | 1 |
| Singh, S | 5 |
| Zvada, SP | 1 |
| Donald, PR | 6 |
| Thee, S | 2 |
| Seifart, HI | 4 |
| Smith, PJ | 6 |
| Simonsson, US | 2 |
| Reynolds, J | 1 |
| Sheng, YJ | 1 |
| Wu, G | 1 |
| He, HY | 1 |
| Zou, YS | 1 |
| Huang, YM | 1 |
| Deng, CL | 1 |
| Budzik, JM | 1 |
| Jarlsberg, LG | 2 |
| Higashi, J | 1 |
| Grinsdale, J | 2 |
| Hopewell, PC | 6 |
| Kato-Maeda, M | 1 |
| Pal, P | 1 |
| Patra, SK | 1 |
| Ray, S | 1 |
| Pandit, S | 1 |
| Choudhury, S | 1 |
| Bhattacharya, S | 1 |
| Skerry, C | 2 |
| Pinn, ML | 3 |
| Bruiners, N | 1 |
| Pine, R | 1 |
| Gennaro, ML | 1 |
| Karakousis, PC | 5 |
| Bagcchi, S | 1 |
| Moore, JL | 1 |
| Keller, SJ | 1 |
| Reves, R | 1 |
| Heilig, CM | 1 |
| Tapy, JM | 1 |
| Bozeman, L | 1 |
| Kyle, RP | 1 |
| Hamilton, CD | 3 |
| Bock, N | 1 |
| Wing, D | 1 |
| Hershfield, E | 1 |
| Goldberg, SV | 1 |
| Yoon, JH | 1 |
| Nam, JS | 1 |
| Kim, KJ | 1 |
| Ro, YT | 1 |
| Dutta, NK | 2 |
| Chigutsa, E | 1 |
| Visser, ME | 1 |
| van Helden, PD | 3 |
| Sirgel, FA | 1 |
| Williams, K | 2 |
| Amoabeng, O | 2 |
| Mdluli, KE | 3 |
| Singh, V | 2 |
| Friis, H | 1 |
| Faurholt-Jepsen, D | 1 |
| Bhatnagar, S | 1 |
| Saini, S | 1 |
| Grewal, HM | 2 |
| Feuerriegel, S | 1 |
| Casali, N | 1 |
| Drobniewski, F | 1 |
| Rodionova, Y | 1 |
| Bakonyte, D | 1 |
| Stakenas, P | 1 |
| Pimkina, E | 1 |
| Augustynowicz-Kopeć, E | 2 |
| Degano, M | 1 |
| Ambrosi, A | 1 |
| Mansjö, M | 1 |
| Rüsch-Gerdes, S | 1 |
| Oshi, SN | 1 |
| Alobu, I | 1 |
| Ukwaja, KN | 1 |
| Oshi, DC | 1 |
| Kumar, SR | 2 |
| Banurekha, VV | 2 |
| Sanjeeva, GN | 2 |
| Dayal, R | 1 |
| Akhmetova, A | 1 |
| Kozhamkulov, U | 1 |
| Bismilda, V | 1 |
| Chingissova, L | 1 |
| Abildaev, T | 1 |
| Dymova, M | 1 |
| Filipenko, M | 1 |
| Ramanculov, E | 1 |
| ten Kate, MT | 1 |
| Bakker-Woudenberg, IA | 1 |
| de Steenwinkel, JE | 1 |
| Symons, G | 1 |
| Venter, A | 1 |
| van Niekerk, C | 1 |
| Everitt, D | 1 |
| Hutchings, J | 1 |
| Burger, DA | 1 |
| Schall, R | 1 |
| Mendel, CM | 1 |
| Ricks, PM | 1 |
| Hershow, RC | 1 |
| Rahimian, A | 1 |
| Huo, D | 1 |
| Johnson, W | 1 |
| Prachand, N | 1 |
| Jimenez, A | 1 |
| Wiebel, W | 1 |
| Paul, W | 1 |
| Phillips, PP | 1 |
| Lipman, MC | 1 |
| Reves, RR | 1 |
| Grosset, J | 9 |
| Vernon, A | 2 |
| Chakraborty, S | 1 |
| Rhee, KY | 1 |
| Sturkenboom, MG | 1 |
| Robijns, K | 1 |
| Harteveld, AR | 1 |
| Greijdanus, B | 1 |
| Uges, DR | 1 |
| Acuña-Villaorduña, C | 1 |
| Ayakaka, I | 1 |
| Dryden-Peterson, S | 1 |
| Nakubulwa, S | 1 |
| Worodria, W | 1 |
| Reilly, N | 1 |
| Hosford, J | 1 |
| Fennelly, KP | 1 |
| Okwera, A | 1 |
| Jones-López, EC | 1 |
| Doustdar, F | 1 |
| Pazhang, M | 1 |
| Mehrnejad, F | 1 |
| Safarzadeh, M | 1 |
| Rabiei, D | 1 |
| Chaparzadeh, N | 1 |
| Falahati, H | 1 |
| Mir-Derikvand, M | 1 |
| den Hertog, AL | 2 |
| Sengstake, S | 1 |
| Anthony, RM | 2 |
| Gillini, L | 1 |
| Centis, R | 1 |
| D'Ambrosio, L | 1 |
| Fedele, A | 1 |
| Aprile, V | 1 |
| Pasanisi, G | 1 |
| Donateo, L | 1 |
| Costa, D | 1 |
| Migliori, GB | 3 |
| Tundo, P | 1 |
| Durham, PG | 2 |
| German, N | 1 |
| Mortensen, N | 1 |
| Dhillon, J | 3 |
| Mitchison, DA | 11 |
| Fourie, PB | 2 |
| Hickey, AJ | 2 |
| Şişmanlar, T | 1 |
| Aslan, AT | 1 |
| Budakoğlu, I | 1 |
| Eum, S | 1 |
| Sarathy, J | 4 |
| Chen, C | 1 |
| Kaya, F | 2 |
| Weiner, DM | 1 |
| Chen, PY | 1 |
| Song, T | 1 |
| Lee, M | 1 |
| Cho, JS | 1 |
| Kim, W | 1 |
| Cho, SN | 1 |
| Olivier, KN | 1 |
| Horita, N | 1 |
| Miyazawa, N | 1 |
| Yoshiyama, T | 2 |
| Kojima, R | 1 |
| Ishigatsubo, Y | 1 |
| Kaneko, T | 1 |
| Corrêa, MF | 1 |
| Fernandes, JP | 1 |
| Fan, L | 1 |
| Yang, X | 1 |
| Bai, D | 1 |
| Yao, J | 1 |
| Yi, L | 1 |
| Njire, M | 1 |
| Tan, Y | 1 |
| Mugweru, J | 1 |
| Wang, C | 1 |
| Guo, J | 1 |
| Yew, W | 1 |
| Tan, S | 1 |
| Grzemska, M | 1 |
| Gie, RP | 2 |
| Adeleke, OA | 1 |
| Monama, NO | 1 |
| Tsai, PC | 1 |
| Sithole, HM | 1 |
| Michniak-Kohn, BB | 1 |
| Meloni, M | 1 |
| Corti, N | 1 |
| Müller, D | 1 |
| Henning, L | 1 |
| Gutteck, U | 1 |
| von Braun, A | 1 |
| Weber, R | 1 |
| Okumura, M | 1 |
| Sasaki, Y | 1 |
| Matsuda, S | 1 |
| Osawa, T | 1 |
| Morimoto, K | 1 |
| Yanai, H | 1 |
| Kurasima, A | 1 |
| Ogata, H | 1 |
| Gotoh, H | 1 |
| Venkatesh, S | 1 |
| Kalpana, S | 1 |
| Agarwal, D | 1 |
| Swanson, RV | 1 |
| Ammerman, NC | 2 |
| Ngcobo, B | 1 |
| Adamson, J | 1 |
| Moodley, C | 1 |
| Dorasamy, A | 1 |
| Moodley, S | 1 |
| Mgaga, Z | 1 |
| Bester, LA | 1 |
| Singh, SD | 1 |
| Almeida, DV | 1 |
| Lin, HS | 1 |
| Cheng, CW | 1 |
| Lin, MS | 1 |
| Chou, YL | 1 |
| Chang, PJ | 1 |
| Lin, JC | 1 |
| Ye, JJ | 1 |
| Singla, M | 1 |
| Kanhiya, K | 1 |
| Eedara, BB | 1 |
| Tucker, IG | 1 |
| Das, SC | 1 |
| Lanoix, JP | 2 |
| Safi, H | 1 |
| Pinn, M | 1 |
| Alland, D | 1 |
| Nuermberger, E | 2 |
| Mota, L | 1 |
| Al-Efraij, K | 1 |
| Campbell, JR | 1 |
| Cook, VJ | 1 |
| Marra, F | 2 |
| Holland, DP | 1 |
| Shuford, S | 1 |
| Crosswell, HE | 1 |
| Cirrincione, KN | 1 |
| Sherman, CM | 1 |
| Menting, S | 1 |
| Pfeltz, R | 1 |
| Warns, M | 1 |
| Siddiqi, SH | 2 |
| Verbeeck, RK | 1 |
| Günther, G | 1 |
| Kibuule, D | 1 |
| Hunter, C | 1 |
| Rennie, TW | 1 |
| Young, EF | 1 |
| Perkowski, E | 1 |
| Malik, S | 1 |
| Hayden, JD | 1 |
| Braunstein, MS | 1 |
| Vijayakumar, A | 1 |
| Ramesh, K | 1 |
| Zuur, MA | 1 |
| Zheng, R | 1 |
| Tiberi, S | 1 |
| Murali, AL | 1 |
| Low, JL | 1 |
| Bright-Thomas, RJ | 1 |
| Gondker, AR | 1 |
| Morris, J | 1 |
| Ormerod, LP | 2 |
| Robertson, GT | 1 |
| Scherman, MS | 1 |
| Bruhn, DF | 1 |
| Hastings, C | 1 |
| McNeil, MR | 1 |
| Butler, MM | 1 |
| Bowlin, TL | 1 |
| Lee, RB | 1 |
| Lee, RE | 1 |
| Lenaerts, AJ | 6 |
| Rasic, G | 1 |
| Li, L | 1 |
| Bouazzi, OE | 1 |
| Hammi, S | 1 |
| Bourkadi, JE | 1 |
| Tebaa, A | 1 |
| Tanani, DS | 1 |
| Soulaymani-Bencheikh, R | 1 |
| Badrane, N | 1 |
| Bengueddour, R | 1 |
| Hlavsa, MC | 1 |
| Moonan, PK | 1 |
| Cowan, LS | 1 |
| Navin, TR | 5 |
| Kammerer, JS | 1 |
| Morlock, GP | 2 |
| Crawford, JT | 2 |
| Lobue, PA | 1 |
| Suzuki, Y | 1 |
| Miwa, S | 1 |
| Shirai, M | 1 |
| Ohba, H | 1 |
| Murakami, M | 1 |
| Fujita, K | 1 |
| Suda, T | 1 |
| Nakamura, H | 1 |
| Hayakawa, H | 1 |
| Chida, K | 1 |
| Adhvaryu, MR | 1 |
| Reddy, N | 1 |
| Vakharia, BC | 1 |
| Rosenthal, IM | 2 |
| Almeida, D | 3 |
| Inge, LD | 1 |
| Wilson, JW | 1 |
| Ibrahim, M | 2 |
| Truffot-Pernot, C | 10 |
| Cattamanchi, A | 1 |
| Dantes, RB | 1 |
| Metcalfe, JZ | 1 |
| Kawamura, LM | 2 |
| Osmond, D | 1 |
| Kamal, A | 1 |
| Azeeza, S | 1 |
| Malik, MS | 1 |
| Shaik, AA | 1 |
| Rao, MV | 1 |
| Stavrum, R | 1 |
| Myneedu, VP | 1 |
| Arora, VK | 2 |
| Ahmed, N | 1 |
| Herrera-León, L | 1 |
| Pozuelo-Díaz, R | 1 |
| Molina Moreno, T | 1 |
| Valverde Cobacho, A | 1 |
| Saiz Vega, P | 1 |
| Jiménez Pajares, MS | 1 |
| Gong, Z | 1 |
| Basir, Y | 1 |
| Chu, D | 1 |
| McCort-Tipton, M | 1 |
| Benmansour, N | 1 |
| El hord, S | 1 |
| Oudidi, A | 1 |
| Benjelloun, MC | 1 |
| El alami, MN | 1 |
| Méndez, M | 1 |
| Peña, L | 1 |
| Caviedes, L | 1 |
| Zimic, MJ | 1 |
| Moore, DA | 1 |
| Evans, CA | 1 |
| Camacho, A | 1 |
| Pérez-Camacho, I | 1 |
| Rivero, A | 2 |
| Natera, C | 1 |
| García-Lázaro, M | 1 |
| Castón, JJ | 1 |
| Gallo, M | 1 |
| Kindelán, JM | 2 |
| Torre-Cisneros, J | 1 |
| Nayak, K | 1 |
| Subramanyam, S | 1 |
| Venkatesan, P | 3 |
| Narayanan, PR | 2 |
| Shenai, S | 1 |
| Sadani, M | 1 |
| Sukhadia, N | 1 |
| Mehta, A | 1 |
| Pandey, S | 1 |
| Newton, S | 1 |
| Upton, A | 1 |
| Roberts, S | 1 |
| Drinković, D | 1 |
| Hinderaker, SG | 1 |
| Ysykeeva, J | 1 |
| Veen, J | 1 |
| Enarson, DA | 1 |
| Quiliano, M | 1 |
| Gutierrez, A | 1 |
| Narendran, G | 1 |
| Iliayas, S | 1 |
| Santhanakrishnan, R | 1 |
| Menon, PA | 1 |
| Padmapriyadarsini, C | 2 |
| Ramachandran, R | 1 |
| Chinnaiyan, P | 1 |
| Suhadev, M | 1 |
| Sakthivel, R | 1 |
| Egwaga, S | 1 |
| Mkopi, A | 1 |
| Range, N | 1 |
| Haag-Arbenz, V | 1 |
| Baraka, A | 1 |
| Grewal, P | 1 |
| Cobelens, F | 2 |
| Mshinda, H | 1 |
| Lwilla, F | 1 |
| van Leth, F | 1 |
| Williams, KN | 2 |
| Singla, R | 1 |
| Sarda, P | 1 |
| Mohan, A | 2 |
| Makharia, G | 1 |
| Jayaswal, A | 1 |
| Sreenivas, V | 1 |
| Mahan, CS | 1 |
| Walusimbi, M | 1 |
| Johnson, DF | 1 |
| Lancioni, C | 1 |
| Charlebois, E | 1 |
| Baseke, J | 1 |
| Chervenak, KA | 1 |
| Mugerwa, RD | 1 |
| Havlir, DV | 1 |
| Mayanja-Kizza, H | 1 |
| Whalen, CC | 1 |
| Boom, WH | 1 |
| Cansü, E | 1 |
| Erdogan, F | 1 |
| Ulusam, AO | 1 |
| Banerjee, AD | 1 |
| Pandey, P | 1 |
| Ambekar, S | 1 |
| Chandramouli, BA | 1 |
| Leung, CC | 4 |
| Bilal, S | 1 |
| Iqbal, M | 1 |
| Murphy, P | 1 |
| Power, J | 1 |
| Sharma, B | 1 |
| Pal, N | 1 |
| Malhotra, B | 1 |
| Vyas, L | 1 |
| Rishi, S | 1 |
| Boussetta, K | 1 |
| Tinsa, F | 1 |
| Ghaffari, H | 1 |
| Brini, I | 1 |
| Aloui, N | 1 |
| Jaubert, F | 1 |
| Bousnina, S | 1 |
| Gevers, T | 1 |
| Muthaiah, M | 1 |
| Jagadeesan, S | 1 |
| Ayalusamy, N | 1 |
| Sreenivasan, M | 1 |
| Prabhu, SS | 1 |
| Muthuraj, U | 1 |
| Senthilkumar, K | 1 |
| Veerappan, S | 1 |
| Jonmalung, J | 1 |
| Leechawengwongs, M | 1 |
| Caminero, JA | 1 |
| Sotgiu, G | 1 |
| Zumla, A | 1 |
| Seiner, DR | 1 |
| Hegde, SS | 1 |
| Blanchard, JS | 1 |
| Hashida, N | 1 |
| Terubayashi, A | 1 |
| Ohguro, N | 1 |
| Shang, S | 2 |
| Shanley, CA | 2 |
| Caraway, ML | 2 |
| Orme, EA | 2 |
| Henao-Tamayo, M | 2 |
| Hascall-Dove, L | 2 |
| Ackart, D | 2 |
| Basaraba, RJ | 3 |
| Orme, IM | 5 |
| Ordway, DJ | 2 |
| Wallis, RS | 2 |
| Jakubiec, W | 1 |
| Bedarida, G | 1 |
| Silvia, A | 1 |
| Paige, D | 1 |
| Zhu, T | 1 |
| Mitton-Fry, M | 1 |
| Ladutko, L | 1 |
| Campbell, S | 1 |
| Miller, PF | 1 |
| De Groote, MA | 1 |
| Gilliland, JC | 2 |
| Wells, CL | 1 |
| Brooks, EJ | 1 |
| Woolhiser, LK | 1 |
| Gruppo, V | 2 |
| Hutson, S | 1 |
| Fraig, MM | 1 |
| Feng, Y | 1 |
| Guo, N | 1 |
| Lai, R | 1 |
| Campanerut, PA | 3 |
| Ghiraldi, LD | 2 |
| Spositto, FL | 2 |
| Sato, DN | 3 |
| Leite, CQ | 3 |
| Hirata, MH | 2 |
| Hirata, RD | 3 |
| Willemse, M | 1 |
| El-Ridy, MS | 2 |
| Abdelbary, A | 1 |
| Nasr, EA | 2 |
| Khalil, RM | 1 |
| Mostafa, DM | 2 |
| El-Batal, AI | 1 |
| Abd El-Alim, SH | 1 |
| Magden, ER | 1 |
| Weiner, CM | 1 |
| DeGroote, MA | 1 |
| Kendall, LV | 1 |
| Abes, GT | 1 |
| Abes, FL | 1 |
| Jamir, JC | 1 |
| Webb, RM | 1 |
| Penman, A | 1 |
| Holcombe, M | 1 |
| Dobbs, T | 1 |
| Mathew, TA | 1 |
| Hirata, M | 1 |
| de Oliveira, JL | 1 |
| da Silva Junior, GB | 1 |
| Daher, Ede F | 1 |
| Lerra, S | 1 |
| Nazir, T | 1 |
| Mir Qadri, S | 1 |
| Kirmani, M | 1 |
| Kuwabara, K | 1 |
| Kielland, LG | 1 |
| Vage, RA | 1 |
| Eide, GE | 1 |
| Sørnes, S | 1 |
| Naess, A | 1 |
| Werely, CJ | 1 |
| Rosenkranz, B | 1 |
| Roll, S | 1 |
| Magdorf, K | 1 |
| Saleri, N | 1 |
| Dembélé, SM | 1 |
| Villani, P | 1 |
| Carvalho, AC | 1 |
| Cusato, M | 1 |
| Bonkoungou, V | 1 |
| Nacanabo, R | 1 |
| Kouanda, S | 1 |
| Comelli, M | 1 |
| Regazzi, M | 1 |
| Simons, SO | 1 |
| van Ingen, J | 1 |
| van der Laan, T | 1 |
| Mulder, A | 1 |
| Dekhuijzen, PN | 1 |
| Zhou, M | 1 |
| Geng, X | 1 |
| Chen, J | 1 |
| Wang, D | 1 |
| Deng, J | 1 |
| Zhang, Z | 2 |
| Wang, W | 1 |
| Zhang, XE | 1 |
| Wei, H | 1 |
| van den Boogaard, J | 1 |
| Ijdema, D | 1 |
| Boeree, M | 1 |
| Harper, J | 1 |
| Davis, SL | 1 |
| Weir, M | 1 |
| Kramnik, I | 1 |
| Bishai, WR | 4 |
| Pomper, MG | 1 |
| Jain, SK | 2 |
| Kiziltaş, Ş | 1 |
| Çolak, Y | 1 |
| Ulaşoğlu, C | 1 |
| Öztürk, O | 1 |
| Yorulmaz, E | 1 |
| Adali, G | 1 |
| Enç, F | 1 |
| Tuncer, İ | 1 |
| Kalinda, AS | 1 |
| Leiro-Fernandez, V | 1 |
| Valverde, D | 1 |
| Vázquez-Gallardo, R | 1 |
| Botana-Rial, M | 1 |
| Constenla, L | 1 |
| Agúndez, JA | 1 |
| Fernández-Villar, A | 1 |
| Roy, V | 2 |
| Sahni, P | 1 |
| Gupta, P | 2 |
| Sethi, GR | 2 |
| Khanna, A | 1 |
| Yee, DP | 1 |
| Menzies, D | 1 |
| Brassard, P | 2 |
| Roehr, B | 1 |
| Taylor, D | 1 |
| Grundmann, K | 1 |
| Friedrich, C | 1 |
| Cohen, T | 1 |
| Kalandadze, I | 1 |
| Vashakidze, L | 1 |
| Illei, PB | 1 |
| Navascués, A | 1 |
| Gil-Setas, A | 1 |
| Tordoya, IJ | 1 |
| Jiménez-Pajares, MS | 1 |
| Ruiz-Moreno, JL | 1 |
| Peña-Santos, G | 1 |
| Kmietowicz, Z | 1 |
| Alexander, DC | 1 |
| Ma, JH | 1 |
| Blair, J | 1 |
| Chedore, P | 1 |
| Jamieson, FB | 1 |
| Li, SY | 1 |
| Pym, AS | 2 |
| Wallengren, K | 1 |
| Lalloo, U | 1 |
| Chiang, CY | 1 |
| Yu, MC | 1 |
| Shih, HC | 1 |
| Yen, MY | 1 |
| Hsu, YL | 1 |
| Yang, SL | 1 |
| Lin, TP | 1 |
| Bai, KJ | 1 |
| Solanki, R | 1 |
| Jain, NK | 1 |
| Chauhan, LS | 1 |
| Verhagen, LM | 1 |
| López, D | 1 |
| Hermans, PW | 1 |
| Warris, A | 1 |
| de Groot, R | 1 |
| García, JF | 1 |
| de Waard, JH | 1 |
| Bornigia, S | 1 |
| Gherardi, G | 1 |
| Sayahi, H | 1 |
| Pugliese, KM | 1 |
| Shekhtman, A | 1 |
| Lytras, T | 1 |
| Spala, G | 1 |
| Bonovas, S | 1 |
| Panagiotopoulos, T | 1 |
| Manosuthi, W | 1 |
| Sukasem, C | 1 |
| Lueangniyomkul, A | 1 |
| Mankatitham, W | 1 |
| Thongyen, S | 1 |
| Nilkamhang, S | 1 |
| Manosuthi, S | 1 |
| Sungkanuparph, S | 1 |
| Minkowsk, A | 1 |
| Peck, KM | 1 |
| Baughn, AS | 1 |
| Rajendran, V | 1 |
| Sethumadhavan, R | 1 |
| Wanchu, A | 1 |
| Bhatnagar, A | 1 |
| Khullar, M | 1 |
| Sud, A | 1 |
| Bambery, P | 1 |
| Singh, I | 1 |
| Kaur, KJ | 1 |
| Bhade, SR | 1 |
| Kaul, CL | 1 |
| Panchagnula, R | 1 |
| Engemann, JJ | 1 |
| Cheng, AC | 1 |
| Fortenberry, ER | 1 |
| Auclair, B | 1 |
| Mikota, SK | 1 |
| Aguilar, R | 1 |
| Maslow, JN | 1 |
| Jasmer, RM | 3 |
| Hirano, K | 2 |
| Hamasaki, S | 2 |
| Abe, C | 2 |
| Daley, CL | 2 |
| Castro, KG | 4 |
| Jereb, JA | 3 |
| Koppaka, VR | 1 |
| Cohn, DL | 3 |
| Marks, SM | 1 |
| Ijaz, K | 5 |
| Iademarco, MF | 3 |
| Sterling, T | 1 |
| Munsiff, SS | 1 |
| Frieden, TR | 1 |
| Dekker, TG | 1 |
| Lötter, AP | 1 |
| Danckwerts, MP | 1 |
| Ebrahim, S | 1 |
| Pillay, V | 1 |
| Mohan, B | 1 |
| Benito González, JJ | 1 |
| Benito González, F | 1 |
| Santa Cruz Ruiz, S | 1 |
| Gómez González, JL | 1 |
| Coscarón Blanco, E | 1 |
| Cordero Sánchez, M | 1 |
| del Cañizo Alvarez, A | 1 |
| Kunimoto, D | 1 |
| Warman, A | 1 |
| Beckon, A | 1 |
| Doering, D | 1 |
| Melenka, L | 1 |
| DELATTRE, M | 1 |
| CORDICE, JW | 1 |
| HILL, LM | 1 |
| WRIGHT, LT | 1 |
| YEAGER, RL | 4 |
| MUNROE, WG | 2 |
| DESSAU, FI | 4 |
| McDERMOTT, W | 4 |
| ORMOND, L | 3 |
| MUSCHENHEIM, C | 4 |
| DEUSCHLE, K | 4 |
| McCUNE, RM | 3 |
| TOMPSETT, R | 4 |
| CAMPAGNA, M | 2 |
| CALIX, A | 1 |
| HAUSER, G | 1 |
| PHILLIPS, S | 3 |
| LARKIN, JC | 1 |
| LITZENBERGER, WL | 1 |
| HORTON, GE | 2 |
| HAIMSOHN, JS | 1 |
| BURGER, F | 1 |
| LATAPI, F | 1 |
| GARZA TOBA, M | 1 |
| MARQUEZ ITURRIBARRIA, F | 1 |
| STEENKEN, W | 2 |
| WOLINSKY, E | 4 |
| SCHWARTZ, WS | 3 |
| MOYER, RE | 2 |
| McCUNE, R | 1 |
| POTTER, BP | 1 |
| CHANG, SF | 1 |
| ORGANICK, A | 1 |
| BATTEN, J | 1 |
| DEGLI ESPOSTI, A | 2 |
| DE SIMONI, G | 11 |
| SPINA, G | 7 |
| ZORINI, AO | 4 |
| FERRARI, S | 4 |
| MORELLINI, M | 4 |
| MIYAMOTO, Y | 1 |
| SATO, N | 1 |
| TACHIBANA, T | 1 |
| YANAGISAWA, K | 1 |
| DUGGELI, O | 1 |
| NICK, J | 1 |
| STEWART, SM | 3 |
| MURDOCH, JM | 1 |
| CROFTON, JW | 1 |
| HAY, D | 2 |
| GRIVA, L | 1 |
| MARENGO, G | 1 |
| RANDONE, M | 1 |
| SESIA, L | 1 |
| BESTA, B | 1 |
| LUCCHESI, M | 1 |
| ZUBIANI, M | 1 |
| STORNIELLO, G | 4 |
| FANTOLI, U | 2 |
| BISETTI, A | 4 |
| CATTENEO, C | 1 |
| FANTILI, U | 1 |
| CATTANEGO, C | 1 |
| MARIANI, B | 2 |
| DI DOMENICO, G | 1 |
| SACCO, F | 4 |
| ZUCCHETTI, B | 3 |
| GUALA, B | 4 |
| GUERRA, P | 4 |
| FURUTA, M | 1 |
| DONNERBERG, RL | 1 |
| ATWELL, RJ | 2 |
| BROWNING, RH | 2 |
| MONALDI, V | 1 |
| BLASI, A | 1 |
| CURCI, G | 1 |
| DE PASQUALE, N | 1 |
| LA ROSA, G | 1 |
| STAITI, A | 1 |
| REALE, M | 1 |
| GARAVENTA, A | 1 |
| PAOLI, G | 1 |
| COSTA, G | 2 |
| MORETTI, E | 2 |
| DI PORTO, A | 1 |
| RELLINI, G | 1 |
| ROCCHI, V | 1 |
| FREERKSEN, E | 2 |
| ROSENFELD, M | 1 |
| MAZZINI, C | 1 |
| SMITH, MM | 1 |
| MONTALBINE, V | 1 |
| CORSINI, F | 1 |
| SCHWARTZ, JA | 1 |
| MONACO, U | 1 |
| CAIONE, C | 1 |
| MUZI, F | 1 |
| POGGIO, G | 1 |
| WRUBL, A | 1 |
| GIOVA, C | 2 |
| ROTTINI, E | 2 |
| PICCHIO, E | 2 |
| FIORENTINI, M | 2 |
| CROISSANT, J | 1 |
| GYSELEN, A | 1 |
| DE BRABANDERE, R | 1 |
| CALLENS, L | 2 |
| PECORA, DV | 1 |
| ARRIGONI, G | 1 |
| CIVINO, A | 1 |
| SISTI, MA | 1 |
| SCODITTI, G | 1 |
| SALVETTI, F | 2 |
| CELLERINO, A | 3 |
| PIOVANO, V | 2 |
| EMANUELE, B | 1 |
| GRUMBACH, F | 1 |
| DI RUGGIERO, A | 1 |
| MARINELLI, N | 1 |
| CANIGLIA, M | 1 |
| DE SIMONI, GE | 1 |
| KAMEYAMA, Y | 1 |
| HIRASHIKI, Y | 1 |
| KUNIGOSHI, U | 1 |
| LINATI, A | 1 |
| WEBB, WR | 1 |
| SPARKUHL, K | 1 |
| RITCHIE, JA | 1 |
| CAMPBELL, AE | 1 |
| CUTHBERT, J | 1 |
| BRUCE, LG | 1 |
| TOGURI, E | 1 |
| ALLISON, ST | 1 |
| MACLEOD, HM | 1 |
| SANTOPADRE, I | 2 |
| POLIMENI, L | 1 |
| BUTT, H | 1 |
| HAAPANEN, J | 1 |
| GILL, R | 1 |
| RUSSELL, WF | 1 |
| KASS, I | 4 |
| OSEWSKI, T | 1 |
| SALIBA, A | 2 |
| BEATTY, OA | 2 |
| SERI, I | 2 |
| JACOBS, S | 1 |
| GILLIS, S | 1 |
| TEXLER, K | 1 |
| BONATI, F | 1 |
| BERTONI, L | 1 |
| CASALONE, G | 1 |
| GANZETTI, G | 1 |
| MANGIAROTTI, S | 1 |
| CELOTTI, A | 1 |
| SALA, L | 1 |
| D'AMBROGIO, G | 1 |
| DE PALMA, M | 1 |
| MIRABELLI, S | 1 |
| CINQUEGRANA, A | 1 |
| FELDER, E | 1 |
| PITRE, D | 1 |
| TIEPOLO, U | 1 |
| GUGLIELMETTI, P | 1 |
| SIGNORINI, LF | 1 |
| PIN, R | 1 |
| PINES, A | 2 |
| HEYMER, A | 1 |
| BARANYAI, E | 2 |
| HAMVASI, G | 1 |
| RIVERA, E | 1 |
| SOMNER, AR | 2 |
| BRACE, AA | 1 |
| TODOROFF, T | 1 |
| FRANZOSI, P | 1 |
| HALL, E | 1 |
| RIDDELL, RW | 1 |
| UEDA, C | 1 |
| TAO, TT | 1 |
| KUMASHIRO, Y | 1 |
| ZADOR, L | 1 |
| OTH, M | 1 |
| CATTANEO, C | 1 |
| FOSTER, JH | 1 |
| KILLEN, DA | 1 |
| RHEA, WG | 1 |
| DIVELEY, WL | 1 |
| MCCRACKEN, RL | 1 |
| HUBBARD, WW | 1 |
| CHAVES, AD | 2 |
| CATENA, E | 1 |
| ALIPERTA, A | 1 |
| ROCCO, V | 1 |
| MIGLIOLI, S | 1 |
| CALABRESE, L | 1 |
| TANI, P | 2 |
| POPPIUS, H | 1 |
| GRECO, S | 1 |
| DUSI, U | 1 |
| MENOZZI, V | 1 |
| STUPENENGO, RH | 1 |
| WENDY, CD | 1 |
| RUSSO, V | 1 |
| PFUETZE, KH | 1 |
| PYLE, MM | 1 |
| JANCIK, E | 3 |
| ZELENKA, M | 1 |
| TOUSEK, J | 1 |
| MAKOVA, M | 1 |
| WAGNER, J | 1 |
| MONDESHKI, M | 1 |
| PASHMAKOV, I | 1 |
| MITCHELL, JH | 1 |
| RUIZ, RC | 1 |
| OKULICZ JASINKA, H | 1 |
| ZIERSKI, M | 3 |
| SNAJDR, V | 1 |
| KRAKORA, P | 1 |
| FISER, F | 1 |
| CHODOUNSKA, V | 1 |
| SABAR, IR | 1 |
| BAYGIN, R | 1 |
| DEENSTRA, H | 1 |
| CORPE, RF | 3 |
| GOMAA, TM | 1 |
| GALE, GL | 1 |
| KERR, WK | 1 |
| BERNARD, E | 1 |
| PIERON, R | 1 |
| GROUNDS, JG | 1 |
| SZENDROEI, Z | 1 |
| CSERNUS, A | 1 |
| ACEVEDO, RC | 1 |
| HERRERO, JJ | 1 |
| PILHEU, J | 1 |
| RODRIGUEZ, E | 1 |
| PETTY, TL | 1 |
| DALRYMPLE, GV | 1 |
| ALBRECHT, KF | 1 |
| GOW, JG | 2 |
| EVANS, DA | 2 |
| VELU, S | 1 |
| DAWSON, JJ | 1 |
| DEVADATTA, S | 1 |
| FOX, W | 5 |
| KULKARNI, KG | 1 |
| MOHAN, K | 1 |
| RAMAKRISHNAN, CV | 1 |
| STOTT, H | 1 |
| RICHARDSON, RJ | 1 |
| VILARDO, S | 1 |
| COTTIN, S | 1 |
| COZAN, R | 1 |
| VERAN, P | 1 |
| TUOVINEN, PI | 1 |
| SUTINEN, S | 1 |
| LESTON, JM | 2 |
| FOSTIKOV, B | 1 |
| DRAGANIC, J | 1 |
| VRANJESEVIC, G | 1 |
| GRAZIA, G | 1 |
| STEVENSON, FH | 1 |
| KOLUMBAN, K | 1 |
| BALOGH, Z | 1 |
| FILLA, E | 1 |
| COMENALE, D | 1 |
| ROSSI, F | 1 |
| BLALOCK, FA | 2 |
| ENTZ, A | 1 |
| LARSON, CL | 1 |
| WICHT, WC | 1 |
| VULLIEMOZ, P | 1 |
| FAVEZ, G | 1 |
| GIUNIO, N | 1 |
| CHOFNAS, I | 1 |
| SURRETT, NE | 1 |
| SEVERN, HD | 1 |
| GROSS, JH | 1 |
| GOLDHAMMER, EJ | 1 |
| SMITH, AE | 1 |
| ASPEVIK, E | 2 |
| EVENSTAD, E | 1 |
| HAUKENES, G | 1 |
| VERWILGHEN, R | 1 |
| REYBROUCK, G | 1 |
| COSEMANS, J | 1 |
| FOUQUET, J | 1 |
| CORNU, P | 1 |
| TANNER, E | 1 |
| MEDINA, G | 1 |
| CHAPMAN, PT | 1 |
| SHENNAN, DH | 1 |
| VANWYCK, PJ | 1 |
| HORNE, NW | 1 |
| SCHLESS, JM | 1 |
| ALLISON, RF | 1 |
| INGLIS, RM | 1 |
| WHITE, EF | 1 |
| TOPPERMAN, S | 1 |
| VOIGT, H | 1 |
| WILLROTH, P | 1 |
| BOESZOERMENYI, M | 1 |
| FAUSZT, I | 1 |
| BARAT, I | 1 |
| SCHWEIGER, O | 1 |
| HYMAN, C | 1 |
| WILSON, LA | 1 |
| KULKA, F | 1 |
| SCHERER, E | 1 |
| SAWAI, T | 1 |
| SCARPA, A | 1 |
| ZANELLA, A | 1 |
| SCHARL, R | 1 |
| KALLOS, Z | 2 |
| LACZKO, E | 2 |
| DUBRA, FA | 1 |
| PALERMO, FM | 1 |
| SALOMONE, G | 1 |
| CORATO, P | 1 |
| LOSCHI, GC | 1 |
| FORTUNI, M | 1 |
| NAITO, M | 1 |
| Huang, TS | 1 |
| Lee, SS | 1 |
| Tu, HZ | 1 |
| Huang, WK | 1 |
| Chen, YS | 1 |
| Huang, CK | 1 |
| Wann, SR | 1 |
| Lin, HH | 1 |
| Liu, YC | 1 |
| Pandey, R | 4 |
| Zahoor, A | 3 |
| Khuller, GK | 5 |
| Prasad, B | 1 |
| Kerridge, I | 1 |
| Ethell, M | 1 |
| Potter, M | 1 |
| Prentice, HG | 1 |
| Law, WS | 1 |
| Tam, CM | 2 |
| Yew, WW | 3 |
| Chan, CK | 1 |
| Wong, MY | 1 |
| Snyder, DC | 1 |
| Saukkonen, JJ | 1 |
| Bernardo, J | 1 |
| King, MD | 1 |
| Sánchez-Arcilla, I | 1 |
| Vílchez, JM | 1 |
| García de la Torre, M | 1 |
| Fernández, X | 1 |
| Noguerado, A | 1 |
| Kandula, NR | 1 |
| Dworkin, MS | 1 |
| Carroll, MR | 1 |
| Lauderdale, DS | 1 |
| Schuh, A | 1 |
| Zeiler, G | 1 |
| Jain, D | 1 |
| Dash, S | 1 |
| Perlman, DC | 2 |
| Segal, Y | 1 |
| Rosenkranz, S | 1 |
| Rainey, PM | 1 |
| Remmel, RP | 1 |
| Chirgwin, K | 2 |
| Salomon, N | 2 |
| SOLOTOROVSKY, M | 1 |
| GREGORY, FJ | 1 |
| IRONSON, EJ | 1 |
| BUGIE, EJ | 1 |
| O'NEILL, RC | 1 |
| PFISTER, R | 1 |
| MALONE, L | 1 |
| SCHURR, A | 1 |
| LINDH, H | 1 |
| McKENZIE, D | 1 |
| KISER, JS | 1 |
| WILLIAMS, JH | 2 |
| BURGER, FJ | 1 |
| Miyagi, C | 1 |
| Yamane, N | 1 |
| Yogesh, B | 1 |
| Ano, H | 1 |
| Takashima, T | 1 |
| Garca-Doval, I | 1 |
| Lincoln, T | 1 |
| Brannan, GL | 1 |
| Lynch, V | 1 |
| Conklin, TJ | 1 |
| Clancey, T | 1 |
| Rose, DN | 2 |
| Tuthill, RJ | 1 |
| Vásquez-Campos, L | 1 |
| Asencios-Solis, L | 1 |
| Leo-Hurtado, E | 1 |
| Quispe-Torres, N | 1 |
| Salazar-Lindo, E | 1 |
| Bayona, J | 1 |
| Becerra, MC | 1 |
| Criado-Alvarez, JJ | 1 |
| Sanz Cortés, J | 1 |
| Portugal, I | 1 |
| Barreiro, L | 1 |
| Moniz-Pereira, J | 1 |
| Brum, L | 1 |
| Tracevska, T | 1 |
| Jansone, I | 1 |
| Baumanis, V | 1 |
| Nodieva, A | 1 |
| Marga, O | 1 |
| Skenders, G | 1 |
| Cazzadori, A | 1 |
| Allegranzi, B | 1 |
| Scardigli, A | 1 |
| Favari, F | 1 |
| Concia, E | 1 |
| Smirnova, TG | 1 |
| Chernousova, LN | 1 |
| Andreevskaia, SN | 1 |
| Nikolaeva, GM | 1 |
| Parsons, LM | 1 |
| Somoskövi, A | 1 |
| Urbanczik, R | 1 |
| Salfinger, M | 1 |
| van Hest, R | 1 |
| Baars, H | 1 |
| Kik, S | 1 |
| van Gerven, P | 1 |
| Trompenaars, MC | 1 |
| Kalisvaart, N | 1 |
| Keizer, S | 1 |
| Borgdorff, M | 1 |
| Mensen, M | 1 |
| Saukkonen, J | 1 |
| Gordin, FM | 1 |
| Matts, JP | 3 |
| Chaisson, RE | 7 |
| O'Brien, RJ | 4 |
| Gurumurthy, P | 1 |
| Rajasekaran, S | 1 |
| Bhagavathy, S | 1 |
| Mahilmaran, A | 1 |
| Paramesh, P | 1 |
| Blumberg, HM | 1 |
| Priest, DH | 1 |
| Vossel, LF | 1 |
| Sherfy, EA | 1 |
| Hoy, DP | 1 |
| Haley, CA | 1 |
| Rodrigues, Vde F | 1 |
| Telles, MA | 1 |
| Ribeiro, MO | 1 |
| Cafrune, PI | 1 |
| Rossetti, ML | 1 |
| Zaha, A | 1 |
| Onozaki, K | 1 |
| Khokhar, O | 1 |
| Gange, C | 1 |
| Clement, S | 1 |
| Lewis, J | 1 |
| Lambert, LA | 3 |
| Potolidis, E | 1 |
| Mantadakis, E | 1 |
| Zeniodi, MH | 1 |
| Samonis, G | 1 |
| Ridzon, R | 1 |
| Johnson, CM | 1 |
| Marrieta, KS | 1 |
| Valencia Ortega, ME | 1 |
| Onipede, A | 1 |
| Gagneux, S | 1 |
| Aga, RS | 1 |
| DeRiemer, K | 1 |
| Small, PM | 2 |
| McElroy, PD | 3 |
| Yoon, Y | 1 |
| Curry, K | 1 |
| Bower, WA | 1 |
| Spradling, PR | 1 |
| Bell, DJ | 1 |
| Nyirongo, S | 1 |
| Hartkoorn, R | 1 |
| Ward, SA | 1 |
| Molyneux, EM | 1 |
| Cook, PP | 2 |
| Dhingra, VK | 1 |
| Rajpal, S | 1 |
| Aggarwal, N | 1 |
| Aggarwaln, JK | 1 |
| Shadab, K | 1 |
| Ovsiankina, ES | 1 |
| Kasimtseva, OV | 1 |
| Vasil'eva, IA | 1 |
| Wash, P | 1 |
| Burger, A | 1 |
| Norman, J | 1 |
| Folb, PI | 1 |
| Smith, P | 1 |
| Wilkins, JJ | 1 |
| Langdon, G | 1 |
| Pillai, GC | 1 |
| Fredricks, BA | 1 |
| DeCoster, DJ | 1 |
| Sparks, N | 1 |
| Callister, SM | 1 |
| Schell, RF | 1 |
| Maldonado, RA | 1 |
| Yarnell, CT | 1 |
| Holbert, D | 1 |
| Louw, GE | 1 |
| Warren, RM | 1 |
| Murray, MB | 1 |
| Bosman, M | 1 |
| Young, DB | 1 |
| Victor, TC | 1 |
| Barco, P | 1 |
| Pandolfi, JR | 1 |
| Shikama, ML | 1 |
| de Melo, FF | 1 |
| Mamizuka, EM | 1 |
| Gao, XF | 1 |
| Liu, GJ | 1 |
| Wen, J | 1 |
| Xie, Y | 1 |
| Li, YP | 1 |
| Shehab, A | 1 |
| Abd El-Alim, S | 1 |
| Byrne, ST | 1 |
| Denkin, SM | 1 |
| Jereb, J | 1 |
| Singh, P | 1 |
| Mishra, AK | 1 |
| Malonia, SK | 1 |
| Chauhan, DS | 1 |
| Sharma, VD | 1 |
| Venkatesan, K | 1 |
| Katoch, VM | 1 |
| Bakir Ozbey, S | 1 |
| Kasapoğlu, F | 1 |
| Helvaci, S | 1 |
| Aydin, O | 1 |
| Burman, WJ | 2 |
| López-Cortés, L | 1 |
| Castillo, R | 1 |
| Verdejo, J | 1 |
| García, MA | 1 |
| Martínez-Marcos, FJ | 1 |
| Díez, F | 1 |
| Escribano, JC | 1 |
| Canueto, J | 1 |
| Lozano, F | 1 |
| Pasquau, J | 1 |
| Hernández, JJ | 1 |
| Márquez, M | 1 |
| Hoff, D | 1 |
| Aly, S | 1 |
| Ehlers, S | 1 |
| Cantarero, L | 1 |
| Sekiguchi, J | 1 |
| Nakamura, T | 1 |
| Miyoshi-Akiyama, T | 1 |
| Kirikae, F | 1 |
| Kobayashi, I | 1 |
| Zwolska, Z | 1 |
| Morita, K | 1 |
| Suetake, T | 1 |
| Yoshida, H | 1 |
| Mori, T | 1 |
| Kirikae, T | 1 |
| Aragón, LM | 1 |
| Garrigó, M | 1 |
| Moreno, C | 2 |
| Español, M | 1 |
| Coll, P | 1 |
| Marra, CA | 1 |
| Bruchet, N | 1 |
| Richardson, K | 1 |
| Moadebi, S | 1 |
| Elwood, RK | 1 |
| Fitzgerald, JM | 1 |
| Um, SW | 1 |
| Lee, SW | 1 |
| Kwon, SY | 1 |
| Park, KU | 1 |
| Luzi, G | 1 |
| Diamanti, AP | 1 |
| Germano, V | 1 |
| Laganà, B | 1 |
| Di Rosa, R | 1 |
| Salemi, S | 1 |
| Stoppacciaro, A | 1 |
| D'Amelio, R | 1 |
| Markov, M | 1 |
| Patel, K | 1 |
| Raeesy, A | 1 |
| Bant, A | 1 |
| Van Thiel, DH | 1 |
| Nadir, A | 1 |
| Tostmann, A | 1 |
| de Lange, WC | 1 |
| van der Ven, AJ | 1 |
| Dekhuijzen, R | 1 |
| Mishra, TK | 1 |
| Henry, KA | 1 |
| Schwartzman, K | 1 |
| Jomphe, M | 1 |
| Olson, SH | 1 |
| Lau, TY | 1 |
| Björnesjö, KB | 1 |
| Jarnulf, B | 1 |
| Pretet, S | 2 |
| Liard, R | 1 |
| Perdrizet, S | 2 |
| Bismuth, R | 1 |
| Lecoeur, H | 3 |
| Aquinas, M | 1 |
| Truffot, C | 1 |
| Fermanian, J | 1 |
| Dutt, AK | 3 |
| Stead, WW | 3 |
| Van Scoy, RE | 2 |
| Wilkowske, CJ | 2 |
| Jain, VK | 1 |
| Mathur, KC | 1 |
| Andrew, OT | 1 |
| Schoenfeld, PY | 1 |
| Humphreys, MH | 1 |
| Nolan, CM | 3 |
| Sandblom, RE | 1 |
| Thummel, KE | 1 |
| Slattery, JT | 1 |
| Nelson, SD | 1 |
| Cotton, JB | 1 |
| Ligeon-Ligeonnet, P | 1 |
| Durra, A | 1 |
| Sartre, J | 1 |
| Bureau, E | 1 |
| Chetail, N | 1 |
| Grenier, JL | 1 |
| Macnab, MF | 2 |
| Bohmer, PD | 1 |
| Seager, JR | 2 |
| Klemens, SP | 2 |
| Grossi, MA | 1 |
| Cynamon, MH | 5 |
| Anglaret, X | 1 |
| Saba, J | 1 |
| Perronne, C | 1 |
| Lacassin, F | 1 |
| Longuet, P | 1 |
| Leport, C | 1 |
| Vildé, JL | 1 |
| Chapuis, L | 1 |
| Ji, B | 3 |
| Raviglione, MC | 1 |
| Gillespie, SH | 1 |
| Kennedy, N | 1 |
| Nightingale, SL | 1 |
| Wallace, RJ | 1 |
| Dunbar, D | 1 |
| Brown, BA | 1 |
| Onyi, G | 1 |
| Dunlap, R | 1 |
| Ahn, CH | 1 |
| Murphy, DT | 1 |
| Kajiki, A | 1 |
| Padmini, R | 1 |
| Srinivasan, S | 1 |
| Nalini, P | 1 |
| Mahadevan, S | 1 |
| Altman, C | 1 |
| Biour, M | 1 |
| Grangé, JD | 1 |
| Guy, A | 1 |
| Dickinson, JM | 6 |
| Brändli, O | 1 |
| Dreher, D | 1 |
| Morger, D | 1 |
| Choudhury, P | 1 |
| Puri, RK | 1 |
| Radermecker, M | 1 |
| Sakhuja, V | 1 |
| Jha, V | 1 |
| Varma, PP | 1 |
| Joshi, K | 1 |
| Chugh, KS | 1 |
| Hsu, HS | 1 |
| Wang, LS | 1 |
| Wu, YC | 1 |
| Fahn, HJ | 1 |
| Huang, MH | 1 |
| Gunn-Moore, DA | 1 |
| Jenkins, PA | 1 |
| Lucke, VM | 1 |
| Ali, J | 1 |
| McConville, JH | 1 |
| Peto, RJ | 1 |
| Matthews, TJ | 1 |
| Bergmann, KE | 1 |
| Sharpe, CA | 1 |
| Sole, K | 1 |
| Brmbolić, BJ | 1 |
| Boricić, I | 1 |
| Salemović, DR | 1 |
| Jevtović, DL | 1 |
| Ranin, JT | 1 |
| Begić-Janeva, A | 1 |
| Brennan, PJ | 1 |
| MacGregor, RR | 1 |
| Durrheim, DN | 1 |
| Belt, EL | 1 |
| Zaragoza, RM | 1 |
| Hernandez, A | 1 |
| Treviño, M | 1 |
| Diliz, HS | 1 |
| Alvarez, L | 1 |
| Schütte, W | 1 |
| Berghaus, A | 1 |
| Schütte, A | 1 |
| Colmenero, JD | 1 |
| García-Ordoñez, MA | 1 |
| Sebastián, MD | 1 |
| Pérez-Ruiz, E | 1 |
| Sánchez-Lora, J | 1 |
| Sánchez-González, J | 1 |
| Bentabol, G | 1 |
| Juárez, C | 1 |
| Choudhri, SH | 1 |
| Hawken, M | 1 |
| Gathua, S | 1 |
| Minyiri, GO | 1 |
| Watkins, W | 1 |
| Sahai, J | 1 |
| Sitar, DS | 1 |
| Aoki, FY | 1 |
| Long, R | 2 |
| Mor, N | 1 |
| Esfandiari, A | 1 |
| El Sadr, WM | 1 |
| Heifets, LB | 1 |
| Nelson, ET | 1 |
| Telzak, EE | 1 |
| Klein, O | 1 |
| Kreiswirth, BN | 1 |
| Musser, JM | 1 |
| Hoeppner, VH | 1 |
| Zahiri, K | 1 |
| Ramdani, B | 1 |
| Hachim, K | 1 |
| Benghanem, MG | 1 |
| Fatihi, E | 1 |
| Zaid, D | 1 |
| Jouveshomme, S | 1 |
| Dautzenberg, B | 2 |
| Arif, K | 1 |
| Ali, SA | 1 |
| Amanullah, S | 1 |
| Siddiqui, I | 1 |
| Khan, JA | 1 |
| Nayani, P | 1 |
| Colebunders, R | 1 |
| Florence, E | 1 |
| Koumbaniou, C | 1 |
| Nicopoulos, C | 1 |
| Vassiliou, M | 1 |
| Manda-Stachouli, C | 1 |
| Sakellariou, K | 1 |
| Demou, GS | 1 |
| Constantopoulos, SH | 1 |
| Taylor, B | 1 |
| Vordermeier, HM | 1 |
| Wilkinson, KA | 1 |
| Sjölund, A | 1 |
| Pasvol, G | 1 |
| Ivanyi, J | 1 |
| Halsey, NA | 1 |
| Coberly, J | 2 |
| Chaisson, R | 1 |
| Gordin, F | 2 |
| Kharoubi, S | 1 |
| Domoua, K | 1 |
| N'Dhatz, M | 1 |
| Coulibaly, G | 1 |
| Traore, F | 1 |
| Koffi, J | 1 |
| Achi, V | 1 |
| Daix, T | 1 |
| Ouattara, Y | 1 |
| Ouedraogo, M | 1 |
| Beugre, LK | 1 |
| Konan, JB | 1 |
| Coulibaly, V | 1 |
| Coulibaly, IM | 1 |
| Yapi, A | 1 |
| Goyal, A | 1 |
| Nagarkar, NM | 1 |
| Uppal, KS | 1 |
| Mohan, H | 1 |
| Dass, A | 1 |
| Corrigan, D | 1 |
| Paton, J | 1 |
| Connolly, C | 1 |
| Sturm, AW | 1 |
| McAdam, KP | 1 |
| Wilkinson, D | 1 |
| Gangadharam, PR | 1 |
| Geeta, N | 1 |
| Hsu, YY | 1 |
| Wise, DL | 1 |
| Lowrie, DB | 1 |
| Tascon, RE | 1 |
| Bonato, VL | 1 |
| Lima, VM | 1 |
| Faccioli, LH | 1 |
| Stavropoulos, E | 1 |
| Colston, MJ | 1 |
| Hewinson, RG | 1 |
| Moelling, K | 1 |
| Silva, CL | 1 |
| Pozniak, AL | 1 |
| Miller, R | 1 |
| Scanga, CA | 1 |
| Mohan, VP | 1 |
| Joseph, H | 1 |
| Yu, K | 1 |
| Chan, J | 1 |
| Flynn, JL | 1 |
| Lenaerts, AM | 2 |
| Chase, SE | 2 |
| Chmielewski, AJ | 1 |
| Sterling, TR | 1 |
| Alwood, K | 1 |
| Gachuhi, R | 1 |
| Coggin, W | 1 |
| Blazes, D | 1 |
| Eltringham, IJ | 1 |
| Wilson, SM | 1 |
| Oner-Eyüboglu, AF | 1 |
| Kalpaklioglu, AF | 1 |
| Moray, G | 1 |
| Haberal, M | 1 |
| Cheng, SJ | 1 |
| Thibert, L | 1 |
| Sanchez, T | 2 |
| Heifets, L | 2 |
| Miller, C | 1 |
| de Lourdes Garcia, M | 1 |
| Valdespino, JL | 1 |
| Schechter, M | 1 |
| Klukowicz, AJ | 1 |
| Barry, MA | 1 |
| Daniel, N | 1 |
| Geiter, LJ | 3 |
| Szpytma, M | 1 |
| Hejblum, G | 1 |
| Hou, L | 1 |
| Osei-Hyiaman, D | 1 |
| Yang, A | 1 |
| Kano, K | 1 |
| Zwarenstein, M | 1 |
| Schoeman, JH | 1 |
| Vundule, C | 1 |
| Lombard, CJ | 1 |
| Tatley, M | 1 |
| Mangan, JA | 1 |
| Sole, KM | 1 |
| Butcher, PD | 1 |
| Coates, AR | 1 |
| Choi, IS | 1 |
| Park, JB | 1 |
| Kim, SJ | 1 |
| Joh, JW | 1 |
| Lee, SK | 1 |
| Huh, WS | 1 |
| Oh, HY | 1 |
| Kim, SM | 1 |
| Peck, KR | 1 |
| Song, JH | 1 |
| Kim, MK | 1 |
| Ko, YH | 1 |
| Lee, BB | 1 |
| Sharma, AK | 1 |
| Tolani, SL | 1 |
| Rathi, GL | 1 |
| Gupta, HP | 1 |
| Gupta, R | 1 |
| Hannan, MM | 1 |
| Desmond, EP | 1 |
| Mazurek, GH | 1 |
| Puri, MM | 1 |
| Quigley, MA | 1 |
| Mwinga, A | 2 |
| Hosp, M | 2 |
| Lisse, I | 1 |
| Fuchs, D | 1 |
| Godfrey-Faussett, P | 1 |
| Bock, NN | 1 |
| Rogers, T | 1 |
| Tapia, JR | 1 |
| Herron, GD | 1 |
| DeVoe, B | 1 |
| Khan, MY | 1 |
| Kinsara, AJ | 1 |
| Osoba, AO | 1 |
| Wali, S | 1 |
| Samman, Y | 1 |
| Memish, Z | 1 |
| Bowersox, J | 1 |
| James, JS | 1 |
| Torres, G | 1 |
| Moreno, S | 1 |
| Podzamczer, D | 1 |
| Blázquez, R | 1 |
| Iribarren, JA | 1 |
| Ferrer, E | 1 |
| Reparaz, J | 1 |
| Peña, JM | 1 |
| Cabrero, E | 1 |
| Usán, L | 1 |
| Bhalla, RK | 1 |
| Jones, TM | 1 |
| Rothburn, MM | 1 |
| Swift, AC | 1 |
| Pillai, G | 1 |
| Ellard, GA | 2 |
| McCarthy, M | 1 |
| Scalcini, M | 1 |
| Ollé-Goig, J | 1 |
| Kura, MM | 1 |
| Hira, SK | 1 |
| van Loenhout-Rooyackers, JH | 1 |
| Leufkens, HG | 1 |
| Hekster, YA | 1 |
| Kalisvaart, NA | 1 |
| Permar, S | 1 |
| Sun, Z | 1 |
| Spedini, P | 1 |
| Bendayan, D | 1 |
| Raz, M | 1 |
| Kramer, MR | 1 |
| Zulu, I | 1 |
| Farthing, MJ | 1 |
| Mulambo, S | 1 |
| Kelly, P | 1 |
| Rabahi, MF | 1 |
| Rodrigues, AB | 1 |
| Queiroz de Mello, F | 1 |
| de Almeida Netto, JC | 1 |
| Kritski, AL | 1 |
| Zhu, M | 1 |
| Starke, JR | 1 |
| Steiner, P | 1 |
| Stambaugh, JJ | 1 |
| Ashkin, D | 1 |
| Bulpitt, AE | 1 |
| Berning, SE | 1 |
| Lou, HX | 1 |
| Shullo, MA | 1 |
| McKaveney, TP | 1 |
| Armstrong, J | 1 |
| Stafford, J | 1 |
| Bur, S | 1 |
| Martin, PD | 1 |
| Bates, JH | 1 |
| Newton, RW | 1 |
| Springett, VH | 1 |
| Clarke, PD | 1 |
| Nunn, AJ | 2 |
| Vieritz, HD | 1 |
| Anastasatu, C | 1 |
| Plopeanu, D | 1 |
| Ganguin, HG | 1 |
| Köhler, H | 1 |
| van de Kamp, W | 1 |
| Heffernan, JF | 1 |
| Kumar, L | 2 |
| Kumaresan, JA | 1 |
| Maganu, ET | 1 |
| Jiménez del Cerro, LA | 1 |
| Rivera Hernández, F | 1 |
| Tsakalidis, D | 1 |
| Pratsidou, P | 1 |
| Hitoglou-Makedou, A | 1 |
| Tzouvelekis, G | 1 |
| Sofroniadis, I | 1 |
| Kovaleva, SI | 1 |
| Pust, RE | 1 |
| Lacroix, C | 1 |
| Parkin, DP | 1 |
| Laguna, F | 1 |
| Adrados, M | 1 |
| Díaz, F | 1 |
| Martínez, R | 1 |
| García Aguado, C | 1 |
| Puente, S | 1 |
| González Lahoz, JM | 1 |
| de March Ayuela, P | 1 |
| Held, T | 1 |
| Rössler, W | 1 |
| Reichelt, A | 1 |
| Mielke, M | 1 |
| Alexander, M | 1 |
| Schecter, GF | 1 |
| Goodman, PC | 1 |
| Sande, MA | 1 |
| Casal, M | 1 |
| Linares, MJ | 1 |
| Marín, N | 1 |
| Wagay, AR | 1 |
| Singhal, KC | 1 |
| Bhargava, R | 1 |
| Catlin, BJ | 1 |
| Peterson, KL | 1 |
| Judson, FN | 1 |
| Sbarbaro, JA | 1 |
| Schaberg, T | 1 |
| Lode, H | 1 |
| Blumberg, EA | 1 |
| Gil, RA | 1 |
| Dhand, R | 1 |
| Singhi, PD | 1 |
| Rao, KL | 1 |
| Katariya, S | 1 |
| Pitchenik, AE | 1 |
| Aziz, A | 1 |
| Aziz, K | 1 |
| Ishaq, M | 1 |
| Jittinandana, A | 1 |
| Tournier, G | 1 |
| Ladron de Guevara, R | 1 |
| Gallet, S | 1 |
| Bellon, G | 1 |
| Merkel, S | 1 |
| Fischer, P | 1 |
| Weinecke, W | 1 |
| Lecoeur, HF | 1 |
| Wilkins, EG | 1 |
| Roberts, C | 1 |
| Gallinari, C | 1 |
| Aeberhardt, G | 1 |
| Lévy, A | 1 |
| Bernheim, J | 1 |
| Sors, C | 1 |
| Auvergne, B | 1 |
| Lioté, R | 1 |
| Roucoulès, J | 1 |
| Kuntz, D | 1 |
| Davidson, PT | 1 |
| Hanh, LQ | 1 |
| Ellard, DR | 1 |
| Allen, BW | 1 |
| Girling, DJ | 1 |
| Teo, SK | 1 |
| Tan, TH | 1 |
| Ng, HK | 1 |
| Chan, SL | 1 |
| Kondo, E | 2 |
| Kanai, K | 2 |
| Parthasarathy, R | 1 |
| Sarma, GR | 1 |
| Janardhanam, B | 1 |
| Ramachandran, P | 1 |
| Santha, T | 1 |
| Sivasubramanian, S | 1 |
| Somasundaram, PR | 1 |
| Tripathy, SP | 2 |
| Poggi, S | 1 |
| Chastang, C | 1 |
| Moers, D | 1 |
| Wouters, EF | 1 |
| Hupperts, RM | 1 |
| Vreeling, FW | 1 |
| Greve, LH | 1 |
| Janevski, B | 1 |
| Willebrand, D | 1 |
| Berfelo, WF | 1 |
| Rieder, HL | 1 |
| Vil'derman, AM | 1 |
| Pätiälä, J | 1 |
| Jentgens, H | 1 |
| Beckert, W | 1 |
| Deshayes, P | 1 |
| Houdent, G | 1 |
| Morere, P | 1 |
| Lemercier, JP | 1 |
| Desseauve, P | 1 |
| Simonin, JL | 1 |
| Degtiarev, VP | 1 |
| Dye, WE | 1 |
| Gartmann, J | 1 |
| El'nik, VI | 1 |
| Suzuki, T | 1 |
| Bethge, H | 1 |
| Burgher, LW | 1 |
| Postlethwaite, AE | 1 |
| Bartel, AG | 1 |
| Kelley, WN | 1 |
| Krebs, A | 1 |
| Nair, NG | 1 |
| Radhakrishna, S | 1 |
| Subbammal, S | 1 |
| Pavlov, EP | 1 |
| Ota, Y | 1 |
| Venho, VM | 1 |
| Koskinen, R | 1 |
| Perfeito, JB | 1 |
| Hokama, S | 1 |
| Feldman, J | 1 |
| Uçak, D | 1 |
| Uçak, A | 1 |
| Burzoni, FJ | 1 |
| Chicou, FJ | 1 |
| Durante, C | 1 |
| Hetrick, G | 1 |
| Ras, R | 1 |
| Hess, W | 1 |
| Jungbluth, H | 1 |
| Kropp, R | 1 |
| Zimmer, K | 1 |
| Baruffi, W | 1 |
| Fadel, JC | 1 |
| Stottmeier, KD | 1 |
| Beam, RE | 1 |
| Kubica, GP | 1 |
| Schmelev, NA | 1 |
| Eidus, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Multicenter Phase II-study: Pharmacokinetics and Safety of High-Dose Rifampicin and Pyrazinamide in a Shorter Tuberculosis Treatment Compared With Standardized Treatment in Patients With Mild to Moderate Pulmonary TB[NCT04694586] | Phase 2 | 40 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| TBTC Study 28: Evaluation of a Moxifloxacin-based, Isoniazid-sparing Regimen for Tuberculosis Treatment[NCT00144417] | Phase 2 | 433 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| TBTC Study 27: An Evaluation of the Activity and Tolerability of Moxifloxacin During the First Two Months of Treatment for Pulmonary Tuberculosis--A Double-Blind, Randomized, Multicenter Study by the Tuberculosis Trials Consortium[NCT00140309] | Phase 2 | 350 participants | Interventional | 2003-07-31 | Completed | ||
| A Multiple Arm, Multiple Stage, Phase 2, OL, Randomized, Controlled Trial to Evaluate 4 Treatment Regimens of SQ109, Increased Doses of Rifampicin, and Moxifloxacin in Adults With Newly Diagnosed, Smear-positive Pulmonary Tuberculosis[NCT01785186] | Phase 2 | 365 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Essentiality of Isoniazid in Tuberculosis Therapy[NCT01589497] | Phase 2 | 69 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis: A Randomized Controlled Trial[NCT05215990] | Phase 1/Phase 2 | 80 participants (Anticipated) | Interventional | 2022-01-15 | Recruiting | ||
| A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy[NCT03982277] | Phase 2 | 130 participants (Actual) | Interventional | 2019-04-30 | Completed | ||
| Estimation of Plasma Free and Total Drug Levels of Rifampicin, Isoniazid and Pyrazinamide in Patients on Antituberculosis Therapy and Its Correlation With Development of Drug Induced Hepatotoxicity[NCT01456845] | 110 participants (Actual) | Observational | 2010-08-31 | Completed | |||
| TBTC Study 24: A Non-Comparative Study of the Efficacy of a Largely-Intermittent, Six-Month Tuberculosis Treatment Regimen Among Patients Who Will Not Receive Isoniazid Due to Initial Isoniazid Resistance or Intolerance[NCT00023374] | 98 participants (Actual) | Interventional | 2000-08-31 | Completed | |||
| Plasma Drug Concentrations in the Treatment of Multidrug-resistant Tuberculosis in Relation to Minimum Inhibitory Concentrations - a Prospective Observational Study[NCT02816931] | 37 participants (Actual) | Observational | 2016-03-31 | Completed | |||
| An Open Label, Randomized Controlled Trial to Establish the Efficacy and Safety of a Study Strategy Consisting of 6 Months of Bedaquiline (BDQ), Delamanid (DLM), and Linezolid (LNZ), With Levofloxacin (LVX) and Clofazimine (CFZ) Compared to the Current So[NCT04062201] | Phase 3 | 402 participants (Actual) | Interventional | 2019-08-22 | Active, not recruiting | ||
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| Micronutrient Supplementation in Conjunction With Standard Anti-Tuberculosis Therapy in Paediatric (6 Months-15 Years) New Pulmonary Tuberculosis Patients[NCT00801606] | Phase 3 | 403 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of the Following: TMC207 Plus PA-824 Plus Pyrazinamide Plus Clofazimine, TMC207 Plus PA-824 Plus Pyrazinamide, TMC207 Plus PA-824 Plus Clofazimine Alone, TMC207 Plus Pyra[NCT01691534] | Phase 2 | 105 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| A Prospective, Randomized Controlled Study for the Efficacy and Safety of the Substitution of Pyrazinamide and Ethambutol With Moxifloxacin During the Intensive Phase of Treatment of Pulmonary Tuberculosis[NCT04187469] | 286 participants (Anticipated) | Interventional | 2020-03-01 | Not yet recruiting | |||
| Randomized Clinical Trial to Assess the Efficacy of Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis[NCT00376012] | Phase 3 | 300 participants (Actual) | Interventional | 2001-02-28 | Active, not recruiting | ||
| A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes[NCT02129244] | 3,600 participants (Anticipated) | Interventional | 2014-10-31 | Active, not recruiting | |||
| Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Antituberculosis Treatment Induced Hepatotoxicity[NCT00405301] | Phase 4 | 175 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| A Randomized Double Blind Placebo Controlled Trial of Adjunctive Dexamethasone for the Treatment of HIV-infected Adults With Tuberculous Meningitis[NCT03092817] | Phase 3 | 520 participants (Actual) | Interventional | 2017-05-25 | Active, not recruiting | ||
| A Randomized Double Blind Placebo Controlled Non-inferiority Trial of Adjunctive Dexamethasone for the Treatment of HIV-uninfected Adults With Tuberculous Meningitis Stratified by Leukotriene A4 Hydrolase Genotype[NCT03100786] | Phase 3 | 640 participants (Anticipated) | Interventional | 2018-02-08 | Recruiting | ||
| A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177] | Phase 4 | 96 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Pharmacokinetics of Antituberculosis Agents in HIV-Infected Persons With Tuberculosis[NCT00000950] | 50 participants | Interventional | Completed | ||||
| Immune Activation and Drug Absorption in HIV-Infected Patients[NCT01845298] | 7 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults[NCT01782950] | Phase 4 | 400 participants (Anticipated) | Interventional | 2013-02-28 | Recruiting | ||
| Role of Pseudomonas Aeruginosa Biofilms in Exacerbations in Patients With Bronchiectasis With and Without Chronic Obstructive Pulmonary Disease[NCT04803695] | 96 participants (Anticipated) | Observational | 2018-03-01 | Recruiting | |||
| The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV Infection[NCT00001033] | Phase 3 | 650 participants | Interventional | Completed | |||
| Diagnosis of Active Tuberculosis in Endemic Area by Using Enzyme-Linked Immunospot Assay for Gamma-Interferon[NCT00174083] | 200 participants | Observational | 2005-08-31 | Recruiting | |||
| Evaluation of Two Different Preventive Therapy Regimens for Tuberculosis in HIV Infected Persons[NCT00351702] | Phase 3 | 650 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection[NCT00000638] | 2,000 participants | Interventional | Completed | ||||
| Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection[NCT00000636] | 2,000 participants | Interventional | Completed | ||||
| Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania.[NCT00760149] | Phase 2 | 150 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Efficacy of Simultaneous Versus Sequential Antiretroviral Therapy and Antituberculosis Treatment in Patients With AIDS and Active Tuberculosis. Open, Randomized and Controlled, Multisite Clinical Trial.[NCT00737724] | 63 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Other published trials showed definitive expected superiority of Group 1) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Pharmacokinetic parameters will be assessed for rifampicin, moxifloxacin and SQ109:~area under the plasma concentration curve from dosing to the end of the dosing interval (AUC 0-24) (in h*ng/mL)~the observed maximum concentration (Cmax( (in ng/mL)~time to reach Cmax (Tmax)(in hours)~the minimum observed plasma concentration 24 hours following the last dose (Cmin) (in hours),~clearance (Cl) (in mL/minute),~volume of distribution (Vd) (in L),~elimination half-life (T1/2,) (in hours)~free (protein-unbound) fraction (for rifampicin only) (in percent)." (NCT01785186)
Timeframe: 0 - 12 weeks
| Intervention | Rifampicin AUC(mg*h/l) (Geometric Mean) |
|---|---|
| HRZQ | 17.4 |
| Arm 1 (R35) | 170 |
| HR20ZQ | 68.3 |
| HR20ZM | 57.8 |
| HRZE | 24.2 |
From enrollment, the time to stable culture conversion (2 consecutive negative weekly cultures) in liquid media. (NCT01785186)
Timeframe: 0 - 12 weeks
| Intervention | days (Median) |
|---|---|
| Arm 1 (R35) | 48 |
| HRZQ | 63 |
| HR20ZQ | 66 |
| HR20ZM | 55 |
| HRZE | 62 |
All Adverse Events (AE), and AEs considered to be drug-related will coded using standard AE dictionaries. (NCT01785186)
Timeframe: 0 - 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Number of Patients with at least 1 AE | Number of patients with at least 1 SAE | |
| Arm 1 (R35) | 53 | 4 |
| HR20ZM | 49 | 4 |
| HR20ZQ | 42 | 5 |
| HRZE | 92 | 6 |
| HRZQ | 49 | 4 |
PK AUCs of Isoniazid (INH) from 0 to 24 hours obtained at Day 1 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 1
| Intervention | h*ng/mL (Median) |
|---|---|
| RHZE-RHZE | 10725.8 |
| RHZE-RZE | 7970.6 |
| RHZE-RMZE | 7165.1 |
PK AUCs of Isoniazid from 0 to 24 hours obtained at Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 14
| Intervention | h*ng/mL (Median) |
|---|---|
| RHZE-RHZE | 9797.2 |
PK AUCs of Moxiflozacin (Mox) from 0 to 24 hours obtained at Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Moxifloxacin dosing at Day 14
| Intervention | h*ng/mL (Median) |
|---|---|
| RHZE-RMZE | 22498.4 |
Pearson correlation coefficient was used to examine the correlation between TTP and log10 CFU among all qualified samples obtained on study (NCT01589497)
Timeframe: Pre-entry, Day 0, Day 1, Day 2, Day 3, Day 5, Day 7, Day 9, Day 11 and Day 14
| Intervention | correlation coefficient (Number) |
|---|---|
| Overall | -0.75 |
"The daily change in log10 CFU/mL sputum was calculated as follows:~EBA2-14(CFU) = (log10 CFU/mL at day 2 - log10 CFU/mL at day 14)/12.~For a CFU/mL count of 0, the log10 CFU/mL was set to 0." (NCT01589497)
Timeframe: Day 2 and day 14
| Intervention | log10 CFU/ mL (Median) |
|---|---|
| RHZE-RHZE | 0.143 |
| RHZE-RZE | 0.093 |
| RHZE-RMZE | 0.123 |
| RZE-RZE | 0.104 |
"The daily change in log10 CFU/mL sputum was calculated as follows:~EBA0-2(CFU) = (baseline log10 CFU/mL sputum (mean of log10 CFU/mL at pre-entry and day 0) - log10 CFU/mL at day 2)/2.~For a CFU/mL count of 0, the log10 CFU/mL was set to 0." (NCT01589497)
Timeframe: Pre-entry, Day 0 and Day 2
| Intervention | log10 CFU/ mL (Median) |
|---|---|
| RHZE-RHZE | 0.255 |
| RHZE-RZE | 0.385 |
| RHZE-RMZE | 0.111 |
| RZE-RZE | 0.034 |
"The daily change in TTP was calculated as follows:~EBA0-14(TTP) = [baseline TTP (mean of TTP at pre-entry and day 0) - TTP at day 14]/14." (NCT01589497)
Timeframe: Pre-entry, Day 0 and Day 14
| Intervention | hours (Median) |
|---|---|
| RHZE-RHZE | -12 |
| RHZE-RZE | -12 |
| RHZE-RMZE | -13 |
| RZE-RZE | -11 |
"The daily change in TTP was calculated as follows:~EBA0-2(TTP) = (baseline TTP (mean of TTP at pre-entry and day 0) - TTP at day 2)/2." (NCT01589497)
Timeframe: Pre-entry, Day 0 and Day 2
| Intervention | hours (Median) |
|---|---|
| RHZE-RHZE | -31 |
| RHZE-RZE | -30 |
| RHZE-RMZE | -29 |
| RZE-RZE | -25 |
"The daily change in TTP was calculated as follows:~EBA2-14(TTP) = (TTP at day 2 - TTP at day 14)/12." (NCT01589497)
Timeframe: Day 2 and Day 14
| Intervention | hours (Median) |
|---|---|
| RHZE-RHZE | -9 |
| RHZE-RZE | -9 |
| RHZE-RMZE | -12 |
| RZE-RZE | -9 |
"The daily decrease was calculated as follows:~EBA0-14(CFU)= [baseline log10 CFU/mL sputum (mean of log10 CFU/mL at pre-entry and day 0) - log10 CFU/mL at day 14]/14. For a CFU/ml count of 0, the log10 CFU/mL was set to 0.~No formal statistical testing was conducted to compare the arms. Please refer to the explanation in the Protocol Section." (NCT01589497)
Timeframe: Pre-entry, Day 0 and Day 14
| Intervention | log10 CFU/ mL (Median) |
|---|---|
| RHZE-RHZE | 0.134 |
| RHZE-RZE | 0.096 |
| RHZE-RMZE | 0.136 |
| RZE-RZE | 0.119 |
Isoniazid PK parameter CL/F obtained Day 1 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 1
| Intervention | L/hour (Median) |
|---|---|
| RHZE-RHZE | 28.0 |
| RHZE-RZE | 37.6 |
| RHZE-RMZE | 41.9 |
Isoniazid PK parameter CL/F obtained Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 14
| Intervention | L/hour (Median) |
|---|---|
| RHZE-RHZE | 30.6 |
Isoniazid (INH) PK parameter CLast obtained Day 1. The lower limit of quantification of the assay (LLOQ) for INH was 100 ng/mL. The results below the lower limit of quantification were assigned as one-half the value of the LLOQ, which was 50 ng/mL. (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 1
| Intervention | ng/mL (Median) |
|---|---|
| RHZE-RHZE | 50 |
| RHZE-RZE | 50 |
| RHZE-RMZE | 50 |
Isoniazid (INH) PK parameter CLast obtained Day 14. The lower limit of quantification of the assay (LLOQ) for INH was 100 ng/mL. The results below the lower limit of quantification were assigned as one-half the value of the LLOQ, which was 50 ng/mL. (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 14
| Intervention | ng/mL (Median) |
|---|---|
| RHZE-RHZE | 50 |
Isoniazid PK parameter Cmax obtained Day 1 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 1
| Intervention | ng/mL (Median) |
|---|---|
| RHZE-RHZE | 3165 |
| RHZE-RZE | 2920 |
| RHZE-RMZE | 2760 |
Isoniazid PK parameter Cmax obtained Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 14
| Intervention | ng/mL (Median) |
|---|---|
| RHZE-RHZE | 3130 |
Moxifloxacin PK parameter CL/F obtained Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Moxifloxacin dosing at Day 14
| Intervention | L/hour (Median) |
|---|---|
| RHZE-RMZE | 17.8 |
Moxifloxacin PK parameter CLast obtained Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Moxifloxacin dosing at Day 14
| Intervention | ng/mL (Median) |
|---|---|
| RHZE-RMZE | 178 |
Moxifloxacin PK parameter Cmax obtained Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Moxifloxacin dosing at Day 14
| Intervention | ng/mL (Median) |
|---|---|
| RHZE-RMZE | 3010 |
PK AUCs of Ethambutol (EMB) from 0 to 24 hours obtained at Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Ethambutol dosing at Day 1 and Day 14
| Intervention | h*ng/mL (Median) | |
|---|---|---|
| EMB AUC0-24hour at Day 1 | EMB AUC0-24hour at Day 14 | |
| RHZE-RHZE | 11918.8 | 16414.9 |
| RHZE-RMZE | 11322.4 | 15181.2 |
| RHZE-RZE | 11145.8 | 16675.9 |
| RZE-RZE | 10716.8 | 16574.6 |
PK AUCs of Pyrazinamide (PZA) from 0 to 24 hours obtained at Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Pyrazinamide dosing at Day 1 and Day 14
| Intervention | h*ng/mL (Median) | |
|---|---|---|
| PZA AUC0-24hour at Day 1 | PZA AUC0-24hour at Day 14 | |
| RHZE-RHZE | 301214.5 | 249879.1 |
| RHZE-RMZE | 292078.2 | 280071.0 |
| RHZE-RZE | 255283.0 | 201389.7 |
| RZE-RZE | 272853.9 | 252276.8 |
Ethambutol PK parameter CL/F obtained Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Ethambutol dosing at Day 1 and Day 14
| Intervention | L/hour (Median) | |
|---|---|---|
| EMB CL/F Day 1 | EMB CL/F Day 14 | |
| RHZE-RHZE | 93.6 | 57.9 |
| RHZE-RMZE | 83.8 | 56.8 |
| RHZE-RZE | 85.4 | 63.5 |
| RZE-RZE | 76.5 | 60.1 |
Ethambutol PK parameter CLast obtained Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Ethambutol dosing at Day 1 and Day 14
| Intervention | ng/mL (Median) | |
|---|---|---|
| EMB CLast at Day 1 | EMB CLast at Day 14 | |
| RHZE-RHZE | 86.5 | 205.0 |
| RHZE-RMZE | 40 | 164 |
| RHZE-RZE | 85 | 176 |
| RZE-RZE | 86 | 159 |
Ethambutol PK parameter Cmax obtained Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Ethambutol dosing at Day 1 and Day 14
| Intervention | ng/mL (Median) | |
|---|---|---|
| EMB Cmax at Day 1 | EMB Cmax at Day 14 | |
| RHZE-RHZE | 2650 | 2980 |
| RHZE-RMZE | 2470 | 2780 |
| RHZE-RZE | 2040 | 3090 |
| RZE-RZE | 2220 | 2920 |
The log10 CFU count per mL from sputum samples processed by standard method or decontaminated method. (NCT01589497)
Timeframe: Pre-entry, Day 0 and Day 14
| Intervention | log10 CFU/ mL (Median) | ||
|---|---|---|---|
| Pre-entry | Day 0 | Day 14 | |
| Decontaminated Processing Method | 5.89 | 5.58 | 3.74 |
| Standard Processing Method | 5.80 | 5.68 | 4.01 |
Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUCs) of Rifampicin from 0 to 24 hours obtained at Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Rifampicin dosing at Day 1 and Day 14
| Intervention | h*ng/mL (Median) | |
|---|---|---|
| RIF AUC0-24hour at Day 1 | RIF AUC0-24hour at Day 14 | |
| RHZE-RHZE | 37358.8 | 31361.4 |
| RHZE-RMZE | 51434.1 | 26751.2 |
| RHZE-RZE | 42062.6 | 27161.7 |
| RZE-RZE | 39294.0 | 30521.0 |
Pyrazinamide PK parameter CL/F obtained Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Pyrazinamide dosing at Day 1 and Day 14
| Intervention | L/hour (Median) | |
|---|---|---|
| PZA CL/F Day 1 | PZA CL/F Day 14 | |
| RHZE-RHZE | 4.1 | 4.5 |
| RHZE-RMZE | 4.7 | 4.7 |
| RHZE-RZE | 4.8 | 5.4 |
| RZE-RZE | 4.2 | 4.7 |
Pyrazinamide PK parameter CLast obtained Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Pyrazinamide dosing at Day 1 and Day 14
| Intervention | ng/mL (Median) | |
|---|---|---|
| PZA CLast at Day 1 | PZA CLast at Day 14 | |
| RHZE-RHZE | 3370 | 1955.0 |
| RHZE-RMZE | 3130 | 1790 |
| RHZE-RZE | 2850 | 1280 |
| RZE-RZE | 2710 | 1770 |
Pyrazinamide PK parameter Cmax obtained Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Pyrazinamide dosing at Day 1 and Day 14
| Intervention | ng/mL (Median) | |
|---|---|---|
| PZA Cmax at Day 1 | PZA Cmax at Day 14 | |
| RHZE-RHZE | 27650 | 29300 |
| RHZE-RMZE | 28800 | 29300 |
| RHZE-RZE | 27000 | 27000 |
| RZE-RZE | 25800 | 28000 |
Rifampicin PK parameter Clearance (CL/F) obtained Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Rifampicin dosing at Day 1 and Day 14
| Intervention | L/hour (Median) | |
|---|---|---|
| RIF CL/F Day 1 | RIF CL/F Day 14 | |
| RHZE-RHZE | 14.0 | 18.0 |
| RHZE-RMZE | 10.5 | 21.5 |
| RHZE-RZE | 12.5 | 22.1 |
| RZE-RZE | 14.3 | 17.0 |
Rifampicin (RIF) PK parameter Last Concentration (CLast) obtained Day 1 and Day 14. The lower limit of quantification of the assay (LLOQ) for RIF was 40 ng/mL. The results below the lower limit of quantification were assigned as one-half the value of the LLOQ, which was 20 ng/mL. (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Rifampicin dosing at Day 1 and Day 14
| Intervention | ng/mL (Median) | |
|---|---|---|
| RIF CLast at Day 1 | RIF CLast at Day 14 | |
| RHZE-RHZE | 74.5 | 20 |
| RHZE-RMZE | 133 | 20 |
| RHZE-RZE | 20 | 20 |
| RZE-RZE | 20 | 20 |
Rifampicin PK parameter Parameter Maximum Plasma Concentration (Cmax) obtained Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Rifampicin dosing at Day 1 and Day 14
| Intervention | ng/mL (Median) | |
|---|---|---|
| RIF Cmax at Day 1 | RIF Cmax at Day 14 | |
| RHZE-RHZE | 5565 | 7145 |
| RHZE-RMZE | 8660 | 7370 |
| RHZE-RZE | 6060 | 6960 |
| RZE-RZE | 4880 | 8350 |
(NCT01691534)
Timeframe: 14 consecutive days of treatment
| Intervention | log10CFU/ml/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 0.115 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 0.167 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 0.076 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 0.124 |
| Pyrazinamide (Z) | 0.036 |
| Clofazimine (C) | -0.017 |
| Rifafour | 0.151 |
(NCT01691534)
Timeframe: Days 0-14
| Intervention | percentage of change in time/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 6.3 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 7.0 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 4.3 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 4.9 |
| Pyrazinamide (Z) | 2.0 |
| Clofazimine (C) | -0.3 |
| Rifafour | 6.3 |
(NCT01691534)
Timeframe: Day 0-2
| Intervention | percentage of change in time/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 10.6 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 13.2 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 6.0 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 9.1 |
| Pyrazinamide (Z) | 4.7 |
| Clofazimine (C) | 2.1 |
| Rifafour | 12.9 |
(NCT01691534)
Timeframe: Days 7-14
| Intervention | percentage of change in time/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 3.6 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 4.5 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 3.1 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 3.0 |
| Pyrazinamide (Z) | 0.8 |
| Clofazimine (C) | -1.3 |
| Rifafour | 4.4 |
(NCT01691534)
Timeframe: Days 0-2
| Intervention | log10CFU/ml/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 0.161 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 0.196 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 0.062 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 0.132 |
| Pyrazinamide (Z) | 0.080 |
| Clofazimine (C) | 0.018 |
| Rifafour | 0.141 |
(NCT01691534)
Timeframe: Day 7-14
| Intervention | log10CFU/ml/day (Mean) |
|---|---|
| TMC207, PA-824, Pyrazinamide and Clofazimine (J-PA-Z-C) | 0.085 |
| TMC207, PA-824 and Pyrazinamide (J-PA-Z) | 0.146 |
| TMC207, PA-824 and Clofazimine (J-PA-C) | 0.085 |
| TMC207, Pyrazinamide and Clofazimine (J-Z-C) | 0.118 |
| Pyrazinamide (Z) | 0.022 |
| Clofazimine (C) | -0.038 |
| Rifafour | 0.157 |
71 reviews available for pyrazinamide and Koch's Disease
| Article | Year |
|---|---|
Recent advances in antitubercular natural products.
Topics: Animals; Antitubercular Agents; Biological Products; Drug Resistance, Multiple, Bacterial; Genes, Ba | 2012 |
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Lung; Mycobacterium tuberculosis; Tuberculos | 2013 |
Isoniazid derivatives and their anti-tubercular activity.
Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Isoniazid; Mycobacterium tuberculosis; Tuber | 2017 |
Triazole derivatives and their anti-tubercular activity.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Molecu | 2017 |
Recent advances of pyrazole-containing derivatives as anti-tubercular agents.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Molecular Structure; Mycobacterium | 2017 |
Recent advances of imidazole-containing derivatives as anti-tubercular agents.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Imidazoles; Microbial Sens | 2018 |
Anti-tuberculosis activity and its structure-activity relationship (SAR) studies of oxadiazole derivatives: A key review.
Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Models, Molecular; Mycobacterium tuberculosi | 2021 |
An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.
Topics: Animals; Antitubercular Agents; Drug Design; Drug Discovery; Humans; Mycobacterium tuberculosis; Pip | 2021 |
Emerging impact of triazoles as anti-tubercular agent.
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Structure-Ac | 2022 |
Development of physiologically-based pharmacokinetic models for standard of care and newer tuberculosis drugs.
Topics: Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Standard of Care; Tuberculosis | 2021 |
Anti-Tubercular Activity of Pyrazinamide Conjugates: Synthesis and Structure-Activity Relationship Studies.
Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Pyrazinamide; Structure-Activity Relation | 2023 |
Mutations Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis: A Review and Update.
Topics: Amidohydrolases; Antitubercular Agents; Clofazimine; Coenzyme A; Drug Resistance, Bacterial; Fluoroq | 2022 |
Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Ethambutol; HIV; HIV Infections; Humans; Isoniazid; | 2023 |
Global status of phenotypic pyrazinamide resistance in
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sens | 2023 |
[Treatment of tuberculosis: what is new?]
Topics: Antitubercular Agents; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Tuberculosis; Tuberculosis, Mu | 2023 |
Is there a need to optimise pyrazinamide doses in patients with tuberculosis? A systematic review.
Topics: Animals; Antitubercular Agents; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Myco | 2023 |
Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.
Topics: Animals; Antitubercular Agents; Humans; Mycobacterium tuberculosis; Pyrazinamide; Tuberculosis | 2019 |
Targeted protein degradation in antibacterial drug discovery?
Topics: Antibiotics, Antitubercular; Bacterial Proteins; Drug Discovery; Drug Resistance, Bacterial; Humans; | 2020 |
A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes.
Topics: Adult; Antitubercular Agents; Case-Control Studies; Humans; Isoniazid; Observational Studies as Topi | 2020 |
Tuberculosis treatment in children: The changing landscape.
Topics: Antitubercular Agents; Child; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Humans; Is | 2020 |
Tuberculosis in 2019.
Topics: Antitubercular Agents; Ethambutol; Health Policy; Humans; India; Isoniazid; Molecular Diagnostic Tec | 2020 |
Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Liver; Pyrazinamide; Tubercul | 2021 |
Pretomanid for tuberculosis: a systematic review.
Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Co | 2022 |
A comprehensive review on Primary gallbladder tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Female; Gallbladder Diseases; Humans; Isoniazid; Ma | 2018 |
Pharmacokinetics of First-Line Anti-Tubercular Drugs.
Topics: Age Factors; Antitubercular Agents; Child; Drug Overdose; Ethambutol; Food; Genotype; HIV Infections | 2019 |
[Pseudotumor form of primary nasopharyngeal tuberculosis: apropos of 2 new cases and review of the literature].
Topics: Antitubercular Agents; Biopsy; Diagnosis, Differential; Drug Therapy, Combination; Humans; Isoniazid | 2013 |
Isolated tuberculous liver abscess in an immunocompetent adult patient: A case report and literature review.
Topics: Aged; Antitubercular Agents; Biopsy; Blood Chemical Analysis; Drug Combinations; Ethambutol; Humans; | 2016 |
Understanding pharmacokinetics to improve tuberculosis treatment outcome.
Topics: Antitubercular Agents; Diabetes Mellitus; Drug Monitoring; Ethambutol; HIV Infections; Humans; Isoni | 2014 |
The association between CYP2E1 polymorphisms and hepatotoxicity due to anti-tuberculosis drugs: a meta-analysis.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Cytochrome P-450 CYP2E1; Gene Frequency; Genet | 2014 |
Reactive dirty fragments: implications for tuberculosis drug discovery.
Topics: Antitubercular Agents; Drug Discovery; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Myco | 2014 |
Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.
Topics: Antitubercular Agents; Diarylquinolines; Drug Design; Drug Resistance, Bacterial; Drug Therapy, Comb | 2015 |
Pyrazinamide resistance in Mycobacterium tuberculosis fails to bite?
Topics: Antitubercular Agents; Disease Transmission, Infectious; Drug Resistance, Bacterial; Humans; Mycobac | 2015 |
Pyrazinamide and Pyrazinoic Acid Derivatives Directed to Mycobacterial Enzymes Against Tuberculosis.
Topics: Animals; Anti-Bacterial Agents; Humans; Mycobacterium tuberculosis; Prodrugs; Pyrazinamide; Tubercul | 2016 |
Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update.
Topics: Animals; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium tu | 2016 |
Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis.
Topics: Antitubercular Agents; Databases, Factual; Dose-Response Relationship, Drug; Drug Monitoring; Ethamb | 2016 |
Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
Topics: Antitubercular Agents; Drug Monitoring; Ethambutol; Humans; Isoniazid; Microbial Sensitivity Tests; | 2016 |
Efforts towards the development of new antitubercular agents: potential for thiolactomycin based compounds.
Topics: Animals; Antitubercular Agents; Drug Design; Ethambutol; Isoniazid; Microbial Sensitivity Tests; Mol | 2008 |
[Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials].
Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Antitubercular Agents; Chemical and Drug Induced Liver Inju | 2010 |
Pediatric intracranial subdural empyema caused by Mycobacterium tuberculosis--a case report and review of literature.
Topics: Adolescent; Antibiotics, Antitubercular; Craniotomy; Dura Mater; Empyema, Subdural; Humans; Isoniazi | 2010 |
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple; Ethambutol; Extensively Dru | 2010 |
[Not just a success story. On the history of tuberculosis treatment].
Topics: Antitubercular Agents; Ethambutol; History, 17th Century; History, 18th Century; History, 19th Centu | 2012 |
Clinical practice. Latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Male; Practice Guideline | 2002 |
Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Cos | 2003 |
[UROGENITAL TUBERCULOSIS: PATHOGENESIS, DIAGNOSIS AND THERAPY. SURVEY OF THE MOST IMPORTANT PUBLICATIONS OF THE LAST YEARS].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloseri | 1964 |
Laboratory diagnostic aspects of drug resistant tuberculosis.
Topics: Animals; Antitubercular Agents; Bacteriophages; Clinical Laboratory Techniques; Drug Resistance, Bac | 2004 |
Rifampin and pyrazinamide for latent tuberculosis infection: clinical trials and general practice.
Topics: Clinical Trials as Topic; Family Practice; Humans; Pyrazinamide; Rifampin; Tuberculosis | 2004 |
Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Comorbidity; Drug Therapy, Combination; HIV Infe | 2006 |
Antituberculosis drugs and hepatotoxicity.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Dru | 2006 |
[Trends in tuberculosis treatment duration].
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Resistance | 2006 |
The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Mycobacterium tuberculos | 2006 |
Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; In | 2008 |
Pyrazinamide.
Topics: Animals; Antitubercular Agents; Humans; Pyrazinamide; Treatment Outcome; Tuberculosis | 2008 |
[Toxicity of pyrazinamide in antituberculous treatments (author's transl)].
Topics: Chemical and Drug Induced Liver Injury; Diarrhea; Drug Eruptions; Gout; Humans; Isoniazid; Nausea; P | 1980 |
Short-course therapy for tuberculosis.
Topics: Drug Therapy, Combination; Humans; Pyrazinamide; Rifampin; Streptomycin; Substance-Related Disorders | 1982 |
[Re-evaluation of pyrazinamide].
Topics: Clinical Trials as Topic; Female; Humans; Male; Pyrazinamide; Surveys and Questionnaires; Tuberculos | 1994 |
Feline tuberculosis: a literature review and discussion of 19 cases caused by an unusual mycobacterial variant.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Cat Diseases; Cats; Diagnosis, Differential; | 1996 |
New horizons in the treatment of tuberculosis.
Topics: Animals; Drug Design; Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; Mycolic Acids; Pyra | 1997 |
[Antitubercular chemotherapy].
Topics: Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Clinical Protocols; Drug | 1997 |
[Pharyngeal tuberculosis: an analytical study and report of 10 cases].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Male; Middle Aged; Pharyn | 1998 |
Role of individual drugs in the chemotherapy of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule; Drug Resistance; D | 2000 |
Role of individual drugs in the chemotherapy of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule; Drug Resistance; D | 2000 |
Role of individual drugs in the chemotherapy of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule; Drug Resistance; D | 2000 |
Role of individual drugs in the chemotherapy of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule; Drug Resistance; D | 2000 |
Treatment of tuberculosis.
Topics: Adult; Aminosalicylic Acids; Capreomycin; Child; Cycloserine; Drug Resistance, Microbial; Drug Thera | 1975 |
Advances in the treatment of tuberculosis.
Topics: Aminosalicylic Acids; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Pyrazinamide | 1976 |
Failure of therapy for tuberculosis in human immunodeficiency virus infection.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Drug Therapy, Combi | 1992 |
[Chemoprophylaxis of tuberculosis (lecture)].
Topics: Adolescent; Adult; Age Factors; Antitubercular Agents; BCG Vaccine; Child; Ethambutol; Humans; Infan | 1992 |
[Therapy of tuberculosis].
Topics: Antitubercular Agents; Contraindications; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; | 1990 |
[Which treatment for primary tuberculosis?].
Topics: Acquired Immunodeficiency Syndrome; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Pyrazi | 1989 |
Respiratory pharmacology. Antituberculosis drugs.
Topics: Aminosalicylic Acids; Antitubercular Agents; Cyclosporins; Ethambutol; Humans; Isoniazid; Pyrazinami | 1986 |
[Results of chemotherapy in tuberculosis].
Topics: Ambulatory Care; Anti-Bacterial Agents; Antitubercular Agents; Drug Synergism; Ethambutol; Ethionami | 1971 |
New trends in the chemotherapy of tuberculosis--current aspects.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Ethambutol; Ethionamid | 1974 |
[Tuberculostatic drugs of the second series. (Review of literature)].
Topics: Antitubercular Agents; Cycloserine; Ethionamide; Humans; Phenylthiourea; Pyrazinamide; Thiosemicarba | 1966 |
[Experimental chemotherapy of tuberculosis].
Topics: Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Synergism; Ethambutol; Ethionamide; H | 1969 |
47 trials available for pyrazinamide and Koch's Disease
| Article | Year |
|---|---|
Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children.
Topics: Adolescent; Africa; Antitubercular Agents; Child; Child, Preschool; Drug Administration Schedule; Dr | 2022 |
Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP).
Topics: Adult; Antitubercular Agents; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Humans; | 2022 |
Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: a clinical trial.
Topics: Antitubercular Agents; Clofazimine; Drug Therapy, Combination; Humans; Isoniazid; Prothionamide; Pyr | 2023 |
Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial.
Topics: Clinical Trials, Phase II as Topic; Humans; Isoniazid; Moxifloxacin; Multicenter Studies as Topic; P | 2023 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Moxifloxacin | 2020 |
Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
Topics: Adult; Ambulatory Care Facilities; Antitubercular Agents; Canada; Directly Observed Therapy; Drug Ad | 2014 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Effect of micronutrient supplementation on treatment outcomes in children with intrathoracic tuberculosis: a randomized controlled trial.
Topics: Adolescent; Antitubercular Agents; Body Height; Body Mass Index; Body Weight; Child; Child, Preschoo | 2014 |
Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Female; HIV Infections; Humans; India; I | 2015 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV | 2015 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV | 2015 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV | 2015 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV | 2015 |
A randomized trial comparing standard outcomes in two treatment models for substance users with tuberculosis.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Users; Ethambutol; Ethnicity; Female; | 2015 |
Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis.
Topics: Antitubercular Agents; Decision Support Techniques; Ethambutol; Humans; Isoniazid; Markov Chains; Py | 2016 |
Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
Topics: Adult; Antitubercular Agents; Diabetes Mellitus; Female; Humans; Isoniazid; Male; Middle Aged; Pyraz | 2017 |
Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach.
Topics: Adult; Antitubercular Agents; Blood Sedimentation; Body Weight; Chemical and Drug Induced Liver Inju | 2008 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Patient-centred tuberculosis treatment delivery under programmatic conditions in Tanzania: a cohort study.
Topics: Adult; Antitubercular Agents; Cohort Studies; Directly Observed Therapy; Ethambutol; Humans; Isoniaz | 2009 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count.
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymph | 2010 |
Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.
Topics: Acetamides; Adolescent; Adult; Animals; Antitubercular Agents; Area Under Curve; Dose-Response Relat | 2011 |
Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
Topics: Antitubercular Agents; Area Under Curve; Child, Preschool; Coinfection; Female; HIV Infections; Huma | 2011 |
Blood levels of pyrazinamide in children at doses administered under the Revised National Tuberculosis Control Program.
Topics: Antitubercular Agents; Body Weight; Child; Child, Preschool; Communicable Disease Control; Humans; I | 2012 |
Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
Topics: Analysis of Variance; Antibiotics, Antitubercular; Cross-Over Studies; Drug Combinations; Ethambutol | 2002 |
Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong.
Topics: Aged; Antitubercular Agents; Drug Administration Schedule; Female; Hong Kong; Humans; Isoniazid; Mal | 2003 |
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Topics: Adolescent; Adult; Antitubercular Agents; Cost Savings; Cost-Benefit Analysis; Costs and Cost Analys | 2004 |
[Treatment of latent tuberculosis among homeless population. Comparison between wo therapeutic approaches].
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Human | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program.
Topics: Adolescent; Adult; Antitubercular Agents; Female; Humans; Male; Middle Aged; Pyrazinamide; Rifampin; | 2004 |
[Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients].
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Isoniazid; | 2007 |
Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni | 2007 |
Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses.
Topics: Antitubercular Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Ma | 2008 |
Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town.
Topics: Antitubercular Agents; Drug Combinations; Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; | 1994 |
[Re-evaluation of pyrazinamide].
Topics: Clinical Trials as Topic; Female; Humans; Male; Pyrazinamide; Surveys and Questionnaires; Tuberculos | 1994 |
[Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide].
Topics: Adult; Antitubercular Agents; Drug Combinations; Drug Resistance, Microbial; Female; Humans; Isoniaz | 1993 |
[Compliance, efficacy and tolerability of the therapeutic regimen recommended by National Consensus on Tuberculosis].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitubercular Agents; Child; Chi | 1997 |
Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Biological Availability; Diarrh | 1997 |
Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinica
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antibiotics, Antitubercular; Antituber | 1997 |
Hepatic enzyme abnormalities in children on triple therapy for tuberculosis.
Topics: Adolescent; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; | 1999 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
A randomised controlled trial of lay health workers as direct observers for treatment of tuberculosis.
Topics: Adult; Antitubercular Agents; Community Health Workers; Drug Combinations; Female; Humans; Isoniazid | 2000 |
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Cohort St | 2001 |
The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
Topics: Antibiotics, Antitubercular; Area Under Curve; Biological Availability; Chromatography, High Pressur | 2001 |
Reintroducing antituberculosis therapy after Stevens-Johnson syndrome in human immunodeficiency virus-infected patients with tuberculosis: role of desensitization.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antitubercular Age | 2001 |
Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis.
Topics: Adult; Aging; Antitubercular Agents; Area Under Curve; Child; Chromatography, Gas; Drug Monitoring; | 2002 |
Intensive short course chemotherapy for treatment of Greek children with tuberculosis.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combinat | 1992 |
A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Follo | 1990 |
Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Clinical Trials as Topic; Follow-Up Studies; Humans; | 1986 |
734 other studies available for pyrazinamide and Koch's Disease
| Article | Year |
|---|---|
Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
Topics: Bacterial Proteins; Fatty Acid Synthases; Microbial Sensitivity Tests; Mycobacterium tuberculosis; P | 2007 |
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
Topics: Animals; Antitubercular Agents; Blood; Cell Line; Humans; In Vitro Techniques; Intracellular Membran | 2006 |
A facile synthesis and antimycobacterial evaluation of novel spiro-pyrido-pyrrolizines and pyrrolidines.
Topics: Anti-Bacterial Agents; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Mycobact | 2009 |
Synthesis, characterization and in vitro biological evaluation of some novel 1,3,5-triazine-Schiff base conjugates as potential antimycobacterial agents.
Topics: Anti-Bacterial Agents; Humans; Mycobacterium tuberculosis; Schiff Bases; Triazines; Tuberculosis | 2013 |
Synthesis and antimycobacterial evaluation of 5-alkylamino-N-phenylpyrazine-2-carboxamides.
Topics: Amides; Anti-Bacterial Agents; Antitubercular Agents; Humans; Pyrazinamide; Structure-Activity Relat | 2015 |
Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives.
Topics: Animals; Antifungal Agents; Antioxidants; Antitubercular Agents; Benzimidazoles; Cell Survival; Chlo | 2015 |
Design, development of new synthetic methodology, and biological evaluation of substituted quinolines as new anti-tubercular leads.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Drug Design; HEK293 Cells; Humans; Microbia | 2016 |
Three-component, one-pot synthesis of anthranilamide Schiff bases bearing 4-aminoquinoline moiety as Mycobacterium tuberculosis gyrase inhibitors.
Topics: Aminoquinolines; Animals; Antitubercular Agents; DNA Gyrase; Humans; Microbial Sensitivity Tests; My | 2017 |
Recent developments of coumarin-containing derivatives and their anti-tubercular activity.
Topics: Antitubercular Agents; Coumarins; Drug Design; Microbial Sensitivity Tests; Molecular Structure; Myc | 2017 |
Antibacterial and anti-TB tat-peptidomimetics with improved efficacy and half-life.
Topics: Anti-Bacterial Agents; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Erythrocyte | 2018 |
Synthesis and biological evaluation of anti-tubercular activity of Schiff bases of 2-Amino thiazoles.
Topics: Amination; Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; S | 2020 |
Whole-genome sequencing for surveillance of tuberculosis drug resistance and determination of resistance level in China.
Topics: Antitubercular Agents; Drug Resistance; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sens | 2022 |
Tuberculosis treatment incompletion in patients with lung cancer: occurrence and predictors.
Topics: Aged; Humans; Logistic Models; Lung Neoplasms; Pyrazinamide; Risk Factors; Taiwan; Tuberculosis | 2021 |
Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
Topics: Adult; Antitubercular Agents; Child; Drug Combinations; Ethambutol; Female; Humans; Infant; Isoniazi | 2022 |
No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients.
Topics: Adult; Antitubercular Agents; Ethambutol; HIV Infections; Humans; Isoniazid; Pyrazinamide; Rifampin; | 2022 |
LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: Implications for therapeutic drug monitoring.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Ethambutol; Humans; Is | 2021 |
PanB over-representation as part of pyrazinamide action: a proteomic insight.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacteriu | 2021 |
A nanocompartment system contributes to defense against oxidative stress in
Topics: Animals; Antitubercular Agents; Macrophages; Mice, Inbred BALB C; Mycobacterium tuberculosis; Organe | 2021 |
Pyrazinamide Susceptibility Is Driven by Activation of the SigE-Dependent Cell Envelope Stress Response in Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium | 2021 |
Prediction of lung exposure to anti-tubercular drugs using plasma pharmacokinetic data: Implications for dose selection.
Topics: Animals; Antitubercular Agents; Ethambutol; Humans; Isoniazid; Lung; Mice; Pyrazinamide; Tuberculosi | 2022 |
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Diarylquinolines; Disease Models, Anima | 2022 |
Visualizing Pyrazinamide Action by Live Single-Cell Imaging of Phagosome Acidification and Mycobacterium tuberculosis pH Homeostasis.
Topics: Antitubercular Agents; Homeostasis; Humans; Hydrogen-Ion Concentration; Mycobacterium tuberculosis; | 2022 |
Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro.
Topics: Animals; Antitubercular Agents; Clofazimine; Ethambutol; Humans; Isoniazid; Mice; Mycobacterium tube | 2022 |
[Investigation of pncA, rpsA and panD Gene Mutations Associated with Resistance in Pyrazinamide-Resistant Mycobacterium tuberculosis Isolates and Spoligotyping].
Topics: Antitubercular Agents; Humans; Mutation; Mycobacterium tuberculosis; Pyrazinamide; Tuberculosis; Tub | 2022 |
Intracellular Activity of Poly (DL-Lactide-co-Glycolide) Nanoparticles Encapsulated with Prothionamide, Pyrazinamide, Levofloxacin, Linezolid, or Ethambutol on Multidrug-Resistant
Topics: Anti-Bacterial Agents; Antitubercular Agents; Ethambutol; Humans; Levofloxacin; Linezolid; Mycobacte | 2023 |
Primary psoas tuberculosis abscess with an iliac bone lytic lesion: a case report.
Topics: Adult; Antitubercular Agents; Female; Humans; Isoniazid; Psoas Abscess; Pyrazinamide; Rifampin; Tube | 2022 |
Diagnostic Accuracy of Therapeutic Drug Monitoring During Tuberculosis Treatment.
Topics: Antitubercular Agents; Drug Monitoring; Ethambutol; HIV Infections; Humans; Isoniazid; Pyrazinamide; | 2022 |
Enteropathogen spectrum and effect on antimycobacterial pharmacokinetics among children with tuberculosis in rural Tanzania: a prospective cohort study.
Topics: Antitubercular Agents; Child; Cohort Studies; Ethambutol; Female; Humans; Isoniazid; Male; Prospecti | 2022 |
Pyrazinamide enhances persistence of T-cell memory induced by tuberculosis subunit vaccine LT70.
Topics: Animals; Antigens, Bacterial; CD4-Positive T-Lymphocytes; Immunologic Memory; Mice; Mice, Inbred C57 | 2022 |
Cephem-Pyrazinoic Acid Conjugates: Circumventing Resistance in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; beta-Lactams; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis | 2022 |
Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis.
Topics: Adult; Antitubercular Agents; Bayes Theorem; Drug Monitoring; Humans; Pyrazinamide; Tuberculosis | 2022 |
Altered drug exposures of first-line TB drugs in a moxifloxacin-containing treatment regimen.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Moxifloxacin; Pregnanes; Pyrazi | 2022 |
Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Isoniazid; Li | 2022 |
Development of a novel anti-tuberculosis nanodelivery formulation using magnesium layered hydroxide as the nanocarrier and pyrazinamide as a model drug.
Topics: Antitubercular Agents; Escherichia coli; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Hyd | 2022 |
Tuberculosis: Common Questions and Answers.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Latent Tuberculosis; Pyrazinamide; Rifampin; T | 2022 |
Pyrazinamide resistance in rifampicin discordant tuberculosis.
Topics: Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Mutation; Mycobacterium tuber | 2022 |
A Mycobacterium tuberculosis-Infected Patient Who Could Not Tolerate Oral Intake Successfully Treated Using an Intravenous Tedizolid-Containing Regimen.
Topics: Aged; Anti-Bacterial Agents; Antitubercular Agents; Cutaneous Fistula; Ethambutol; Humans; Isoniazid | 2022 |
Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents.
Topics: Amidohydrolases; Antitubercular Agents; Carboxylic Acids; Drug Resistance, Bacterial; Humans; Microb | 2022 |
Development and Optimization of a New UPLC-UV/MS Method through DoE and MLR for Detecting Substandard Drug Products to Treat Tuberculosis.
Topics: Antitubercular Agents; Chromatography, Liquid; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin | 2022 |
A high-throughput LC-MS/MS method for simultaneous determination of isoniazid, ethambutol and pyrazinamide in human plasma.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Chromatography, Liquid; Ethambutol; Hum | 2023 |
Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide.
Topics: Antitubercular Agents; Diarylquinolines; Humans; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberc | 2022 |
Hybridization Approach Toward Novel Antituberculars: Design, Synthesis, and Biological Evaluation of Compounds Combining Pyrazinamide and 4-Aminosalicylic Acid.
Topics: Aminosalicylic Acid; Animals; Antitubercular Agents; COVID-19; Humans; Lactones; Mice; Mycobacterium | 2023 |
Deciphering the mechanism of resistance by novel double mutations in pncA in Mycobacterium tuberculosis using protein structural graphs (PSG) and structural bioinformatic approaches.
Topics: Antitubercular Agents; Computational Biology; Drug Resistance, Bacterial; Humans; Microbial Sensitiv | 2023 |
Urinary excretion of metformin in diabetic patients with and without tuberculosis.
Topics: Antitubercular Agents; Diabetes Mellitus; Humans; India; Isoniazid; Metformin; Pyrazinamide; Tubercu | 2023 |
Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic Modeling.
Topics: Animals; Antitubercular Agents; Humans; Lung; Mice; Nitroimidazoles; Pyrazinamide; Tuberculosis | 2023 |
The Dysbiosis Triggered by First-Line Tuberculosis Antibiotics Fails to Reduce Their Bioavailability.
Topics: Animals; Antitubercular Agents; Biological Availability; Dysbiosis; Humans; Isoniazid; Mice; Moxiflo | 2023 |
Quantitative
Topics: Amidohydrolases; Antitubercular Agents; Humans; Magnetic Resonance Spectroscopy; Microbial Sensitivi | 2023 |
Acquired drug resistance during the turnaround time for drug susceptibility testing impacts outcome of tuberculosis.
Topics: Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; P | 2023 |
Anti-tubercular therapy (ATT) induced exfoliative dermatitis-A case series.
Topics: Antitubercular Agents; Dermatitis, Exfoliative; Humans; Isoniazid; Pyrazinamide; Tuberculosis | 2023 |
Ability of the MeltPro MTB/PZA Assay to Detect Susceptibility to Pyrazinamide in Rifampin-Resistant Tuberculosis Patients.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mutation; My | 2023 |
Molecular and cellular remodeling of HepG2 cells upon treatment with antitubercular drugs.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Hep G2 Cells; Humans; Isoniazid; Pyra | 2023 |
IL-10 Modulation Increases Pyrazinamide's Antimycobacterial Efficacy against Mycobacterium tuberculosis Infection in Mice.
Topics: Animals; Antitubercular Agents; Interleukin-10; Mice; Mycobacterium tuberculosis; Pyrazinamide; Tube | 2023 |
A physiologically-based pharmacokinetic model for tuberculosis drug disposition at extrapulmonary sites.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis | 2023 |
Protein binding investigation of first-line and second-line antituberculosis drugs.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Levofloxacin; Linezolid; Moxifloxacin; Protein | 2023 |
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV; HIV Infections; Huma | 2023 |
Effect of HIV infection on plasma exposure to first-line TB drugs and target attainment in children.
Topics: Antitubercular Agents; Child; Child, Preschool; Coinfection; HIV Infections; Humans; Isoniazid; Pyra | 2023 |
Calcitriol enhances pyrazinamide treatment of murine tuberculosis.
Topics: Animals; Antitubercular Agents; Calcitriol; Female; Mice; Mice, Inbred C57BL; Pyrazinamide; Tubercul | 2019 |
Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Humans; Markov Chains; Nitroimidazoles; Prevalence; | 2019 |
Pancreatic tuberculosis diagnosed by endoscopic ultrasound-guided fine needle aspiration in a 14-year-old adolescent.
Topics: Abdominal Pain; Adolescent; Antitubercular Agents; Cote d'Ivoire; Drug Therapy, Combination; Endosco | 2020 |
Determinants of serum concentration of first-line anti-tuberculosis drugs from China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Case-Control Studies; China; Chro | 2019 |
[Tuberculosis].
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Mycobacterium tuberculosis; Pyrazinamide; Rifa | 2019 |
Association of ABCC Gene Polymorphism With Susceptibility to Antituberculosis Drug-Induced Hepatotoxicity in Western Han Patients With Tuberculosis.
Topics: Adult; Alanine Transaminase; Antitubercular Agents; Asian People; ATP-Binding Cassette Transporters; | 2020 |
Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Mathematics; Moxifloxacin; Mycobacterium t | 2020 |
Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative?
Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, P | 2019 |
The impact of inclusion, dose and duration of pyrazinamide (PZA) on efficacy and safety outcomes in tuberculosis: systematic review and meta-analysis protocol.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Meta-Analysis as Topic; Patient Safety; Pyr | 2019 |
Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS/MS.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Calibration; Chromatography, High Pres | 2020 |
Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis.
Topics: Adult; Antitubercular Agents; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Pyrazinamide; Tu | 2020 |
The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD.
Topics: Amidohydrolases; Antitubercular Agents; Bacterial Proteins; Carboxy-Lyases; Crystallography, X-Ray; | 2020 |
Structure guided prediction of Pyrazinamide resistance mutations in pncA.
Topics: Amidohydrolases; Amino Acid Substitution; Antitubercular Agents; Datasets as Topic; DNA Mutational A | 2020 |
Tuberculosis treatment: one-shot approach or cascade of regimens?
Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, P | 2020 |
High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.
Topics: Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2020 |
Reply to Decroo
Topics: Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2020 |
Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Isoniazid; Mal | 2020 |
Topics: Amino Acids; Anti-Bacterial Agents; Antitubercular Agents; Aspergillus flavus; Candida albicans; Cel | 2020 |
Pyrazinamide triggers degradation of its target aspartate decarboxylase.
Topics: Antitubercular Agents; Bacterial Proteins; Carboxy-Lyases; Drug Resistance, Bacterial; Endopeptidase | 2020 |
Fully weekly antituberculosis regimen: a proof-of-concept study.
Topics: Animals; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Isoniazid; | 2020 |
Tuberculosis sepsis after tocilizumab treatment.
Topics: Antibodies, Monoclonal, Humanized; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; | 2020 |
Ocular adverse events in drug sensitive TB patients on daily fixed dose combination anti-TB drugs: A record review study from Kerala, India.
Topics: Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol; | 2020 |
The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis.
Topics: Aged; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incide | 2020 |
Primary breast tuberculosis in an HIV-infected patient.
Topics: Adult; Antitubercular Agents; Biopsy; Breast; Ethambutol; Female; HIV Infections; Humans; Isoniazid; | 2020 |
Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis.
Topics: Antitubercular Agents; Bayes Theorem; Ethambutol; Humans; Isoniazid; Pyrazinamide; Tuberculosis | 2021 |
Cyclic Peptide [R
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Autophagy; Cytokines; Drug Therapy, Combinatio | 2020 |
Hemophagocytic syndrome associated with Mycobacterium bovis in a patient with X-SCID: a case report.
Topics: Antibiotics, Antitubercular; High-Throughput Nucleotide Sequencing; Humans; Infant; Interleukin Rece | 2020 |
Evaluation and Docking Study of Pyrazine Containing 1, 3, 4-Oxadiazoles Clubbed with Substituted Azetidin-2-one: A New Class of Potential Antimicrobial and Antitubercular.
Topics: Antifungal Agents; Antitubercular Agents; Aspergillus niger; Azetidines; Candida albicans; Drug Eval | 2021 |
Completeness of tuberculosis case notifications in Germany in 2013-2017: first results of an inventory study.
Topics: Antitubercular Agents; Databases, Factual; Disease Notification; Germany; Humans; Incidence; Informa | 2020 |
Drug Exposure and Minimum Inhibitory Concentration Predict Pulmonary Tuberculosis Treatment Response.
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Pharmaceutical Preparations; Prospective | 2021 |
Safety of Pyrazinamide for the Treatment of Tuberculosis in Older Patients Over 75 Years of Age: A Retrospective Monocentric Cohort Study.
Topics: Aged; Antitubercular Agents; Cohort Studies; Humans; Pyrazinamide; Retrospective Studies; Tuberculos | 2021 |
Tuberculosis in the intensive care unit: alternative treatment regimens and association with mortality.
Topics: Adult; Amikacin; Antibiotics, Antitubercular; APACHE; Brazil; Drug Administration Routes; Drug Admin | 2021 |
Quantification of pyrazinamide, isoniazid, acetyl-isoniazid, and rifampicin by a high-performance liquid chromatography method in human plasma from patients with tuberculosis.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Female; Humans; Isoniazid; Male; Middle Aged; Pil | 2021 |
An explainable machine learning platform for pyrazinamide resistance prediction and genetic feature identification of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Machine Learning; Microbial Sensitivity T | 2021 |
Point-of-Care Ultrasound Image of Intra-Abdominal Lymphadenopathy in Tuberculosis.
Topics: Abdomen; Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Lymph Nodes; Lymphadenopathy; | 2020 |
Clinical characteristics of pyrazinamide-associated hepatotoxicity in patients at a hospital in Lima, Peru.
Topics: Adult; Chemical and Drug Induced Liver Injury; Hospitals; Humans; Peru; Pyrazinamide; Tuberculosis | 2020 |
Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; | 2021 |
Successful Use of Rifamycin-Sparing Regimens for the Treatment of Active Tuberculosis in Lung Transplant Recipients.
Topics: Ethambutol; Humans; Isoniazid; Lung; Lung Transplantation; Moxifloxacin; Pyrazinamide; Rifamycins; T | 2021 |
Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Mycobacterium tuberculosis; Pyrazinamide; | 2022 |
Factors Affecting the Pharmacokinetics of Pyrazinamide and Its Metabolites in Patients Coinfected with HIV and Implications for Individualized Dosing.
Topics: Antitubercular Agents; Coinfection; Female; HIV Infections; Humans; Male; Pyrazinamide; Tuberculosis | 2021 |
Pulmonary Tuberculosis in Older Adults: Increased Mortality Related to Tuberculosis Within Two Months of Treatment Initiation.
Topics: Aged; Antitubercular Agents; Humans; Pyrazinamide; Retrospective Studies; Tuberculosis; Tuberculosis | 2021 |
Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations.
Topics: Adult; Antitubercular Agents; Child; Child, Preschool; Ethambutol; Female; Humans; Isoniazid; Male; | 2022 |
Detection of pyrazinamide resistance of Mycobacterium tuberculosis using nicotinamide as a surrogate.
Topics: Antitubercular Agents; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tes | 2017 |
Identification of drug candidates that enhance pyrazinamide activity from a clinical compound library.
Topics: Antitubercular Agents; Drug Evaluation, Preclinical; Drug Synergism; Humans; Mycobacterium tuberculo | 2017 |
A 25-Year-Old Woman With a Deceptive Pancreas Cyst: All Is Not as It Appears!
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Endoscopic Ultrasound-Guided Fine Needle As | 2018 |
pH Conditions under Which Pyrazinamide Works in Humans.
Topics: Antitubercular Agents; Humans; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Mycobacteriu | 2017 |
Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs.
Topics: Adult; Antitubercular Agents; Fasting; Female; Food; Humans; India; Isoniazid; Male; Middle Aged; Py | 2017 |
Improved Bactec MGIT 960 Pyrazinamide Test Decreases Detection of False Mycobacterium tuberculosis Pyrazinamide Resistance.
Topics: Amidohydrolases; Antitubercular Agents; Diagnostic Errors; Drug Resistance, Bacterial; Humans; Micro | 2017 |
Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Topics: Adult; Age Distribution; Aged; Alcohol Drinking; Aminosalicylic Acid; Antitubercular Agents; Cohort | 2017 |
Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation.
Topics: Anti-HIV Agents; Antitubercular Agents; HIV Infections; Humans; Pyrazinamide; Tuberculosis | 2017 |
Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.
Topics: Adult; Aged; Amidohydrolases; Antitubercular Agents; China; Drug Resistance, Multiple, Bacterial; Fe | 2017 |
Tuberculosis of the tonsil simulating a cancer.
Topics: Adenoids; Adult; Antitubercular Agents; Diagnosis, Differential; Ethambutol; Female; Humans; Isoniaz | 2017 |
Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum.
Topics: Animals; Antitubercular Agents; Drug Tolerance; Mycobacterium tuberculosis; Pyrazinamide; Rabbits; R | 2018 |
Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Thera | 2018 |
Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.
Topics: Adolescent; Age Factors; Antitubercular Agents; Body Weight; Child; Child, Preschool; Coinfection; D | 2018 |
First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Chromatography, High Pressure | 2018 |
Improved Stability of Tuberculosis Drug Fixed-Dose Combination Using Isoniazid-Caffeic Acid and Vanillic Acid Cocrystal.
Topics: Antitubercular Agents; Caffeic Acids; Crystallization; Drug Combinations; Drug Stability; Drug Stora | 2018 |
Tuberculosis treatment outcome and predictors in northern Ethiopian prisons: a five-year retrospective analysis.
Topics: Adolescent; Adult; Aftercare; Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Directly O | 2018 |
Sex differences and factors influencing the duration of the QT interval in patients on anti-tuberculosis therapy.
Topics: Antitubercular Agents; Clinical Trials as Topic; Electrocardiography; Ethambutol; Female; Gatifloxac | 2018 |
Rapid and sensitive method for simultaneous determination of first-line anti-tuberculosis drugs in human plasma by HPLC-MS/MS: Application to therapeutic drug monitoring.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Ethambutol; Humans; Is | 2018 |
Improving treatment outcome assessment in a mouse tuberculosis model.
Topics: Administration, Oral; Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combinat | 2018 |
Protein Binding of First-Line Antituberculosis Drugs.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Male; | 2018 |
Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Dried Blood Spot Testing; Drug Monitorin | 2018 |
Computational discovery of potent drugs to improve the treatment of pyrazinamide resistant Mycobacterium tuberculosis mutants.
Topics: Amidohydrolases; Antitubercular Agents; Binding Sites; Drug Discovery; Drug Resistance, Multiple, Ba | 2018 |
A Breast Lump in an Elderly Lady - Carcinoma or else ?.
Topics: Aged; Antitubercular Agents; Biopsy, Fine-Needle; Breast; Breast Neoplasms; Ethambutol; Female; Huma | 2016 |
Is sequencing better than phenotypic tests for the detection of pyrazinamide resistance?
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Te | 2018 |
Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients.
Topics: Adolescent; Adult; Antitubercular Agents; Humans; India; Isoniazid; Pilot Projects; Prospective Stud | 2018 |
Impact of immunopathology on the antituberculous activity of pyrazinamide.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Female; Humans; Microbial Viability; Mycobac | 2018 |
Characterizing the Effects of Glutathione as an Immunoadjuvant in the Treatment of Tuberculosis.
Topics: Adjuvants, Immunologic; Anti-Bacterial Agents; Antitubercular Agents; Cell Line; Drug Therapy, Combi | 2018 |
Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Ethambutol; Genome, Bacterial; Genotype; Humans; | 2018 |
Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Ethambutol; F | 2020 |
Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility.
Topics: Adamantane; Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; D | 2018 |
Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity.
Topics: Comorbidity; Diabetes Mellitus; Drug Monitoring; Humans; Pyrazinamide; Tuberculosis | 2019 |
Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Hum | 2018 |
Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Desensitization, Immunologic; Drug Hypersensi | 2019 |
Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan.
Topics: Adolescent; Adult; Aged; Amidohydrolases; Antitubercular Agents; Child; Drug Resistance, Bacterial; | 2019 |
Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania.
Topics: Adult; Amidohydrolases; Antitubercular Agents; Female; Humans; Male; Microbial Sensitivity Tests; Mi | 2019 |
Metformin induced autophagy in diabetes mellitus - Tuberculosis co-infection patients: A case study.
Topics: Adult; Antitubercular Agents; Autophagy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Etham | 2019 |
Overcoming the pitfalls of automatic interpretation of whole genome sequencing data by online tools for the prediction of pyrazinamide resistance in Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Computational Biology; Datasets as Topic; DNA, Bacterial; Dr | 2019 |
A Short Regimen for Rifampin-Resistant Tuberculosis.
Topics: Humans; Pyrazinamide; Rifampin; Tuberculosis | 2019 |
Tuberculosis in Older Adults: Seattle and King County, Washington.
Topics: Aged; Antitubercular Agents; Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary; Washington | 2020 |
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
Topics: Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans; Hydrogen-Io | 2019 |
Subtherapeutic Rifampicin Concentration Is Associated With Unfavorable Tuberculosis Treatment Outcomes.
Topics: Antitubercular Agents; Humans; India; Isoniazid; Prospective Studies; Pyrazinamide; Rifampin; Treatm | 2020 |
Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study.
Topics: Algorithms; Antitubercular Agents; Body Weight; Child Nutrition Disorders; Child, Preschool; Drug Ad | 2019 |
Optimization of a paediatric fixed dose combination mini-tablet and dosing regimen for the first line treatment of tuberculosis.
Topics: Adult; Antitubercular Agents; Child; Humans; Isoniazid; Pyrazinamide; Rifampin; Tablets; Tuberculosi | 2019 |
Density functional and molecular docking studies towards investigating the role of single-wall carbon nanotubes as nanocarrier for loading and delivery of pyrazinamide antitubercular drug onto pncA protein.
Topics: Amidohydrolases; Antitubercular Agents; Crystallography, X-Ray; Drug Carriers; Humans; Molecular Doc | 2013 |
[Primary sinonasal tuberculosis: apropos of a case].
Topics: Aged; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Maxil | 2013 |
Factors associated with the rapid implementation process of the fixed-dose combination RHZE tuberculosis regimen in Brazil: an ecological study.
Topics: Antitubercular Agents; Brazil; Drug Combinations; Ethambutol; Health Plan Implementation; Humans; In | 2013 |
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Disease | 2013 |
Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
Topics: Acetylation; Age Factors; Antitubercular Agents; Child; Child, Preschool; Chromatography, High Press | 2013 |
Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the simultaneous determination of five first-line antituberculosis drugs in plasma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Chromatography, Liquid; Dr | 2013 |
Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene.
Topics: Amidohydrolases; Anti-Bacterial Agents; Brazil; DNA, Bacterial; Drug Resistance, Bacterial; Humans; | 2013 |
Antituberculosis therapy-associated cutaneous leukocytoclastic vasculitis.
Topics: Adolescent; Antitubercular Agents; Humans; Male; Prednisolone; Pyrazinamide; Rifampin; Treatment Out | 2013 |
Rationalizing use of fluoroquinolones and pyrazinamide in the battle against multidrug-resistant tuberculosis.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Female; Fluoroquinolones; Moxi | 2013 |
Study of pyrazinamidase structural changes in pyrazinamide resistant and susceptible isolates of Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Mutation; Mycobacterium | 2013 |
Estimation of content of anti-TB drugs supplied at centres of the Revised National TB Control Programme in Tamil Nadu, India.
Topics: Antitubercular Agents; Cycloserine; Drug Stability; Drug Storage; Drug Therapy, Combination; Ethambu | 2013 |
Immunotherapeutic efficacy of recombinant Mycobacterium smegmatis expressing Ag85B-ESAT6 fusion protein against persistent tuberculosis infection in mice.
Topics: Acyltransferases; Animals; Antigens, Bacterial; Antitubercular Agents; Bacteria; Bacterial Load; Bac | 2014 |
Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Laboratory Proficiency T | 2013 |
Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.
Topics: Adult; Antitubercular Agents; Area Under Curve; Case-Control Studies; Chemical and Drug Induced Live | 2014 |
Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.
Topics: Adult; Antitubercular Agents; Area Under Curve; Case-Control Studies; Chemical and Drug Induced Live | 2014 |
Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.
Topics: Adult; Antitubercular Agents; Area Under Curve; Case-Control Studies; Chemical and Drug Induced Live | 2014 |
Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.
Topics: Adult; Antitubercular Agents; Area Under Curve; Case-Control Studies; Chemical and Drug Induced Live | 2014 |
Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.
Topics: Antitubercular Agents; Child; Child, Preschool; Electronic Data Processing; Female; Humans; Infant; | 2014 |
Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California.
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide | 2014 |
An unusual cause of breast lump: isolated tuberculosis of the breast.
Topics: Antitubercular Agents; Biopsy, Fine-Needle; Breast Diseases; Ethambutol; Female; Humans; Isoniazid; | 2014 |
Cervical lymphadenopathy--pitfalls of blind antitubercular treatment.
Topics: Adolescent; Adult; Antitubercular Agents; Biopsy; Diagnostic Errors; Ethambutol; Female; Histiocytic | 2014 |
Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.
Topics: Animals; Antitubercular Agents; Bacterial Load; Cell Line; Colony Count, Microbial; Disease Models, | 2014 |
Novel drug combination for tuberculosis to be tested across 50 sites.
Topics: Antitubercular Agents; Aza Compounds; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; | 2014 |
Outbreak of pyrazinamide-monoresistant tuberculosis identified using genotype cluster and social media analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Bacteriological Techniques; Child; Cluster Analysis; Disea | 2014 |
Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Korea and analysis of the correlation between the mutations and pyrazinamidase activity.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Gene Expression Profiling; Human | 2014 |
Thioridazine for treatment of tuberculosis: promises and pitfalls.
Topics: Animals; Antitubercular Agents; Female; Isoniazid; Mycobacterium tuberculosis; Pyrazinamide; Rifampi | 2014 |
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Therapy, | 2015 |
Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Genetic Variation; Humans; Mutat | 2014 |
Investigating gender disparities in the profile and treatment outcomes of tuberculosis in Ebonyi state, Nigeria.
Topics: Adult; Antitubercular Agents; Cohort Studies; Coinfection; Ethambutol; Female; Health Status Dispari | 2015 |
Mutations in the pncA and rpsA genes among 77 Mycobacterium tuberculosis isolates in Kazakhstan.
Topics: Adolescent; Adult; Aged; Amidohydrolases; Antitubercular Agents; Child; DNA, Bacterial; Drug Resista | 2015 |
Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combi | 2014 |
Safe and effective treatment for patients with isoniazid drug resistance.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Ethambutol; Female; Humans; Isoniazid; Male; Pyra | 2015 |
In reply.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Ethambutol; Female; Humans; Isoniazid; Male; Pyra | 2015 |
A reader's guide to the bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Clofazimine; Diarylquinolines; Female; HIV Infections; Humans; Male; Nitroimidazoles; Pyrazinamide; | 2015 |
An interlaboratory quality control programme for the measurement of tuberculosis drugs.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Monitoring; Humans; Immunoassay; Isoniazid | 2015 |
High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study.
Topics: Adult; Antitubercular Agents; Coinfection; Ethambutol; Female; Follow-Up Studies; HIV Infections; Hu | 2015 |
Biochemical Characterization and Computational Identification of Mycobacterium tuberculosis Pyrazinamidase in Some Pyrazinamide-Resistant Isolates of Iran.
Topics: Amidohydrolases; Amino Acid Sequence; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Ba | 2015 |
Is Europe ready to reach tuberculosis elimination? An outbreak report from Southern Italy.
Topics: Adult; Child, Preschool; Communicable Disease Control; Contact Tracing; Disease Outbreaks; Ethambuto | 2015 |
Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy. [Corrected].
Topics: Administration, Inhalation; Antitubercular Agents; Desiccation; Dry Powder Inhalers; Humans; Nanopar | 2015 |
Is Hyperuricemia Overlooked when Treating Pediatric Tuberculosis Patients with Pyrazinamide?
Topics: Adolescent; Allopurinol; Antitubercular Agents; Child; Child, Preschool; Drug Administration Schedul | 2015 |
The association between sterilizing activity and drug distribution into tuberculosis lesions.
Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis | 2015 |
Currently Used Low-Dose Pyrazinamide Does Not Increase Liver-Injury in the First Two Months of Tuberculosis Treatment.
Topics: Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Dru | 2015 |
[The effect of renal replacement therapy on the plasma concentration of antituberculosis drugs].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Kidney Diseases; Male; Mi | 2015 |
The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children.
Topics: Antitubercular Agents; Body Weight; Child; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; | 2015 |
Combined Atomistic Molecular Calculations and Experimental Investigations for the Architecture, Screening, Optimization, and Characterization of Pyrazinamide Containing Oral Film Formulations for Tuberculosis Management.
Topics: Administration, Oral; Animals; Antitubercular Agents; Calorimetry, Differential Scanning; Cell Survi | 2016 |
Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
Topics: Adult; Aged; Antitubercular Agents; Drug Monitoring; Female; HIV Infections; Humans; Isoniazid; Line | 2015 |
[CLINICAL EFFECTS OF TREATMENT FOR MYCOBACTERIUM TUBERCULOSIS INFECTION IN PATIENTS AT A SPECIALIZED HOSPITAL IN 2011].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Drug Resistance, Bacterial | 2015 |
Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
Topics: Antitubercular Agents; Child; Child, Preschool; Chromatography, High Pressure Liquid; Female; Follow | 2016 |
Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy.
Topics: Animals; Antitubercular Agents; Clofazimine; Disease Models, Animal; Drug Combinations; Drug Therapy | 2016 |
The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver I | 2016 |
Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Topics: Adolescent; Age Factors; Antitubercular Agents; Child; Child, Preschool; Chromatography, Liquid; Coi | 2016 |
Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Administration, Inhalation; Aerosols; Antitubercular Agents; Che | 2016 |
High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.
Topics: Animals; Antitubercular Agents; Female; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Myco | 2016 |
A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies.
Topics: Acetaminophen; Antitubercular Agents; Cell Line; Chemical and Drug Induced Liver Injury; Child, Pres | 2016 |
Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature.
Topics: Antitubercular Agents; Humans; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Mycobacteriu | 2016 |
Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.
Topics: Administration, Inhalation; Aerosols; Animals; Antitubercular Agents; Esters; Guinea Pigs; Male; Mic | 2016 |
Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Female; Genotyping Techniques; Humans; | 2016 |
Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?
Topics: Antitubercular Agents; Drug Combinations; Drug Monitoring; Humans; Isoniazid; Pyrazinamide; Rifampin | 2016 |
Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis.
Topics: Bacterial Proteins; Carboxy-Lyases; Coenzyme A; Drug Resistance, Bacterial; Humans; Mutation, Missen | 2016 |
Drug-related hepatitis in patients treated with standard anti-tuberculosis chemotherapy over a 30-year period.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver I | 2016 |
Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; L | 2017 |
In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Carboxy-Lyases; Culture Media; Disease Models, A | 2017 |
First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.
Topics: Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Monitoring; Female; | 2016 |
Human tuberculosis due to Mycobacterium bovis in the United States, 1995-2005.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Presch | 2008 |
Drug lymphocyte stimulation test in the diagnosis of adverse reactions to antituberculosis drugs.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ethambutol; Female; Follow-Up Studies; Humans | 2008 |
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Disease Models, Animal; | 2008 |
Update on the treatment of tuberculosis.
Topics: Antitubercular Agents; Comorbidity; Directly Observed Therapy; Disease Progression; Drug Therapy, Co | 2008 |
A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolin | 2009 |
Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Female; Humans; Isoniazid; Male; Middle Aged; Myc | 2009 |
In-depth molecular characterization of Mycobacterium tuberculosis from New Delhi--predominance of drug resistant isolates of the 'modern' (TbD1) type.
Topics: Bacterial Typing Techniques; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Humans; India; | 2009 |
[Differentiation of species within the Mycobacterium tuberculosis complex by molecular techniques].
Topics: Animals; Bacterial Proteins; Carboxylic Acids; Cattle; Chaperonin 60; DNA Gyrase; DNA, Bacterial; Hu | 2009 |
A rapid and robust liquid chromatography/tandem mass spectrometry method for simultaneous analysis of anti-tuberculosis drugs--ethambutol and pyrazinamide in human plasma.
Topics: Antitubercular Agents; Chromatography, Liquid; Ethambutol; Humans; Pyrazinamide; Tandem Mass Spectro | 2009 |
[Primary tuberculosis of the tongue].
Topics: Adult; Antitubercular Agents; Humans; Isoniazid; Male; Pyrazinamide; Rifampin; Tongue Diseases; Tube | 2009 |
Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients.
Topics: Antitubercular Agents; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tes | 2009 |
Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; | 2009 |
Incomplete immunological recovery following anti-tuberculosis treatment in HIV-infected individuals with active tuberculosis.
Topics: Acquired Immunodeficiency Syndrome; Analysis of Variance; beta 2-Microglobulin; Biomarkers; CD4-Posi | 2009 |
Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing.
Topics: Amidohydrolases; Antitubercular Agents; DNA, Bacterial; Drug Resistance, Bacterial; Genetic Associat | 2009 |
Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand.
Topics: Amidohydrolases; Antitubercular Agents; DNA Mutational Analysis; Drug Resistance, Bacterial; Genes, | 2009 |
Serious adverse reactions in a tuberculosis programme setting in Kyrgyzstan.
Topics: Adult; Antitubercular Agents; Communicable Disease Control; Humans; Kyrgyzstan; Pyrazinamide; Rifamp | 2009 |
Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance.
Topics: Amidohydrolases; Amino Acid Substitution; Antitubercular Agents; Bacterial Proteins; Binding Sites; | 2010 |
New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.
Topics: Antitubercular Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacteri | 2010 |
Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Female; Guinea Pigs; Isoniazid; Lung; Mice; | 2010 |
Incision infection with Mycobacterium tuberculosis after total hip arthroplasty without any primary tuberculosis focus.
Topics: Arthroplasty, Replacement, Hip; Drug Therapy, Combination; Ethambutol; Female; Hip Dislocation, Cong | 2011 |
PhoY2 but not PhoY1 is the PhoU homologue involved in persisters in Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Colony Count, Microbial; Disease Models, Animal; | 2010 |
The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Pyrazinamide; Rifa | 2010 |
Human bovine tuberculosis - remains in the differential.
Topics: Adult; Antitubercular Agents; Drug Resistance, Bacterial; Female; Humans; Isoniazid; Male; Microbial | 2010 |
Comparison of MGIT 960 & pyrazinamidase activity assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Culture Media; Drug Resistance, Microbial; Hydrogen-Ion Conc | 2010 |
Mediastina Tuberculosis mass in a three-month-old boy.
Topics: Adrenal Cortex Hormones; Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combinati | 2010 |
Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Aza Compounds; Diarylquinolines; Disease Models, Animal; Femal | 2010 |
Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of mycobacterium tuberculosis from South India.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; India; Microbial Sensiti | 2010 |
Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amidohydrolases; Anti-Bacterial Agents; Antitubercular A | 2010 |
Kinetics and inhibition of nicotinamidase from Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Cloning, Molecular; Humans; Mycobacterium bovis; Mycobacteri | 2010 |
Anterior segment optical coherence tomography findings of presumed intraocular tuberculosis.
Topics: Aged; Anterior Eye Segment; Antitubercular Agents; Cataract Extraction; Corneal Edema; Drug Therapy, | 2011 |
Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Female; Flow Cytometry; Guinea Pigs; Mycobacterium | 2011 |
Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BAL | 2011 |
Half-century-old TB drugs get a facelift in new cocktails.
Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combin | 2010 |
Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.
Topics: Animals; Antitubercular Agents; Female; Guinea Pigs; Lung; Mice; Pyrazinamide; Tuberculosis | 2011 |
Mycobacteria infection in incomplete transverse myelitis is refractory to steroids: a pilot study.
Topics: Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Magnetic Resonance Imaging; Male; Met | 2011 |
Rapid detection of resistance to pyrazinamide in Mycobacterium tuberculosis using the resazurin microtitre assay.
Topics: Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium bovis; Mycobacterium | 2011 |
Pyrazinamide plasma concentrations in young children with tuberculosis.
Topics: Antitubercular Agents; Child; Child, Preschool; Female; Humans; Infant; Male; Plasma; Pyrazinamide; | 2011 |
Niosomal encapsulation of the antitubercular drug, pyrazinamide.
Topics: Animals; Antitubercular Agents; Drug Carriers; Female; Guinea Pigs; Hydrogen-Ion Concentration; Lipo | 2011 |
Torticollis in mice intravenously infected with Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Autopsy; Aza Compounds; Disease Models, Animal; Drug Therapy, Combin | 2011 |
The variable clinical presentation of tuberculosis otitis media and the importance of early detection.
Topics: Adolescent; Adult; Audiometry, Pure-Tone; Early Diagnosis; Ethambutol; Female; Humans; Isoniazid; Ma | 2011 |
Decline in tuberculosis with 19 years of universal directly observed therapy in a comprehensive statewide program.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Centers for Disease Con | 2011 |
Evaluation of the microscopic observation drug susceptibility assay for detection of Mycobacterium tuberculosis resistance to pyrazinamide.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Microscopy; | 2011 |
Tuberculosis-associated chronic kidney disease.
Topics: Antitubercular Agents; Ethambutol; Fever; Humans; Isoniazid; Kidney Failure, Chronic; Male; Pyrazina | 2011 |
Primary nasal tuberculosis-a rare clinical entity.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Epistaxis; Female; Humans; Isoniazid; Nasal | 2011 |
[Anti-tuberculosis chemotherapy and management of adverse reactions].
Topics: Aged, 80 and over; Antitubercular Agents; Child; Drug Administration Schedule; Drug Hypersensitivity | 2011 |
Anti-tuberculosis drugs and human polymorphonuclear leukocyte functions.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethambutol; Flow | 2011 |
Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Burkina Faso; | 2012 |
Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide.
Topics: Adolescent; Adult; Aged, 80 and over; Amidohydrolases; Antitubercular Agents; Female; Humans; Male; | 2012 |
Rapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method.
Topics: Amidohydrolases; Antitubercular Agents; Colorimetry; DNA, Bacterial; Drug Resistance, Microbial; Hum | 2011 |
Therapeutic drug monitoring in the treatment of tuberculosis patients.
Topics: Adult; Aged; Alcoholism; Antibiotics, Antitubercular; Antitubercular Agents; Chromatography, High Pr | 2012 |
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions.
Topics: Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Fluoroquinolones; Gene Expres | 2012 |
A case of isolated pancreatic tuberculosis mimicking pancreatic carcinoma.
Topics: Aged; Antitubercular Agents; Biopsy, Fine-Needle; Diagnosis, Differential; Drug Therapy, Combination | 2011 |
Pyrazinamide: a frontline drug used for tuberculosis. Molecular mechanism of action resolved after 50 years?
Topics: Amidohydrolases; Antitubercular Agents; Humans; Mycobacterium tuberculosis; Pyrazinamide; Tuberculos | 2012 |
Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with Mycobacterium tuberculosis.
Topics: Animals; BCG Vaccine; Combined Modality Therapy; Female; Granuloma; Guinea Pigs; Isoniazid; Lung; My | 2012 |
N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Case-Control Studies; Chemical and Drug | 2011 |
Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec.
Topics: Aged; Aged, 80 and over; Antitubercular Agents; Cohort Studies; Drug Resistance, Bacterial; Female; | 2012 |
Trial tests new combination of drugs to treat tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Aza Compounds; Clinical Trials as Topi | 2012 |
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BAL | 2012 |
Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009.
Topics: Adult; Antitubercular Agents; Chi-Square Distribution; Drug Resistance, Bacterial; Drug Therapy, Com | 2012 |
Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.
Topics: Animals; Antitubercular Agents; Female; Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; Pyrazina | 2012 |
[Retroperitoneal abscess in a patient under BCG treatment cause a bladder cancer].
Topics: Abdominal Abscess; Aged; Antitubercular Agents; BCG Vaccine; Humans; Isoniazid; Lung Neoplasms; Male | 2012 |
[Bilateral tuberculous mastitis nulliparous patient, initially treated as idiopathic granulomatous mastitis].
Topics: Adult; Antitubercular Agents; Diagnostic Errors; Drug Therapy, Combination; Ethambutol; Female; Gran | 2012 |
New drug combination for TB is tested in unique trial.
Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Fluoroquinolones; | 2012 |
Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA.
Topics: Amidohydrolases; Antitubercular Agents; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Microbia | 2012 |
Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide.
Topics: Analysis of Variance; Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Anima | 2012 |
Improved consistency in dosing anti-tuberculosis drugs in Taipei, Taiwan.
Topics: Adult; Aged; Antitubercular Agents; Body Weight; Dose-Response Relationship, Drug; Drug Combinations | 2012 |
Outcomes of Category III DOTS treatment in immunocompetent patients with tuberculosis pleural effusion.
Topics: Adolescent; Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; D | 2012 |
Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
Topics: Acetyltransferases; Adolescent; Age Factors; Antitubercular Agents; Area Under Curve; Biological Ava | 2012 |
Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; False Positive Reactions; Humans; Microbial Sensi | 2013 |
Analogs of the antituberculous agent pyrazinamide are competitive inhibitors of NADPH binding to M. tuberculosis fatty acid synthase I.
Topics: Antitubercular Agents; Bacterial Proteins; Fatty Acid Synthases; Humans; Mycobacterium tuberculosis; | 2012 |
Evaluation of tuberculosis underreporting in Greece through comparison with anti-tuberculosis drug consumption.
Topics: Antitubercular Agents; Epidemiological Monitoring; Ethambutol; Greece; Humans; Isoniazid; Latent Tub | 2012 |
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydrox | 2013 |
Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.
Topics: Animals; Antitubercular Agents; Female; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Myco | 2012 |
Drug resistance mechanism of PncA in Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Binding Sites; Drug Resistance, Multiple, Bacterial; Hydroge | 2014 |
Antitubercular therapy decreases nitric oxide production in HIV/TB coinfected patients.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biomarkers; CD4 Lymphocyte Count; CD4-Pos | 2002 |
Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.
Topics: Adolescent; Adult; Aged; Alcoholism; Antibiotics, Antitubercular; Antitubercular Agents; Chemical an | 2003 |
Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; Pr | 2002 |
Population pharmacokinetics of antituberculous drugs and treatment of Mycobacterium bovis infection in bongo antelope (Tragelaphus eurycerus isaaci).
Topics: Amikacin; Animals; Antelopes; Antitubercular Agents; Area Under Curve; Ethambutol; Female; Isoniazid | 2002 |
From the Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; Pr | 2002 |
Evaluation of BACTEC MGIT 960 PZA medium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA): compared with the results of pyrazinamidase assay and Kyokuto PZA test.
Topics: Amidohydrolases; Culture Media; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Myc | 2002 |
Fatal liver injury associated with rifampin-pyrazinamide treatment of latent tuberculosis infection.
Topics: Adverse Drug Reaction Reporting Systems; Antitubercular Agents; Centers for Disease Control and Prev | 2003 |
Management of latent tuberculosis infection in immigrants.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cost-Benefit Analysis; Drug Resistanc | 2003 |
Management of latent tuberculosis infection in immigrants.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Emigration and Immigration; Health Care Costs; Humans; | 2003 |
Anti-tuberculosis 4FDC tablets--mystery to chemistry.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Combinations; Drug Stability; Drug Storage; | 2003 |
Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
Topics: Administration, Oral; Antibiotics, Antitubercular; Antitubercular Agents; Chemistry, Pharmaceutical; | 2003 |
A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Drug Combinations; Drug | 2003 |
[Tuberculous otitis media. Report of 3 cases].
Topics: Adult; Aged; Amoxicillin; Antitubercular Agents; Cerebrospinal Fluid Otorrhea; Drug Combinations; Ea | 2003 |
Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Centers for Disease Control and Preventio | 2003 |
Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; Py | 2003 |
[Action of pyrazinamide on experimental and clinical tuberculosis].
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1952 |
Use of pyrazinamide (aldinamide) in the treatment of tuberculous lymphadenopathy and draining sinuses; a preliminary report.
Topics: Disease; Humans; Lymph Nodes; Niacin; Nicotinic Acids; Pyrazinamide; Sternum; Tuberculosis; Tubercul | 1953 |
Pyrazinamide (aldinamide*) in the treatment of pulmonary tuberculosis.
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Pyrazinamide-isoniazid in tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1954 |
Observations on the combined use of pyrazinamide (Aldinamide) and isoniazid in the treatment of pulmonary tuberculosis; a clinical study.
Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Observations on pyrazinamide (Aldinamide) in pulmonary tuberculosis.
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Further studies with aldinamide in experimental tuberculosis of the guinea pig.
Topics: Guinea Pigs; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1953 |
[Pyrazinamide in the treatment of cutanoeus tuberculosis: report of a case].
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Cutaneous | 1954 |
The antituberculous activity of pyrazinamide in vitro and in the guinea pig.
Topics: Guinea Pigs; In Vitro Techniques; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Pyrazinamide; | 1954 |
The chemotherapy of pulmonary tuberculosis with pyrazinamide used alone and in combination with streptomycin, para-aminosalicylic acid, or isoniazid.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Streptomycin; Tube | 1954 |
Pyrazinamide-isoniazid in tuberculosis. I. Results in 58 patients with pulmonary lesions one year after the start of therapy.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
The influence of pyrazinamide-isoniazid on M. tuberculosis in animals and man.
Topics: Isomerism; Isoniazid; Leadership; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Pyrazinamide; | 1954 |
Experience with pyrazinamide.
Topics: Aminosalicylic Acid; Niacin; Nicotinic Acids; Pyrazinamide; Streptomycin; Tuberculosis; Tuberculosis | 1955 |
Pyrazinamide-isoniazid in tuberculosis. III. Observations with reduced dosage of pyrazinamide.
Topics: Clinical Protocols; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pu | 1955 |
Pyrazinamide-isoniazid: comparison with isoniazid-para-aminosalicylic acid in active pulmonary tuberculosis with the choice of regimens determined by chance.
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Pyrimidines; Tuberculosis; Tu | 1956 |
[First results in the treatment of tuberculous meningitis with the use of pyrazinamide and the first studies on its action on isoniazid-resistant strains].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Pyrimidines; Tuberculosis; Tuberculosis | 1956 |
[Possible therapeutic use of new preparations with antituberculous action (pyrazinamide and cycloserine); preliminary note].
Topics: Anti-Bacterial Agents; Cycloserine; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tub | 1956 |
[Possible therapeutic use of new preparations with antituberculous action (pyrazinamide and cycloserine); preliminary note].
Topics: Anti-Bacterial Agents; Cycloserine; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tub | 1956 |
[Possible therapeutic use of new preparations with antituberculous action (pyrazinamide and cycloserine); preliminary note].
Topics: Anti-Bacterial Agents; Cycloserine; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tub | 1956 |
[Possible therapeutic use of new preparations with antituberculous action (pyrazinamide and cycloserine); preliminary note].
Topics: Anti-Bacterial Agents; Cycloserine; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tub | 1956 |
[Activity of pyrazinamide (pyrazine-2-carboxylic acid amide) in experimental tuberculosis of the cavy].
Topics: Amides; Guinea Pigs; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1956 |
[Activity of pyrazinamide (pyrazine-2-carboxylic acid amide) in experimental tuberculosis of the cavy].
Topics: Amides; Guinea Pigs; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1956 |
[Activity of pyrazinamide (pyrazine-2-carboxylic acid amide) in experimental tuberculosis of the cavy].
Topics: Amides; Guinea Pigs; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1956 |
[Activity of pyrazinamide (pyrazine-2-carboxylic acid amide) in experimental tuberculosis of the cavy].
Topics: Amides; Guinea Pigs; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1956 |
[The effect of pyrazinamide on experimental tuberculosis in mice].
Topics: Animals; Mice; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1956 |
[Clinical experiences with pyrazinamide].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Streptomycin; Tuberculosis; T | 1956 |
[Further observations on pyrazinamide].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Dermatologic Agents; Isoniazid; Pyrazinamide; Tu | 1956 |
Pyrazinamide together with oxytetracycline in patients with tubercle bacilli resistant to streptomycin, PAS and isoniazid.
Topics: Aminosalicylic Acid; Bacillus; Isoniazid; Lacticaseibacillus casei; Niacin; Nicotinic Acids; Oxytetr | 1957 |
[Treatment of chronic pulmonary tuberculosis with pyrazinamide].
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Effects of pyrazinamide on experimental tuberculosis in guinea pigs].
Topics: Animals; Cortisone; Guinea Pigs; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1957 |
[In vitro studies of pyrazinamide action on Mycobacteria tuberculosis showing resistance and sensitivity to specific chemotherapy and antibiotics; comparative studies].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Humans; In Vitro Techniques; Mycobacterium tuberculosi | 1957 |
[Behavior of the Middlebrook-Dubos reaction and of phagocytosis in pulmonary tuberculosis treated with pyrazinamide].
Topics: Humans; Niacin; Nicotinic Acids; Phagocytosis; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Elimination of urinary 17-ketosteroids in pulmonary tuberculosis treated with pyrazinamide].
Topics: 17-Ketosteroids; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Steroids; Tuberculosis; Tuberculosis | 1957 |
[Determination of prothrombin time (Quick test) and plasma fibrinogen in pulmonary tuberculosis treated with pyrazinamide].
Topics: Fibrinogen; Humans; Niacin; Nicotinic Acids; Prothrombin Time; Pyrazinamide; Tuberculosis; Tuberculo | 1957 |
[Blood iodine precipitation and cholesteremia in pulmonary tuberculosis treated with pyrazinamide].
Topics: Cholesterol; Humans; Iodine; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulm | 1957 |
[Peripheral blood picture in pulmonary tuberculosis treated with pyrazinamide].
Topics: Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Blood proteins in pulmonary tuberculosis treated with pyrazinamide; electrophoresis and serodiagnosis].
Topics: Blood Proteins; Electrophoresis; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberc | 1957 |
[Effects of pyrazinamide and cycloserine therapy of tuberculosis on clinical and functional liver reactions and on certain biological tests].
Topics: Anti-Bacterial Agents; Cycloserine; Humans; Liver; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculos | 1957 |
[Pyrazinamide in the treatment of pulmonary tuberculosis].
Topics: Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Combination of pyrazinamide & isoniazid in experimental tuberculosis in guinea pigs].
Topics: Animals; Guinea Pigs; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1956 |
[Liver function and pyrazinamide therapy of pulmonary tuberculosis].
Topics: Liver; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Two new antituberculotic drugs: pyrazinamide & cycloserine].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Niacin; Nicotinic Acids; Pyrazinami | 1957 |
[Action of pyrazinamide on experimental tuberculosis in mice; comparison of oral and subcutaneous administration].
Topics: Animals; Mice; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1956 |
Pyrazinamide-isoniazid in patients with previous isoniazid therapy.
Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
A STATEMENT of pyrazinamide.
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1957 |
[Clinical aspects and experimental data on the use of pyrazinamide in tuberculous infection].
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1957 |
[Pyrazinamide in pulmonary and extrapulmonary tuberculosis; clinical aspects].
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1957 |
[Treatment of pulmonary tuberculosis with high alternating dosage of pyrazinamide and isoniazid].
Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Pyrazinamide in pulmonary tuberculosis; behavior of blood proteins].
Topics: Blood Proteins; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Experimental treatment with pyrazinamide alone].
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Therapies, Investigational; Tuberculosis | 1957 |
[Pyrazinamide-isoniazid mixture in the treatment of chronic pulmonary tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
Further observations of pyrazinamide alone and in combination with other drugs in experimental tuberculosis.
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1957 |
[Use of pyrazinamide in acute tuberculous disseminations; 1 year's experience in the Centro Meningitic di Bologna].
Topics: Child; Humans; Infant; Meningitis; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis | 1957 |
Comparative efficacy of the concurrent use of pyrazinamide and isoniazid with that of other forms of therapy in the treatment of pulmonary tuberculosis.
Topics: Isoniazid; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Therapy of tuberculous adenopathy in infants; clinical experiences with pyrazinamide].
Topics: Child; Humans; Infant; Lymph Nodes; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosi | 1957 |
[Pyrazinamide & pyrazinamide with isoniazid in pulmonary tuberculosis; comparison with other chemotherapeuticantibiotic combinations].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[The phenomenon of tanned skin in tuberculotics treated with pyrazinamide].
Topics: Niacin; Nicotinic Acids; Pigmentation; Pyrazinamide; Tuberculosis | 1957 |
Pyrazinamide and cycloserine in the treatment of pulmonary tuberculosis.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Niacin; Nicotinic Acids; Pyrazinami | 1957 |
[Pyrazinamide and gastric functional response in pulmonary tuberculosis].
Topics: Humans; Niacin; Nicotinic Acids; Pyrazinamide; Stomach; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Pyrazinamide in therapy of cavitary tuberculosis resistant to usual therapy].
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
Pyrazinamide and viomycin in the surgical treatment of pulmonary tuberculosis.
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary; Viomycin | 1958 |
[Possibility of the use of pyrazinamide in renal tuberculosis].
Topics: Kidney; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Renal | 1957 |
[Combined pyrazinamide and isoniazid in therapy of pulmonary tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Liver function tests of pulmonary tuberculosis patients treated with pyrazinamide].
Topics: Liver; Liver Function Tests; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulm | 1957 |
[Experience on the use of pyrazinamide in the treatment of pulmonary tuberculosis. I. Clinical results].
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Experience on the use of pyrazinamide in the treatment of pulmonary tuberculosis. II. Hepatic function & blood proteins in the scope of clinical changes].
Topics: Blood Proteins; Liver; Pyrazinamide; Tuberculosis; Tuberculosis, Hepatic; Tuberculosis, Pulmonary | 1957 |
[Activity of pyrazinamide against experimental tuberculosis].
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1958 |
[Behavior of hemagglutinating antibodies and electrophoretic patterns of globulins in animals vaccinated with killed Koch bacilli and simultaneously treated with cycloserine and pyrazinamide].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antibodies; Cycloserine; Globulins; Mycobacteriu | 1957 |
[Pyrazinamide and gastric functional response in pulmonary tuberculosis].
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Stomach; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Radiological records of the results of combined pyrazinamide-streptomycin-isoniazid therapy].
Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Radiology; Streptomycin; Tuberculosis; Tuberculosi | 1958 |
Clinical and biological investigations on the new antituberculosis drugs (pyrazinamide and cycloserine).
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Cycloserine; Niacin; Nico | 1958 |
[Studies on the changes of the daily amount of tubercle bacilli present in sputum and its resistance against drugs, when patients have been treated with anti-tuberculous agents. I. Combined therapy with pyrazinamide and isonicotinic acid hydrazide].
Topics: Bacillus; Humans; Isoniazid; Lung; Pyrazinamide; Sputum; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Experimental studies on the mode of action of pyrazinamide. I. The relation with isoniazid].
Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1958 |
[Pyrazinamide-isoniazid combination in treatment of bone tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Osteoarticular | 1958 |
Pulmonary resection for tuberculosis under protection of viomycin, promizole and pyrazinamide.
Topics: Niacin; Nicotinic Acids; Pneumonectomy; Pyrazinamide; Sulfathiazole; Sulfathiazoles; Thiazoles; Tube | 1958 |
Treatment of drug-resistant cases of pulmonary tuberculosis with cycloserine and pyrazinamide.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Niacin; Nicotinic Acids; Pyrazinami | 1958 |
Cycloserine combined with pyrazinamide in the treatment of pulmonary tuberculosis.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Niacin; Nicotinic Acids; Pyrazinami | 1958 |
[Behavior of hemagglutinating antibodies & electrophoretic globulins in animals vaccinated with killed Koch's bacillus & contemporaneously treated with cycloserine & pyrazinamide].
Topics: Agammaglobulinemia; Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Bacillus; Cycloseri | 1958 |
[Behavior of the Middlebrook-Dubos reaction & blood protein picture in healthy rabbits treated with pyrazinamide & cycloserine & in rabbits pretreated with the same drugs & successively infected with Mycobacterium tuberculosis bovis].
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Blood Proteins; Cycloserine; Hemaggluti | 1958 |
[Pyrazinamide in solution, for topical use, in the treatment of tuberculous empyema].
Topics: Empyema, Tuberculous; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pul | 1958 |
Pyrazinamide in low dosage in combination with isoniazid or paraaminosalicylic acid in the treatment of pulmonary tuberculosis.
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, P | 1959 |
[Newer tuberculostatics: pyrazinamide & cycloserine].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Niacin; Nicotinic Acids; Pyrazinami | 1958 |
The use of pyrazinamide plus isoniazid in the treatment of pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
[Tests of liver function during pyrazinamide therapy].
Topics: Child; Humans; Infant; Isoniazid; Liver; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberc | 1959 |
[Liver function tests during pyrazinamide therapy].
Topics: Child; Humans; Infant; Liver; Liver Function Tests; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculo | 1959 |
[Observations on therapy of pulmonary tuberculosis with viomycin pyrazinamide & cycloserine].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Humans; Niacin; Nicotinic Acids; Py | 1959 |
[A clinical experience report on combined therapy of pulmonary tuberculosis with cycloserine-pyrazinamide].
Topics: Cycloserine; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
Retreatment of pulmonary tuberculosis. Experiences with various combinations of pyrazinamide, cycloserine, and kanamycin in patients excreting tubercle bacilli resistant to both streptomycin and isoniazid.
Topics: Anti-Bacterial Agents; Bacillus; Cycloserine; Humans; Isoniazid; Kanamycin; Pyrazinamide; Retreatmen | 1960 |
[Pyrazinamide in the treatment of pulmonary tuberculosis].
Topics: Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
[Cycloserine associated with other chemio-antibiotics in the treatment of pulmonary tuberculosis. Clinical contribution on pyrazinamidecycloserine association].
Topics: Anti-Bacterial Agents; Cycloserine; Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
Retreatment of tuberculous patients: an experience with the combined use of high doses of isoniazid, pyrazinamide and cycloserine.
Topics: Cycloserine; Isoniazid; Pyrazinamide; Retreatment; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[On the evaluation of antitubercular agents of second rank].
Topics: Antitubercular Agents; Cycloserine; Pyrazinamide; Tuberculosis; Viomycin | 1960 |
Pyrazinamide-isoniazid treated tuberculous patients: a five year follow-up.
Topics: Follow-Up Studies; Humans; Isoniazid; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
Unusual reactions to anti-tuberculous chemotherapy.
Topics: Hepatitis; Hepatitis A; Humans; Isoniazid; Pyrazinamide; Tuberculosis; Uric Acid | 1960 |
SEQUENTIAL use of paired combinations of isoniazid, streptomycin, para-aminosalicylic acid, and pyrazinamide. A United States Public Health Service tuberculosis therapy trial.
Topics: Aminosalicylic Acid; Antitubercular Agents; Isoniazid; Pyrazinamide; Streptomycin; Tuberculosis; Uni | 1959 |
[Basic derivatives of pyrazine-2-carboxylic acid with antimycobacterial action. Microbiological and pharmacological study].
Topics: Anti-Bacterial Agents; Humans; Pyrazinamide; Tuberculosis | 1962 |
[Experimental and clinical research on the antitubercular activity of the N-(4-morpholinomethyl)-amide of pyrazinecarboxylic acid].
Topics: Amides; Antitubercular Agents; Humans; Pyrazinamide; Tuberculosis | 1962 |
[The use of Piazofoline in the pre- and post-operative treatment of pulmonary tuberculosis].
Topics: Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
[Clinical experimentation with Piazofoline with special reference to hepatic function].
Topics: Humans; Pyrazinamide; Research Design; Tuberculosis | 1962 |
[Piazofoline in the therapy of pulmonary tuberculosis].
Topics: Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
[N-Morpholinomethyl-pyrazinamide: chemico-physical characteristics and determination in biological fluids].
Topics: Humans; Pyrazinamide; Tuberculosis | 1962 |
[The action of small doses of antitubercular drugs administered by intradermal route in experimental tuberculosis. III. Action of pyrazinamide].
Topics: Antitubercular Agents; Humans; Pyrazinamide; Tuberculosis | 1962 |
The tate of patients with drug-resistant tubercle bacilli and pulmonary tuberculosis.
Topics: Anti-Bacterial Agents; Bacillus; Cycloserine; Drug Resistance; Drug Resistance, Microbial; Ethionami | 1962 |
[The importance of medical treatment of pulmonary tuberculosis from a new viewpoint].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Dihydrostreptomycin Sulfate; Ethionamide; Ip | 1962 |
[Treatment of interstitial tuberculotic bladder processes].
Topics: Adrenocorticotropic Hormone; Cortisone; Pyrazinamide; Tuberculosis; Tuberculosis, Urogenital; Urinar | 1963 |
Re-treatment therapy with cycloserine-pyrazinamide. Response in cavity closure and disappearance of tubercle bacilli from sputum.
Topics: Bacillus; Cycloserine; Humans; Lacticaseibacillus casei; Pyrazinamide; Sputum; Tuberculosis; Tubercu | 1962 |
Ethionamide, pyrazinamide and cycloserine used successfully in the treatment of chronic pulmonary tuberculosis.
Topics: Cycloserine; Ethionamide; Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
[Pyrazinamide in association with streptomycin, PAS and isoniazid in the therapy of pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Humans; Isoniazid; Pyrazinamide; Streptomycin; Tuberculos | 1962 |
Bacteriological aspects of the use of ethionamide, pyrazinamide and cycloserine in the treatment of chronic pulmonary tuberculosis.
Topics: Cycloserine; Drug Resistance; Drug Resistance, Microbial; Ethionamide; Humans; Pyrazinamide; Tubercu | 1962 |
Preliminary experiments on the use of "the air-tight cultivation method" in determining blood levels of drugs during the chemotherapy of tuberculosis.
Topics: Bacteriological Techniques; Blood Chemical Analysis; Humans; Isoniazid; Mycobacterium tuberculosis; | 1963 |
[Pyrazinamide in urology].
Topics: Pyrazinamide; Tuberculosis; Tuberculosis, Urogenital; Urology | 1962 |
Pyrazinamide and ethionamide in the treatment of pulmonary tuberculosis in Hong Kong.
Topics: Ethionamide; Hong Kong; Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
[Various biological tests on several groups of subjects with tuberculosis subjected respectively to monotherapy with isoniazid, viomycin, pyrazinamide, cycloserine, ethioniamide and kanamycin].
Topics: Cycloserine; Ethionamide; Isoniazid; Kanamycin; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary; | 1962 |
PYRAZINAMIDE COVERAGE AT THE TIME OF PULMONARY RESECTION FOR TUBERCULOSIS.
Topics: Humans; Pneumonectomy; Postoperative Complications; Preoperative Care; Pyrazinamide; Tuberculosis; T | 1963 |
DRUG THERAPY FOR TUBERCULOUS PATIENTS OUTSIDE THE HOSPITAL.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Hypersensitivity; Drug Resistance; Drug | 1963 |
[THE FOCUS OF INOCULATION IN GUINEA PIGS DURING TREATMENT WITH MORFOZINAMIDE. (INFECTION WITH STRAINS SENSITIVE AND RESISTANT TO CHEMOTHERAPY AND ANTIBIOTICS].
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Drug Resistance; | 1963 |
[THE THERAPY OF PULMONARY TUBERCULOSIS WITH MORPHAZINAMIDE. CLINICAL CONTRIBUTION].
Topics: Antitubercular Agents; Humans; Pyrazinamide; Pyrazines; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
MODERN DRUG TREATMENT OF MYCOBACTERIAL DISEASES.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloseri | 1963 |
SIDE EFFECTS OF AN ANTITUBERCULOUS FIVE-DRUG REGIMEN: ETHIONAMIDE, CYCLOSERINE, PYRAZINAMIDE, VIOMYCIN AND ISONIAZID.
Topics: Amyloidosis; Antitubercular Agents; Cycloserine; Deafness; Drug Hypersensitivity; Duodenal Ulcer; Et | 1963 |
[PRELIMINARY FUNCTIONAL AND MORPHOLOGICAL HEPATIC FINDINGS IN PATIENTS TREATED WITH MORPHAZINAMIDE].
Topics: Antitubercular Agents; Fatty Liver; Humans; Liver Function Tests; Pyrazinamide; Pyrazines; Silicotub | 1963 |
[EXPERIENCE WITH A NONSPECIFIC ANTIINFLAMMATORY AGENT IN PULMONARY TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Inflammatory Agents; Cycloserine; Drug Resistance; D | 1963 |
DRUG RESISTANT MYCOBACTERIAL INFECTION AND ITS RESPONSE TO TREATMENT.
Topics: Cycloserine; Drug Resistance; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium; Mycobact | 1963 |
[CHEMO-ANTIBIOTIC THERAPY IN PULMONARY TUBERCULOSIS].
Topics: Antitubercular Agents; Cycloserine; Ethionamide; Kanamycin; Pyrazinamide; Tuberculosis; Tuberculosis | 1963 |
RECENT ADVANCES IN TREATMENT OF ORGAN TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Child; Cycloserine; Ethionamide; I | 1964 |
CHEMOTHERAPY FOR PATIENTS WITH CULTURES RESISTANT TO STREPTOMYCIN, ISONIAZID AND PAS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Czechoslovakia; Drug Resistance; Drug Resist | 1963 |
[ETHIONAMIDE IN ASSOCIATION WITH PYRAZINAMIDE OR CYCLOSERINE IN THE TREATMENT OF CHRONIC PULMONARY TUBERCULOSIS].
Topics: Cycloserine; Drug Resistance; Drug Resistance, Microbial; Ethionamide; Pyrazinamide; Toxicology; Tub | 1963 |
[SOME CLINICAL ASPECTS OF DRUG RESISTANCE OF TUBERCLE BACILLI ISOLATED FROM PATIENTS WITH FIBRO-CAVERNOUS TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacillus; Culture Media; Drug Resistance; Drug Resistance | 1963 |
SOME PROBLEMS IN THE MANAGEMENT OF TUBERCULOSIS.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antitubercular Agents; | 1964 |
D-CYCLOSERINE IN THE TREATMENT OF PULMONARY TUBERCULOSIS RESISTANT TO THE STANDARD DRUGS: A STUDY OF 116 CASES.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Resistance; Drug Resistance, Microbial; | 1964 |
[EFFECT OF PYRAZINAMIDE ON HEMOSTATIC FACTORS OF THE ORGANISM. (PRELIMINARY COMMUNICATION)].
Topics: Blood Coagulation; Blood Coagulation Tests; Blood Proteins; Hemostatics; Humans; Prothrombin Time; P | 1963 |
[ANTIMICROBIAL SCREEN IN PHTHISIOLOGICAL SURGERY].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agents; Antitubercular Agents; Collapse Th | 1963 |
[THE RESULTS OBTAINED WITH THE COMBINATION OF PYRAZINAMIDE AND ISONIAZID IN THE TREATMENT OF PULMONARY TUBERCULOSIS].
Topics: Humans; Isoniazid; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
[TREATMENT OF TUBERCULOSIS AND DIABETES BECOMING SIMILAR].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Diabetes Mellitus; Ethionamide; Isoniazid; P | 1964 |
CLINICAL ASPECTS, MEDICAL AND SURGICAL, IN THE MANAGEMENT OF BATTEY-TYPE PULMONARY DISEASE.
Topics: Bronchiectasis; Calcification, Physiologic; Drug Resistance; Drug Resistance, Microbial; Epidemiolog | 1964 |
ANTIMICROBIAL THERAPY OF PULMONARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agents; Cycloserine; Dihydrostreptomycin S | 1963 |
INCIDENCE AND MANAGEMENT OF TUBERCULOUS STRICTURES OF THE URINARY TRACT.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Constriction, Pathologic; Humans; Hydronephrosis; Inciden | 1964 |
[THE USE OF ANTIBACILLARY DRUGS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Resistance; Drug Resistance, Microbial; | 1964 |
A SPUTUM SURVEY OF CASES OF PULMONARY TUBERCULOSIS TWO TO THREE YEARS AFTER STARTING TREATMENT IN A RURAL AREA IN KENYA.
Topics: Child; Drug Resistance; Drug Resistance, Microbial; Health Surveys; Humans; Infant; Isoniazid; Kenya | 1964 |
[NEW COMBINATIONS OF ANTITUBERCULAR AGENTS IN THE TREATMENT OF RENAL TUBERCULOSIS].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antitubercular Agents; | 1964 |
[THE TREATMENT OF TUBERCULOSIS WITH 2ND LINE DRUGS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antibiotics, Antitubercular; Cyclo | 1964 |
[ANTIMICROBIAL TREATMENT OF TUBERCULOSIS WITH SUBSIDIARY DRUGS. 2ND LINE DRUGS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agents; Antitubercular Agents; Bacteriolog | 1964 |
INHIBITION OF PYRAZINAMIDE HYPERURICEMIA BY SMALL DOSES OF ACETYLSALICYLIC ACID.
Topics: Aspirin; Blood Chemical Analysis; Drug Therapy; Humans; Hyperuricemia; Pyrazinamide; Toxicology; Tub | 1964 |
PULMONARY TUBERCULOSIS.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Child; Cycloserine; Drug Resista | 1964 |
A STUDY OF THE INFLUENCE OF THE ISONIAZID INACTIVATOR PHENOTYPE ON REVERSION IN GENITO-URINARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriology; Genetics, Medical; Geriatrics; Isoniazid; M | 1964 |
A CONTROLLED COMPARISON OF STREPTOMYCIN PLUS PYRAZINAMIDE AND STREPTOMYCIN PLUS PAS IN THE RETREATMENT OF PATIENTS EXCRETING ISONIAZID-RESISTANT ORGANISMS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriology; Biomedical Research; Drug Resistance; Drug | 1964 |
A SIMPLE TABLET TEST FOR THE DETECTION OF PYRAZINAMIDE IN THE URINE.
Topics: Behavior; Biomedical Research; Chemical Phenomena; Chemistry; Drug Resistance; Drug Resistance, Micr | 1964 |
TREATMENT OF PATIENTS WITH CULTURES RESISTANT TO THE PRIMARY ANTI-TUBERCULOSIS DRUGS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Bacteriological Techniques; Biomed | 1964 |
[LUNG TUBERCULOMAS].
Topics: Adolescent; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Bronchoscopy; | 1963 |
[APROPOS OF ETHIONAMIDE JAUNDICE].
Topics: Alanine Transaminase; Alcoholism; Aminosalicylic Acid; Aminosalicylic Acids; Aspartate Aminotransfer | 1964 |
RELAPSE IN TREATED CASES OF PULMONARY TUBERCULOSIS. I. THREE-YEAR FOLLOW-UP OF 312 PATIENTS DISCHARGED FROM THE HOSPITAL WITH MEDICAL APPROVAL, 1947-1954.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Communicable Disease Control; Foll | 1964 |
[DRUG TREATMENT OF RENAL TUBERCULOSIS].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloseri | 1964 |
[NEW DRUGS IN THE TREATMENT OF PULMONARY TUBERCULOSIS].
Topics: Cycloserine; Ethionamide; Kanamycin; Pyrazinamide; Toxicology; Tuberculosis; Tuberculosis, Pulmonary | 1964 |
[COMPLICATIONS IN THE TREATMENT OF PULMONARY TUBERCULOSIS WITH PYRAZINAMIDE].
Topics: Pyrazinamide; Toxicology; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
[INDICATIONS AND UTILITY OF INTRATHECAL AND INTRAVENTRICULAR TREATMENT IN THE THERAPY OF TUBERCULAR MENINGITIS].
Topics: Child; Chlorpromazine; Humans; Injections; Injections, Spinal; Isoniazid; Prednisolone; Pyrazinamide | 1963 |
TREATMENT OF TUBERCULOSIS OF THE KNEE.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Child; Drug Therapy; Ethionamide; Humans; Iso | 1964 |
[EFFECT OF PYRAZINAMIDE ON INACTIVE DUODENAL ULCER].
Topics: Chemical and Drug Induced Liver Injury; Drug Therapy; Duodenal Ulcer; Hepatitis; Liver Function Test | 1964 |
[CHEMO-ANTIBIOTIC THERAPY OF TUBERCULOSIS IN DIABETICS AND ITS REPERCUSSIONS ON GLUCIDE METABOLISM].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Blood Glucose; Carbohydrate Metabo | 1964 |
ALTERNATING REGIMENS OF STREPTOMYCIN-PYAZINAMIDE, ISONIAZID-PARA-AMINOSALICYLIC ACID AT BATTEY STATE HOSPITAL.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Drug Therapy | 1964 |
[CLINICAL EXPERIENCE WITH THE COMBINED APPEARANCE OF TUBERCULOSIS AND VIRUS HEPATITIS].
Topics: Adrenocorticotropic Hormone; Aminosalicylic Acid; Aminosalicylic Acids; Collapse Therapy; Drug Thera | 1964 |
INFECTION OF MICE WITH MYCOBACTERIUM TUBERCULOSIS, STRAIN H37RA.
Topics: Animals; Isoniazid; Lung; Mice; Mycobacterium bovis; Mycobacterium tuberculosis; Pharmacology; Pyraz | 1964 |
[ENZYMATIC STUDY OF THE LIVER IN PULMONARY TUBERCULOSIS. RESEARCH ON A POSSIBLE HEPATOTOXIC EFFECT OF ANTIBACTERIAL MEDICATIONS].
Topics: Alanine Transaminase; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Aspartate Am | 1964 |
CHEMOTHERAPY OF PREVIOUSLY TREATED PATIENTS WITH PULMONARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Hypersensitivity; Drug Resistance; Drug | 1964 |
POTT'S DISEASE TREATED WITHOUT SPINAL FUSION.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Drug Therapy; Humans; Isoniazid; P | 1964 |
RE-TREATMENT OF DRUG-RESISTANT PULMONARY TUBERCULOSIS AT BATTEY STATE HOSPITAL.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Resistance; Drug Resistance, Microbial; | 1964 |
A PRELIMINARY REPORT ON A NEW ANTITUBERCULOUS DRUG 4-AMINO-2-HYDROXY-PHENYL-1, 3, 4,-OXADIAZOL-2-OL WS 127.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Biomedical Research; Blood; Cyclos | 1964 |
SPUTUM CONVERSION IN CHRONIC TUBERCULOSIS WITH POLYRESISTANT BACILLI.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Bacillus; Cycloserine; Dihydrostre | 1964 |
ANTITUBERCULOUS DRUGS AND SIDEROBLASTIC ANAEMIA.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Anemia; Anemia, Hypochromic; Anemia, Siderobl | 1965 |
[TUBERCULOUS MENINGITIS WITH RESISTANT KOCH BACILLI; RECOVERY OWING TO CYCLOSERINE-PYRAZINAMIDE COMBINATION].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Resistance; Drug Resistance | 1964 |
[AMBULATORY AND HOSPITAL THERAPY OF TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antit | 1964 |
DRUG RESISTANCE IN PULMONARY TUBERCULOSIS; TREATMENT WITH ETHIONAMIDE IN VARIOUS DRUG COMBINATIONS.
Topics: Cycloserine; Drug Combinations; Drug Resistance; Drug Resistance, Microbial; Drug Therapy; Drug Tole | 1965 |
PYRAZINAMIDE AND ETHIONAMIDE IN RESISTANT PULMONARY TUBERCULOSIS IN AFRICANS. AN 18-MONTH FOLLOW-UP OF 32 PATIENTS.
Topics: Drug Therapy; Ethionamide; Follow-Up Studies; Pyrazinamide; Toxicology; Tuberculosis; Tuberculosis, | 1965 |
CHEMOTHERAPY OF TUBERCULOSIS.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Classific | 1964 |
RENAL CALCIFICATION IN GENITO-URINARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Therapy; Isoniazid; Nephrectomy; Nephrocalcinosis; P | 1965 |
THE USE OF ETHIONAMIDE IN COMBINED DRUG REGIMENS IN THE RE-TREATMENT OF ISONIAZID-RESISTANT PULMONARY TUBERCULOSIS.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Resi | 1965 |
[EXPERIENCES AND RESULT WITH SECONDARY DRUGS (ETHIONAMIDE, D-CYCLOSERINE, PYRAZINAMIDE AND VIOCIN) IN SURGICAL TREATMENT OF PULMONARY TUBERCULOSIS].
Topics: Antitubercular Agents; Cycloserine; Ethionamide; Humans; Pneumonectomy; Pyrazinamide; Tuberculosis; | 1964 |
A CONTROLLED CLINICAL TRIAL OF ETHIONAMIDE, CYCLOSERINE AND PYRAZINAMIDE IN PREVIOUSLY TREATED PATIENTS WITH PULMONARY TUBERCULOSIS.
Topics: Cycloserine; Drug Therapy; Ethionamide; Isoniazid; Pyrazinamide; Radiography, Thoracic; Streptomycin | 1965 |
CHEMOTHERAPY REGIMENS USED IN RETREATMENT OF PULMONARY TUBERCULOSIS. I. OBSERVATIONS ON THE EFFICACY OF COMBINATIONS OF KANAMYCIN, ETHIONAMIDE AND EITHER CYCLOSERINE OR PYRAZINAMIDE.
Topics: Cycloserine; Drug Resistance; Drug Resistance, Microbial; Drug Therapy; Ethionamide; Kanamycin; Pyra | 1965 |
CHEMOTHERAPY REGIMENS USED IN RETREATMENT OF PULMONARY TUBERCULOSIS. II. OBSERVATIONS ON THE EFFICACY OF COMBINATIONS OF ETHAMBUTOL, CAPREOMYCIN AND COMPANION DRUGS, INCLUDING 4-4 DIISOAMYLOXYTHIOSEMICARBANILIDE.
Topics: Antitubercular Agents; Capreomycin; Cycloserine; Drug Resistance; Drug Resistance, Microbial; Drug T | 1965 |
[COMBINED EFFECT OF ETHIONAMIDE AND PYRAZINAMIDE OR KANAMYCIN ON THE COURSE OF EXPERIMENTAL CHRONIC TUBERCULOSIS IN GUINEA PIGS].
Topics: Animals; Ethionamide; Guinea Pigs; Kanamycin; Pyrazinamide; Research; Tuberculosis | 1965 |
ANTI-TUBERCULOSIS THERAPY DURING PREGNANCY.
Topics: Communicable Diseases; Ethionamide; Female; Humans; Infant; Pregnancy; Pregnancy Complications; Preg | 1965 |
[Application of pyrazinamide in our thoracic surgery].
Topics: Pulmonary Surgical Procedures; Pyrazinamide; Thoracic Surgery; Thoracic Surgical Procedures; Tubercu | 1959 |
[Examination for pyrazinamide-resistant tubercle bacilli. 4th Report: Experiment of PZA treatment in mice infected with pyrazinamide sensitive and resistant strains of tubercle bacilli and the emergence of PZA restant strains].
Topics: Animals; Bacillus; Mice; Pyrazinamide; Tuberculosis | 1959 |
[Endocavitary aspiration with the aid of local introduction of prednisolone derivatives and chemoantibiotics].
Topics: Cycloserine; Prednisolone; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
[On the tuberculostatic effect of pyrazinamide].
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1959 |
An investigation of the value of ethionamide with pyrazinamide or cycloserine in the treatment of chronic pulmonary tuberculosis. A report from the Research Committee of the British Tuberculosis Association.
Topics: Antitubercular Agents; Cyclopropanes; Cycloserine; Ethionamide; Humans; Pyrazinamide; Tuberculosis; | 1961 |
[Clinical results of the use of pyrazinamide in aerosols in pulmonary tuberculosis].
Topics: Aerosols; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[Pyrazinamide aerosol in the treatment of tuberculosis].
Topics: Aerosols; Pyrazinamide; Tuberculosis | 1961 |
[Pyrazinamide in the treatment of pulmonary tuberculosis].
Topics: Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
[On the therapeutic and side effects of morfazinamide in the treatment of tuberculosis].
Topics: Humans; Pyrazinamide; Pyrazines; Tuberculosis | 1962 |
[Combined therapy of massive doses of isoniazid, pyrazinamide, and sulfisoxazole for patients with pulmonary tuberculosis resistant to streptomycin, paraaminosalicylic acid, and isoniazid].
Topics: Aminosalicylic Acid; Humans; Isoniazid; Psychotherapy, Multiple; Pyrazinamide; Streptomycin; Sulfani | 1961 |
USPHS-CDC news.
Topics: Centers for Disease Control and Prevention, U.S.; Chemical and Drug Induced Liver Injury; Communicat | 2003 |
Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan.
Topics: Amidohydrolases; Antitubercular Agents; DNA, Bacterial; Drug Resistance, Bacterial; Drug Resistance, | 2003 |
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Topics: Administration, Inhalation; Aerosols; Animals; Antibiotics, Antitubercular; Antitubercular Agents; A | 2003 |
Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis.
Topics: Administration, Oral; Animals; Antitubercular Agents; Delayed-Action Preparations; Drug Carriers; Dr | 2003 |
Mycobacterium tuberculosis infection following allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Anemia, Aplastic; Antitubercular Agents; Drug Therapy, Combination; Humans; Immunocompromised | 2003 |
Tuberculosis prevention in Mexican immigrants: limitations of short-course therapy.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Chemical and Drug Induced Liver Injury; Child; Child | 2004 |
[Septic loosening of a Wagner revision stem provoked by Mycobacterium tuberculosis].
Topics: Acetabulum; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Arthroplasty, Replacement, Hip | 2003 |
Pancytopenia due to extensive hemophagocytosis following anti-tubercular treatment.
Topics: Adult; Antitubercular Agents; Biopsy, Needle; Bone Marrow; Hepatomegaly; Histiocytosis; Humans; Ison | 2004 |
The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis.
Topics: Adult; Age Distribution; Antitubercular Agents; Area Under Curve; Female; HIV Infections; Humans; Ma | 2004 |
Pyrazinoic acid amide; an agent active against experimental murine tuberculosis.
Topics: Amides; Animals; Humans; Mice; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1952 |
The effect of pyrazinamide (aldinamide) on experimental tuberculosis in mice.
Topics: Animals; Mice; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1952 |
Pyrazinamide (aldinamide) in experimental tuberculosis of the guinea pig.
Topics: Guinea Pigs; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1952 |
Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis.
Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Genetic and phenotypic characterization of pyrazinamide-resistant mycobacterium tuberculosis complex isolates in Japan.
Topics: Amidohydrolases; Antitubercular Agents; DNA Fingerprinting; DNA Transposable Elements; DNA, Bacteria | 2004 |
Rifampicin/pyrazinamide therapy should not be used for latent tuberculosis infection.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Liver; Pyrazinamide; Rifampin; Tuberculosi | 2004 |
Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Drug Combinati | 2004 |
Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin/pyrazinamide with isoniazid regimens.
Topics: Antitubercular Agents; Carrier State; Drug Administration Schedule; Drug Therapy, Combination; Femal | 2004 |
Drug resistance trends among previously treated tuberculosis patients in a national registry in Peru, 1994-2001.
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Ethambutol; Humans; Isoniazid; Peru; Py | 2004 |
Antituberculosis drugs and hepatotoxicity.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; Is | 2004 |
[Use of pyrazinamide as an indicator of tuberculosis epidemiology in Castilla-La Mancha].
Topics: Antitubercular Agents; Disease Notification; Drug Utilization; Humans; Incidence; Pyrazinamide; Spai | 2004 |
pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal.
Topics: Amidohydrolases; Animals; Antitubercular Agents; Mutation; Mycobacterium tuberculosis; Portugal; Pyr | 2004 |
Spectrum of pncA mutations in multidrug-resistant Mycobacterium tuberculosis isolates obtained in Latvia.
Topics: Amidohydrolases; Antitubercular Agents; Codon; Drug Resistance, Multiple, Bacterial; Humans; Latvia; | 2004 |
Is the recommendation not to use rifampin plus pyrazinamide for latent tuberculosis treatment always imperative?
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Drug Thera | 2004 |
[Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; DNA, Bacterial; | 2004 |
Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotics, Antitubercular; Chemical and Drug Induced Liv | 2004 |
Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
Topics: Adolescent; Adult; Aspartate Aminotransferases; Bilirubin; Chemical and Drug Induced Liver Injury; D | 2004 |
Treatment of latent tuberculosis infection: back to the beginning.
Topics: Antitubercular Agents; Female; Humans; Male; Pyrazinamide; Rifampin; Treatment Outcome; Tuberculin T | 2004 |
Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis in Brazil.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Mut | 2005 |
Simple fibroblast-based assay to test the pyrazinamide susceptibility of Mycobacterium tuberculosis.
Topics: Amidohydrolases; Antitubercular Agents; Fibroblasts; Humans; Microbial Sensitivity Tests; Mycobacter | 2005 |
Autoimmune hepatitis and thyroiditis associated with rifampin and pyrazinamide prophylaxis: an unusual reaction.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination; Hepatitis, Aut | 2005 |
Completing tuberculosis prophylaxis in jail: targeting treatment and a comparison of rifampin/pyrazinamide with isoniazid regimens.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Pr | 2005 |
Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Human | 2005 |
Optimal latent TB control methods.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Pyrazinamide; Rifampin; Tubercu | 2005 |
Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
Topics: Administration, Inhalation; Animals; Antitubercular Agents; Area Under Curve; Biological Availabilit | 2005 |
Significant increases in the levels of liver enzymes in mice treated with anti-tuberculosis drugs.
Topics: Alanine Transaminase; Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combinat | 2005 |
[Medicine and television: a diagnosis history].
Topics: Adult; Antitubercular Agents; Cholestasis, Intrahepatic; Diagnostic Errors; Hepatitis B; Hepatitis C | 2005 |
Does resistance to pyrazinamide accurately indicate the presence of Mycobacterium bovis?
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bacterial Typing Techniques; Child; Drug Resi | 2005 |
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis.
Topics: Aerosols; Alginates; Animals; Antitubercular Agents; Drug Carriers; Drug Evaluation, Preclinical; Fe | 2005 |
National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Health Surveys; Hospitalization; Huma | 2005 |
Concurrence of granular cell tumor and Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bronchoscopy; Ethambutol; Granular Cell Tumor; Humans; Isoniazid; Lung; Male; | 2005 |
Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Antitubercular Agents; Chemical and Drug Induced Liver In | 2006 |
Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Ethambutol; HIV Infections; Humans; Infant; | 2006 |
Rifampin and pyrazinamide for treatment of latent tuberculosis infection.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Hospitalization; Humans; Liver Diseas | 2006 |
Adverse drug reactions observed during DOTS.
Topics: Adolescent; Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; D | 2004 |
[Efficiency of preventive chemotherapy in children and adolescents from the bacterial isolation foci of tuberculous infection].
Topics: Adolescent; Anti-Bacterial Agents; Antitubercular Agents; Child; Drug Resistance, Bacterial; Female; | 2006 |
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
Topics: Adult; Antitubercular Agents; Area Under Curve; Cohort Studies; Ethambutol; Female; Humans; Isoniazi | 2006 |
Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients.
Topics: Absorption; Adult; Antitubercular Agents; Female; Humans; Male; Models, Biological; Pyrazinamide; Tu | 2006 |
Rapid pyrazinamide susceptibility testing of Mycobacterium tuberculosis by flow cytometry.
Topics: Antitubercular Agents; Flow Cytometry; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculos | 2006 |
Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Male; Patient | 2006 |
Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients.
Topics: Antitubercular Agents; Base Sequence; DNA Primers; Drug Resistance, Microbial; Humans; Mutation; Myc | 2006 |
Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diary | 2006 |
pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil.
Topics: Amidohydrolases; Antitubercular Agents; Brazil; Drug Resistance; Humans; Microbial Sensitivity Tests | 2006 |
Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Injections, Subcutaneous; Liposomes; Lung; | 2007 |
Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antitubercular Agents; Aspirin; Disease Models, An | 2007 |
Safety of the rifampin and pyrazinamide short-course regimen for treating latent tuberculosis infection.
Topics: Antitubercular Agents; Drug Administration Schedule; Humans; Liver; Practice Guidelines as Topic; Py | 2007 |
[Case report: tuberculosis of parotid gland].
Topics: Adult; Antitubercular Agents; Biopsy; Diagnosis, Differential; Ethambutol; Humans; Isoniazid; Lymph | 2007 |
Short-course regimens for latent tuberculosis: what is ready for prime time?
Topics: Antitubercular Agents; Humans; Isoniazid; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberc | 2007 |
Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolin | 2007 |
Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant mycobacterium tuberculosis strains.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Te | 2007 |
Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Te | 2007 |
Adverse drug reactions associated with first-line anti-tuberculosis drug regimens.
Topics: Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Isoniazid; Pyrazinam | 2007 |
Successful treatment with intravenous immunoglobulins in a patient affected by dermatomyositis/systemic lupus erythematosus overlap syndrome and tuberculosis.
Topics: Antitubercular Agents; Dermatomyositis; Female; Humans; Immunoglobulins, Intravenous; Immunologic Fa | 2007 |
Liver and pancreatic injury induced by antituberculous therapy.
Topics: Adult; Antitubercular Agents; Biopsy; Chemical and Drug Induced Liver Injury; Cholangiopancreatograp | 2007 |
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; | 2007 |
Geography and genealogy of the human host harbouring a distinctive drug-resistant strain of tuberculosis.
Topics: Antitubercular Agents; Consanguinity; Demography; Drug Resistance, Bacterial; Geography; Host-Pathog | 2008 |
Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Topics: Adult; Aged; Antitubercular Agents; Case-Control Studies; Chemical and Drug Induced Liver Injury; Dr | 2008 |
[Experimental therapy with so-called "minor" tuberculostatics].
Topics: Aminosalicylic Acids; Animals; Antitubercular Agents; Cycloserine; Ethambutol; Ethionamide; Guinea P | 1966 |
[Pyrazinamide, cycloserine and ethionamide in the complex treatment of pulmonary tuberculosis].
Topics: Cycloserine; Drug Synergism; Ethionamide; Humans; Pyrazinamide; Tuberculosis | 1967 |
Determination of isonicotinic acid hydrazide in blood serum.
Topics: Cycloserine; Humans; Indicators and Reagents; Isoniazid; Pyrazinamide; Spectrophotometry; Tuberculos | 1967 |
Pyrazinamide is a major antituberculosis drug.
Topics: Humans; Liver; Pyrazinamide; Tuberculosis | 1982 |
[Activity of intermittently administered rifampicin and cyclopentyl rifamycin (or DL473) on experimental tuberculosis in the mouse].
Topics: Animals; DNA-Directed RNA Polymerases; Drug Therapy, Combination; Female; Isoniazid; Mice; Pyrazinam | 1983 |
[Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].
Topics: Animals; Antibiotics, Antitubercular; Drug Therapy, Combination; Female; Humans; Isoniazid; Lung; Mi | 1982 |
Present chemotherapy for tuberculosis.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; Mycobacterium tube | 1982 |
Antituberculous agents. Isoniazid, rifampin, streptomycin, ethambutol, and pyrazinamide.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Tubercul | 1983 |
Modern treatment of tuberculosis.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combi | 1982 |
Current concept of short-term chemotherapy of tuberculosis.
Topics: Drug Combinations; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Time Factors; Tuberculosis | 1981 |
Tuberculosis in patients with end-stage renal disease.
Topics: Adult; Aged; Ethambutol; Female; Humans; Immunity, Cellular; Isoniazid; Kidney Failure, Chronic; Mal | 1980 |
A service program of antituberculosis chemotherapy with five drugs for four months in the treatment of drug addicts and prisoners with pulmonary tuberculosis in Hong Kong. Hong Kong Chest Service/British Medical Research Council.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Ethambutol; Heroin | 1980 |
Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis.
Topics: Acetaminophen; Adult; Capreomycin; Ciprofloxacin; Drug Combinations; Drug Overdose; Ethambutol; Fema | 1994 |
Drugs for tuberculosis.
Topics: Adult; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol; Hum | 1995 |
[Tuberculous dacryocystitis].
Topics: Acute Disease; Child, Preschool; Dacryocystitis; Dacryocystorhinostomy; Humans; Isoniazid; Male; Myc | 1995 |
Treating tuberculosis with one combination drug.
Topics: Antitubercular Agents; Drug Combinations; Ethambutol; Humans; Isoniazid; Patient Compliance; Pyrazin | 1994 |
Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model.
Topics: Animals; Antibiotics, Antitubercular; Drug Therapy, Combination; Female; Isoniazid; Mice; Pyrazinami | 1994 |
Empiric antituberculosis treatment: benefits for earlier diagnosis and treatment of tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Body Weight; Drug Administratio | 1994 |
Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice.
Topics: Animals; Antitubercular Agents; Colony-Forming Units Assay; Drug Therapy, Combination; Female; Immun | 1994 |
Early bactericidal activity as a method of assessment of drugs for the treatment of tuberculosis.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Evaluation, Preclinical; Isoniazid; Microbial Sensitivity | 1994 |
Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Clinical Pro | 1994 |
From the Food and Drug Administration.
Topics: Antitubercular Agents; Blood Donors; Drug Approval; Drug Combinations; Electromagnetic Phenomena; Eq | 1994 |
Rifampin-resistant Mycobacterium kansasii.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Antitubercular Agents; Ciprofloxacin; Clinical Protocols; | 1994 |
Short course chemotherapy for tuberculosis in children.
Topics: Adolescent; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Dose-Response Relations | 1993 |
[Hepatic toxicity of antitubercular agents. Role of different drugs. 199 cases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Child; Child, Pr | 1993 |
Turning intermittent regimens into daily regimens using blister-packs. An exploration in murine tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Administration Schedule; Drug Packaging; Drug Therapy, Combinat | 1993 |
From the Centers for Disease Control and Prevention. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis.
Topics: Adult; Antitubercular Agents; Child; Drug Resistance, Microbial; Drug Therapy, Combination; Ethambut | 1993 |
Pyrazinamide.
Topics: Female; Humans; Pregnancy; Pyrazinamide; Tuberculosis | 1993 |
CDC recommends four-drug treatment of tuberculosis in multidrug-resistant era.
Topics: Adult; Centers for Disease Control and Prevention, U.S.; Child; Drug Therapy; Drug Therapy, Combinat | 1993 |
Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis.
Topics: Adult; Antitubercular Agents; Child; Drug Resistance, Microbial; Drug Therapy, Combination; Ethambut | 1993 |
[Tuberculosis treatment in 1992].
Topics: Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; P | 1993 |
The high incidence of tuberculosis among renal transplant recipients in India.
Topics: Adult; Antitubercular Agents; Ethambutol; Female; Follow-Up Studies; Humans; Incidence; India; Isoni | 1996 |
Management of primary chest wall tuberculosis.
Topics: Abscess; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Combined Modality Therapy; Debri | 1995 |
Pyrazinamide--on the antituberculosis drug frontline.
Topics: Amidohydrolases; Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Resistance, | 1996 |
Hepatotoxic effects of tuberculosis therapy. A practical approach to a tricky management problem.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; | 1996 |
Whither the roles of rifater and rifamate?
Topics: Antitubercular Agents; Drug Combinations; Humans; Isoniazid; Pyrazinamide; Rifampin; Trimethoprim; T | 1996 |
Tuberculosis Control Programme Practical Guidelines, 1996--treatment regimens.
Topics: Antitubercular Agents; Ethambutol; Humans; Practice Guidelines as Topic; Pyrazinamide; Tuberculosis | 1996 |
Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Esters; Humans; Microbial Sensitivity | 1996 |
Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility.
Topics: Animals; Antitubercular Agents; Culture Media; Drug Resistance, Microbial; Female; Mice; Microbial S | 1996 |
Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.
Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Culture Media; Drug Combinations; Drug Inte | 1996 |
Focal tuberculosis of the liver with local hemorrhage in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Ethambutol; Granuloma; Histocytochemistry; Homosexuality, | 1996 |
Four-drug initial therapy for TB is standard treatment.
Topics: Aminosalicylic Acid; Drug Therapy, Combination; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomy | 1996 |
Tuberculosis control programme guidelines--treatment regimens.
Topics: Antitubercular Agents; Body Weight; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol; | 1996 |
Tuberculosis and renal transplantation.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Follow-Up Studies; Humans; Ison | 1996 |
[Tuberculosis of the middle ear: a rare extrapulmonary manifestation].
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Diagnosis, Differential; Ear Diseases; Ear, Midd | 1996 |
Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Cells, Cultured; Clarithr | 1997 |
Short-course chemoprophylaxis evaluated in gold miners with chronic silicosis.
Topics: Antitubercular Agents; Gold; Humans; Isoniazid; Mining; Patient Compliance; Pyrazinamide; Rifampin; | 1997 |
[Tuberculosis in hemodialysis].
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Female; Humans; Isoniazid; Male; Middle Aged; Pyrazi | 1997 |
Physician compliance with national tuberculosis treatment guidelines: a university hospital study.
Topics: Antitubercular Agents; Cerebrospinal Fluid; Drug Administration Schedule; Drug Therapy, Combination; | 1998 |
Isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Developing Countries; Drug Therapy, Co | 1998 |
Is pyrazinamide really the third drug of choice in the treatment of tuberculosis?
Topics: Adult; Aged; Antitubercular Agents; Arthritis; Female; Humans; Male; Middle Aged; Prospective Studie | 1998 |
Does AIDS impair the absorption of antituberculosis agents?
Topics: Absorption; Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antitubercular Agents; Biological | 1998 |
Peptide-specific T cell response to Mycobacterium tuberculosis: clinical spectrum, compartmentalization, and effect of chemotherapy.
Topics: Adolescent; Adult; Antigens, Bacterial; Antitubercular Agents; Bacterial Proteins; BCG Vaccine; Cell | 1998 |
Prevention of tuberculosis in HIV-1.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Resistance, Microbial; HIV-1; Hum | 1998 |
Short-term tuberculosis prophylaxis is effective in persons with HIV.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Humans; Isoniazid; Patient Compliance; | 1998 |
Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Chemical | 1998 |
From the Centers for Disease Control and Prevention. Use of short-course tuberculosis preventive therapy regimens in HIV-seronegative persons.
Topics: Antitubercular Agents; Drug Administration Schedule; HIV Seronegativity; Humans; Practice Guidelines | 1998 |
[Efficacy of a short 6 month therapeutic coursefor HIV infected tuberculosis patients in Abidjan, Côte d'Ivoire].
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antitubercular Agents; Cohort Studies; Cote d | 1998 |
Tuberculosis of the pyriform fossa--a rare entity.
Topics: Adult; Antitubercular Agents; Diagnosis, Differential; Drug Therapy, Combination; Ethambutol; Humans | 1998 |
Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Cohort Studies; Drug Therapy, C | 1999 |
Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide.
Topics: Administration, Oral; Analysis of Variance; Animals; Antitubercular Agents; Biocompatible Materials; | 1999 |
Therapy of tuberculosis in mice by DNA vaccination.
Topics: Animals; Antigens, Bacterial; Antitubercular Agents; Bacterial Proteins; Chaperonin 60; Chaperonins; | 1999 |
Reply: Treatment of tuberculosis in HIV-infected patients.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination; HIV Infections; Human | 1999 |
Reactivation of latent tuberculosis: variations on the Cornell murine model.
Topics: Animals; Antitubercular Agents; Dexamethasone; Disease Models, Animal; Genetic Variation; Glucocorti | 1999 |
Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, C | 1999 |
Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antitubercular Ag | 1999 |
Evaluation of a bacteriophage-based assay (phage amplified biologically assay) as a rapid screen for resistance to isoniazid, ethambutol, streptomycin, pyrazinamide, and ciprofloxacin among clinical isolates of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Ciprofloxacin; Drug Resistance, Microbial; Ethambutol; Evaluation Studies as | 1999 |
Unusual clinical manifestation of tuberculosis in a renal transplant recipient.
Topics: Adult; Antitubercular Agents; Ethambutol; Fatal Outcome; Female; Humans; Isoniazid; Kidney Transplan | 1999 |
pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada.
Topics: Amidohydrolases; Antitubercular Agents; DNA Fingerprinting; DNA Transposable Elements; DNA, Bacteria | 2000 |
New agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide.
Topics: Animals; Antitubercular Agents; Cattle; Culture Media; Drug Resistance, Microbial; Humans; Hydrogen- | 2000 |
Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Drug Administr | 2000 |
Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China.
Topics: Adolescent; Adult; Aged; Amidohydrolases; Antitubercular Agents; China; DNA Mutational Analysis; DNA | 2000 |
Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model.
Topics: Animals; Antitubercular Agents; Colony-Forming Units Assay; Disease Models, Animal; Drug Therapy, Co | 2000 |
Second episode of tuberculosis in an HIV-infected child: relapse or reinfection?
Topics: AIDS-Related Opportunistic Infections; Amoxicillin-Potassium Clavulanate Combination; Antibiotics, A | 2000 |
Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Resistance | 2000 |
Treatment of tuberculosis: a well-standardised protocol.
Topics: Adult; Child; Clinical Protocols; Ethambutol; France; Humans; Isoniazid; Pyrazinamide; Rifampin; Tim | 2000 |
Tuberculous abscess of the graft in a renal transplant recipient after chronic rejection: case report.
Topics: Abscess; Adult; Antitubercular Agents; Chronic Disease; Drug Therapy, Combination; Ethambutol; Femal | 2000 |
Tuberculosis after renal transplantation.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Follow-Up Studies; Huma | 2000 |
Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States.
Topics: Amidohydrolases; Antitubercular Agents; Bacterial Proteins; California; Centers for Disease Control | 2001 |
Contralateral pleural effusion during chemotherapy for tuberculous pleural effusion.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid; Pleural Effusion | 2000 |
Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates.
Topics: Adult; Antitubercular Agents; Cohort Studies; Drug Therapy, Combination; Female; Georgia; Humans; Ma | 2001 |
Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Fatal Outc | 2001 |
Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Female; Humans; Isoniazid; Male; Micr | 2001 |
CPCRA researchers present OI studies at Vancouver.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Antifung | 1996 |
Medical advances with international impact.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antibiotics, Antitubercular; Antitubercular | 1998 |
A short two-drug regimen prevents active TB.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Clinical Trials as Topic; Drug Therapy | 1998 |
New TB therapy works for HIV-positive patients.
Topics: Antitubercular Agents; Clinical Trials as Topic; Disease Progression; HIV Infections; Humans; Isonia | 1998 |
Short course preventive therapy for tuberculosis is successful in HIV-infected patients.
Topics: AIDS-Related Opportunistic Infections; Clinical Trials as Topic; Drug Administration Schedule; Drug | 1998 |
Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; CD4 Lymphocyte Count; Con | 2001 |
Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Fatal Outcome; Female; Georgia; Human | 2001 |
Tuberculous otitis media -- a diagnostic dilemma.
Topics: Adult; Antitubercular Agents; Diagnosis, Differential; Drug Therapy, Combination; Ear Diseases; Faci | 2001 |
US guidelines for treatment of latent tuberculosis revised.
Topics: Chemical and Drug Induced Liver Injury; Drug Combinations; Humans; Practice Guidelines as Topic; Pyr | 2001 |
Treatment of tuberculosis in Haiti.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Haiti; H | 2001 |
From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
Topics: Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combinatio | 2001 |
Tuberculosis: guidelines changed for latent TB treatment.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Centers for Disease Control and Preven | 2001 |
Pyrazinamide use as a method of estimating under-reporting of tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Disease Notification; Humans; Netherlands; Pyrazinamide; R | 2001 |
Revised treatment and testing guidelines for latent tuberculosis infection.
Topics: Adolescent; Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Child; Child, P | 2000 |
Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
Topics: Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combinatio | 2001 |
Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.
Topics: Antitubercular Agents; Colony Count, Microbial; Culture Media; Drug Resistance, Bacterial; Humans; H | 2002 |
Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.
Topics: Antitubercular Agents; Cell Survival; Colony Count, Microbial; Culture Media; Drug Interactions; Dru | 2002 |
Tuberculosis presenting as immune thrombocytopenic purpura.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Autoimmune Diseases; Drug Therapy, Combination; Ethamb | 2002 |
[Latent tuberculosis infection: diagnosis and treatment].
Topics: Antitubercular Agents; BCG Vaccine; Humans; Isoniazid; Predictive Value of Tests; Pyrazinamide; Rifa | 2002 |
Tuberculosis preventative treatment also prevented diarrhoea in HIV-infected patients in Zambia.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Diarrhea; Drug Therapy, Combination; Follow-Up S | 2002 |
Noncompliance with tuberculosis treatment by patients at a tuberculosis and AIDS reference hospital in midwestern Brazil.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Antitubercular Agents; Brazil; Child; C | 2002 |
Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population.
Topics: Anti-Infective Agents; Antitubercular Agents; Drug Resistance, Microbial; Drug Resistance, Multiple; | 2002 |
Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Maryland; Prisoners; Pyrazinamide; Rifampi | 2002 |
Tuberculosis in the 1980s: a case for short-course chemotherapy.
Topics: Animals; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Ethamb | 1979 |
Side effects of drugs used to treat tuberculosis.
Topics: Aminosalicylic Acids; Animals; Antitubercular Agents; Capreomycin; Chemical and Drug Induced Liver I | 1975 |
The treatment of tuberculosis.
Topics: Aminosalicylic Acids; Capreomycin; Ethambutol; Ethionamide; Humans; Isoniazid; Prothionamide; Pyrazi | 1975 |
The cost of antituberculous drug regimens.
Topics: Antitubercular Agents; Biological Availability; Drug Administration Schedule; Drug Therapy; Humans; | 1979 |
[The abdominal tuberculoses].
Topics: Aftercare; Cycloserine; Ethambutol; Ethionamide; Gastrointestinal Diseases; Humans; Mesentery; Perit | 1978 |
[Tuberculosis in Romania (author's transl)].
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Ethambutol; Female; Humans; Infant; Infant, Newbor | 1979 |
The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy.
Topics: Drug Evaluation; Humans; Pyrazinamide; Rifampin; Tuberculosis | 1978 |
[New methods of chemotherapy also for extrapulmonary tuberculosis?].
Topics: Female; Humans; Male; Pyrazinamide; Rifampin; Time; Tuberculosis; Tuberculosis, Urogenital | 1978 |
[Short term chemotherapy of tuberculosis. Current status of short term chemotherapy].
Topics: Antitubercular Agents; Drug Resistance, Microbial; Humans; Prognosis; Pyrazinamide; Tuberculosis; Tu | 1978 |
Experimental investigations of bacteriological mechanisms in short course chemotherapy.
Topics: Animals; Drug Therapy, Combination; Guinea Pigs; Mice; Mycobacterium tuberculosis; Pyrazinamide; Rif | 1976 |
Proceedings: Latest results of East African/British Medical Research Council short course chemotherapy studies.
Topics: Drug Evaluation; Humans; Isoniazid; Pyrazinamide; Recurrence; Rifampin; Streptomycin; Tuberculosis | 1975 |
Rationale for chemotherapy of tuberculosis and current recommendations.
Topics: Antitubercular Agents; Child; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Mycobacteriu | 1992 |
Case holding in patients with tuberculosis in Botswana.
Topics: Botswana; Drug Therapy, Combination; Humans; Isoniazid; National Health Programs; Patient Compliance | 1992 |
Effect of pyrazinamide on ciclosporin levels.
Topics: Adult; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Humans; Kidney Failure, Ch | 1992 |
Tuberculosis in the 1990's: resurgence, regimens, and resources.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Child; Drug Administration Schedule; Drug Interacti | 1992 |
Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.
Topics: Animals; Colony Count, Microbial; Drug Combinations; Female; Isoniazid; Mice; Mycobacterium tubercul | 1992 |
Transmission of multidrug-resistant tuberculosis among immunocompromised persons in a correctional system--New York, 1991.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Ethionamide; HIV Seropositivity; Huma | 1992 |
From the Centers for Disease Control. Transmission of multidrug-resistant tuberculosis among immunocompromised persons, correctional system--New York, 1991.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Ethionamide; HIV Seropositivity; Huma | 1992 |
Stability of isoniazid, rifampin and pyrazinamide in suspensions used for the treatment of tuberculosis in children.
Topics: Ascorbic Acid; Child; Chromatography, High Pressure Liquid; Drug Stability; Humans; Isoniazid; Pyraz | 1991 |
AIDS and tuberculosis in Spain. A report of 140 cases.
Topics: Acquired Immunodeficiency Syndrome; Drug Therapy, Combination; Ethambutol; Female; Humans; Incidence | 1991 |
[Resistance to pyrazinamide in tuberculosis patients].
Topics: Drug Resistance, Microbial; Humans; Mycobacterium tuberculosis; Pyrazinamide; Tuberculosis | 1991 |
[Tuberculosis of the larynx, oral cavity and pharynx].
Topics: Adult; Diagnosis, Differential; Drug Therapy, Combination; Endoscopy; Ethambutol; Humans; Isoniazid; | 1991 |
Contribution of pyrazinamide to antituberculosis chemotherapy.
Topics: Drug Resistance, Microbial; Ethambutol; Humans; Pyrazinamide; Tuberculosis | 1991 |
Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Drug Administration Schedule; Drug Therapy, Combination; | 1991 |
[Resistance to pyrazinamide in tuberculosis patients].
Topics: Drug Resistance, Microbial; Humans; Mycobacterium tuberculosis; Pyrazinamide; Spain; Tuberculosis | 1991 |
Alteration in the levels of pyrazinamide in pleural fluid following simultaneous administration of prednisoline in patients of tubercular pleural effusion.
Topics: Adolescent; Adult; Aged; Body Fluids; Female; Humans; Male; Middle Aged; Pleura; Pleural Effusion; P | 1990 |
A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Aspartate Aminotransferases; Cost-Benefit Analysis; | 1990 |
Incorporation of pyrazinamide into community-wide treatment of tuberculosis.
Topics: Community Health Services; Humans; Pyrazinamide; Tuberculosis; United States | 1990 |
Cerebellar syndrome caused by isoniazid.
Topics: Aged; Cerebellar Diseases; Female; Humans; Isoniazid; Kidney Failure, Chronic; Pyrazinamide; Pyridox | 1990 |
Drug combinations and the bioavailability of rifampicin.
Topics: Antitubercular Agents; Biological Availability; Drug Combinations; Humans; Isoniazid; Pyrazinamide; | 1990 |
Tuberculosis control and the AIDS epidemic in developing countries.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Developing Countries; Diagnosis, Different | 1990 |
Drug resistance of Mycobacterium tuberculosis isolated from treated patients in Pakistan.
Topics: Adolescent; Adult; Aminosalicylic Acid; Antitubercular Agents; Drug Resistance, Microbial; Ethambuto | 1989 |
Problems of tuberculosis treatment in Thailand.
Topics: Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Female; Humans; Isoniazid; Mal | 1989 |
[Tuberculosis in children in 1989].
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Age Factors; Anti-Bacterial Agents; BCG Vaccine; Chi | 1989 |
[Tuberculous ulcer of the tongue: clinical case].
Topics: Adult; Female; Humans; Isoniazid; Pyrazinamide; Rifampin; Tongue Diseases; Tuberculosis; Tuberculosi | 1989 |
[Recommendations for the therapy of tuberculosis. (Position: December, 1988)].
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Tubercul | 1989 |
Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.
Topics: Animals; BCG Vaccine; Colony Count, Microbial; Drug Administration Schedule; Drug Therapy, Combinati | 1989 |
Management of non-respiratory tuberculosis.
Topics: Humans; Mycobacterium bovis; Pyrazinamide; Tuberculosis | 1986 |
[Routine use of 6-month antitubercular treatment in 300 patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Therapy, Combination; Drug T | 1986 |
[Pyrazinamide, hyperuricemia and gouty arthritis].
Topics: Adult; Arthritis, Gouty; Humans; Male; Pyrazinamide; Tuberculosis; Uric Acid | 1988 |
Drugs for tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Drug Administrati | 1988 |
American Thoracic Society. Medical Section of the American Lung Association: Treatment of tuberculosis and tuberculosis infection in adults and children.
Topics: Adult; Age Factors; Blood Cell Count; Blood Urea Nitrogen; Child; Creatinine; Drug Administration Sc | 1986 |
Antituberculous agents.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Tubercul | 1987 |
The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis.
Topics: Acetylation; Adolescent; Adult; Biological Availability; Drug Combinations; Humans; Isoniazid; Middl | 1986 |
Triton WR-1339 as a biological-response modifier in mycobacterial infection.
Topics: Animals; Cell Membrane; Detergents; Drug Therapy, Combination; Lentinan; Lung; Male; Mice; Mycobacte | 1986 |
Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide.
Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child, Pres | 1986 |
[Prevention of resistance to rifampicin by pyrazinamide in experimental tuberculosis in the mouse].
Topics: Animals; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Lung; Mice; Mycobacterium tu | 1985 |
[The latest topics concerning pyrazinamide].
Topics: Adolescent; Adult; Animals; Child; Drug Resistance, Microbial; Drug Synergism; Female; Humans; Isoni | 1985 |
Short-course chemotherapy for extrapulmonary tuberculosis. Nine years' experience.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Female; Humans; Isonia | 1986 |
Successful treatment of tuberculous brain abscess.
Topics: Brain Abscess; Ethambutol; Humans; Male; Middle Aged; Pyrazinamide; Tomography, X-Ray Computed; Tube | 1985 |
Tuberculosis in an Indochinese refugee camp: epidemiology, management and therapeutic results.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female | 1985 |
[Reevaluation studies on the chemotherapeutic effect of pyrazinamide in experimental mouse tuberculosis].
Topics: Animals; Male; Mice; Mice, Inbred Strains; Pyrazinamide; Tuberculosis | 1985 |
[Characteristics of drug-induced hepatitis in patients with tuberculosis].
Topics: Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Ethionamide; Hu | 1972 |
[Proceedings: Ambulatory chemotherapy of tuberculosis in Finland (organization)].
Topics: Ambulatory Care; Aminosalicylic Acids; Antitubercular Agents; Capreomycin; Ethambutol; Ethionamide; | 1973 |
[Drug therapy of tuberculosis].
Topics: Amides; Aminosalicylic Acids; Antitubercular Agents; Capreomycin; Drug Therapy, Combination; Ethambu | 1974 |
In vitro and in vivo studies to assess the suitability of antituberculous drugs for use in intermittent chemotherapy regimens.
Topics: Animals; Antitubercular Agents; Cycloserine; Ethambutol; Ethionamide; Guinea Pigs; In Vitro Techniqu | 1968 |
Drugs for tuberculosis.
Topics: Aminosalicylic Acids; Costs and Cost Analysis; Cycloserine; Drug Synergism; Ethambutol; Ethionamide; | 1968 |
In vitro and in vivo studies to assess the suitability of anti-tuberculous drugs for use in intermittent chemotherapy regimens.
Topics: Animals; Antitubercular Agents; Cycloserine; Ethambutol; Ethionamide; Guinea Pigs; In Vitro Techniqu | 1968 |
[Histological follow-up studies on drug induced liver necroses].
Topics: Aspartate Aminotransferases; Biopsy; Chemical and Drug Induced Liver Injury; Ethionamide; Follow-Up | 1973 |
[Algodystrophy associated with antitubercular chemotherapy: 22 cases].
Topics: Adult; Antitubercular Agents; Cycloserine; Ethambutol; Ethionamide; Female; Humans; Isoniazid; Male; | 1969 |
[Results of outpatient treatment of tuberculous patients in a rural area of the Moldavian SSR].
Topics: Adolescent; Adult; Ambulatory Care; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Ethion | 1974 |
Bacteriology of tuberculosis with special reference to kanamycin and related drugs.
Topics: Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; Ethionamide; H | 1966 |
[Treatment with new antitubercular agents].
Topics: Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; Drug Synergism; Ethambutol; Ethionam | 1968 |
[Experimental studies on intermittent use of rifampicin alone or combined with other secondary antituberculous drugs].
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Antitubercular Agents; Body Weight; Ethambutol | 1971 |
[Advances and principles in tuberculostatic therapy].
Topics: Adult; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; Ethambu | 1971 |
Treatment of tuberculosis today in Nebraska.
Topics: Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Hypersensitivity; Ethambutol; Ethiona | 1973 |
New antituberculosis drugs and concepts of prophylaxis.
Topics: Aminosalicylic Acids; Antitubercular Agents; Arthritis; Chemical and Drug Induced Liver Injury; Chil | 1974 |
Intermittent chemotherapy for adults with tuberculosis.
Topics: Administration, Oral; Adult; Drug Resistance, Microbial; Ethambutol; Humans; Injections, Intramuscul | 1974 |
Hyperuricemia induced by ethambutol.
Topics: Allopurinol; Creatinine; Diuretics; Ethambutol; Ethanol; Gout; Humans; Isoniazid; Lactates; Pyrazina | 1974 |
What is drug resistance?
Topics: Drug Resistance, Microbial; Humans; Isoniazid; Microbial Sensitivity Tests; Mutation; Mycobacterium | 1969 |
A comparison of various measures of sensitivity of M. tubercolosis to pyrazinamide.
Topics: Culture Media; Drug Resistance, Microbial; Humans; Hydrochloric Acid; Hydrogen-Ion Concentration; Mi | 1970 |
Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis.
Topics: Amidohydrolases; Citrates; Culture Media; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; M | 1970 |
[Specificity of antituberculous action in vitro of pyrazine-2-carboxylic acid derivatives].
Topics: Animals; Antitubercular Agents; Drug Resistance, Microbial; Methods; Mice; Microbial Sensitivity Tes | 1971 |
[Studies on the effects of antituberculosis agents against tubercle bacilli in the resting state, using streptomycin-dependent strain (18-b). II. Studies in vivo].
Topics: Animals; Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Isoniazid; Kanamycin; Male; | 1971 |
The effect of pyrazinamide, rifampicin and cycloserine on the blood levels and urinary excretion of isoniazid.
Topics: Cycloserine; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis | 1971 |
Genetic variations in the acetylation of isoniazid and other drugs.
Topics: Adult; Aminobenzoates; Aminosalicylic Acids; Asian People; Black People; Body Weight; Depression; Fe | 1968 |
Clinical activity of cycloserine in the treatment of tuberculosis.
Topics: Adult; Aged; Chronic Disease; Cycloserine; Drug Resistance, Microbial; Ethambutol; Female; Humans; M | 1970 |
Experimental studies on therapeutic effects of various combinations of antituberculosis drugs. I. Comparison of various regimens in treatment of experimental mouse tuberculosis infected with drug-susceptible mycobacteria.
Topics: Aminosalicylic Acids; Animals; Antitubercular Agents; Cycloserine; Ethambutol; Ethionamide; Isoniazi | 1967 |
Retreatment of tuberculosis patients with combined drug therapy.
Topics: Brazil; Cycloserine; Drug Resistance, Microbial; Ethionamide; Humans; Isoniazid; Pyrazinamide; Tuber | 1969 |
[Liver function in tuberculosis treated with pyrazinamide, cycloserine, ethionamide and isoniazid].
Topics: Antitubercular Agents; Cycloserine; Ethionamide; Humans; Isoniazid; Liver; Pyrazinamide; Tuberculosi | 1969 |
Problems of treatment of drug resistance in the developing countries.
Topics: Africa; Aminosalicylic Acids; Antitubercular Agents; Costs and Cost Analysis; Developing Countries; | 1969 |
[Attempt at intermittent chemotherapeutic treatment of patients with bacilli resistant to streptomycin and isoniazid (cooperative survey by the antitubercular services of Marrakech, Meknes, Tangiers)].
Topics: Cycloserine; Drug Resistance, Microbial; Drug Synergism; Ethionamide; Humans; Isoniazid; Morocco; Py | 1969 |
[Prospective cooperative examination of the hepatic toxicity of pyrazinamide].
Topics: Adolescent; Adult; Aged; Bilirubin; Biopsy; Child; Female; Humans; Liver; Liver Function Tests; Male | 1970 |
International conference.
Topics: Antitubercular Agents; Child; Cycloserine; Ethionamide; Humans; International Cooperation; Mass Ches | 1967 |
[Therapy of resistant chronic diseases with 2nd type drugs. Observations on 34 cases made in the Sanatorio São Sebastião, Lapa, Estado do Paraná].
Topics: Analgesics; Brazil; Ethionamide; Humans; Pyrazinamide; Tuberculosis | 1967 |
The absorption and excretion of pyrazinamide. I. Preliminary study in laboratory animals and in man.
Topics: Animals; Female; Humans; Kidney; Liver; Lung; Male; Pyrazinamide; Rabbits; Tuberculosis | 1968 |
[New combinations of drugs for the treatment of drug-resistant tuberculosis].
Topics: Aminosalicylic Acids; Antitubercular Agents; Drug Resistance, Microbial; Ethionamide; Humans; Isonia | 1968 |
[Control methods for the demonstration in the urine of tuberculostatic drugs of secondary importance].
Topics: Cycloserine; Ethionamide; Ferricyanides; Fluorescence; Humans; Indicators and Reagents; Methods; Pyr | 1968 |